Factors affecting the detection of Clostridium difficile in faecal samples by Davies, Kerrie Ann
1 
 
 
 
Factors affecting the detection of Clostridium difficile in faecal 
samples 
 
Kerrie Ann Davies 
 
Submitted in accordance with the requirements for the degree 
of Doctor of Philosophy  
The University of Leeds 
School of Medicine 
 
 
April 2019 
  
2 
 
 
The candidate confirms that the work submitted is her own, except where work which has 
formed part of jointly authored publications has been included. The contribution of the 
candidate and the other authors to this work has been explicitly indicated below. The 
candidate confirms that appropriate credit has been given within the thesis where 
reference has been made to the work of others.  
 
Section 6.2.1 of Chapter 4 contains work from a jointly authored publication; Davies K, 
Planche T and Wilcox M. The predictive value of quantitative nucleic acid amplification 
detection of Clostridium difficile toxin gene for faecal sample toxin status and patient 
outcome. PLoS One 13(12): e0205941 2018. The concept of the work was devised by Kerrie 
Davies, the analysis and initial draft of the manuscript was completed by Kerrie Davies with 
review by Dr Tim Planche and Prof Mark Wilcox. 
 
This copy has been supplied on the understanding that it is copyright material and that no 
quotation from the thesis may be published without proper acknowledgement.  
 
The right of Kerrie Davies to be identified as Author of this work has been asserted by 
Kerrie Davies in accordance with the Copyright, designs and Patents Act 1988.   
3 
 
Acknowledgements 
There are so many people who I need to thank for their part in helping me to achieve this 
thesis.  
The Department of Health study, for which I was scientific coordinator, was conducted 
prior to this PhD, but I have reused the data for further analysis within the thesis. I would 
therefore like to thank all of the sites that took part in the multi-centre study; Leeds 
Teaching Hospitals NHS trust, St Georges’ University Hospitals NHS Foundation Trust, UCL 
Hospitals NHS Foundation Trust and Oxford University Hospitals NHS Foundation Trust, 
with special thanks to Dr Tim Planche for all of his support and guidance. I would also like 
to thank the Department of Health, who funded both this initial study and the PlaciD study.   
The PlaciD study research was carried out by a team which has included Claire Berry 
(Clinical Scientist), Claire Brown (Research Nurse) and Faye Pinker (Research Nurse). My 
own contributions, fully and explicitly indicated in the thesis, for the PlaciD study were to 
devise the study, be study chief investigator, write the study protocol, apply for ethical 
approval, devise data collection sheets and databases, perform the majority of the 
laboratory testing of the samples and analyse the data.  The other members of the team 
and their contributions have been as follows; The Research Nurses recruited all of the 
participants, collected their samples and their data; Claire Berry performed laboratory 
testing of the samples during my maternity leave (four months). Thanks go to all of the 
team. I would also like to thank all of the participants in the PlaciD study, who generously 
gave their time, and poo, to help make the study a success!  
The gut models require a huge team effort to keep them running, therefore the research 
using this system has been carried out by a team which has included; Dr Tony Buckley (PI), 
Dr Caroline Chilton (PI), Dr Ines Moura (research assistant), Dr Hannah Harris (research 
assistant), Duncan Ewin (technician), Sharie Shearman (technician), Emma Clarke 
(technician), Kate Owens (technician), Bill Spittal (senior technician) and Flor Sporta 
(Summer student). My own contributions, fully and explicitly indicated in the thesis, have 
been to devise the experiments using gut model samples to monitor proliferation of 
C. difficile within the gut models using commercial assays, to test the samples, except 
where tested by Flor Sporta, as detailed within the thesis, and analyse the data.   The other 
members of the team and their contributions have been as follows; individual gut model 
experiments devised and overseen by the PI in each case; all the technical aspects of 
keeping the gut models running was completed by the technical team (technicians and 
4 
 
research assistants), including taking the daily samples; Flor Sporta tested some of the gut 
model samples using the DS2 assays, as explicitly indicated in the thesis. I would like to 
thank each and every one of them for their assistance.  
All PCR ribotyping was carried out by the C. difficile Ribotyping Network of England and 
Northern Ireland (CDRN), as explicitly stated within the thesis. I would like to thank Dr 
Warren Fawley and his team at CDRN for their contribution and support.  
The Healthcare Associated Infections Research Group is a special place to work and I feel 
very privileged to be part of such a great team. Every single person deserves my thanks, but 
I’d especially like to thank Dr Jane Freeman, for being my ever steady friend who always 
steers me right; Dr Baljit Saundh, my dear friend who helps me to ‘relax the chaos’; 
Georgina Davis, my great friend and dedicated cheering squad, who never lets me quit; and 
of course Prof Mark Wilcox, my PhD Supervisor and mentor, who has given me the 
opportunity to fly. A great debt of thanks also goes to Dr John Heritage; not only is he the 
reason I came to Leeds to study Microbiology as an undergraduate, but he was also my PhD 
co-supervisor, even after he had retired. I appreciate all of the wisdom and advice he has 
imparted over the many years I have known him.  
Huge thanks go to my family; for standing by me, for keeping me encouraged and inspired. 
To my children Alf and Sid, for being patient when I couldn’t play, and for making me laugh 
whenever they could; to my mum and dad for being so supportive and proud; to my 
extended Leeds family for supporting us all and providing ‘donations’ when needed. Special 
thanks obviously go to Graeme, my amazing husband; without him this thesis, my career 
and my self-belief would be naught.  
This PhD thesis is dedicated to my dad; for inspiring me to be the scientist that he never got 
the chance to be.  
5 
 
Abstract 
Clostridium difficile infection (CDI) laboratory diagnostic assays have variable performance, 
but reasons behind this variability are not well defined. In contrast to previous findings, the 
PCR ribotype of the organism only appears to be a factor in reduced sensitivity for toxin 
enzyme immunoassays (EIAs), not glutamate dehydrogenase (GDH) EIAs. Growth curve 
data demonstrated that GDH is produced during the exponential phase of growth, and the 
sensitivity of the GDH assay in vivo may be related to the amount of protein produced by 
the organism, as very high levels of GDH were detected during growth of C. difficile in an in 
vitro gut model. Indeed the levels of GDH, measured in both gut model and patient samples, 
correlated with organism bioload. In addition, the median faecal levels of GDH in recurrent 
CDI cases were significantly higher than in patients with a single infection episode. 
Interestingly, when patients had sequential faecal samples tested, 27% with an initial GDH-
positive/toxin-negative result had a subsequent toxin positive sample, after a median of 
eight days. Further studies, with supplementary assays for gut inflammation, are required, 
to determine if these are ‘missed’ infections or insignificant sub-clinical levels of toxin. A 
laboratory test that could predict risk of recurrence would be an important tool to inform 
choice of appropriate C. difficile treatment and prevention options. Indeed GDH detection 
may offer such an opportunity; a cohort of patients has been identified who were 
consistently GDH positive, even after resolution of symptoms, who subsequently 
developed recurrent CDI following additional antimicrobial therapy. The cycle threshold (CT) 
value of PCR assays for the detection of toxin gene may also provide additional information, 
as low CT (<25) was significantly associated with toxin positivity, presence of PCR ribotype 
027 and mortality. Low CT was also associated with recurrence but was not a significant 
finding. 
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1.0 Introduction 
1.1 Historical context 
Clostridium difficile is widely recognised as the predominant cause of nosocomial diarrhoea 
in the western world (Crobach et al, 2009). This anaerobic spore-forming bacillus was first 
identified in 1935 as a commensal bacterium of children, although the authors did note 
that the organism was pathogenic when broth supernatants were injected into Guinea pigs 
(Hall and O’Toole, 1935). The organism was later shown to be the aetiological agent of 
pseudomembranous colitis and antibiotic-associated diarrhoea (AAD) (George et al, 1978; 
Bartlett et al, 1978), after the identification of a clostridial toxin that was neutralised by 
Clostridium sordelii antitoxin in the faeces of pseudomembranous colitis patients and 
patients with antibiotic-associated diarrhoea (Larson and Price, 1977; Rifkin et al, 1977). 
C. difficile infection only represents 10-20% of cases of antibiotic-associated diarrhoea 
(Kelly et al, 1994; Gerding, 1989); Staphylococcus aureus, Clostridium perfringens and 
Klebsiella oxytoca among others, have also been implicated in this condition (Sparks et al, 
2001; Altemeier et al, 1963; Bartlett and Gerding, 2006; Högenauer, 2006). Importantly, 
pseudomembranous colitis may also be caused by Salmonella (Hovius and Rietra, 1982), 
which could cause misidentification as Clostridium difficile infection if imaging alone is used 
for diagnosis. In the majority of cases, however, no organism can be isolated from AAD 
patients, and it is postulated that diarrhoea in some of these patients is as a result of 
disrupted carbohydrate catabolism from depleted anaerobic faecal microbiota (Bartlett, 
2002; Young and Schmidt, 2004). Also, some antibiotics, for example erythromycin and the 
clavulanic acid component of co-amoxiclav, can affect gut motility, and may therefore 
increase frequency and softness of motions in some patients (Barlett, 2002). 
Recently, a new classification of Clostridium difficile has been proposed as 
Clostridioides difficile (Lawson et al, 2016). However, Clostridium difficile still appears to be 
the preferred option in the current literature and the bacterium will be referred to as such 
throughout this thesis. 
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1.2 Virulence factors 
1.2.1 Toxins 
The ability to produce toxins is one of the key factors that makes C. difficile such a 
successful pathogen. The organism produces two large glucosyltransferase protein toxins, 
toxin A and toxin B, both of which target the actin cytoskeleton of cells by inactivation of 
Rho proteins (Ras-homologous proteins), allowing the secretion of chloride ions into the 
gut lumen via cell tight junctions that have become opened (Just et al, 1995; Giry et al, 
1995), resulting in diarrhoea. Toxin A is a 308,103 Da enterotoxin (Dove et al, 1990) with 
approximately 45% homology at the amino acid level with the 269,000 Da cytotoxin toxin B 
(Barroso et al, 1990; Aktories 1997). Although described as an enterotoxin, toxin A also has 
cytotoxic activity; however, toxin B is 100-fold more potent than toxin A (Tucker et al, 1990) 
as a cytotoxin. Both toxins are encoded on a 19.6Kb, non-mobile pathogenicity locus 
(PaLoc), alongside tcdC (regulator), tcdD (positive regulator, nomenclature later changed to 
tcdR) and tcdE (mediator of cell release) (Braun et al, 1996; Hundsberger et al, 1997; Voth 
and Ballard, 2005). Non-toxigenic strains of C. difficile do not contain the PaLoc within the 
chromosome (Rupnik et al, 1998). 
The toxins bind to human epithelial cells via a combined repetitive oligopeptide (CROP) 
domain, and a hydrophobic protein sequence that allows insertion into host membranes 
(Dingle et al,  2008). Despite the high degree of homology, the toxins appear to have 
different effects in experimental models; in a mouse model toxin B causes damage to 
epithelia, and increases inflammation to a much greater extent than toxin A.  Indeed, the 
incidence of mortality in this model is also higher with toxin B, compared with toxin A 
(Carter et al, 2015). In a hamster model, however, toxin A appears to be the more potent 
toxin (Carter et al, 2015). These differences may be due to the fact that the two toxins have 
different target receptors (Chaves-Olarte et al, 1997). In addition, toxin A may have a wider 
range of targets (GTPases) to which it can bind (Pruitt et al, 2012). Mutants lacking either 
tcdA (encoding toxin A) or tcdB (encoding toxin B) have been investigated to determine the 
role of each toxin in virulence (Lyras et al, 2009; Kuehne et al, 2014), with conflicting 
results; one study highlighted that only toxin B was required for virulence, since mutants 
expressing tcdA but not tcdB did not cause disease (Lyras et al,  2009), while the other 
study found that mutants with knocked out expression of either tcdA or tcdB could cause 
disease (Kuehne et al, 2014). 
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During the exponential phase of growth, the regulator tcdC  is expressed in higher 
amounts, thereby inhibiting the expression of tcdA and tcdB (Matamouros et al, 2007); 
once in a stationary phase of growth, tcdR expression initiates expression of tcdA and tcdB 
(Mani and Dupuy, 2001). The product of expression of tcdR also promotes its own 
expression, in a positive feedback loop, thereby increasing the expression of toxins even 
further (Mani and Dupuy, 2001). Increased toxin production has been linked with changes 
to the negative regulator TcdC (Spigaglia and Mastrantonio, 2002; Murray et al, 2009). The 
tcdC gene of a type of C. difficile known as PCR ribotype 027, and certain other 
PCR ribotypes, has been shown to be truncated, producing an altered amino acid sequence 
(Spigaglia and Mastrantonio, 2002; Murray et al, 2009), potentially reducing the ability of 
the negative regulator to repress production of toxins A and B (Spigaglia and Mastrantonio, 
2002). However, a strain with an intact tcdC gene has been shown to be a ‘hyper-producer’ 
of both functional toxins A and B, whilst conversely, a strain with a truncated tcdC 
produced low levels of functional toxins (Murray et al, 2009). There is also considerable 
sequence heterogeneity in tcdB between strains (Stabler et al, 2006), and purified toxin B 
from PCR ribotype 027 was found to be 4-fold more toxic in a mouse model, than toxin B 
from other PCR ribotypes (Lanis et al, 2013). This may imply that factors other than the 
tcdC gene have a role to play in the regulation of toxin production. 
In addition to the two main toxins, a small number of C. difficile strains also produce 
another toxin (binary toxin), which has ADP-ribosyltransferase activity (Voth and Ballard, 
CMR 2005). This toxin is not encoded within the PaLoc, but within a separate Cdt locus; a 
6.2kb region including two toxin genes, cdtA and cdtB, and a regulatory gene (cdtR) 
(Gerding et al, 2014). These two toxins, collectively known as binary toxin, are much 
smaller than toxin A or toxin B, with a relative molecular mass of only 53 kDa and 98.8 kDa 
for CdtA and CdtB respectively (Gerding et al, 2014). It is thought that binary toxin may 
increase cell adherence of C. difficile by causing fibronectin to be displayed on the surface 
of the target cell (Schwan et al, 2014). The clinical significance of binary toxin is still 
uncertain. In one cohort of clinical samples however, the presence of binary toxin genes 
was associated with samples with demonstrable toxin A or B, as measured by cell-
cytotoxicity assay, compared with samples positive for the presence of a toxigenic strain, 
but not free toxin (Berry et al, 2017), suggesting a role in toxin-mediated disease.  In 
addition, mortality was higher in the group positive for the binary toxin genes (RR 1.68). It 
should be noted that this study only detected the presence of cdt genes not free toxin 
however, as assays  for functional binary toxin are not readily available. 
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The genes encoding binary toxin are carried by some of the strains of C. difficile termed 
‘hypervirulent’, such as PCR ribotypes 027, 078 and 251 (Wehrhahn et al, 2018; Rupnik et 
al, 1998; Toxinotyping website database), and it is therefore postulated that binary toxin 
contributes to the more severe infections seen in these PCR ribotypes.  Indeed, there have 
been reports of CDI caused by PCR ribotype 033, a non-toxigenic strain (in that it does not 
contain the PaLoc), but which does produce binary toxin (Eckert et al, 2013). Given that the 
mechanism of action of binary toxin is to increase adherence of C. difficile to the epithelial 
cells but without affecting cell leakage however (Schwan et al, 2014), it is unclear how toxin 
mediated disease occurred in these patients. 
 
1.2.2 Spores 
Clostridium difficile is an anaerobic spore-forming bacterium that forms sub-terminal 
spores on nutrient limitation (Sorg and Sonenshein, 2008). The spores provide protection 
for the organism when in an oxygen-rich environment, as the vegetative cells are extremely 
sensitive to the presence of oxygen (Sorg and Sonenshein, 2008). In addition, the spores 
are heat-stable and resistant to gastric acid, whereas the vegetative cells are not, thereby 
providing protection to the organism when passing through the upper GI tract (Sorg and 
Sonenshein, 2008). Chemicals that induce spores to outgrow into vegetative cells are 
known as germinants, and for C. difficile these include primary bile acids, such as 
taurocholate (Giel et al, ne 2010). These primary bile acids have been found to increase in 
antibiotic-disrupted gut microbiomes (Theriot et al, 2014), due to a decrease in the species 
of gut bacteria that metabolize primary bile salts into secondary bile salts. Indeed, one 
study found that bacteria within the phyla Firmicutes and Bacteroidetes were essential to 
this process, and microbiomes depleted in these organisms were more likely to support the 
germination of C. difficile spores (Theriot et al, 2014). For Bacillus subtilis, the process of 
germination is well documented; the germinant binds to specific receptors on the spore 
and leads to the rehydration of the core, which, in turn, causes the cortex of the spore 
(which surrounds the core) to undergo rehydration and expansion (Setlow, 2014).  At this 
point, the spore has lost its dormancy and the outgrowth of the vegetative cell begins 
(Setlow, 2014). It could be assumed that the process of germination, albeit with different 
germinants from B. subtilis, is similar in C. difficile (De Hoon et al, 2010). It has been 
suggested that primary bile acids require glycine to act as a co-germinant for C. difficile 
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(Sorg and Sonenshein, 2008), as germination was increased when glycine was added to 
media containing taurocholate, compared with taurocholate alone. 
Spores are able to survive in the environment for long periods, and are resistant to cleaning 
agents that do not contain hypochlorite (Fawley et al, 2007). Environmental contamination 
has been demonstrated in hospital settings where patients with CDI have been treated 
(Fawley et al, 2007; Eckstein et al, 2007) leading to a possible cross-infection risk to other 
patients. In addition, the fact that spores are alcohol-resistant means that alcohol hand 
cleansers are not adequate to decontaminate hands, and good hand-washing with soap 
and water is required to prevent further spread of spores (Wilson et al, 1985; Boyce and 
Pittet, 2002). 
 
1.2.3 Other Virulence Factors 
Given that the walls of cells in the intestines are covered in a mucus layer, C. difficile will 
need to bind to the mucus layer in order to achieve contact with the epithelial cell layer 
(Tasteyre et al, 2001). The flagella of the bacterium play a crucial role in this adherence, 
rather than providing motility to the organism (Tasteyre et al, 2001; Baban et al, 2013). 
Interestingly, C. difficile can adhere to the mucus layer of mice but not the mucus layer of 
pigs (Tasteyre et al, 2001), perhaps suggesting why mice can be used as an infection model 
for this organism. There are differences in the role of flagella in different strains of 
C. difficile (Baban et al, 2013), with some strains having a single flagellum, while others are 
peritrichously flagellated. In addition, flagella appear to play a role in expression of toxins A 
and B (Aubry et al,  2012), as mutants with the gene for flagella protein (fliC) removed had 
significantly increased expression of toxins A and B and the regulator protein TcdR, and had 
increased virulence in a hamster model. In contrast, mutants lacking other flagellar protein 
genes had decreased expression of toxins. A secondary cell signalling molecule, cyclic 
diguanylate (c-di-GMP), decreases expression of genes encoding flagella via the alternative 
sigma factor SigD, and therefore, c-di-GMP also affects expression of toxins (Purcell et al, 
2012, McKee et al, 2013). Further cellular adherence during colonisation is provided by 
C. difficile surface layer proteins (SLP) (Calabi et al, 2002) which have been shown to bind to 
collagen, thrombospondin and vitronectin.  Interestingly, however, they do not provide 
adherence to fibronectin (Calabi et al, 2002), which, as discussed above, is more highly 
expressed in cells affected by binary toxin, suggesting that alternative cell surface proteins 
are involved in adherence to cells after the release of binary toxin. 
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Increased intracellular levels of c-di-GMP also increase clumping of cells, potentially leading 
to biofilm formation (McKee et al, 2013), along with other virulence factors such as a 
putative quorum-sensing protein LuxS (Dapa et al, 2013). There may be a possible link 
between the formation of biofilm and sporulation, as a sporulation mutant, Spo0A, was 
unable to form biofilms (Dapa et al, 2013). In addition, these biofilms are more resistant to 
vancomycin than planktonic cells (Dapa et al, 2013).  
One recent study highlights another possible virulence mechanism for C. difficile, as the 
organism appears resistant to the increased concentration of heme, found in the gut lumen 
when infected epithelial cells use a heme efflux pump (Knipple et al, 2018). Although 
capsule can be demonstrated on some strains of C. difficile by electron microscopy, in vivo 
the presence of capsule does not appear to be required for virulence, as many of the 
strains with capsules were toxin negative strains and were unable to produce infection in a 
hamster model (Davies and Boriello, 1990). In addition, capsule does not appear to be 
related to cell adhesion (Baldassarri et al, 1991). C. difficile also possesses several hydrolytic 
enzymes, although production of these enzymes varies between strains (Seddon et al, 
1990). Virulence, as measured by the Syrian hamster model, appears to correlate with the 
presence of these hydrolytic enzymes (Seddon et al, 1990). It is therefore theorised that 
the enzymes are responsible for damaging tissues within the gut, aiding further adhesion of 
the bacterium (Seddon et al, 1990). A recent study, using whole-genome sequencing to 
identify differences in open reading frames (ORFs) within the accessory genome of 
different C. difficile strains, found several ORFs that were associated with higher virulence 
strains (Lewis et al, 2017). Some of the ORFs could be identified as cell-surface proteins, or 
proteins associated with transcription. However, there were several with unknown 
function, highlighting that there are possibly further virulence factors within the accessory 
genome that are still to be identified.   
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1.3 Clinical manifestations 
The majority of patients with C. difficile infection (CDI) will have symptoms of diarrhoea, 
which can vary from mild to severe, with or without abdominal cramping/pain and colitis 
(including pseudomembranous colitis) (Burnham and Carroll, 2013). Conversely, it is 
recognised that some people can carry C. difficile in their gut without being symptomatic 
(asymptomatic carriage) (Shim et al, 1998). 
In the majority of cases, CDI diarrhoea will begin within a few days of antibiotic use; 
however, onset can vary from concurrent with the antibiotic course to several weeks 
following completion of the course (Mogg et al, 1979).  The watery diarrhoea can be 
extremely debilitating with >10 episodes per day, and often patients become afraid to 
move far from toilet facilities (Madeo and Boyack, 2010; Guillemin et al, 2014). Many 
patients also experience distress and embarrassment while symptomatic, and continued 
anxiety following infection due to the possible recurrence of symptoms (Madeo and 
Boyack, 2010; Guillemin et al, 2014). 
In addition to diarrhoea, patients may also exhibit increased temperature, abdominal 
cramps and increased white blood cell count (Mogg et al, 1979). One study found fever in 
~28% of cases, abdominal cramps in ~22% and increased white cell count in ~50% of cases 
(Bartlett et al, 1980). Leucocytes can also be detected in the faeces of CDI patients, 
although this test is rarely used clinically (Mogg et al, 1979). Increased leakage of albumin 
through the damaged gut can also lead to hypoalbuminaemia, detectable from patient 
serum (Olson et al, ICHE 1994). 
Pseudomembranous colitis, the presence of distinctive plaques (volcano lesions) on the 
colonic surface, is associated with CDI, although it is not present in all cases, even in severe 
infection (Bartlett, 2002). Mogg et al. suggested several reasons why plaques may not be 
visualized on sigmoidoscopy or histology; obscuration by mucus and faecal material, failure 
to sample the plaque/mucosa junction itself, or the timing of the sigmoidoscopy (Mogg et 
al, 1979). In addition, the variation in severity of cases means that not all patients will 
develop pseudomembranous colitis (Bartlett and Gerding, 2008). 
In severe disease, patients may develop paralytic ileus, where the bowel fails to move 
faecal contents through the bowel. If this occurs patients will not exhibit the classic 
diarrhoea seen in most CDI cases (Bartlett and Gerding, 2008). Paralytic ileus may develop 
into toxic megacolon, where the colon swells and dilates as faeces and gas builds up inside 
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the colon (Sunenshine and McDonald, 2006). This is a life-threatening condition, and 
patients may exhibit pain, fever, nausea/vomiting, tachycardia and lethargy (Mogg et al, 
1979). 
Disruption to the normal host gut microbiome provides a niche for the growth and 
proliferation of C. difficile. The phenomenon whereby the normal gut microbiota in healthy 
individuals prevents colonisation by pathogens was first named colonisation resistance by 
van De Waaij et al. in 1971, after observations that healthy mice were not colonised by 
repeated challenges of Enterobacteriacea, but once pre-treated with antibiotics, they 
became colonised (van de Waaij et al, 1971). Additionally, once the antibiotic challenge had 
been removed, colonisation resistance was gradually re-established. Further experiments 
highlighted that anaerobic bacteria, rather than aerobic bacteria, were fundamental to 
colonisation resistance (van de Waaij et al, 1971). Colonisation resistance provides 
protection against overgrowth of endogenous potentially pathogenic organisms (carried in 
small number by many individuals) and exogenous pathogens when ingested (Vollaard and 
Clasener, 1994). The presence of the right balance of microorganisms is further 
strengthened by the importance of other physiological factors such as an intact mucosal 
membrane, gastric acid pH and gut motility (van de Waaij et al, 1983). 
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1.4 Recurrence 
C. difficile infection can recur in ~20% of patients, despite appropriate antimicrobial 
therapy (Cornely et al, 2012; Kelly and LaMont, 2008). In addition, patients who have 
suffered one recurrent episode are at increased risk of developing a second recurrence 
(40%), and then patients with a second recurrence are at even greater risk of developing a 
third recurrence (60%) (figure 1.1)  (McFarland et al, 1994; McFarland et al, 2002). This 
repeated cycle of infection leaves many patients with heightened anxiety about additional 
infections long after resolution of symptoms (Madeo and Boyack, 2010; Guillemin et al,  
2014) and with a higher risk of mortality compared with CDI patients without recurrence 
(36% vs 26%, p <0.001) (Olsen et al, 2015). 
 
 
Figure 1.1 The increasing risk of recurrence of infection for patients with CDI 
 
Recurrence is likely linked to a still depleted gut microbiome; indeed, antibiotics used to 
treat the initial primary case of CDI can also further deplete the natural gut microbiome 
(Kelly and LaMont, 2008). The majority of secondary infections usually occur within 4-8 
weeks, but in one recent study 29% of recurrent cases were seen at up to 12 weeks after 
resolution of the initial infection (Wilcox et al, 2017). The depleted gut microbiome, with 
reduced colonisation resistance, leaves a niche that can be further exploited either by the 
strain responsible for the first infection or by a second strain (Wilcox et al, 1998). The 
recurrence rates in patients treated for their primary CDI with either metronidazole or 
vancomycin appear similar (20.2% vs 18.4% respectively) (Kelly and LaMont, 2008); 
however, patients treated with fidaxomicin have an ~50% reduced risk of recurrence 
compared with vancomycin, presumably due to the narrower spectrum of action of this 
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agent, and its more gut-sparing action (Cornely et al, 2012, Louie et al, 2011). Antibiotic 
treatments will be discussed in further detail later in section 1.7. 
It has been postulated that in addition to lack of colonisation resistance, due to damage to 
the gut microbiome, the host immune response also has a part to play in the risk of 
recurrence. Patients with low levels of either toxin A immunoglobulin gamma (IgG) or 
toxin B IgG were significantly more likely to have recurrent CDI than patients with high 
levels of these immunoglobulins (Kyne et al, 2001a; Aronsson et al, 1985). A recently 
developed human monoclonal antibody against C. difficile toxin B (bezlotoxumab) 
significantly reduced the rate of recurrence, by ~38%, when used as an adjunctive therapy 
alongside normal CDI treatment antibiotics, compared with those patients who received 
antibiotics alone (Wilcox et al, 2017), highlighting the role of the immune system in 
preventing recurrent infections. Interestingly, subjects given a human monoclonal antibody 
against C. difficile toxin A (plus antibiotic) did not have a lower risk of recurrent CDI 
compared with those receiving antibiotics alone. This suggests, but does not prove, that 
toxin B has more importance in human infection than toxin A. 
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1.5 Asymptomatic carriage 
The carriage of C. difficile in the absence of clinical symptoms (diarrhoea) is defined as 
asymptomatic carriage, although a consensus on the exact definition of this condition is 
lacking (Furuya-Kanamori et al, 2015; Crobach et al, 2018). One study indicated that 
asymptomatic carriage has a protective effect, with less risk of these individuals going on to 
develop CDI (Shim et al, 1998), and indeed IgG levels have been shown to be higher in 
asymptomatically colonised individuals (Kyne et al, 2001b), supporting this ‘protective’ 
effect. However, a study following asymptomatically colonised patients in the geriatric 
setting  found that 16.3% of them went on to develop CDI (Nissle et al, 2016). In addition, 
of the eight cases of CDI in the study, seven (87.5%) of them had been asymptomatically 
colonised on admission to the facility (Nissle et al, 2016). This was a small study however, 
and the authors highlight that they did not manage to reach the sample size required to 
have adequate power within the study, mostly because of the difficulty in getting repeat 
specimens from the participants.  In addition, the initial proportion of individuals that were 
positive for C. difficile on admission was high (16.4%), compared with other reported 
ranges of 0.6-15% in the elderly (Furuya-Kanamori et al, 2015), which means the results 
from this study may not be generalisable.  Another, similarly small study, found that 37% of 
the asymptomatically colonised hospitalised individuals went on to develop CDI (Mcfarland 
et al, 1989). It is important however, in studies of this kind, that there is a clear 
differentiation between patients carrying toxigenic and non-toxigenic strains of C. difficile, 
as toxigenic strains appear to increase CDI risk, whereas colonisation by non-toxigenic 
strains is protective (Blixt et al, 2017; Gerding et al, 2018). The proportion of patients who 
developed CDI if they carried a toxigenic strain was three-times that of patients who 
carried a non-toxigenic strain in a recent cohort study (Blixt et al, 2017).  
The proportion of asymptomatic carriers from different settings varies, for example 
carriage in healthy individuals ranges from 0-15%, while carriage in elderly patients in 
long-term care facilities ranges from 0-51% (Furuya-Kanamori et al, 2015). In the UK only 
0.5% of healthy individuals in the community were found to carry C. difficile. Importantly, 
rates may be lower than reported, depending on how samples are screened; for example, 
PCR for toxigenic C. difficile will ‘miss’ any non-toxigenic strains (Furuya-Kanamori et al, 
2015), although non-toxigenic strains will not go on to cause CDI. The duration that 
individuals remain colonised appears variable, with participants in one study remaining 
positive for C. difficile for a median of 8.5 days (Samore et al, 1994); however, these 
patients were only followed until discharge from hospital. Further, extended studies have 
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found 32% of individuals remained positive for C. difficile for 5-7 months (Kato et al, 2001), 
although these were healthy individuals, not previously hospitalised patients. 
Treatment to eradicate colonisation is not recommended (SHEA/IDSA guidelines) 
(McDonald et al, 2018), as there has been varied success with attempts to use vancomycin 
and metronidazole to successfully eradicate C. difficile (Johnson et al, 1992).  While 
vancomycin did appear to initially eradicate C. difficile, this effect was temporary, and 
carriage rates were actually higher in this group two months after treatment.  There was no 
difference in faecal excretion of C. difficile between patients treated with metronidazole 
and those given a placebo. Given that antibiotic disruption of the gut microbiome is a 
predisposing factor for CDI, theoretically ‘treating’ colonisation, could actually drive 
development of CDI. In addition, faecal excretion of C. difficile is often transient (Johnson et 
al, 1992). Potentially, therefore, knowledge of colonisation status may be more useful in 
terms of antibiotic stewardship and infection prevention, as colonised individuals shed 
spores into the environment for up to six months (Riggs et al, 2007), and onto their skin, 
although at a lower rate than CDI patients (Guerrero et al, 2013). Whole genome 
sequencing of isolates from asymptomatic carriers and CDI cases has shown that 
transmission from carriers may be a rare event, but that carriers are a potential source of 
transmission (Eyre et al, 2013c). Indeed, the authors highlight that the rate of transmission 
is so low that in order to obtain sufficient power, ~3000 individuals would need to be 
included in a study to determine true transmission rates.  
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1.6 Risk factors 
C. difficile infection is not an infection that occurs in otherwise healthy individuals. As 
discussed in section 1.3 of this introduction, perturbation of the gut microbiota provides a 
niche for the growth and proliferation of the organism. This perturbation may be caused by 
many factors, and as such, become risks for developing CDI (Barlett and Gerding, 2008). 
Risk factors for development of CDI include: advancing age, comorbidities, long hospital 
stay and exposure to antibiotics (Bartlett and Gerding, 2008).  
 
1.6.1 Antibiotics 
Almost all antibiotic classes have been associated with CDI, although third-generation 
cephalosporins and clindamycin are historically most often implicated in inducing CDI 
(Bartlett and Gerding, 2008). With the increasing use of alternative antibiotics however, 
several other agents/classes have also been implicated as risk factors for CDI, such as 
fluoroquinolones (Bartlett and Gerding, 2008). The propensity for a specific antibiotic to 
result in CDI could be related to the effect of that drug on the host gut microbiome (Pultz 
and Donskey, 2005), as there appears to be increased risk from those drugs that both 
disrupt the gut microbiome and have no activity against C. difficile. For example, C. difficile 
is generally resistant to cephalosporins, and C. difficile PCR-ribotype 027 is resistant to 
fluoroquinolones (Dingle et al, 2017). Indeed, fluoroquinolone resistance may have been a 
key driver of the increased prevalence of PCR-ribotype 027 prior to 2007 (Dingle et al, 
2017.) 
In a mouse model, antibiotics appear to form three distinct groups, each with decreasing 
propensity to induce CDI (Pultz and Donskey, 2005).  As described above, this effect is 
related to both the activity of the drug against normal gut microbiome and against 
C. difficile itself, with those agents with the narrowest spectrum of action having the least 
propensity to induce infection in the mouse model. There are however, documented cases 
of CDI where the only antibiotic exposure was a single dose, given prophylactically before 
surgery (Privitera et al, 1991), and, indeed, surgery itself has been highlighted as a risk 
factor for CDI, presumably due to the antibiotic exposure (Abou Chakra et al, 2014). The 
bacterial phyla and families affected by different antibiotic classes have been investigated 
using 16S rRNA amplification and pyrosequencing (Vincent et al, 2013). In univariate 
analyses, the phylum Bacteroidetes and the families Bacteriodaceae and Clostridiales 
Incertae Sedis XI were significantly reduced in faecal samples from patients with CDI, 
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compared with controls. In addition, there was a bloom of Enterococcaceae. After multi-
variate analysis, prior use of cephalosporins or fluoroquinolones by the patients and a 
decrease in Clostridiales Incertae Sedis XI within the patient’s faecal samples were 
significantly associated with CDI. It should be noted however, that the faecal samples from 
patients classified as CDI cases, were identified by a mixture of diagnostic methods, 
including toxigenic culture, which only identified the presence of a toxigenic strain. It is 
possible therefore, that the some of the people in the case group were only colonised. 
These factors are still relevant for the acquisition of C. difficile itself however, regardless of 
whether it causes disease or not. 
A systematic review and meta-analysis of risk factors for CDI in 1998 found that exposure 
to antibiotics was significantly associated with both CDI and carriage of C. difficile (Bignardi, 
1998). In addition, antibiotics were ranked, by meta-analysis, with aztreonam having the 
highest odds ratio (OR) of 61.7, although the 95% confidence intervals (CI) were very wide 
at 8.6-444.5. Of interest, cefotaxime was second highest in the ranking with an OR of 36.2 
(95% CI 19-68.9) and fluoroquinolones were about half way down the rankings with an OR 
of 8 (95% CI 4.5-14.3). As this meta-analysis was conducted in 1998 however, many of the 
studies demonstrating risk associated with fluoroquinolones had not been published, and 
so the risk associated with fluoroquinolones in this meta-analysis may be underestimated.  
Fluoroquinolones potentially cause relatively little disruption of the gut microbiota as they 
have little activity against anaerobes (BNF, 2019); however, this class of antibiotics have 
been shown to be a risk factor for the development of CDI. This may partially be related to 
the emergence of a fluoroquinolone-resistant strain of C. difficile, PCR ribotype 027 (Pepin 
et al, 2005). In one study in 2010, 55% of CDI cases had prior exposure to fluoroquinolones 
alone (Howell et al, 2010). In addition, a recent UK study has shown that country-wide 
antibiotic stewardship, restricting the use of fluoroquinolones, correlates with the decrease 
in cases across the UK since 2007 (Dingle et al, 2017), highlighting the impact of this 
antibiotic on driving C. difficile infection. Indeed, antimicrobial stewardship, not just of 
fluoroquinolones, offers the opportunity to modify the risk of CDI in patients. 
 
1.6.2 Polypharmacy 
If risk of CDI is related to disruption of the normal host gut microbiota, it follows that 
increased duration of therapy and multiple concomitant antibiotics would increase the CDI 
risk, as there would theoretically be even more disruption of the gut microbiota. Indeed, a 
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case/control study demonstrated that CDI cases were significantly more likely to have 
received multiple concomitant antibiotics (Gerding et al, 1986) than controls (80% vs 56% 
respectively, p <0.002). A cohort study in 2011 demonstrated that the risk of CDI increased 
from a hazard ration (HR) of 2.5 for two antibiotics up to 9.6 for those patients who 
received five antibiotics, when compared to patients who received one antibiotic (Stevens 
et al, 2011).  In addition, in a recent multicentre case/control study the risk of CDI 
increased by 1.2 (95% CI 1.1-1.3) for each additional antibiotic the patient received (Davies 
et al, 2016c). In the same study, antibiotics were more likely to have been prescribed for 
treating an infection (acute use) than for prophylaxis. This may be because certain 
antibiotics are unlikely to be used for prophylaxis, or that prophylactic drugs are given for a 
shorter duration. Similarly, in an earlier study, there was a significant difference between 
cases and controls that received antibiotics to treat an infection (59% vs 31% respectively, 
p <0.0001) (Gerding et al, 1986). In addition, significantly more control individuals than 
cases had received short-courses of prophylactic antibiotics (38% vs 20% respectively, 
p <0.01).  
Although the impact of duration of antibiotic therapy is not clear from the literature, due to 
the differing study methodologies used in published studies and the different prescribing 
habits/policies in study centres, one multivariate analysis did find a correlation between 
longer duration of therapy and increased risk of CDI (Pepin et al, 2005a). This was however, 
a retrospective analysis conducted at the height of a PCR ribotype 027 outbreak, so the 
results may not be generalisable. Another retrospective single centre study found a dose 
dependant effect, with an unadjusted HR for risk of CDI of 1.5 for four-seven days of 
antibiotic compared with <four days, increasing to a HR of 3.4 for 8-18 days and 9.8 for >18 
days of antibiotic (Stevens et al, 2011).  There was also an increase in risk of CDI with 
increasing daily doses of antibiotic (Stevens et al, 2011). The risk from antibiotics may not 
only be related to the effects of the agent on the gut microbiota. Of note, some antibiotics 
appear to stimulate increased toxin production over other antibiotics in an in vitro model of 
the human gut (Saxton et al, 2009). 
 
1.6.3 Exposure to healthcare facilities 
CDI is most often diagnosed in patients with previous exposure to a healthcare facility, 
although there has been a rise in the number of cases in otherwise healthy individuals from 
the community setting (Chitnis et al, 2013). Multivariate analyses demonstrate that prior 
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hospitalisation is a risk factor for CDI, even after adjusting for other confounding factors 
such as age (Melzer et al, 2019; Davies et al, 2016c).  Environmental contamination with 
spores of C. difficile has been shown to be higher in healthcare facilities than other 
environments (McFarland et al, 1989) and the spore acquisition rate in patients increases 
with increased length of stay in hospital facilities , from 13% during a two-week stay to 50% 
in stays >four weeks (Raveh et al, 2006). Indeed, the colonisation rate in hospitalised 
patients is higher than in the general population (10-40% vs 2-3%) (Bartlett, 1994; Sundram 
et al, 2009).  It therefore follows that exposure to environments with higher bioload of 
spores would lead to a higher risk of developing CDI. Duration of hospital stay was 
significantly associated with CDI, but not carriage, in a qualitative review of 49 studies 
(Bignardi, 1998).   Interestingly, the PCR ribotypes circulating in the hospital and 
community are largely similar, although certain PCR ribotypes are associated with either 
the community (002, 020 and 056) or hospital setting (027) (Fawley et al, 2016).  In 
addition, although antibiotics are a risk factor for community associated CDI cases 
(Deshpande et al, 2013) there have been reports of these community-onset cases occurring 
without previous exposure to antibiotics (Bauer et al, 2008). 
 
1.6.4 Increased Age 
The number of cases of CDI in the elderly is disproportionately higher than for younger age 
groups, with 93% of deaths due to CDI in the USA in 2008 (McDonald et al, 2006; Miniño et 
al, 2011) and 84% in 2011 (Lessa et al, 2015) occurring in those greater than 65 years old. 
This may be due to a number of factors including waning immunity and the increased 
frequency of hospital visits likely to occur in this population (Di Bella et al, 2013). In 
addition, increasing Charleson comorbidity score, demonstrating frailty of patients due to 
the number of concomitant comorbidities, is significantly associated with risk of CDI in 
univariate analysis, but not on multivariate analysis after adjusting for age (Davies et al, 
2016c). This may be due to the likelihood that aging patents are the most likely to have 
several comorbidities, and that several of these comorbidities, such as UTI, COPD and 
diabetes may increase the likelihood of the patients being prescribed antibiotic therapy 
(Abou Chakra et al, 2014).  The influence of age on treatment outcomes in CDI can be 
mathematically modelled and has been shown to predict lower clinical cure (17%), greater 
recurrence (17%) and lower sustained clinical response (13%) for each increased decade of 
life (Louie et al, 2013). 
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1.6.5 Proton Pump Inhibitors 
There is conflicting information regarding the risk for CDI that comes from taking proton 
pump inhibitors (PPIs) (Faleck et al, 2016; Dial et al, 2004; Vesteinsdottir et al, 2012), and 
one review of PPIs in 2014 highlights that there is insufficient evidence to either rule-in or 
rule-out PPIs as a risk factor for CDI (Biswal, 2014). The difference in risk reported between 
studies may be due to ascertainment bias; i.e. the choice of the groups in which to study 
this phenomenon (Novack et al, 2014).  Indeed, a recent study comparing risk factors 
between a single-centre cohort and a multi-centre cohort found that PPIs were associated 
with an increased risk in the single-centre cohort (OR 1.8), but not in the multi-centre 
cohort (Davies et al, 2016c). Spores of C. difficile are resistant to gastric acid (Wilson et al, 
1985), therefore, theoretically, increasing gastric pH by using PPIs should have little effect 
on acquisition of C. difficile. It is postulated that PPIs allow microbial colonisation of the 
upper GI tract (Bavishi and Dupont, 2011), however, whether this holds true for C. difficile, 
which usually proliferates in the colon, has yet to be proved. One in vitro study 
demonstrated increased expression of toxin A on exposure to alkaline environments and 
PPIs (Stewart and Hegarty, 2013). Again, however, it is unclear if PPIs would have this effect 
in vivo, as the pH of the colon is already more alkaline. 
 
1.6.6 Risk factors for complicated CDI and recurrence 
In addition to risk factors for a primary case of CDI, there are factors associated with 
increased risk for either complicated infection or recurrence. A systematic review of 24 
studies found; increased age, continued use of antibiotics (following diagnosis with CDI), 
PPIs and the strain type of C. difficile were most frequently associated with recurrence 
(About Chakra et al, 2014). Unfortunately, as the authors did not perform a meta-analysis, 
due to the heterogeneity of the study methodologies, the level of significance of these 
factors cannot be assigned. Indeed, even for the factor >65 years old, the results are 
reported as a combination of HRs (range 1.75-1.92) and ORs (range 1.32-10.42), making 
interpretation of the data difficult. The same authors assessed 18 studies for risk factors for 
complicated CDI, and 30 studies for risk of mortality from CDI; increased age, raised white 
cell count, renal failure (as measured by raised serum creatinine) and the presence of 
comorbidities were frequently associated with complicated CDI cases, while mortality was 
associated with all of these plus hypoalbuminaemia and infection with PCR ribotype 027. 
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Current diagnostic guidelines define severe CDI using white cell counts >15cellx109/L, raised 
serum creatinine (>1.5mg/dL IDSA/SHEA, >133µM or ≥1.5 times baseline for ESCMID) and 
serum albumin <30g/dL (ESCMID only) (McDonald et al, 2018; Crobach et al, 2016). 
 
1.6.7 Prediction of risk 
There have been attempts to combine risk factors into prediction models for recurrent CDI 
with varied success. One recent study used data gathered from a derivation cohort of 7,538 
patients to define the risk factors for the prediction model, before testing in a validation 
cohort of 15,077 patients (Reveles et al, 2018).  Following logistic regression, risks for 
recurrence were identified as prior antibiotic therapy with 3rd- or 4th- generation 
cephalosporins, prior PPI use, prior use of anti-diarrhoea agents, CDI defined as non-severe 
and CDI with community onset. Each risk was assigned a score, which allowed the 
prediction model to classify risk as low, medium or high. In the validation set, those 
classified as low risk had a recurrence rate of 8.9%, those with medium risk had a 
recurrence rate of 20.2% and those with high risk had a recurrence rate of 35.0%. While the 
model appeared successful in the validation cohort, it should be noted that some of the 
factors identified as risks in this study have not been identified previously, such as anti-
diarrhoeal agents, highlighting again the influence of the cohort that is studied and possible 
ascertainment bias.  In addition, this study included cases that were coded as CDI within 
the hospital database. This would likely therefore, include cases diagnosed by NAAT for 
toxin gene; potentially diluting the pool of ‘true’ cases with some patients who simply had 
carriage of C. difficile (Polage et al, 2015).  
In contrast, another group that used the same study design of a derivation (n = 9,386) and 
validation cohort (n = 1,865) were unable to produce a successful prediction model 
(Escobar et al, 2017). Although the sample size of the validation cohort was smaller than 
the first study, the derivation cohort was larger, suggesting that it was unlikely to be 
underpowered. Of note, the first study appears to have included fewer potential prediction 
factors than the second study, and combined several factors into a definition of ‘severe CDI’ 
where only at least one of the factors had to be positive, rather than using each of those 
variables as an independent predictor.  It remains to be seen if the first model still performs 
as well when used on a dataset derived from different facilities or even from a different 
country. 
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1.6.8 Asymptomatic carriage 
Risk factors for asymptomatic carriage are similar to risk factors for CDI and include 
previous hospitalisation, history of CDI, use of PPIs, and presence of anti-toxin B IgG (Loo et 
al, 2011; Kong et al, 2015). Interestingly however, asymptomatic carriers were less likely to 
have been prescribed an antibiotic in the previous eight weeks than CDI patients (OR 1.04 
vs 5.25).  Colonisation may therefore not depend on disruption to the gut microbiota, in 
the same way that CDI does (Furuya-Kanamori et al, 2015). Further research into risk 
factors for asymptomatic colonisation is required, especially in settings outside of the 
hospital.   
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1.7 Treatment 
Guidelines are available for treatment options in C. difficile infection from both the 
European Society for Clinical Microbiology and Infectious Disease (ESCMID) and jointly from 
the Infectious Disease Society of America (IDSA) and the Society for Healthcare 
Epidemiology of America (SHEA) (Debast et al, 2014, McDonald et al, 2018). Whilst the 
IDSA/SHEA guidelines are up-to-date, the European guidelines are some six years old, and 
do not reflect some of the newer trials of recently developed antibiotics, or the latest 
information regarding older therapies. 
Both sets of guidelines recommend that any predisposing antibiotic is stopped, although 
the evidence for this recommendation is unclear from the literature (Debast et al, 2014, 
McDonald et al, 2018). In addition, empirical treatment is recommended on suspicion of 
CDI, while awaiting laboratory test results, in the IDSA/SHEA guidelines (McDonald et al, 
2018). It should be noted however, that diagnostic samples should be taken before staring 
any empirical therapy, as use of concomitant C. difficile targeting antibiotics can affect 
C. difficile recovery from faecal samples (Sunkesula et al, 2013). 
 
1.7.1 Metronidazole 
Metronidazole is a nitroimidazole antibiotic with activity against nucleic acid synthesis by 
disrupting the DNA of microbial cells (Freeman et al, 1997). The amount of drug excreted 
via the bowel is quite low, with the majority of excretion via bile and urine (Bartlett, 2010), 
which is not ideal for a treatment drug for CDI, however it is thought that metronidazole 
can cross into the bowel through the ‘leaky’ cells of the colon that have been affected by C. 
difficile toxin (Sullivan et al, 2001).  Despite not being an ideal treatment option however, 
lack of alternative antibiotics with activity against CDI led to the promotion of 
metronidazole as a treatment of choice (Freeman et al, 1997). 
Mounting evidence demonstrates the inferiority of metronidazole treatment compared 
with other CDI antibiotics. The time to resolution of diarrhoea for patients on 
metronidazole is significantly longer by ~1.5 days, than it is for those on vancomycin 
(Wilcox and Howe, 1995). In addition, there are reports of treatment failure on 
metronidazole; 38% in one study (Fernandez et al, 2004) and 22% in another (Musher et al, 
2005). Of note, in the first study, patients with serum albumin level of <2.5g/L were more 
likely to fail metronidazole therapy (OR 11.7, 95% CI 4.0-31.6), suggesting that these were 
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patients with more severe infection.  Data from a trial of another potential C. difficile agent, 
tolevamer, allowed the direct comparison of metronidazole and vancomycin, as both drugs 
were used as a comparator in the study. Clinical success, defined as resolution of diarrhoea 
and abdominal symptoms, was significantly higher in the vancomycin arm, compared with 
metronidazole (81.1 vs 72.7%, p = 0.02) (Johnson et al, 2014). In addition, when only severe 
cases were compared there was a higher proportion of patients that had clinical resolution 
in the vancomycin arm, compared with metronidazole, although this was not significant at 
the p = 0.05 level (78.5% vs 66.3% p = 0.059). The 2014 ESCMID guidelines still recommend 
oral metronidazole 500mg three times daily for treatment of non-severe CDI, while 2018 
IDSA/SHEA guidelines only recommend using metronidazole when access to alternative 
treatments is restricted, and then only for non-severe cases (Debast et al, 2014, McDonald 
et al, 2018). In a recent network meta-analysis, metronidazole was only ranked 11 out of 
the 13 drugs reviewed (Beinortas et al, 2018), giving further weight to the argument for not 
using metronidazole.  Others argue that there is still a role for metronidazole in the 
treatment of CDI, but that patients should be carefully selected, as younger patients (<65 
years old) with mild disease were significantly more likely to have clinical resolution on 
metronidazole treatment than those patients who were older than 65 with mild disease 
(OR 1.63, 95%CI 1.29-2.06) (Appaneal et al, 2018). 
 
1.7.2 Vancomycin 
Vancomycin is a glycopeptide antibiotic with bactericidal activity against both aerobic and 
anaerobic Gram-positive bacteria.  The drug binds to the cell wall, blocking polymerisation 
of glycopeptides (Hammes and Neuhaus, 1974). This action inhibits synthesis of the cell 
wall and damages the cytoplasmic membrane (Hammes and Neuhaus, 1974). Vancomycin 
is usually used intravenously to treat infections, however, oral administration is 
recommended for treatment of C. difficile, as there is very poor absorption via the gut, 
meaning that high levels of the drug can be achieved in the large intestine to treat the 
infection (Hammes and Neuhaus, 1974). Oral administration of vancomycin may select for 
vancomycin-resistant enterococci (Edlund et al, 1997), which meant at one point, 
metronidazole was used in preference to vancomycin for treatment of CDI (Pelaez et al, 
2002). It should be noted however, that oral metronidazole treatment for CDI has also 
been associated with overgrowth of vancomycin resistant enterococci (Al-Nassir et al, 
2008).  
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Current treatment guidelines state that vancomycin (or fidaxomicin in the US) should be 
used as the first treatment option for all initial episodes of CDI (2018 IDSA/SHEA) or for all 
initial cases of severe CDI (2014 ESCMID) at a dosage of 125mg four times daily (Debast et 
al, 2014, McDonald et al, 2018).  This difference reflects the age of the ESCMID guidelines, 
as recent evidence does not support the use of metronidazole rather than vancomycin for 
mild infections, as described in the section above.  Vancomycin is also the recommended 
treatment option for fulminant or severe CDI in the IDSA/SHEA guidelines, but at a dosage 
of 500mg four times daily, approximately four times the dose recommend by ESCMID, as 
the latter states that the current evidence for increased dosage of vancomycin is not 
sufficient, if the patient does not have ileus. 
There are several dosing options for treating recurrent infections with vancomycin, 
including tapered and pulsed regimens (Debast et al, 2014, McDonald et al, 2018). Tapered 
vancomycin regimens decrease the total dose each day, gradually weaning the patient off 
the antibiotic (Debast et al, 2014, McDonald et al, 2018), and theoretically allowing the 
host microbiome to begin re-establishing, while still supressing the growth of any 
remaining C. difficile. One study found that vancomycin tapered regimens were significantly 
more successful when the final day contained three doses (81% cured), compared with one 
(61% cured, p =0.03), and when patients had only had ≤two recurrences of CDI (78% 
cured), compared with ≥three recurrences (62%, p = 0.13), although this was not a 
significant finding (Sirbu et al, 2017). Presumably, the higher success rate in patients with 
≤two recurrences of CDI reflects the more damaged microbiome of those patients with 
≥three recurrences, due to repeated treatments. Careful selection of patients suitable for 
tapered vancomycin treatment therefore needs to be considered. A randomised controlled 
trial comparing vancomycin taper with faecal microbiota transplantation (FMT), see section 
1.9.3, was ended early, as futility analysis demonstrated lack of efficacy in both arms; 
vancomycin cure rate 58.3%, FMT cure rate 43.8% (Hota et al, 2017), and the authors cited 
patient selection as a factor in the failure of the study. A systematic review of different 
extended regimens of vancomycin for CDI found that taper-pulse regimens had a higher 
clinical success incidence than pulsed regimens alone (58-100% vs 26-81% respectively) 
(Murphy et al, 2018). It should be noted however, that there is a lack of good quality 
studies of these alternative dosing regimens, as the systematic review only included five 
studies.  
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Recent use of vancomycin as a longer-term prophylactic agent has shown promise, with a 
success rate of 95% over 200 patients-months of follow up (Zhang et al, 2019). This was 
however, a retrospective study, not a study designed to determine the clinical success of 
this regimen. In addition, although there were no reported side effects, there was no 
attempt to determine the level of vancomycin resistant enterococci carried by any of the 
treated individuals. Of note, repeated oral administration of vancomycin can lead to 
elevated serum levels (Edlund et al, 1997), despite poor uptake by the gut, so toxicity in 
long-term oral use of vancomycin should not be ruled out. 
 
1.7.3 Fidaxomicin 
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase and therefore 
transcription (Lin et al, 2018). The drug has a narrower spectrum of action than 
vancomycin, and causes less damage to the host gut microbiota, specifically Bacteroides 
spp., and with variable effects on communities of bifidobacteria (Chilton et al, 2014b, 
Chilton et al, JAC 2015). In addition, recurrence of in vitro modelled CDI has been seen with 
vancomycin but not with fidaxomicin (Chilton et al, 2014b). Indeed, in a randomised 
controlled Phase III trial,  in patients treated for a first recurrence of CDI, secondary 
recurrence within 28 days was reduced from 35.5% in the vancomycin arm to 19.7% in the 
fidaxomicin arm, a reduction of ~50%  (p = 0.45) (Cornely et al, 2012, ). The impact of 
fidaxomicin on secondary recurrence within 14 days was even more stark, with 27% of 
patients experiencing recurrence in the vancomycin arm compared with 8% in the 
fidaxomicin arm (p = 0.003). In a second Phase III clinical trial there was also a reduction in 
recurrence of ~50% in the fidaxomicin arm compared to patients treated with vancomycin 
(Louie et al, 2011). Fidaxomicin was only recommended for treatment of recurrent cases of 
CDI in the 2014 ESCMID guidelines, as the initial randomised controlled trials were only 
powered to determine non-inferiority of fidaxomicin compared with vancomycin (Cornely 
et al, 2012, Louie et al, 2011), and there was no evidence at this time regarding the use of 
fidaxomicin in severe infections (Debast et al, 2014). The 2018 IDSA/SHEA guidelines 
however, recommend fidaxomicin as an alternative treatment option to vancomycin, for 
first episodes of CDI (McDonald et al, 2018). 
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The high up-front-cost of fidaxomicin, compared with vancomycin, may influence choice of 
drug for initial episodes. However, economic analyses show that it is as cost-effective to 
use fidaxomicin for the initial case of CDI rather than vancomycin, due to the decreased 
downstream costs associated with the higher recurrence rate with vancomycin (Watt et al, 
2016). Interestingly, sub-group analyses showed that fidaxomicin was cost-saving for 
cancer patients compared with vancomycin. Although this study was conducted in 
Germany and direct healthcare costs will differ across countries, there will be similarities in 
relative patterns of costs. For treating recurrent CDI cases, fidaxomicin is the second most 
cost-effective option, after FMT (Lapointe-Shaw et al, 2016). 
A recent systematic review conducted a network meta-analysis, which allowed the authors 
not only to compare antibiotic treatments for CDI, but also to rank them (Beinortas et al, 
2018).  The comparison included 24 clinical trials (three unpublished at the time of the 
analysis) with 13 different antibiotic treatment options; vancomycin, fidaxomicin, 
metronidazole, tecioplanin, fucidic acid, bacitracin, ridinilazole, LFF571, cadazolid, 
nitazoxanide, surotomycin, tolevamer, rifaximin.  They were unable to include any of the 
studies on faecal microbiota transplant (FMT), probiotics or immunotherapies, as they did 
not meet the inclusion criteria. For sustained clinical cure, teicoplanin (OR 0.37, 95% CI 
0.14-0.94) and fidaxomicin (0.67, 0.55-0.82) performed significantly better than 
vancomycin, and vancomycin performed significantly better than metronidazole (0.73, 
0.56-0.95). The evidence for the use of teicoplanin is limited, however, with only two small 
trials of ~ 50 patients each, both of which date from before 1996. Importantly however, 
vancomycin was superior to all agents for primary symptomatic cure, but vancomycin and 
metronidazole were only ranked ninth and 11th for prevention of recurrence. Patients on 
fidaxomicin had significantly fewer episodes of recurrence than patients on vancomycin or 
metronidazole; thereby having greater sustained clinical cure. This analysis gives further 
weight to the argument of using fidaxomicin as a first-line treatment for CDI. Indeed, as 
discussed above, it may also be the most cost-effective option, due to the decreased risk of 
recurrence and therefore decreased patient time spent in hospital (Watt et al, 2016; 
Burton et al, 2017). 
In addition to its action in sparing the gut microbiota, fidaxomicin appears to persist on the 
spores of C. difficile and inhibits the outgrowth of the vegetative cell from the spore, then 
by  turn, toxin production by the cell in vitro (Chilton et al, 2016). The fact that active 
fidaxomicin can be detected for extended periods after dosing has been completed was 
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first seen in the in vitro human gut model, where fidaxomicin was detectable in the model 
for 21 days after installation had finished, compared with four days for vancomycin (Chilton 
et al, 2014b; Chilton et al, 2015). In addition, detection of toxin from sequential patient 
faecal samples in an in vivo study, demonstrated that while both fidaxomicin and 
vancomycin reduced toxin (A and B) detection at the mid-point (3-5 days) of therapy, only 
samples from fidaxomicin-treated patients maintained low toxin A levels up to the end of 
follow up (19-38 days after treatment initiation) (Thabit et al, 2016). Interestingly, this drop 
in the level of toxin A was even seen in patients treated with fidaxomicin who developed 
recurrence.  There was also a significant association between high toxin levels (both A and 
B) and presence of vegetative cells (p = 0.003 for toxin A and 0.007 toxin B respectively) 
and spores (p <0.001 for both).  This evidence for reduced numbers of spores in faecal 
samples, and the direct effect of fidaxomicin on spore outgrowth discussed above, means 
that it is possible, therefore, that fidaxomicin could reduce onward transmission, as well as 
treating the infection. This hypothesis is supported by a small study in vivo which 
demonstrated reduced environmental contamination in the rooms of patients treated with 
fidaxomicin compared with those treated with vancomycin; 36.8% of environmental 
samples showed contamination vs 57.6% respectively, p = 0.02. (Biswas et al, 2015).  A 
larger, multicentre study substantiates the results of the first, small study but has yet to be 
published (Davies et al, 2019a). 
 Similar to the different dosing regimens for vancomycin, extended fidaxomicin dosing has 
been investigated, as theoretically this would be less detrimental to the gut microbiota. 
Pulsed-tapered and tapered-pulsed dosing allowed recovery of bifidobacteria within an 
in vitro model, whilst still clearing C. difficile infection, and with no signs of recurrence 
during the length of the experiment (Chilton et al, 2015). These data  have been replicated 
in a randomised controlled trial comparing pulsed fidaxomicin over a longer time period 
than standard therapy (200mg twice daily for five days, followed by 200mg once daily on 
alternate days from day 7 to 25) with standard vancomycin therapy of 125mg four times a 
day for ten days (Guery et al, 2018). Sustained clinical cure, defined as initial resolution of 
symptoms and no recurrence, was assessed at three time points; days 40 (30 days post end 
of vancomycin treatment), 55 (30 days post end of fidaxomicin treatment) and 90. There 
was no difference in initial resolution of systems, however the proportion of patients on 
extended-pulsed fidaxomicin with sustained clinical cure at day 30 (after treatment) was 
significantly higher than for those patients on standard vancomycin (70% vs 59% 
respectively, p = 0.03). The difference in sustained clinical cure remained significant at day 
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90, with a 14% difference between fidaxomicin- and vancomycin-treated patients (p = 
0.007). Importantly, the authors also looked at the bacterial diversity in the faecal samples 
from the two different patient groups and showed that bacterial diversity increased in the 
fidaxomicin group over the study period to a greater extent than those in the vancomycin 
arm. Additional data are required to compare extended-pulsed vancomycin regimens with 
the extended fidaxomicin regimen studied here, especially the impact of vancomycin on 
the microbiota over that time.  Without a randomised controlled trial comparing the two 
extended-pulsed regimens it is difficult to know the best choice for patients and, indeed, 
decisions should be taken on a patient-by-patient basis.  
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1.8 Novel antimicrobial treatments 
1.8.1 Tigecycline 
The antibiotic tigecycline, a broad-spectrum agent, has been suggested as a possible 
treatment for CDI, as it has shown activity against C. difficile in vitro, with very low MICs of 
0.06mg/L (Baines et al, 2006). As a broad-spectrum agent tigecycline does affect the gut 
microbiome, particularly affecting the bifidobacteria and bacteroides both in vitro and in 
vivo, although to a lesser extent for bacteroides in vivo (Baines et al, 2006, Nord et al, 
2006). However, the drug did not induce proliferation of the organism or production of 
toxins in the in vitro model (Baines et al, 2006). Of note, in both experiments there was an 
increase in some enterobacteria in patients who received tigecyline (Nord et al, 2006), 
most notably Klebsiella spp.  Enterobacterial bloom has been demonstrated with an in vitro 
model, including gene exchange from carbapenemase-resistant Enterobacteriaceae (CPEs) 
(Rooney et al, 2017a; Rooney et al, 2017b). There is the possibility therefore, that using 
tigecycline could leave patients at increased risk of carbapenemase-resistant 
Enterobacteriaceae colonisation. It should be emphasised, however, that tigecycline has no 
regulatory approval for use as CDI treatment option. 
 
1.8.2 Cadazolid 
Cadazolid, a quinoxolidinone antibiotic was another agent that showed promise in in vitro 
studies against C. difficile. Because the drug inhibits bacterial protein synthesis, it decreases 
production of both toxins and spores of C. difficile (Locher et al, 2014), and appeared 
bactericidal in vitro. In addition, Phase I studies demonstrated that active cadazolid was 
found in the faeces of patients at a peak of 5675 times the levels of the MIC90 0.25mg/L, 
and daily levels of > 1651 times higher than the MIC90 (Gehin et al, 2015). Cadazolid 
reduced the total viable count of C. difficile and the titre of cytotoxin within an in vitro gut 
model to below the limit of detection, when used at doses comparable to those found 
within the human gut, and appeared to have minimal impact on the gut microbiota (Chilton 
et al, 2014a). In addition, there was no recurrence of infection observed within the model. 
Cadazolid had similar efficacy to vancomycin for the treatment of C. difficile in a Phase II 
study (Louie et al, 2015) but with greater sustained clinical cure due to a reduction in 
recurrence of 18.2-25.0% for the different dose regimens tested compared with 50% 
recurrence in the vancomycin arm. A recent report however, from two Phase III 
randomised clinical trials of cadazolid compared with vancomycin, only demonstrated non-
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inferiority to vancomycin in one of the two studies (Gerding et al, 2019) and the drug is no 
longer being developed for use in CDI. Importantly however, cadazolid was found not to be 
inferior to vancomycin in either of the trials when the investigators determined if clinical 
cure had occurred, instead of a per protocol analysis. The authors highlighted that the lack 
of a standardised definition of clinical cure makes such per protocol analyses difficult. 
 
1.8.3 Ridinilazole 
Antibiotics that target C. difficile but with a narrow spectrum of action can potentially 
provide greater protection to the gut microbiota. One such agent, ridinilazole is currently in 
Phase III trials (Clinicaltrial.gov, 2019). Ridinilazole has a low MIC90 of 0.25µg/ml against 
C. difficile; lower than fidaxomicin MIC90 0.5µg/ml (Goldstein et al, 2013), but MICs were 
raised for isolates with known multiple resistance to other agents, although this was not 
statistically significant (Freeman et al, 2015). Exposure to sub-MIC levels of ridinilazole 
reduced production of toxin A and B by 91 and 100% respectively when measured using a 
commercial EIA with a limit of detection of 0.31ng/mL (Bassères et al, 2016). In addition, 
sub-MIC levels of the antibiotic appear to inhibit the formation of the cell septum during 
cell division, thereby affecting the ability of the organism to proliferate (Bassères et al, 
2016). 
The narrow spectrum of action of this antibiotic is demonstrated when used within the 
human gut model, as Clostridium spp. were the only commensal bacteria that declined 
after the installation of the drug to the model (Baines et al, 2015). Unlike the cadazolid gut 
model study described above however, the total count of C. difficile did not fall below the 
limit of detection, although counts did fall by ~1.5 log10 cfu/mL over the seven days of 
installation, with a further fall of 2 log10 cfu/mL by the end of the experiment.  In addition, 
the level of toxin, as measured by cell-cytotoxicity assay, dropped below the limit of 
detection ~ 7 days after the end of the instillation of the drug.  Ridinilazole was found to be 
safe and well tolerated in a Phase I study, with a mean concentration of 547 times the 
MIC90 detected within faecal samples of patients on day 5 of receiving 250mg twice daily 
(Vickers et al, 2015). 
In a Phase II randomised controlled trial comparing ridinilazole with vancomycin that was 
powered for non-inferiority, ridinilazole actually demonstrated superiority to vancomycin, 
with 66.7% of patients having sustained clinical cure at 30 days, compared with 42.2% in 
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the vancomycin arm (Vickers et al, 2017), estimated difference 21.1% (90% CI 3.1-39.1, p = 
0.0004). In several sub-group analyses, sustained clinical cure was higher with ridinilazole, 
however due to the low sample size these were not significant. For PCR ribotype 027 
sub-group analyses, sustained clinical cure was higher in the vancomycin group, but again 
this was not significant. In addition, there was a high proportion of participants in this study 
who were <65 years old, which may not truly reflect the population most likely to require 
this treatment option.  The Phase III study has only just begun recruiting, so results from 
this study will not be available for at least another two years. 
 
1.8.4 Surotomycin 
Another antibiotic that was found not to be inferior to vancomycin in a Phase II RCT was 
surotomycin, a daptomycin-derived antibiotic (Lee et al, 2016). The rate of initial clinical 
cure was similar between the two different doses of surotomycin (125mg twice a day and 
250mg twice a day) compared with vancomycin standard therapy with >86% success in all 
three groups. As with other newly developed drugs with a narrower spectrum of action 
than vancomycin, the recurrence rate of 17.2% for 250mg surotomycin twice daily was 
significantly lower than the recurrence rate of 35.6% in the vancomycin arm (p = 0.035). 
Sustained clinical cure was not significantly different between any of the comparisons, 
however the sustained clinical cure in the 250mg surotomycin arm was 70.1% compared 
with 56.1% in the vancomycin arm. Interestingly, although the recurrence rate was higher 
in patients from any of the arms receiving concomitant antibiotics, the recurrence rate in 
these patients in the 250mg surotomycin arm was lower than for vancomycin patients who 
received concomitant antibiotics (37.5 vs 58.8%). The Phase II data demonstrating non-
inferiority for initial clinical cure was supported by both in vitro model data and animal 
model data, where surotomycin was effective at killing C. difficile, and was comparable to 
vancomycin (Chilton et al, 2014c, Mascio et al, 2012). It should be noted however, that 
surotomycin did not prevent recurrence in the in vitro model and led to overgrowth of 
Enterobacteriacae (Chilton et al, 2014c).   
The Phase II results did not appear to translate into efficacy in Phase III RCTs however (Boix 
et al, 2016; Daley et al, 2017). In one Phase III trial the proportion of patients with clinical 
cure when treated with 250mg twice daily of surotomycin (79%) was lower than for 
patients treated with standard vancomycin therapy (84%), and surotomycin therefore 
failed to show non-inferiority (Boix et al, 2016). Importantly, the reduction in recurrence 
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seen in the Phase II studies was not seen in this Phase III study, as sustained clinical cure 
was similar between the two arms of the study with 60.6% of surotomycin patients 
remaining cured of their infection compared with 61.4% of patients treated with 
vancomycin. Interestingly sustained clinical cure was higher for patients treated with 
surotomycin vs those treated with vancomycin if the infection was caused by PCR ribotype 
027; however this was not statistically significant. In contrast, in the second Phase III study, 
surotomycin was found not to be inferior to vancomycin for initial clinical cure; the authors 
suggest this difference may be due to some differences in the patient populations in these 
studies, with those in the second study being younger (median age 57.1 vs 61.3% years) 
and with milder disease (32.6 vs 25.6%) (Daley et al, 2017). However, again, the decrease in 
cases of recurrence demonstrated in the Phase II study was not seen (Daley et al, 2017), as 
sustained clinical cure was not significantly different between the two arms (63.3% vs 
59.0% respectively).  There was a higher impact on sustained clinical cure for PCR ribotype 
027 infections  with a significantly higher number of patients remaining free from 
recurrence when treated with surotomycin (64.4%) compared with those treated with 
vancomycin (37.8%), similar to the previous study (Boix et al, 2016; Daley et al, 2017). The 
authors suggest that the conflicting results between the Phase II and Phase III studies may 
be due to the high rate of recurrence seen in the patients treated with vancomycin in the 
Phase II study, as the lower rates of recurrence in the vancomycin arm of the surotomycin 
Phase III studies were similar to those seen in Phase III studies of other antibiotics used to 
treat C. difficile (Daley et al, 2017). In addition, the definition of CDI in the Phase II and III 
studies differed, with diagnosis in Phase II requiring a positive stool test for toxin A and/or 
B, while diagnosis in the Phase III studies was based on a positive stool test by either a toxin 
detection assay or by NAAT for toxin genes. Indeed >50% of cases in the Phase III studies 
were diagnosed by NAAT (Boix et al, 2016; Daley et al, 2017). This highlights the difficulty in 
designing randomised controlled trials, as the impact of the baseline characteristics of the 
patients enrolled, how CDI is diagnosed, and the definitions of cure and recurrence, can 
influence the results of the study, as demonstrated by both the surotomycin and cadazolid 
studies. It is very unlikely that either of these two antibiotics will be taken further in 
development as a treatment option for CDI. 
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1.8.5 Other novel antibiotics 
Several other antibiotics are being developed or are being used for the treatment of CDI, 
including ramoplanin, fusidic acid, nitazoxanide, LFF571 and rifaximin, with varying rates of 
success (Petrosillio et al, 2018). Current evidence on the efficacy of these agents is 
insufficient however to show superiority over fidaxomicin and ridinilazole (Beinortas et al, 
2018). Rifaximin, although bactericidal for C. difficile, is not recommended for use in the 
treatment of CDI due to the high levels of resistance found in C. difficile isolates (NG et al, 
2019).  However, rifaximin used as a follow-on treatment for either metronidazole or 
vancomycin standard therapy has been shown to reduce recurrence by ~50% from 29.5% in 
the placebo group to 15.9% in those that received rifaximin, although this was not a 
statistically significant finding (Major et al, 2018). 
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1.9 Alternative treatment options 
Alternative methods, other than traditional antimicrobial therapy for curing CDI, have been 
investigated. As CDI is a toxin-mediated disease, it makes sense that binding the toxin 
within the gut lumen may reduce the impact the toxin can have on the gut tissue. One 
agent developed for this purpose is tolevamer, a polymer that neutralises both toxin A and 
toxin B (Braunlin et al, 2004). Tolevamer not only resolved infection in 80% of the treated 
mice in a CDI mouse model, but also none of the animals had a relapse of infection when 
treatment was stopped (Kurtz et al, 2001).  This is in contrast to those mice that had been 
treated with metronidazole where 80% had relapse of infection after withdrawal of the 
metronidazole treatment.   When used to treat a simulated CDI infection in an in vitro gut 
model however, tolevamer was not able to reduce cytotoxin levels within the model 
(Baines et al, 2009). Indeed, tolevamer failed to show efficacy in Phase III studies (Johnson 
et al, 2014). In addition, in a recent meta-analysis tolevamer was significantly inferior when 
compared to all of the agents in the comparison, with the exception of LFF571 and 
bacitracin (Beinortas et al, 2018). 
 
1.9.1 Immunoglobulin 
Pooled human immunoglobulin was suggested as an adjunctive therapy in 1997, but 
current guidelines do not recommend its use, due to a lack of evidence regarding efficacy 
(Salcedo et al, 1997; Debast et al, 2014, McDonald et al, 2018). Indeed, a systematic review 
in 2016 only found a total of 17 published studies examining passive immunotherapy in 
humans (Diraviyam et al, 2016). While the studies were generally favourable, there was a 
lack of rigorous, controlled studies to enable the true effect of this treatment option to be 
determined (Diraviyam et al, 2016). 
 
1.9.2 Bezlotoxumab 
A more focussed immunotherapy has been developed, rather than using pooled 
immunoglobulins as described above. Two humanised monoclonal antibodies were 
developed, one anti-toxin A, actoxumab, and one anti-toxin B, bezlotoxumab; when mixed 
together denoted as actoxumab-bezlotoxumab. Bezlotoxumab binds within the CROP 
domain of toxin B, thereby preventing toxin B from binding to cells of the gut epithelium 
(Orth et al, 2014). In a mouse model of acute infection, actoxumab-bezlotoxumab 
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significantly reduced fluid accumulation and protected the gut epithelium, with no 
evidence of inflammation or damage to the epithelial cells (Yang et al, 2015). In addition, 
when mice, pre-treated with actoxumab-bezlotoxumab and that survived an initial primary 
infection with C. difficile, were re-challenged with an antibiotic, they were protected 
against further infection, unlike mice that had not been pre-treated with actoxumab-
bezlotoxumab (Yang et al, 2015).  Warn et al have used rodent models to demonstrate a 
period after primary infection during which the risk for recurrent infection is highest (Warn 
et al, 2016). This ‘at-risk window’ is due to possible spore outgrowth when the antibiotic 
that had been used to treat the primary infection has been stopped and the concentration 
has fallen, combined with a lack of recovery of the host microbiota. In rodent models, 
actoxumab-bezlotoxumab reduces the risk of recurrence during this ‘at-risk window’ and 
thereby provides time for the microbiota to recover, leading to fewer recurrent infections 
(Warn et al, 2016). 
In a pooled analysis of two randomised controlled trials for standard therapy combined 
with actoxumab-bezlotoxumab, actoxumab alone or bezlotoxumab alone, bezlotoxumab 
significantly reduced recurrence by ~38% compared with standard therapy plus placebo, 
with no impact on initial clinical cure (Wilcox et al, 2017). Interestingly, although there was 
reduced recurrence in the actoxumab-bezlotoxumab arm compared with placebo, there 
was no additional benefit over the arm devoted to bezlotoxumab alone. This supports the 
hypothesis that toxin B is more important for clinical infection than toxin A, as discussed in 
the virulence section of this introduction. However, sub-group analyses demonstrated a 
greater effect from actoxumab-bezlotoxumab in participants that had an infection caused 
by PCR ribotype 027, compared with bezlotoxumab alone, although this was not significant 
and numbers in each group were small. In vitro data suggests that changes in some of the 
epitopes on the toxin B protein in the CROP region in some strains of C. difficile, including 
PCR ribotype 027, correlated with decreased bezlotoxumab potency (Hernandez et al, 
2015). While further studies in humans, with much larger numbers are required to 
understand fully any decreased effect against certain PCR ribotypes of C. difficile, 
bezlotoxumab provides a way to reduce not only recurrent infections, but also the number 
of days a patient spends in hospital (Basu et al, 2018).  Reduced hospital readmissions and 
costs associated with recurrent CDI, such as additional antibiotics, nursing and other 
healthcare costs, make bezlotoxumab a cost-effective option, with 0.12 quality-adjusted 
life-years (QALYs) gained compared with placebo (Prabhu et al, 2017), and $19,824 saved 
per QALY gained. 
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1.9.3 Faecal Microbiota Transplantation 
Faecal microbiota transplantation (FMT) is recommended for patients that have had 
multiple recurrences of CDI, and who have failed antimicrobial therapy (Debast et al, 2014, 
McDonald et al, 2018). Augmentation of a patient’s gut microbiome by using an infusion of 
donor faeces was first reported in 1958 by Eiseman et al, and the idea gained increased 
interest after the publication of a randomised controlled trial between FMT and 
vancomycin with or without bowel lavage for treating recurrent CDI (van Nood et al, 2013). 
Patients who had had at least one recurrence of CDI were eligible for inclusion, although 
the majority of cases 35/43 had >one recurrence. For those randomised to receive FMT, 
13/16 (81.3%) were cured (with no recurrence within ten weeks) after one infusion, while a 
further two patients were cured after a second infusion from a different donor; giving 
overall cure in 93.8% of patients with one or two infusions. In comparison, only 31% of the 
patients in the vancomycin arm and 23% of patients in the vancomycin with bowel lavage 
arm remained free from CDI after ten weeks. The trial showed superiority of FMT over both 
vancomycin regimens early (p <0.0001), and the study was stopped, as it would have been 
unethical to continue with patients in the failing vancomycin arms. It should be noted that 
the proportion of patients who failed to have resolution of symptoms after treatment with 
vancomycin was higher than anticipated, which could have been due to the selection of 
patients with multiple recurrences (van Nood et al, 2013). Interestingly, the vancomycin 
regimen was 500mg four times a day, rather than 125mg, and it could be argued that this 
higher dose of vancomycin would be even more detrimental to the gut microbiome, and 
thereby not allow re-establishment of colonisation resistance, leading to further 
recurrences. Another randomised controlled trial of 64 patients however, also found a 
significant difference between the numbers of patients with no recurrence at eight weeks 
when treated with FMT vs 125mg four times per day of vancomycin (Hvas et al, 2019). FMT 
was also found to be superior to fidaxomicin (200mg twice a day) with 71% of patients 
treated with FMT remaining symptom free at eight weeks compared with 33% of patients 
treated with fidaxomicin (p = 0.009) (Hvas et al, 2019). 
Many of the randomised controlled trials on FMT are small, and therefore more liable to be 
influenced by confounders, such as the population studied. Meta-analysis can be used to 
determine if the pooled results are generalisable to a larger population. A recent 
meta-analysis of FMT randomised controlled trials included eight studies in the analysis, 
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with a total of 537 patients (Hui et al, 2019). Pooled relative risk for recurrence with FMT 
was 0.38 (95% CI 0.16-0.87, p = 0.02) with an overall recurrence rate of 11% (Hui et al, 
2019), demonstrating the effectiveness of this treatment option. 
Guidelines for the use of FMT have been issued jointly by the British Society of 
Gastroenterology (BSG) and the Healthcare Infection Society (HIS) (Mullish et al, 2018) to 
try to provide some standardisation to the use of this currently unregulated treatment 
option. Concerns over safety are partially addressed, with recommendations over the 
selection of potential donors (Mullish et al, 2018). The need for FMT should be judged on 
an individual patient basis however, balancing patient cure with possible unknown long 
term consequences. Donor selection is not only based on the results of screening for 
infectious diseases, which needs to be extensive, but also concerns the general health of 
the donor; the link between gut microbiome composition and health is still being 
investigated but there are increasing reports of the role that the microbiome plays in other 
health conditions (Skonieczna-Żydecka et al, 2018; Zheng et al, 2019). One 
recommendation in the guidelines, for example, is to use donors with a body mass index 
(BMI) of ≥18 and ≤30kg/m2, as there have been reports in mice of donor faeces from obese 
mice causing thin mice to become obese (Ridaura et al, 2013).  In addition, there have been 
case reports of patients dying from aspiration pneumonia when FMT was delivered via 
nasogastric (NG) or nasoduodenal (ND) tube (Bang et al, 2017; Baxter et al, 2015; van 
Beurden et al, 2017). The current recommendation is to use NG, ND, nasojejunal tube or 
enema for infusion of FMT (Mullish et al, 2018), but that NG should be used with caution in 
patients with risk of regurgitation. An alternative to liquid FMT is pre-prepared 
gastric-resistant faecal capsules, which can be swallowed (Youngster et al, 2016).  
 
1.9.4 Microbiome therapeutics 
Attempts have been made to reduce the risks associated with FMT by producing 
preparations of organisms that may perform the same function of FMT, namely resolution 
of the gut microbiome. RBX2660 is a suspension of live microbes that has been used with 
some success when used in a similar way to FMT, with an overall success of 87.1% in 
preventing a further episode of recurrence within eight weeks (Orenstein et al, 2016). It 
should be noted that the primary end-point of this study was product related adverse 
events (AEs), and 28/31 patients experienced at least one AE. These were mostly 
gastrointestinal in nature, and the majority resolved within seven days; there were no 
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product related serious AEs.  An alternative agent being developed, SER109 only uses 
spores from Firmicutes, rather than a suspension of microbes (Khanna et al, 2016). 
Theoretically, this reduces the possibility of transferring an unknown infectious agent to 
the recipient. However, although Phase Ib trial results appeared successful with 96.7% of 
patients remaining recurrence free, the Phase II trial results of this agent have so far not 
proved successful (Khanna et al, 2016; press release from Seres Therapeutics 2019). A post-
trial analysis by the company suggests that the decreased efficacy of SER-109 could have 
been due to suboptimal dosing, as a lower dose was used than the Phase Ib study. In 
addition, CDI was defined using PCR-based diagnostics; further testing of samples 
demonstrated that a significant number of these patients did not have C. difficile toxin in 
their samples (press release from Seres Therapeutics, 2019). If patients who were only 
carriers of C. difficile rather than having C. difficile infection were included on the study, 
this would have impacted the outcome measure for the trial. Further studies of SER-109 
are therefore continuing (press release from Seres Therapeutics, 2019). 
In addition, the use of non-toxigenic C difficile to enhance colonisation resistance and, 
therefore, reduce recurrence, has been investigated via RCT (Gerding et al, 2015). The oral 
formulation of spores was found to be well tolerated and patients in the treatment arm 
reported fewer events of diarrhoea and abdominal pain than patients in the placebo arm. 
Four different doses of spores were evaluated, and a dose dependant effect was found, 
with faecal colonisation seen in 71% of patients treated with the highest dose, compared 
with 63% of patients treated with the lowest dose.  In addition, reduction of recurrence 
was dose dependant, with the lowest recurrence rate in the patient group that received 
the highest dose of spores (5% vs 30% placebo, OR 0.28, P=0.006). Although not 
demonstrated in vivo, the PaLoc has been transferred to non-toxigenic strains within the 
laboratory (Brouwer et al, 2016), suggesting that there may be a potential risk if using non-
toxigenic C. difficile as a treatment option.  
 
1.9.5 Microbiome protective therapeutics 
In addition to the therapeutics discussed above, that have been designed to enhance the 
microbiome, there are investigational drugs that are designed to reduce the negative 
impact of antibiotics on the gut microbiota, and so reduce the risk of CDI.  SYN-004 
(ribaxamase) is a beta-lactamase that is designed to be taken orally at the same time as a 
beta-lactam antibiotic (Connelly et al, 2017). The beta-lactamase then degrades the 
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antibiotic that is excreted within the gastrointestinal tract of the patient, thereby 
protecting the gut microbiome from damage by the antibiotic. Results from Phase IIa and 
IIb studies indicate that SYN-004 is effective at reducing the level of ceftriaxone in the gut 
of patients to below the level of detection (Kokai-Kun et al, 2017a), and reduced the risk of 
subsequent CDI by 2.4% (95% CI -0.6-5.9, p=0.045) (Kokai-Kun et al, 2017b).  Another agent 
in development is DAV-132. This is an oral adsorbent agent, which binds to antibiotics 
excreted via the gastrointestinal tract, thereby lowering the antibiotic concentration and 
protecting the microbiota (de Gunzberg et al, 2015). DAV-132 is currently being 
investigated in an RCT in Europe (clinicaltrial.gov, 2019).    
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1.10 Infection control and prevention 
The financial burden on the healthcare economy from this pathogen is considerable. Each 
case has been estimated to cost the NHS approximately £7,000 due to the increased use of 
isolation facilities, specialised barrier nursing and extended hospital stay (Wiegand  et al, JHI 
2012), with estimates of $5.4-6.3 billion per year in the US (Zhang et al, BMC Infec Dis 
2016). In the UK, there is increased financial pressure on NHS Trusts as a result of financial 
penalties for failing to meet infection reduction targets set by the Department of Health 
(Department of Health, 2016).  Therefore, although the driver of Department of Health 
targets is reduction of morbidity and mortality, the reduction of the burden of C. difficile 
infection also has important economic implications, as well as those for the care and well-
being of patients, and there are several measures that can be taken to reduce C. difficile 
burden. 
 
1.10.1Transmission 
Transmission of C. difficile is via the faecal-oral route, following ingestion of spores, 
presumably primarily from contaminated hands (Durovic et al, 2018). A recent review of 24 
transmission studies found 53.3% of studies reported that, in the hospital setting, direct 
contact with a previous case was the source of infection; however 40% reported that 
contact with the hospital environment was the source for cases of CDI (Durovic et al, 2018). 
In addition, the most commonly cited environmental source was the patients’ room 
(25% of studies), followed by wards (13%), bathrooms (13%) and toilets (13%). Indeed, the 
risk of acquiring C. difficile after being nursed in a room that previously housed a patient 
positive for C. difficile was 1.73 (95% CI 1.15-2.55), with a mean time to acquisition of 3.2 
days, compared with 18.9 days for those patients nursed in areas that did not previously 
house C. difficile-positive patients (MacFarland et al, 1989). A multivariate analysis of 
factors affecting acquisition of C. difficile found admission to a room that previously housed 
a patient positive for C. difficile was independently associated with C. difficile acquisition 
(hazard ratio 2.35) (Shaughnessy et al, 2011). The risk appears to be highest within the first 
48 hours of exposure to that environment with a relative risk of 2.23 (95% CI 1.24-4.01) 
(MacFarland et al, 1989). There have been several recent transmission studies, using a 
combination of typing techniques and spatial links to demonstrate likely transmission from 
a previous CDI case (Walker et al, 2012; Martin et al, 2018; Mawer et al, 2017; Eyre et al, 
2017; Eyre et al, 2013a).  In all of these studies a direct or indirect link between previous 
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CDI cases or C. difficile positive patients could only be demonstrated for ~20% of cases. This 
highlights that there may be alternative sources of transmission, in addition to previous CDI 
cases. Infection control and prevention methods however try to reduce the likelihood of 
transmission via these pathways. 
Hand hygiene is a key way of reducing the risk of C. difficile transmission and/or acquisition. 
In one study, when the hands of nursing staff were checked for contamination after contact 
with patients positive for C. difficile carriage, 59% of them became contaminated 
(MacFarland et al, 1989), including their fingernails, fingertips, palms and the underside of 
rings. One important difference for hand hygiene with C. difficile however, is that alcohol 
skin gels are ineffective against the spores of the bacterium.  Indeed, as discussed in 
section 1.2.2, the spores are resistant to alcohol (Wilson et al, 1985). Hands can however, 
be effectively cleaned by physical washing, with standard soap and water or antibacterial 
soaps (Boyce and Pittet, 2002). However current ESCMID guidelines only recommend 
switching from alcohol-based gels to soap and water in a C. difficile outbreak setting, due to 
the effectiveness of alcohol-based gels for preventing other hospital-acquired infections 
(Tschudin-Sutter et al, 2018). The guidelines also recommend using personal protective 
equipment (PPE) including gowns and gloves in both outbreak and endemic settings, 
although the use of PPE is a stronger recommendation for the outbreak situation than the 
endemic setting (Tschudin-Sutter et al, 2018).  Isolation of patients is recommended in both 
endemic and outbreak situations (Tschudin-Sutter et al, 2018) although there is no 
recommendation on if this should be in individual rooms, or via cohorting of symptomatic 
patients together, presumably due to the differing availability of individual side rooms in 
different institutions.  
Individual side rooms may make decontamination of the environment easier, as all 
high-touch areas should be decontaminated, using an appropriate cleaning agent, on a 
daily basis, and after vacation of the room by the patient (Tschudin-Sutter et al, 2018). The 
spores of C. difficile have been shown to remain in the hospital environment for up to 12 
weeks, with only a ≤3 log10 reduction from the starting inoculum during that time (Otter 
and French, 2009), and are more likely found in room of patients with symptomatic CDI, as 
opposed to asymptomatic carriage (MacFarland et al, 1989; Riggs et al, 2007). In one study, 
where floors were intentionally contaminated with a C. difficile spore preparation of 106cfu, 
spores could be recovered up to five months later (Kim et al, 1981). When the starting 
inoculation was 104cfu however, spores could only be recovered at a maximum of four 
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weeks later; demonstrating that a higher starting inoculum enhances the chance that some 
spores will remain in the environment long-term.  In addition to contamination via 
contaminated hands, the environment can also be seeded by spores via aerosolisation 
(Best et al, 2010), most commonly when there is activity near a symptomatic patient. 
Aerosolised spores can also be recovered from the air above toilets following flushing, 
thereby further contaminating the environment (Best et al, 2012). Hypochlorite-based 
agents are more effective than those containing quaternary ammonium compounds at 
removing C. difficile spores from the environment (Fawley et al, 2007), and accelerated 
hydrogen peroxide-based agents are comparable with bleach containing 5g/L free chlorine, 
at inactivating spores in ≤10 minutes (Perez et al, 2005). 
Cleaning practices must be maintained at an appropriate level; one outbreak of C. difficile 
has been associated with failure to adequately clean the re-usable mop-heads that were 
used to clean the ward (Sooklal et al, 2014). Several of the cleaning agents described above 
can be hazardous to cleaning staff, if not used appropriately (Perez et al, 2005), and require 
all high-touch areas to be physically cleaned adequately. Alternative, no-touch systems for 
room decontamination have now been developed. These consist of systems using either 
ultra-violet-C (UVC) light, or hydrogen peroxide vapour (HPV).  UVC systems, where the 
light damages the bonds in DNA, require direct line-of-sight with the surface to be 
decontaminated and reduce the number of spores on surfaces by 2-4log10 (Havill et al, 
2012; Nerandzic et al, 2010). HPV systems, in contrast, which damage membrane lipids, 
DNA and protein by free radicals, reduce the number of spores on surfaces by ~6log10 
(Havill et al, 2012). As highlighted by a review in 2015, however, currently most studies of 
these systems have been tested on seeded environmental surfaces (Barbut, 2015) and 
further evaluation of their clinical impact is required. 
 
1.10.2 Surveillance 
Surveillance of CDI cases is recommended in both the endemic and outbreak setting 
(Tschudin-Sutter et al, 2018), however the evidence level for this is low. Nevertheless, it is 
logical that up-to-date knowledge of the current number and location of cases, along with 
the strain associated with those cases can help to direct available infection prevention and 
control resources better. Surveillance requires accurate diagnosis however; methods that 
can also detect colonised patients as well as actual cases of CDI could falsely inflate 
reported CDI rates (Davies et al, 2017; Longtin et al, 2013). In Europe, the European Centre 
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for Disease Prevention and Control (ECDC) has initiated a standardised programme of 
surveillance of C. difficile (ECDC,  2019.) to overcome the issue that several European 
countries do not have national CDI surveillance programmes of their own.  The results of 
the pilot project, reported in 2016, demonstrate that two of those countries without their 
own national systems had high levels of PCR ribotype 027 (van Dorp et al, 2016), perhaps 
due to a lack of knowledge about circulating outbreak strains.  Additional to the issue of 
accurate diagnostics, surveillance systems can only record those cases that were clinically 
suspected and therefore tested; thereby missing potential cases. Results from a study of 
482 hospitals across 20 countries in Europe in 2012-2013 estimated that there were a total 
of ~40,000 missed cases per annum in those 482 hospitals (Davies et al, 2014). Indeed, the 
proportion of cases attributed to PCR ribotype 027 in a country was inversely correlated 
with the testing rate in that country (Davies et al, 2014), again suggesting that lack of 
knowledge about circulating strains prevents appropriate outbreak control methods being 
put in to place. An earlier study of 97 hospitals in 34 countries in Europe demonstrated a 
correlation between the number of tests performed/10,000 patient bed days (pbds) and 
the number of cases/10,000pbds (Bauer et al, 2008), supporting the adage ‘the more you 
look, the more you find’. However, this was not replicated in the later study (Davies et al, 
LID 2014) for either reported, or actual measured cases of CDI.  This may be due to the 
increased sample size of the later study, thereby possibly including centres with greater 
heterogeneity of testing policies (Davies et al, 2014). These differences however, highlight 
the need for standardised case definitions, diagnostic methods, clinical parameters and 
appropriate denominators for rate data, to make surveillance successful. 
 
1.10.3 Antibiotic stewardship 
C. difficile infection is most often precipitated by antimicrobial exposure, as discussed 
earlier in the introduction. Antimicrobial stewardship may therefore reduce the burden of 
CDI; reducing the number of potentially susceptible patients would reduce the number of 
CDI cases. The decrease in cases since 2007 seen in two areas within the UK, has been 
correlated with the decrease in fluoroquinolone and cephalosporin prescribing over the 
same period within those regions, but not with overall levels of antimicrobial prescribing 
(Dingle et al, 2017). Importantly, PCR ribotype 027 is resistant to fluoroquinolones, in 
contrast to many other types of C. difficile (Freeman et al, 2018), and in one of the two 
regions the proportion of cases due to PCR ribotype 027 dropped from ~67% to ~3% during 
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the period of decreased fluoroquinolone use.  Currently, antibiotic stewardship is largely 
driven by the policies of local centres, or by national guidelines (Debast et al, 2014; 
McDonald et al, 2018). In the developing era of personalised medicine however, there may 
be potential for diagnostic assays that can predict those patients who would be most 
susceptible to C. difficile infection and, therefore, those in whom antimicrobial stewardship 
would be most advised. These tests may focus on markers of dysbiosis of the gut 
microbiota, such as the levels of bacterial metabolites found in the urine (Obrenovich et al, 
2017), or on carriage of specific organisms, such as C. difficile. 
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1.11 Typing methods 
Investigation of C. difficile outbreaks is reliant on being able to distinguish between 
different strains of the bacterium, for which several methods have been developed. Gurtler 
developed a method using the DNA sequence of the region encoding the intergenic spacer 
region between the 16S and 23S ribosomal subunits of C. difficile (Gurtler,  1993). This 
highly variable region of DNA can be cleaved into sections using restriction endonucleases, 
with the resultant unique pattern of DNA fragments attributed to a specific PCR ribotype 
(Stubbs et al, 1999). Improvements made to the sequence of the primers used, improved 
the reproducibility of the method (Bidet et al, 1999), and this method was then used by the 
Clostridium difficile Ribotyping Network of England and Northern Ireland (CDRN). The CDRN 
was developed as a response to the growing number of CDI cases in England, with an aim 
to drive down transmission (Wilcox, et al, 2012). Recent advances in technology have 
allowed a shift from visualisation of the fragments using gel electrophoresis, to 
measurement of fragment lengths on a sequencer (Fawley et al, 2015), enabling greater 
standardisation of the method. The current library of strains held at the CDRN is >900 
(personal communication). 
PCR ribotyping, although used world-wide, is not the only typing system for C. difficile, for 
example PCR ribotype 027 is also known as pulsed field gel electrophoresis (PFGE) NAP1, 
restriction enzyme assay (REA) B1 or toxinotype III (McDonald  et al, 2005; Rupnik et al, 
1998). Due to the large sections of DNA, cleaved by enzymes from the whole genome of 
the organism in PFGE, separation of the fragments takes longer than standard 
electrophoresis, and requires alternating and rotating currents to be applied to the gel 
(Schwartz and Cantor, 1984; Wren and Tabaqchali, 1987). PFGE was first used to define 
strains of C. difficile in 1996 (Kato et al, 1996), demonstrating that some patients had 
relapse of their original infecting strain, while others acquired a new infection with a 
different strain (reinfection). PFGE has modest discrimination for strains of C. difficile, and 
some strains are non-typeable using this method, due to DNA degradation (Kato et al, 
1996; Alonso et al, 2005). Improvements to the method however, have reduced DNA 
degradation, and therefore, increased the number of isolates for which a PFGE type can be 
derived (Corkill et al, 2000; Alonso et al, 2005). 
C. difficile can also be typed based on the toxin genes within the genome, when compared 
to a reference strain, VP1 10463 (Rupnik et al, 1998).  Restriction fragment length 
polymorphism (RFLP)-PCR amplifies the section of DNA containing the toxin genes tcdA and 
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tcdB, which is then cut with DNAse enzymes and checked for polymorphisms (Rupnik et al, 
1998). Ten overlapping PCR amplification products enable the entire PaLoc to be analysed 
(Rupnik et al, 1998), with 31 toxinotypes currently known (Toxinotype website database, 
2019). 
Several other typing methods have been used for C. difficile, including serogrouping 
(Delmee et al, 1985), restriction endonuclease analysis (REA) (Devlin et al, 1987), multilocus 
sequence type (MLST) (Marsh et al, 2010) and multilocus variable-number tandem repeat 
analysis (MLVA) (Fawley et al, 2008; Fawley and Wilcox, 2011). Each method has a different 
level of discrimination; MLVA does achieve increased discrimination over PCR ribotyping, 
and can be used for enhanced analysis of transmission where the same PCR ribotype has 
been identified (Fawley et al, 2008; Fawley and Wilcox, 2011). MLST is less discriminatory 
than MLVA but can provide information on the genetic lineage of the isolate (Marsh et al, 
2010). Advances in technology have made whole genome sequencing (WGS) of C. difficile 
available to many laboratories. Although termed whole genome sequencing, the sequence 
of the entire genome is not determined, for example the region used for PCR ribotyping is 
not included in WGS (Eyre et al, 2013b), making it impossible to derive a PCR ribotype from 
WGS currently. One advantage of methods such as PCR ribotyping, MLVA and WGS over 
other typing methods, is that they can be used to track transmission as they can be 
adjusted to examine the relatedness of isolates, not just place isolates into a defined 
category, as, for example, PFGE does (Eyre et al, 2013b). 
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1.12 Epidemiology 
C. difficile infection became of public interest in the UK and worldwide after several high-
profile incidents in healthcare institutions (Kostkova et al 2013). These outbreaks were 
often associated with the PCR ribotype 027 (McDonald et al, NEJM 2005; Pepin et al, 2004; 
Loo et al, 2005). Typing of C. difficile isolates is therefore, a useful tool for examining the 
spread of infection and understanding outbreaks, and new typing methods, such as WGS, 
provide new information on transmission pathways for CDI. Indeed, although CDI was 
traditionally thought to spread from case to case, the source of infection in the majority of 
cases remains unclear, as a recent study reported that only 20-25% of inpatient CDI cases 
could be linked with another CDI case when using WGS (Walker et al, 2012). Of note, in-
patient asymptomatic carriage rates of C. difficile have been shown to be higher (up to 
21%) than those seen in the community (1.6%) (Rea et al,  2012), and may contribute to 
transmission within the hospital setting (Furuya-Kanamori, 2015). 
 
1.12.1 Changing patterns of epidemiology 
Typing isolates of C. difficile also demonstrates how patterns of C. difficile types have 
changed over time and how they vary between locations; e.g. hospital vs community, or by 
country. Before the world-wide outbreaks of PCR ribotype 027, the predominant strain in 
the UK was PCR ribotype 001, with little variation seen in circulating hospital strains 
(Freeman et al, 2010). Increased infection control and prevention measures in the UK, 
including mandatory reporting of all CDI cases from hospitals, led to a decline of outbreaks, 
including those caused by PCR ribotype 027 (Wilcox et al, 2012). After the decline of 
PCR ribotype 027 in the UK, the heterogeneity of circulating strains within the hospital 
environment increased and, indeed, appears similar to the diversity of strains within the 
community (Fawley et al, 2016). 
CDI case incidence has continued to increase across Europe in the last decade, with a mean 
of 4.1/10,000patient bed days (pbds) across 34 countries in 2008 and a mean of 
7.0/10,000pbds across 20 countries in 2012/2013 (Bauer et al, 2011; Davies et al, 2014); 
albeit with marked variation between countries. In the same period, the testing rate also 
increased from a mean of 52.1tests/10,000pbds to 65.8/10,000pbds, and when 
undiagnosed cases are added to those actually reported, the case rate rises by 2.4-2.9 fold, 
highlighting ascertainment bias (Davies et al, 2014).  Targeted testing of patients may also 
impact on reported CDI incidence; those tested for CDI are significantly older in Italy than in 
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four other countries studied, suggesting that testing in Italy is targeted to those thought to 
be most ‘at risk’ (Davies et al, 2016b; Davies et al, 2017). Comparisons of case incidences 
between centres and countries are therefore compounded by factors such as clinical 
suspicion, testing policies and testing methodologies (Davies et al, 2014; Longtin et al, 
2013; Davies et al, 2016b; Davies et al, 2017). 
A recent systematic review has attempted to determine the global burden of C. difficile 
(Balsells et al, 2019), and estimates a mean of 3.54 hospital-associated cases/10,000pbds 
and 2.24/1,000 admissions across the 41 countries included in the studies in the meta-
analysis.  The incidence was substantially lower in the community with a mean of 
0.55/1000 admissions. It should be noted however, that this may not be the most 
appropriate measure for community infections, as it will only capture those that were sick 
enough to require hospital admission. Interestingly, the authors note that the CDI incidence 
was highest in North America; however, although they mention that diagnostic methods 
may affect incidence data, they fail to mention that laboratories in the US largely use stand-
alone PCR assays for CDI diagnosis, which have been shown to overcall the number of true 
cases of CDI (Davies et al, 2016b; Polage et al, JAMA 2015). This may therefore partly 
explain the high incidence levels reported in the USA. 
The diversity of PCR ribotypes across Europe has increased from a total of 65 different 
PCR ribotypes found in the 2008 study to the 125 found in the 2012/2013 study (Bauer et 
al, 2011; Davies et al, 2016a). Distribution of ribotypes varies markedly across Europe, with 
the greatest proportion of PCR ribotype 027 in Eastern Europe (figure 1.2), a shift from the 
high prevalence seen in the UK in 2008 (Davies et al, 2016a, Davies et al, 2019c, Bauer et al, 
2011). The prevalence of PCR ribotype 027 and 176 (a closely related strain), is inversely 
related to the overall diversity of PCR ribotypes within a country; i.e. outbreaks of one 
strain dominate in these countries, while those countries with fewer outbreaks have 
increased diversity of circulating strains (Davies et al, 2016a). Within-country clustering is 
seen, using WGS, for PCR ribotypes 356, 018, 176, 001/072 and 027, while other 
PCR ribotypes, such as 078, 015, 002, 014 and 020, appear to have a European-wide 
distribution (Eyre et al, 2018). This is suggestive of two different patterns of spread for 
these PCR ribotypes, and that those with European-wide distribution may have a common 
source (Eyre et al, 2018). Some PCR ribotypes are found in animal faecal samples, such as 
078 and 014 (Knetch et al, 2014; Knight et al, 2016), it is therefore postulated that the food 
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chain may be a potential source for those PCR ribotypes distributed across Europe (Eyre et 
al, 2018).  
 
Figure 1.2. Reproduced from Eurosurveillance (with permission).  Geographical 
distribution of Clostridium difficile PCR ribotypes, by participating European 
countrya, in the EUCLID study, 2012–13 and 2013b (n = 1,196). Pie charts show the 
proportion of the most common ribotypes by country and the number in the centre of the 
charts is the number of typed isolates in the country. a Austria, Belgium, Bulgaria, Czech 
Republic, Finland, France, Germany, Greece, Hungary, Ireland, Italy, the Netherlands, 
Poland, Portugal, Romania, Slovakia, Spain, Sweden and United Kingdom. None of the 
faecal samples submitted from Slovenia during the two sampling days were found to be 
positive for C. difficile or its toxins. b The countries submitted inpatient diarrhoeal samples 
on two sampling days (one day in winter, in December 2012 or January 2013, and one day 
in summer, in July or August 2013) 
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1.12.2 PCR ribotype 027 
Further to epidemiological information, typing can also highlight different clinical outcomes 
between strains. Increased severity of infection and greater mortality has been associated 
with PCR ribotype 027 (Loo et al, 2005; Pepin et al, 2005b). In a study of 1,144 CDI cases 
the presence of PCR ribotype 027 was associated with severe CDI (OR 1.73, 0.037), and 
mortality (OR 2.02, p = 0.009) compared with infection caused by an alternative 
PCR ribotype, after multivariate analysis (Rao et al, 2015). One difficultly however, when 
comparing studies describing the relationship of PCR ribotype 027 and severity of infection, 
is the variation in the definition of severity. In the ESCMID guidelines, severity is defined as 
severe colitis and/or the presence of one of several other markers, including raised white 
cell count above 15x109/L, serum albumin <30g/L, rise in serum creatinine >1.5X baseline 
values or >133µM (Debast et al, 2014). Severity can also be described based on ICU 
admission, serious comorbidities or immunodeficiency in patients aged >65 years (Debast 
et al, 2014). IDSA/SHEA guidelines describe severe infection in similar terms to ESCMID, but 
presence of hypotension, shock, ileus or megacolon is defined as fulminant infection 
(McDonald et al, 2018). One study of 236 cases of CDI found no association between 
presence of PCR ribotype 027 and severity; however, severity was based on death within 
30 days (Cloud et al, 2009). In this case then PCR ribotype 027 was not associated with 
mortality, rather than not being associated with severity as the study title suggests; 
however this study may have been underpowered for mortality as an outcome measure. A 
later study also found no association between PCR ribotype and severity, after multivariate 
analysis to control for other confounders, such as age and raised white blood cell count, 
although presence of PCR ribotype 027 was associated with severity  in univariate analysis 
(OR 2.33, p = 0.035) (Walk et al, 2012). Severity in this study was defined as admission to 
ICU, requiring interventional surgery for CDI symptoms, or death within 30 days of 
diagnosis, and the authors acknowledge that they may have missed some cases of severe 
infection using these criteria (Walk et al, 2012). 
One reason for the increased severity of infection with this PCR ribotype may be increased 
production of toxin by this strain (Warny et al, 2005), although this has been disputed by 
both batch and continuous culture system experiments (Merrigan et al, 2010; Freeman et 
al,  2007).  Experiments can also be compounded by the choice of comparator non-027 
strain, as production of toxin in batch culture appears to be strain dependant (Merrigan et 
al, 2010).  In addition, continuous culture systems, rather than batch culture show that 
PCR ribotype 027 produces toxin for longer than does PCR ribotype 001, but not at a higher 
69 
 
level (Freeman et al, 2007). The high levels seen in the batch culture model may therefore 
be due to an accumulation of toxin and potentially do not give a true representation of 
toxin production by this strain. An alternative method that overcomes the limitations of 
batch culture experiments uses a continuous culture system to model the interplay 
between C. difficile, normal bowel microbiota and antimicrobials introduced into the 
system (Freeman et al, 2003). This human gut model has been validated against the colonic 
microbiota of sudden death victims (Macfarlane et al, 1998), and has been shown to be 
clinically reflective of in vivo CDI (Freeman et al, 2002). Indeed, the model has successfully 
predicted clinical failure of treatment options in vitro that went on to fail Phase II clinical 
trials, such as tolevamer (Baines et al, 2009; Johnson et al, 2014). 
In addition to robust toxin production, increased sporulation and an increased binding 
capacity of toxin B,  over other PCR ribotypes, has also been observed with PCR ribotype 
027 (Merrigan et al, 2010; Stabler et al, 2008). Patients with PCR ribotype 027 may also 
have higher levels of C-reactive protein (CRP) and faecal calprotectin, a measure of gut 
inflammation, over those with other PCR ribotypes (Goldenberg and French, 2011; Peretz 
et al, 2016). The emergence of fluoroquinolone resistance in PCR ribotype 027 has been 
suggested as a reason for the proliferation of this strain, as historical strains (collected prior 
to 2001) were fully susceptible to gatifloxacin and moxifloxacin (McDonald et al, 2005). In 
contrast 100% of tested strains of PCR ribotype 027 collected after 2001 were resistant to 
gatifloxacin, and 42% were resistant to moxifloxacin (McDonald et al, 2005). Indeed, more 
recent strains of PCR ribotype 027, collected from across Europe, demonstrate multi-drug 
resistance, specifically to moxifloxacin, rifampicin, imipenem and metronidazole (Freeman 
et al, 2018). The emergence of fluoroquinolone resistance has been shown to have been 
acquired from two different lineages; FQR1 and FQR2, with spread throughout Europe 
largely being due to FQR2 (He et al, 2013). 
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1.13 Laboratory diagnosis 
From a clinical point of view, it is important to understand the status of the disease of the 
patient, to ensure they receive the correct treatment and that the appropriate 
infection-control precautions are used (Bignardi et al, 2013). This requires accurate 
diagnostics. Laboratory diagnostics of CDI have been a contentious subject for some time 
with no agreement on the optimal method for detection as numerous comparison studies 
have been published showing conflicting variations in the performance of diagnostic assays 
(Fang et al, 2017; Planche and Wilcox, 2015; Planche et al,  2013). Indeed, at several 
microbiology and infectious disease conferences in recent years, debates have been held 
on the virtues of differing diagnostic algorithms (Fang et al, 2017). It is important to note 
that the prevalence of a disease in the study population affects the positive and negative 
predictive value of a detection assay. The higher the prevalence, the better the assay will 
perform (Planche et al, 2008). It is a weakness of many studies that they use a selected 
population for study with a prevalence level much higher than that seen in routine clinical 
practice, so falsely inflating the predictive value of the assays in question.  The decision as 
to which assay to use is compounded by the issue of what to detect; the organism, its 
toxins or its DNA (Planche et al, 2013). 
 
1.13.1 Assays for detection of toxin 
Detection of toxin B directly from a diluted faecal sample using a cell cytotoxicity assay is 
often quoted as the gold standard method for laboratory diagnosis (Planche et al, 2013), 
however this method is not without its limitations. For example, whilst some positive 
results can be detected within six hours, negative results cannot be confirmed until 48 
hours after inoculation of the tissue culture. Additionally, there is no consensus on 
methodology, including but not limited to which cell line and faecal dilution to use, which 
may account for the different sensitivities reported for this assay. Indeed, human foreskin 
fibroblast (HFS) cells have been shown to be more sensitive for detection of toxin B than 
Chinese hamster ovary (CHO), human lung fibroblasts or Hep-2 cells (Tichota-Lee et al, 
1987). 
Rapid enzyme immunoassays (EIAs) were developed to detect C. difficile toxin A directly 
from a faecal sample and to reduce the time to diagnosis to less than two hours (Lyerly et 
al, 1983). Subsequently these assays were modified to detect both toxins A and B after the 
discovery of toxin A negative/toxin B positive disease-causing strains (Rupnik M et al, 1998; 
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Borriello et al, 1992). Comparison studies of commercially available toxin detection EIAs 
show huge variation in the performance of these assays with some sensitivities <50% in a 
low-prevalence setting (Planche et al,  2008; Eastwood et al, 2009). Alternate views on the 
need for repeat testing using EIAs has led to further confusion about appropriate CDI 
diagnostics (Mohan et al, 2006; Manabe et al, 1995). Department of Health (UK) guidance, 
based upon one large study in 2009, recommended that diagnosis of CDI should not be 
based on the sole use of a toxin EIA (Eastwood et al, 2009; Wilcox and Eastwood,  2009; 
Department of Health, 2009) but did not offer an alternative diagnostic strategy. 
 
1.13.2 Assays for detection of C. difficile 
Due to the long turn-around time and the technical difficulty of using cell lines to detect 
toxin, alternative methods have been developed for CDI diagnosis. As people can carry non-
toxigenic strains of C. difficile in their gut (Shim et al, 1998), culture of C. difficile from a 
faecal sample is not diagnostic for CDI. Cytotoxigenic culture aims to solve this problem by 
identifying patients with pathogenic C. difficile isolates in their faeces. Ensuring that this 
test is only performed on diarrhoeal faecal samples (usually Bristol stool chart types 5-7) 
should ensure that people with asymptomatic carriage, those in whom C. difficile is 
detected but who have no symptoms (Shim et al, 1998), are not falsely diagnosed with CDI. 
Following standard C. difficile culture, the isolates are tested for the ability to produce toxin 
(Bouza et al, 2001); however, this does not indicate the presence of toxin in the original 
faecal sample, only the ability of the isolate to produce toxin in laboratory conditions. 
Importantly, the detection of free-toxin, not the detection of an isolate with toxin 
producing ability has been shown to be associated with mortality (Planche et al, 2013). 
Unfortunately, because of the need for two incubation steps in this method, the turn-
around time can be even longer than that for the cell cytotoxicity assay. 
Commercial assays with alternative targets for detection of C. difficile have been 
developed, such as a test for glutamate dehydrogenase (GDH), an enzyme associated with 
the cell surfaces of many bacteria (Anderson et al, 1993). The variability seen in the 
performance of toxin EIAs does not seem to be present with C. difficile-specific GDH EIAs 
(Shetty et al,  2001), perhaps suggesting that there is less target heterogeneity i.e. GDH has 
less antigen variability than C. difficile toxins. One disadvantage of GDH assays, however, is 
that they cannot distinguish between toxigenic and non-toxigenic strains, meaning that 
they have to be used in conjunction with another, toxin-detecting assay to diagnose CDI. 
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Detection of toxin gene DNA using nucleic acid amplification tests (NAAT) offer an 
alternative, rapid and potentially high-throughput method for screening faecal samples for 
toxigenic C. difficile. It has been suggested that a PCR assay for toxin genes (Cepheid 
GeneXpert® C. diff, US) is more sensitive for certain PCR ribotypes of C. difficile than GDH 
EIAs (Tenover et al, 2010), even though the genes for GDH have been shown to be 
ubiquitous in C. difficile (Carman et al, 2012). It should be noted, however, that the number 
of samples examined in this study was small in total and hence the numbers of each 
PCR ribotype even smaller (Tenover et al, 2010). In addition, NAATs, in similarity with 
cytotoxigenic culture, cannot detect free toxin within a faecal sample, only the presence of 
a potentially toxigenic strain; indeed, it may also be detecting dead bacteria rather than 
living cells or cells in which expression of the gene encoding toxin cannot be expressed. In 
order to determine if the gene is being expressed, a reverse transcriptase assay would be 
required, to convert mRNA to DNA, but there is no such current C. difficile molecular assay 
available.   
The potential for standalone NAATs to overdiagnose CDI has therefore, been highlighted 
(Polage et al, 2015), as patients with samples that are NAAT-positive/toxin-positive were 
significantly associated with higher bacterial load, greater antibiotic exposure, 
inflammation of the gut, presence of diarrhoea (all p <0.001), and longer duration of 
diarrhoea (p = 0.03), compared with patients that had NAAT-positive/toxin-negative 
samples (Polage et al, 2015). In addition, CDI-attributable mortality was significantly higher 
in NAAT-positive/toxin-positive patients compared with NAAT-positive/toxin-negative 
patients (8.4% vs 0.6%, p = 0.001). This was confirmed by a small study in 2018 where 30-
day mortality was significantly higher in the toxin-positive group compared with the NAAT-
positive group (31% vs 18%, p = 0.03) (Avni et al, 2018). In contrast however, a more recent 
study demonstrated that there was not a significant difference between CDI-related 
complications or 30-day mortality between NAAT-positive and toxin-positive patients; 
although toxin-positivity was significantly associated with recurrence (adjusted OR 1.89, 
161-2.23) (Guh et al, 2019). It should be noted however that the first study was a 
prospective study designed and powered to compare NAAT and toxin assay results, while 
the last study was a retrospective data analysis. 
Ensuring accurate diagnosis is important not just for the treatment of patients and for 
infection prevention, but because often CDI rates are used as a performance measure 
within healthcare facilities. A study in the US reporting the number of deaths per annum 
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related to CDI had to add a sensitivity analysis to account for the different diagnostic 
methods used by the hospitals included within the study; such is the effect of diagnostic 
methodology (Lessa et al, 2015). Indeed, within the US, a diagnostic assay factor is applied 
to all centrally reported CDI incidence data to allow for meaningful comparison between 
different healthcare institutions (Lessa et al, 2015) The phenomenon of diagnostic methods 
impacting on reported CDI rates has also been observed within Canada and Europe (Boagty 
et al, 2017; Davies et al, 2016b; Davies et al, 2017). 
To try to reduce the potential for increased detection of false positives when using 
standalone NAATs, some centres have tried to employ diagnostic stewardship (Goret et al, 
2018; Yen et al, 2018). One recent study demonstrated that moving to standalone NAATs 
increased compliance with faecal sample rejection policies (Goret et al, 2018). There have 
also been attempts to enhance current faecal sample rejection policies by asking for 
Infection Prevention review of potential cases before a sample is even sent to the 
laboratory. A study at one US centre demonstrated that diagnostic stewardship and 
education reduced the rate of requests for NAAT testing by 2-fold, and therefore, also 
reduced the reported CDI incidence (Yen et al, 2018). Whilst improved testing criteria may 
seem like a suitable solution, it often relies on clinical suspicion, which has been shown to 
‘miss’ 23% of CDI cases in a large, multi-centre, European study of 482 hospitals (Davies et 
al, 2014). In addition, missed cases were significantly younger than those that were 
diagnosed at the hospital, suggesting that clinical suspicion is higher in older patients; while 
increasing age is a known risk factor for CDI (McDonald et al, 2006; Minino et al, 2011, 
Lessa et al, 2015), it does not mean that younger patients cannot have the infection. 
Another multi-centre European study demonstrated that patients tested in Italy were 
significantly older than in the other four countries that were studied (Davies et al, 2016), 
suggesting targeted testing of patents in Italy, and younger cases will be missed. Diagnostic 
stewardship may therefore exacerbate the situation, by missing potential cases that do not 
fit the traditional risk factors for CDI, leaving greater opportunity for lack of effective 
infection prevention precautions and the possibility of complications in undiagnosed 
patients. 
 
1.13.3 Algorithmic approach 
Combining different types of tests into diagnostic algorithms for CDI has been suggested as 
an alternative to poorly performing stand-alone assays (Crobach et al, 2016, McDonald et 
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al, 2018). Assays detecting GDH are often used as the first assay in many of these two- or 
three-stage algorithms (Crobach et al, 2016, McDonald et al, 2018).  Following a large 
multi-centre UK study, an optimal algorithm was determined: GDH (or NAAT) followed by 
toxin detection (by EIA or cell cytotoxicity) (Planche et al, 2013). This led to updated 
guidance from the Department of Health in England in 2012 which was later followed by 
both Wales and Scotland (Department of Health, 2012). In addition, the ESCMID diagnostic 
guidelines were updated to reflect these recommendations (Crobach et al, 2016), while the 
latest US guidelines from IDSA/SHEA partially recommended the algorithm, but with 
allowance for using standalone NAAT with appropriate diagnostic stewardship (McDonald 
et al, 2018).  The algorithm divides patients into three groups; those with CDI, those 
without CDI and those with C. difficile but no CDI (as they have no demonstrable toxin in 
their stool), also termed potential C. difficile excretors (PCDEs) (Planche et al, 2013). 
Additionally, this study also confirms the findings described above, that the presence of 
toxin in a patient’s faecal sample correlates with mortality and severity of infection, in 
contrast to the presence of toxin genes (DNA) or toxigenic strains (Planche et al, 2013; 
Longtin et al, 2013). 
 
1.13.4 Novel technologies 
The most recent advances in CDI diagnostic methods have been ultrasensitive C. difficile 
toxin assays (Pollock, 2016; Song et al, 2015; Banz et al, 2018).  Although not all of these 
assays are commercially available yet (one was launched at the European Congress for 
Clinical Microbiology and Infectious Disease 2019), they offer the potential to detect C. 
difficile toxin levels below the limit of detection of CCNA (Banz et al, 2018). These assays 
also offer the potential to give greater clarity to samples where current diagnostic methods 
give discrepant results. A recent study using this methodology demonstrated that there 
were significant differences between median toxin concentrations in faecal samples from 
CDI cases and asymptomatic carriers, but only when cases/carriers were defined by 
standard toxin detection and not when defined by NAAT positivity (NAAT cases had 
significant diarrhoea, NAAT carriers had no diarrhoea and no prior antibiotics) (Pollock et 
al, 2019). Further studies are required using this technology to determine the clinical 
significance of low-level toxin-positive results. 
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1.13.5 Additional laboratory assays that could be used to aid CDI diagnosis 
Laboratory tests that can highlight the extent of gut inflammation may offer some further 
ways of stratifying those patients with the most severe disease. Both lactoferrin, and 
calprotectin, released by polymorphonuclear leucocytes in the gastrointestinal tract, have 
been investigated for this purpose (Langhorst and Boone, 2012). A case/control study 
found higher levels of both inflammatory markers in patients with CDI, compared with 
controls (Barbut et al, 2017). In addition, the levels in cases were higher in those patients 
with demonstrable free toxin in their faecal samples (Barbut et al, 2017), highlighting the 
effect of toxin on the gut mucosa. Calprotectin has also been found to be a marker for 
severe infection, with an AUROC of 0.821 for severe infection (Kim et al, 2017). Another 
study however, found that raised faecal lactoferrin levels significantly correlated with 
severity of CDI, while faecal calprotectin levels were raised, but not significantly (Swale et 
al, 2014). Further research into the use of adjunctive tests for CDI diagnosis is required but 
lactoferrin has been suggested as an adjunct to a test algorithm for CDI (Wren et al, 2009). 
 
1.13.6 Clinical context 
Although many studies have highlighted the variability in performance of CDI laboratory 
diagnostic assays, there is a paucity of data on the reasons for these differences. There are 
also few data on the clinical course of CDI and the optimal time for each of the different 
diagnostic assays to be used. For instance, depending on the stage of disease a test may 
‘perform’ badly or well as a marker of CDI. For example, if a patient is in recovery phase 
when tested, is toxin still detectable? What does a GDH-positive/toxin-negative or 
GDH-positive/culture-negative result mean; i.e. the presence of disease or the presence of 
a non-viable organism with detectable GDH?  These potential confounding issues have not 
been considered when patient samples are tested in evaluations of CDI tests, even though 
they may have a bearing on performance. Only in large, multicentre studies can these 
possible effects be minimised and true differences between assays of the same type be 
highlighted.  Indeed, within one large multicentre study variability in assay performance 
was seen across four different hospital sites (Planche et al, 2013). These geographical 
differences would not be seen in a single-centre study and could possibly skew assay 
performance data.  
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1.14 Aims 
This study aims to determine if sample, patient and/or bacterium factors could affect the 
performance of CDI diagnostic assays and to determine the optimal time for each of these 
assays to be used during the clinical course of CDI, or highlight alternative uses for current 
diagnostic assays. 
 
1.14.1 Primary objectives 
To determine if the PCR ribotype of C. difficile strains affects the performance of C. difficile 
diagnostic assays; 
to study the proliferation of C. difficile within a human gut model in order to elucidate how 
the different detection targets increase and decrease over the course of the infection; 
to study the clinical course of C. difficile infection within patients to determine if the results 
seen in vitro can be extrapolated to patients; 
to determine the optimal times to use each of the diagnostic assays during the clinical 
course of C. difficile infection. 
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2. Materials and methods 
This section gives details of methods that were commonly used throughout the study. 
Specific methods, especially where they deviate from the methods listed below, are 
detailed within each chapter. In addition, methods only used within one chapter are 
described within the relevant chapter. Please note that wherever faecal samples are tested, 
they are mixed using a vortex generator (Fisons Scientific Equipment, UK) for 30 seconds to 
ensure a homogenised sample, before removal of part of that sample for testing.  
 
2.1 Reference methods 
2.1.1 Cell-cytotoxicity neutralisation assay 
Monolayers of Vero cells (European collection of animal cell cultures), UK) were grown in 
96-well flat bottomed microtitre trays (VWR, UK) in 160µl of Dulbecco medium (Invitrogen, 
UK). Cell monolayers were prepared by the research technicians within the Healthcare 
Associated Infections (HCAI) research group, and then passed to the researcher. To test the 
faecal samples for the presence of C. difficile toxin(s) they were diluted 1:5 in 
phosphate-buffered saline, pH 7.5, and mixed with a vortex (Fisons Scientific Equipment, 
Loughborough, UK) for 30 seconds before being spun in a centrifuge at 16000g for 
10 minutes. Twenty microliters of diluted sample were added to one well of the microtitre 
tray, mixed and then 20µl was removed and added to the next well. This pattern was 
repeated for the two wells on the row below on the microtitre tray, which had been 
protected by the prior addition of 20µl of C. sordelli antitoxin (Prolab Diagnostics, UK). The 
microtitre trays were incubated for 48 hours in an incubator with 10% CO2 (Panasonic 
MCO-5AC-PE, Japan) at 37°C. The cells were examined for rounding after 24 and 48 hours 
using x40 magnification (Leica DMIL, UK ); >50% rounding in only the unprotected cells 
indicated the presence of C. difficile toxin.  Where samples appeared contaminated after 
incubation in the cell-monolayer, the original diluted sample was pushed through a 0.45µm 
syringe filter (Nalgene CA membrane filter, VWR, UK) using a two mL syringe (Fisher 
Scientific, UK), and the resultant filtrate was retested using the procedure outlined above. 
If the cell-cytotoxicity result was still unclear after a second re-test it was recorded as such.  
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2.1.2 Isolation of C. difficile from faecal samples 
One millilitre (or equivalent volume) of faecal samples was added to one millilitre 50:50 v/v 
ethanol and water to kill vegetative organisms before inoculation onto Brazier’s agar (Oxoid, 
UK) supplemented with 250mg/L  cycloserine and 8mg/L cefoxitin (Oxoid, UK) and 2% lysed 
horse blood (Oxoid, UK). Plates were incubated anaerobically for 48 hours at 37°C in an A95 
anaerobic workstation (Don Whitley, UK) then examined for growth typical of C. difficile 
(grey-brown colonies with an irregular edge and horse manure odour). Suspect isolates 
were checked for green/yellow fluorescence under longwave (365 nm) UV light and latex 
agglutination for somatic antigen (Microgen Bioproducts Ltd, UK). Confirmation of ID of the 
organism was based on the criteria in table 2.1.  
 
 C. difficile C. bifermentans 
C. sordellii 
C. glycolicum 
C. innocuum 
Fluorescence under 
UV at 365 nm 
+ - + 
Latex agglutination + + - 
Table 2.1 Criteria used to determine the identity of isolates demonstrating typical 
colony morphology for C. difficile on CCEY 
 
2.1.3 Cytotoxigenic culture assay 
Isolates confirmed as C. difficile were sub-cultured into four ml pre-reduced brain heart 
infusion (BHI) broth (Oxoid, UK). After anaerobic incubation at 37°C for 48h, one ml of 
broth supernatant was removed and spun at 16,000g in a centrifuge for 10 minutes. 
Twenty microliters of this BHI broth supernatant was then tested for the presence of toxin 
using the cell-cytotoxicity assay as described above. 
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2.1.4 Total viable counts and spore counts 
Total viable counts were determined by a variation of the method of Miles and Misra 
(Miles et al, 1938, Levett 1991); samples were diluted 10-fold in pre-reduced peptone 
water to 10-6 with 20µL inoculated onto pre-reduced Brazier’s agar supplemented as 
described in section 2.1.2., in triplicate for each dilution. The agar plates were incubated 
anaerobically for 48 hours in an A95 anaerobic workstation (Don Whitley, UK) before 
colonies were counted.  
Spore counts were determined after alcohol shock; one ml of the batch culture broth was 
added to one ml ethanol (50% w/v) and left at room temperature for 1 hour. Ten-fold 
dilutions were prepared from the alcohol shock fluid and plated out using the Miles and 
Misra technique as described above.   
 
2.1.5 Storage of isolates at -20°C 
For each sample positive for C. difficile, a C. difficile colony isolated on Brazier’s agar,  
supplemented as described in section 2.1.2., was harvested using a sterile loop and used to 
inoculate a Columbia blood agar plate (Oxoid, UK), streaking out for single colonies. Plates 
were incubated  at 37oC in an A95 anaerobic workstation (Don Whitley, UK) for seven days 
to encourage germination and out-growth of spores. All growth (if pure) was harvested 
from the plate using a sterile cotton tip swab and inoculated into a cryogenic microtube 
(Sarstedt Inc, UK) containing one ml nutrient broth with 10% glycerol. Microtubes were 
stored in Nalgene cryoboxes (Sarstedt Inc, UK) in a -80oC freezer (New Brunswick, Austria).  
 
2.1.6 PCR ribotyping 
All the C. difficile isolates identified from the study were typed by the C. difficile Ribotyping 
Network of England and Northern Ireland (CDRN) laboratory using PCR ribotyping as 
described by the CDRN protocol (Stubbs et al, 1999). Briefly, DNA was extracted from 
isolate suspensions in water using the DX kit on the Qiagen Xtractor (Qiagen Ltd, UK) 
automated DNA extraction platform. DNA was amplified using primers targeted to the 16s-
23s rRNA intergenic spacer region designed by Bidet et al (1999) on the Verti thermocycler 
(Life Technologies, UK). Amplified products were either visualised on agarose gels following 
electrophoresis on the Midi I 128mmx110mm (Thermofisher Scientific Ltd) (used for 
isolates from the Department of Health study) or fragment lengths were measured on the 
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3130XL Gene Analyser (Thermofisher Scientific Ltd, UK) sequencer (used for isolates from 
the PlaciD study). Band patterns from both methods were compared to library reference 
strains of C. difficile using bioNumerics (Applied maths, Belgium) to determine PCR ribotype. 
 
2.2 Commercially available methods 
2.2.1 C. diff chek-60™ (Techlab Ltd, USA); a commercial enzyme 
immunoassay for the detection of C. difficile glutamate dehydrogenase 
(GDH).  
One hundred microliters of faecal samples were diluted in 400µL of kit sample diluent; to 
ensure there was enough sample volume (including dead volume) these were double the 
recommended volumes. Samples were mixed using a vortex mixer then spun in a 
centrifuge at 10,000g for 10 minutes. Sample tubes were loaded onto the DS2 instrument 
(Dynex Technologies, USA) along with all of the kit consumables; wash buffer (phosphate-
buffered saline containing detergent and 0.2% thimerosal), conjugate (a highly specific 
mouse monoclonal antibody to GDH conjugated to horseradish peroxidase), substrate 
(tetramethylbenzidine and peroxide), stop solution (0.6 N sulphuric acid), and the required 
number of pre-coated wells from the microplate kit. The wells were pre-coated with an 
immobilised polyclonal antibody to glutamate dehydrogenase. The DS2 was 
pre-programmed to carry out the following steps; 50µL of conjugate and 100µL of diluted 
sample were added to individual wells, plates were shaken to mix the contents thoroughly 
whilst they are incubated at 37°C for 20 minutes (this is shorter than the 50 minutes stated 
in the kit instructions, as the shaking reduces the incubation time; this is recommended by 
the manufacture), each well was washed with 350µL wash buffer for a total of three times 
before the addition of 100µL of substrate. After a further 10 minutes of shaking incubation 
at room temperature, 50µL of stop solution was added to each well. The resultant colour 
change was read using a dual wavelength (450/620nm) spectrophotometer built into the 
DS2. On each plate run, a positive and negative control well was added. The test procedure 
for the controls was as described, with the exception that 100µL of either positive or 
negative control (included in the kit) were added to the control wells instead of diluted 
sample. For the results of a microplate run to be accepted, the positive and negative 
control OD values had to fall within quality control limits; positive control >0.500 and 
negative control <0.080. If the QC failed, the testing for that sample batch was repeated on 
the same day. As the kit is designed for diagnosis from patient specimens, there are set 
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cut-off values stated in the kit insert; an OD ≥0.080 indicates a positive result, with <0.080 
indicting a negative result.  
 
2.2.2 Tox AB II™ (Techlab Ltd, USA); a commercial enzyme immunoassay for 
the detection of C. difficile toxins A and B 
The sample buffer for the TOX AB II™ assay and the C. diff Chek-60™ assay are the same, as 
they are made by the same manufacturer (Techlab Ltd, USA). The initial sample preparation 
steps are therefore the same and only need to be carried out once, in order to perform 
both assays. Additionally, the same reagents and test procedure can be used for both 
assays, with the exception of the microplate wells, the positive control and the conjugate, 
which are specific to each assay. The microplate wells in the TOX AB II™ assay are coated 
with a goat polyclonal antibody against both toxins (A and B) which has been affinity 
purified and immobilised onto the wells. The conjugate contains a mixture of a monoclonal 
mouse toxin A antibody and a polyclonal goat toxin B antibody, both conjugated to 
horseradish peroxidase.  The cut-off values and QC values for the TOX AB II™ kit are the 
same as for the GDH kit, described above.   
 
2.2.3 Premier Toxins A & B™ (Meridian Bioscience, Inc. Europe, UK); a 
commercial enzyme immunoassay for the detection of C. difficile toxins A 
and B  
Two hundred microliters of faecal sample were added to 800µL of kit sample diluent; these 
were double the recommended volumes, to ensure there was enough residual volume, 
included dead volume, to run the assay on the DS2. These volumes were recommended by 
the manufacturer (verbal communication). Samples were mixed using a vortex mixer 
(Fisons Scientific Equipment, UK) then spun in a centrifuge at 2,750g for 5 minutes. Sample 
tubes were loaded onto the DS2 instrument along with all of the kit consumables; wash 
buffer (phosphate-buffered saline containing detergent and 0.2% thimerosal), conjugate 
(polyclonal goat anti-toxin A and anti-toxin B antibodies conjugated to horseradish 
peroxidase), substrate (tetramethylbenzidine and peroxide), stop solution (1M phosphoric 
acid), and the required number of pre-coated wells from the microplate kit. The wells were 
pre-coated with an immobilised mouse monoclonal anti-toxin A antibody and a polyclonal 
goat anti-toxin B antibody.  The DS2 was pre-programmed to carry out the following steps; 
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50µL of conjugate and 100µL of diluted sample were added to individual wells, plates were 
shaken to mix the contents thoroughly whilst they were incubated at 37°C for 20 minutes 
(as with the Techlab assays, this is shorter than the 50 minutes stated in the insert, as the 
shaking reduces the incubation time, but is also recommended by the manufacturer of this 
assay). Each well was washed with 350µL wash buffer for a total of three times before the 
addition of 100µL of substrate. After a further 10 minutes of shaking incubation at room 
temperature, 50µL of stop solution was added to each well. The resultant colour change 
was read using a dual wavelength (450/630nm) spectrophotometer built into the DS2. On 
each plate run, a positive and negative control well was added. The test procedure for the 
controls was as described, with the exception that 100µL of either positive or negative 
control (included in the kit) were added to the control wells instead of diluted sample. For 
the results of a microplate run to be accepted, the positive and negative control OD values 
had to fall within quality control limits; positive control >0.100 and negative control <0.100. 
If the QC failed, the testing for that sample batch was repeated on the same day. As the kit 
is designed for diagnosis from patient specimens, there are set cut-off values stated in the 
kit insert; an OD ≥0.100 indicates a positive result, with <0.100 indicting a negative result.  
 
2.2.4 GeneXpert®, C.diff (Cepheid UK Ltd., UK); a commercial multi-plex PCR 
assay for the detection of the tcdB gene, the truncated form of the tcdC gene, 
and the binary toxin gene from faecal samples 
A Copan dual swab (Copan Diagnostics, USA) was used to remove a small amount of faecal 
material from the sample; this was the only validated swab for use with this assay at the 
time. The swab was dipped into the faecal sample until half of the swab tip was covered by 
faecal material (as per manufacturer’s instructions); only one swab of the pair within the 
dual swab was used (as per manufacturer’s verbal instructions).  The swab was snapped off 
into the kit sample buffer before the buffer was mixed using a vortex (Fisons Scientific 
Equipment, UK) for 30 seconds. A plastic pipette was used to transfer the entire volume of 
the sample buffer into the sample well within the GeneXpert® cartridge.  All other test 
reagents are already pre-prepared within the cartridge. The cartridge lid was snapped shut 
and the cartridge placed into the GeneXpert® XVI machine (for samples in the Department 
of Health study) or the GeneXpert® IV machine (for all other analyses) (both Cepheid, USA). 
The assay has a run time of 47 minutes, and inbuilt internal controls to check both the 
extraction and amplification stages. Pre-specified algorithms within the machine software 
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determine if the test is valid (if the internal control has been detected within the correct 
cycle threshold [CT] value parameters). The algorithm also produces results for detection of 
tcdB, the truncated form of tcdC, and the binary toxin gene, based upon both the CT value 
and the end-point threshold value. Results were recorded as positive or negative, as 
determined by the algorithm, for each of these genes; the software algorithm can also 
produce a ‘presumptive 027’ result, if all three of the targets are detected within the 
correct parameters. The actual CT values and end point values were also recorded. If a 
sample result was invalid, the sample was tested once more. The result of the second test 
was recorded in the study database (even if it was invalid again).  
 
2.2.5 BD Max™ C.diff (Becton Dickinson and Company, Sparks, MD, USA); a 
commercial multiplex assay for the detection of the tcdB gene from faecal 
samples 
A plastic 10µL loop (Starstedt Inc, UK) was used to remove a 10µL portion of a faecal 
material from the sample before adding to the sample buffer tube supplied with the kit. A 
septum cap (included in the kit) was added to the tube before the contents were mixed 
using a vortex (Fisons Scientific Equipment, UK).  One test strip from the kit was used per 
sample; strips contained lysis tube, extraction tube (magnetic DNA affinity beads, 
Achromopeptidase and sample processing control in a freeze dried pellet), C. difficile 
master mix (tcdB specific primers and probe, sample processing control specific probe in a 
freeze dried pellet), wash buffer, elution buffer, neutralisation buffer, a waste reservoir and 
pipette tips. The sample tube and test strip were added to the BD MAX™ system. The assay 
has a run time of 56 minutes, and has inbuilt controls to check both the extraction and 
amplification stages. The software within the BD Max™ system contains a pre-specified 
algorithm to determine in a test is valid, and what the result of a test is; positive (tcdB 
detected), negative (no tcdB detected), unresolved (no amplification of internal control, 
possibly due to sample inhibition), indeterminate (no results due to system failure) or 
incomplete (run did not complete). If a sample result was unresolved, indeterminate or 
incomplete, the sample was tested once more. The result of the second test was recorded 
in the study database (even if it was unresolved again).  
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2.3 Gut model 
The gut model is a temperature-controlled, triple chemostat system linked by weir cascade, 
representing the pH and nutrient availability of the proximal to distal colon (figure 2.1), 
using bespoke glassware (Soham Scientific, UK). The system was sparged with oxygen-free 
nitrogen from a nitrogen generator (Parker Balston, UK) to keep the system anaerobic. The 
pH of each vessel was monitored using MLO pH meters (Brighton Systems Ltd, UK) and 
either acid or alkali was added automatically to ensure that each vessel was kept at the 
correct pH; vessel one pH 5.5 (+/-0.2), vessel two pH 6.2 (+/-0.2), vessel three pH 6.8 (+/-0.2). 
A 10% w/v pooled faecal slurry was prepared using saline and donated healthy stools 
(collected under ethical approval from University of Leeds HSLTLM/12/061 and MREC15-
070) that were mixed using a 400 paddle blender stomacher (Seward Ltd, UK ), before 
300mL of the pooled faecal slurry was added to the system to introduce gut microbiota to 
the vessels.  A defined growth medium, as previously described (Freeman et al, JAC 2003), 
was added to the system at a continuous flow rate of 0.015h-1 via a masterflex digital (HV-
77921-60) peristaltic pump (Cole Palmer Ltd, UK), to mimic bowel transit time. Each vessel 
was kept at 37°C as it is jacketed by a water filled layer, circulating through a Grant P5 
heated waterbath (Grant Instruments Ltd, UK).  
The levels of faecal bacteria were monitored by culturing gut model fluid on selective agars 
(Freeman et al, 2003); once populations of bacteria had stabilised the model was classed as 
reaching ‘steady state’.   C. difficile spores (~107 cfu/mL) were added twice, each dose one 
week apart, and again the bacterial populations in the models were left to stabilise. 
Clindamycin was instilled into the gut model (33.9 mg/L four times per day, for 7 days) to 
induce simulated CDI.  C. difficile total viable counts, spore counts and toxin levels were 
enumerated daily. A CDI treatment antibiotic was then added to the system, C. difficile 
total viable counts, spore counts and toxin levels were monitored for further defined 
periods; the specifics of each gut model experiment are given in Chapter 2. The gut models 
were set-up, maintained and sampled by the technicians and research assistants within the 
HCAI research group, under the guidance of the PI for that set of models; Kerrie Davies 
tested gut model fluid from each model using the commercial assays. Permission was 
granted for the use of excess gut model fluid to be used by Kerrie Davies for this PhD 
project from the funder of each set of gut models. 
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Figure 2.1. Image of the triple-stage chemostat gut model  
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3. Organism factors affecting detection by commercial assays 
 
3.1 Introduction 
Rapid enzyme immunoassays (EIAs) were developed to detect C. difficile toxins A and B 
directly from a faecal sample and to reduce the time to diagnosis to less than two hours 
(Lyerly et al, 1983). Comparison studies of commercially available toxin detection EIAs 
show huge variation in the performance of these assays with some sensitivities <50% in a 
low-prevalence setting (Eastwood et al, 2009). In addition, commercial assays with 
alternative targets for detection of C. difficile have been developed, such as a test for 
glutamate dehydrogenase (GDH), an enzyme associated with the cell surfaces of many 
bacteria (Anderson et al, 1993). The variability seen in the performance of toxin EIAs does 
not seem to be present with C. difficile-specific GDH EIAs (Shetty et al, 2011), perhaps 
suggesting that there is less target heterogeneity i.e. GDH has less antigen variability than 
C. difficile toxins. One disadvantage of GDH assays, however, is that they cannot distinguish 
between toxigenic and non-toxigenic strains, meaning that they have to be used in 
conjunction with another, toxin-detecting assay to diagnose CDI.  
Detection of toxin gene DNA using nucleic acid amplification tests (NAAT) offer an 
alternative, rapid and potentially high-throughput method for screening faecal samples for 
toxigenic C. difficile. It has been suggested that a PCR assay for toxin genes (Cepheid 
geneXpert® C. diff, US) is more sensitive for certain PCR ribotypes of C. difficile than GDH 
EIAs (Tenover et al, 2010), even though the genes for GDH have been shown to be 
ubiquitous in C. difficile (Carman et al, 2012). It should be noted, however, that the number 
of samples examined in this study was small in total and the number of each PCR ribotype 
even smaller (Tenover et al, 2010).  
Here a previously collected data set, comparing commercial C. difficile detection assays, 
was interrogated to determine if the PCR ribotype of the organism affected detection by 
these assays. In addition, the production of GDH by the organism was explored using 
growth curves. Key findings in this chapter are; 
 Performance of commercial toxin detection assays varied for different PCR 
ribotypes, specifically non-027 ribotypes 
 Performance of commercial GDH detection assays did not vary for different PCR 
ribotypes 
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 GDH appeared to be produced during the exponential phase of growth of the 
organism 
 
3.2 Methods 
3.2.1 Effect of PCR ribotype on EIA performance (GDH and toxins) 
3.2.1.1 Analysis of existing data set for evidence of decreased sensitivity for 
detection of certain PCR ribotypes by commercial enzyme immunoassays from 
faecal samples 
Hypothesis 
The commercial enzyme immunoassays for both GDH and toxin detection have decreased 
sensitivity for certain ribotypes of C. difficile. 
Methods 
Diarrhoeal faecal samples, collected as part of a large, multicentre evaluation of CDI 
laboratory diagnostics were tested with two reference methods; cell cytotoxicity and 
cytotoxigenic culture, and by three enzyme immunoassays (EIAs); one for detection of 
glutamate dehydrogenase (C. diff CHEK-60™, Techlab, USA) and two for the detection of 
toxins A and B (Toxin AB II™, Techlab, USA and Premier Toxins A & B™, Meridian, USA) 
(Planche et al, 2013). Assays and reference methods were performed on the same day by 
the same evaluator at three sites (one in Leeds and two in London) or two evaluators in 
one site (Oxford). In total, one evaluator worked at each of the two London sites, two at 
Leeds, and three at Oxford. Kerrie Davies was one of the evaluators at the Leeds site and 
scientific coordinator for the entire study. All analysis from these data within this thesis was 
completed by Kerrie Davies. Ethical approval for the extended use of the study data for this 
thesis was granted by the NHS REC, approval number 12/EE/0495. The initial study ethical 
approval number was 10/H0715/34. 
Commercial enzyme immunoassays 
All of the commercial EIAs were performed on an automated platform (DS2, Dynex 
Magellan Biosciences, USA) to reduce operator error, following manufacturer’s protocols 
given in the kit insert, with minor changes listed within materials and methods section 2.2. 
The optical density (OD) of each test was recorded as well as the result defined by the 
assay (using manufacturer’s set cut-offs). 
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Reference methods 
The cell-cytotoxicity neutralisation assay, culture and the cytotoxigenic culture assay were 
performed as described in materials and methods section 2.1.  
PCR ribotyping 
The C. difficile isolates identified from the study were typed using PCR ribotyping by the 
C. difficile Ribotyping Network of England and Northern Ireland (CDRN) as previously 
described (Stubbs et al, 1999) and as expounded in the methods section 2.1.6. 
Analysis 
Median optical densities (OD) for different PCR ribotypes of C. difficile were compared 
using Mann-Whitney tests to determine if certain PCR ribotypes produced higher optical 
density readings than others. The detection rates of the EIAs for different PCR ribotypes 
were compared using Chi-squared (χ2) tests, thereby highlighting if particular PCR ribotypes 
were more likely to be missed (give a negative result) by an assay than other PCR ribotypes. 
Only the results of toxigenic strains of C. difficile were analysed for the two-toxin detection 
EIAs, whereas all strains were included for the GDH assay analysis as this assay can detect 
both toxigenic and non-toxigenic strains of C. difficile. 
  
3.2.1.2 Investigation of batch cultures for evidence of decreased sensitivity for 
detection of certain PCR ribotypes by commercial enzyme immunoassays 
Hypothesis 
The commercial enzyme immunoassays for both GDH and toxin detection have decreased 
sensitivity for detecting certain ribotypes because different ribotypes produce different 
amounts of the assay target molecule. 
Methods 
Different strains of C. difficile were inoculated into 200LBHI to give monocultures of each 
strain. Broths were incubated anaerobically (A95 workstation, Don Whitley, UK) for 48 
hours, to obtain peak levels of GDH and toxin production. After incubation, the broths were 
serially diluted 10-fold in sterile phosphate-buffered saline (PBS). Each dilution was tested 
with the commercial assays (as per manufactures’ instruction and described in materials 
and methods section 2.2) substituting the patient specimen with the dilution of broth to be 
tested. Total viable counts for each broth were determined by serial plating of 20µL 
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volumes onto CCEY (materials and methods section 2.1.4) and incubating anaerobically for 
48 hours before counting colonies. All assays were performed in triplicate.  
Isolates tested included representatives of PCR ribotypes 001, 002, 005, 014, 015, 020, 027, 
106 (CDRN library strains). These isolates were selected as they were either the most 
common strains in previous studies (001, 027, 015 and 014) (Davies et al, 2014), the most 
commonly ‘missed’ strains during the Department of Health study (005, 0202 and 014) 
(Planche et al, 2013), or have been highlighted as strains where there are discrepancies 
between methods (002, 027 and 106) (Tenover et al, 2010).  
 
3.2.1.3 Dilutions after 24 hours growth 
Hypothesis 
The commercial enzyme immunoassays for both GDH and toxin detection have decreased 
sensitivity for detecting certain ribotypes because different ribotypes produce different 
amounts of the assay target molecule at 24 hours  
Methods 
The previous experiment was repeated for three strains (002, 014, 027), but with only an 
initial incubation period of 24 hours and using 2-fold dilutions of the final broths instead of 
10-fold dilutions.   
 
3.2.1.4 Investigation of the growth curve of C. difficile to determine where in the 
growth cycle GDH detection peaks 
Hypothesis 
That GDH is produced as the C. difficile cells proliferate, allowing detection of GDH early in 
the growth cycle of the bacterium. 
Methods 
Growth curve 1 
A 0.5 Macfarland suspension of C. difficile growth harvested from overnight culture of 
C. difficile on CCEY was made in PBS. The strain used was a clinical strain from a case of CDI 
in Maine Medical centre, Portland, USA in 2005, kept in research group archive; it is PCR- 
ribotype 027 and is susceptible to clindamycin (MIC of 0.5mg/L). This strain is used 
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throughout this thesis for growth curves and gut model experiments. A 200µl volume of 
the 0.5 McFarland suspension was added to 200mL of pre-reduced BHI broth before 
anaerobic incubation on a rotary shaker (Compact orbital shaker, Cole Palmer, UK). 
The broth was sampled for total viable counts/spore counts/GDH EIA OD/Toxin EIA OD and 
toxin titre (cell-cytotoxicity neutralisation assay) (materials and methods sections 2.1 and 
2.2) at the following time points; 0, 3, 6, 24, 27, 30, 48, 51, 54, 72, 75 and 78 hours post 
inoculation.  
For the GDH and toxin EIAs, 100µL of the batch culture broth was added to 400µL EIA 
buffer (to simulate a patient sample).  Samples were then tested as per manufacturer’s 
instructions for patient samples on the DS2 instrument (materials and methods section 2.2). 
Where samples tested using the enzyme immunoassays reached the maximum OD value, 
they were diluted (1/10 dilution series) and tested again. The OD value was then calculated 
from the dilution. See sections 4.2.1.3 and 4.3.1.3 in Chapter 2 for an explanation of the 
maximum OD threshold of the enzyme immunoassays.  
Cytotoxin titres were determined using the cell-cytotoxicity neutralisation assay (CCNA) 
using the method described previously (materials and methods section 2.1.1) with the 
exception that 20µL of the batch culture fluid was diluted across the toxin tray by doubling 
dilutions up to a maximum of six times.  
Growth curve 2. 
The second growth curve was set up as per the first growth curve with the following 
exceptions;  
1) The initial inoculum was 200µL of a spore preparation of known concentration, to give a 
final spore concentration of 1.6x104cfu/mL in the 200mL BHI. There will be an initial lag 
phase before growth begins but this may give some interesting information about whether 
GDH can be detected at that time or not, as in the gut model there was some ‘turnover’ of 
the organism before germination was seen to occur. This was in the gut model, however, 
and conditions will therefore be different from those seen in batch culture.   
2) The batch culture fluid was tested for total viable counts/spore counts/GDH EIA 
OD/Toxin EIA OD and cytotoxin titre (cell-cytotoxicity) at the following time points; 0, 2, 4, 
6, 8, 24, 26, 28, 30, 32, 48, 50, 52, 54, 56, 72, 74, 76, 78 and 80 hours post inoculation. 
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3.2.2 Effect of the presence of spores and vegetative cells on the diagnosis 
of CDI when using PCR to detect C. difficile toxin genes 
3.2.2.1 Can the commercial C. difficile toxin gene PCR assay detect DNA from 
C. difficile spores as well as DNA from vegetative cells? 
Hypothesis 
That the commercial C. difficile toxin gene PCR assay Xpert® C.diff cannot detect DNA from 
C. difficile spores.  
Methods 
Cleaning spore preparations to remove residual DNA 
Five microliters of commercial DNAse I suspension (Sigma Aldrich, UK) and 5µl of DNAse 
buffer (Sigma Aldrich, UK) were added to 50µL of a spore preparation before it was 
incubated at room temperature for 15 minutes, as per manufacturer’s instructions. After 
15 minutes, 5µl of STOP solution (Sigma Aldrich, UK) were added and the spore preparation 
was incubated at 70°C for a further 10 minutes. The spore preparation was allowed to cool 
before 50µL was tested with the Cepheid GeneXpert® C. diff PCR assay. 
As the PCR assay gave a positive result for the spore preparation after it had been treated 
appropriately with DNAse, the spore preparation was then diluted using 10-fold serial 
dilutions and each dilution was treated with DNAse as before. Each dilution was then 
tested using the Cepheid  GeneXpert® C. diff PCR assay.  
In addition, to determine if spores are lysed by sonication (the method of DNA extraction 
used by the Cepheid  GeneXpert® C. diff PCR assay), the spore preparation that had been 
diluted to 1/1000 was sonicated for 10 minutes in a sonicating waterbath (45 kHz, USC100T, 
VWR Scientific, UK). This preparation was not treated with DNAse before it was tested with 
the Cepheid GeneXpert® C. diff PCR assay.  
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3.3 Results 
3.3.1 Effect of PCR ribotype on EIA performance (GDH and toxins) 
3.3.1.1 Analysis of existing data set for evidence of decreased sensitivity for 
detection of certain ribotypes by commercial enzyme immunoassays from faecal 
samples 
There were 1295 samples from which C. difficile was isolated; 1291 (99.6%) of which had an 
OD available for C. DIFF Tox AB II™, and C. DIFF CHEK-60™assays, whilst there were only 
961 (74.2%) with an OD result for the Premier™ Tox A/B assay. The three most common 
PCR ribotypes isolated were 014 (n = 128), 015 (133) & 027 (104). The median OD values 
for both toxin EIAs were significantly higher for PCR ribotype 027 than for other PCR 
ribotypes (table 3.1). In addition, the median OD value for PCR ribotype 015 was higher 
than for other PCR ribotypes when using the C. diff Tox AB II™ assay, but not for the other 
toxin EIA (table 3.1). The higher OD values for PCR ribotype 027 may account for the 
increased sensitivity of the test for this strain, as both toxin EIAs were significantly less 
likely to ‘miss’ PCR ribotype 027 than any other PCR ribotype (p = <0.0001). There were 
significant differences between the OD values for the two toxin assays for PCR ribotypes 
027 and 015, with the median ODs being significantly higher with the C. DIFF Tox AB II™ 
assay than the Premier™ Tox A/B assay (027, p = 0.007; 015, p = 0.03) (figure 3.1). It is 
interesting to note, however, that although there were differences in the median ODs for 
these PCR ribotypes between the two assays, they failed to detect C. difficile toxins in 
similar numbers of samples containing these isolates. The Premier™ Tox A/B missed 16% of 
samples containing PCR ribotype 027 and 37% of samples containing PCR ribotype 015 
compared with 15% (027) and 38% (015) using the C. DIFF Tox AB II™ assay.  
The two toxin EIAs most commonly failed to detect toxin in samples containing the same 
three PCR ribotypes of C. difficile, 005, 014 and 020, although they were not statistically 
more likely to ‘miss’ these PCR ribotypes than other PCR ribotypes (table 3.2.). 
Cytotoxigenic culture confirmed that 95% of these isolates were capable of producing toxin, 
however direct cell-cytotoxicity was only positive in 30% of the isolates tested.  
The variation of median OD values across PCR ribotypes seen with toxin EIAs was not 
present for the C. DIFF CHEK-60™ (GDH) assay (table 3.1). Additionally, this assay was not 
statistically more likely to miss any one PCR ribotype over others. In fact, even the three 
most commonly missed PCR ribotypes were in very low numbers; 002 (9.9% missed), 015 
(6.8% missed) and 027 (6.7% missed).  
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Assay 
Median OD for C. difficile PCR ribotype (RBT) 
RBT 
014 
Non-
014 
RBT 
Mann 
Whitney  
(p value) 
RBT 
015 
Non-
015 
RBT 
Mann 
Whitney  
(p value) 
RBT 
027 
Non-027 
RBT  
Mann 
Whitney  
(p value) 
Premier™ Tox 
A/B 
0.03 0.02 0.4 0.04 0.02 0.1 1.93 0.02 <0.0001 
C. DIFF TOX 
AB II™ 
0.11 0.05 0.12 0.38 0.04 <0.0001 3 0.03 <0.0001 
C. DIFF CHEK-
60™ 
3 3 0.07 3 3 0.5 3 3 0.06 
Table 3.1 The median OD of the three most common PCR ribotypes in the DoH 
study for each EIA, with comparisons to the median OD for PCR ribotypes other 
than the one selected 
 
 
Figure 3.1 Comparison between the OD values of the two toxin EIAs for PCR 
ribotype 027 and 015  
P = 0.007 P =0.03 
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Percentage 
of PCR 
ribotype 
005 missed 
(%) 
Significance 
of missing 
PCR 
ribotype 
005 over 
other PCR 
ribotypes  
(χ2 p value) 
Percentage 
of PCR 
ribotype 
014 missed  
(%) 
Significance 
of missing 
PCR 
ribotype 
014 over 
other PCR 
ribotypes  
(χ2 p value) 
Percentage 
of PCR 
ribotype 
020 missed  
(%) 
Significance 
of missing 
PCR 
ribotype 
020 over 
other PCR 
ribotypes  
 (χ2 p value) 
 
Premier™ 
Tox A/B  64.7 0.107 58.3 0.346 55.9 0.806 
C. DIFF Tox 
AB II™ 54.4 0.073 46.1 0.571 46.8 0.667 
Table 3.2. The three PCR ribotypes most commonly ‘missed’ by the two toxin EIAs 
and the significance of the ‘missed’ result 
 
3.3.1.2 Investigation of batch cultures for evidence of decreased sensitivity for 
detection of certain PCR ribotypes by commercial enzyme immunoassays 
There is little variation in the quantity of GDH detected by the EIA for the different PCR 
ribotypes, as shown by both the OD values and the titre at which the test first becomes 
negative (figure 3.2).  PCR ribotype 002 does, however, appear to have less GDH detected 
than the other PCR ribotypes; the dilution at which the test first becomes negative is 10-
fold lower than any other PCR ribotype (figure 3.2) and the median OD values are 
substantially lower than any other PCR ribotype (Figure 3.3). PCR ribotype 014 also appears 
to have lower median OD values than other PCR ribotypes, although they are not as low as 
002.  
The same pattern of results is observed with the toxin EIA OD values, where PCR ribotypes 
002 and 014 have the lowest median OD values and 002 becomes negative at a dilution 
100-folder lower than the other PCR ribotypes (figures 3.2 and 3.4). The dilutions at which 
014 becomes negative were inconsistent; there was a 100-fold difference between the 
three replicates. It should be noted that the cell-cytotoxin titre was also lower for 
PCR ribotype 002 than other PCR ribotypes.  
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The drop-off between dilutions is very stark, which may be a product of the 10-fold 
dilutions used. The experiment was therefore repeated for PCR ribotypes 002, 014 and 027 
in the next experiment using 2-fold dilutions to try to close the gap on the steep drop-off.  
 
Figure 3.2. Graph showing the first titre for each C. difficile PCR ribotype that gave 
a negative result on the GDH and toxin EIAs, along with the Log10 total viable 
count and cytotoxin titre for the starting broth 
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Figure 3.3. The decreasing median OD values of the broths for each of the 
different C. difficile PCR ribotypes, when tested using the GDH EIA (C. DIFF CHEK-
60™). Red line indicates the diagnostic cut-off value for a positive sample (as 
defined by the kit insert) 
 
 
Figure 3.4. The decreasing median OD values of the broths for each of the 
different C. difficile PCR ribotypes, when tested using the toxin EIA (C. DIFF Tox 
AB II™). Red line indicates the diagnostic cut-off value for a positive sample (as 
defined by the kit insert) 
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3.3.1.3 Dilutions after 24 hours incubation. 
There was less variation between the PCR ribotypes for the level of GDH and toxin detected 
by the enzyme immunoassays than seen in the previous experiment (figure 3.5). Previously, 
the amount of GDH detected for ribotypes 002 and 014 was much lower than that detected 
for ribotype 027. In this experiment, however, there is little difference (figure 3.6). The 
same pattern is true for the level of toxin detected; previously there were higher levels for 
isolates of ribotype 027 (figure 3.7). Interestingly, although the level of toxin detected by 
the EIA appears to be similar between the three ribotypes, there is a large difference 
between the toxin titres when measured using the CCNA, with isolates of ribotype 027 
having a titre of 12 compared with 7 or 9 for isolates of ribotypes 002 and 014 respectively. 
The logTVCs were lower (by about one log10) than the previous experiment, they were 
however, reasonably consistent across the ribotypes with a standard deviation of log10 TVC 
= 0.236. Interestingly, there were no spores detected for isolates of ribotype 002. It should 
be noted that the cultures were only grown for 24 hours this time, compared with 48 hours 
in the previous experiment.  
 
Figure 3.5 Graph showing the first titre for each C. difficile PCR ribotype that gave 
a negative result on the GDH and toxin EIAs, along with the log10 total viable 
count and cytotoxin titre for the starting broth 
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Figure 3.6. Graph showing the decreasing median OD values on the GDH EIA assay 
(C. DIFF CHEK-60™) for each of the different C. difficile PCR ribotypes. Red line 
indicates the cut-off value for a positive sample 
 
 
Figure 3.7. Graph showing the decreasing median OD values on the Toxin AB II EIA 
assay (C. DIFF Tox AB II™) for each of the different C. difficile PCR ribotypes. Red 
line indicates the cut-off value for a positive sample 
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3.3.1.4 Investigation of the growth curve of C. difficile to determine where in the 
growth cycle GDH detection peaks 
First growth curve 
The growth curve (figure 3.8) shows the initial logarithmic phase of growth within the first 
24 hours. After this point, growth plateaus as the organism enters stationary phase. The 
GDH curve mirrors that of the total viable counts, with the biggest increase in GDH 
detection between 6 and 24 hours, although it does appear to lag slightly behind the 
growth curve (as measured by TVCs).  
 
 
Figure 3.8. Growth curve showing growth of C. difficile as measured by total 
viable counts, spore counts, GDH production and toxin titre; starting inoculum 
was viable cells 
 
Second growth curve 
The growth curve of PCR ribotype 027 with a starting inoculum of spores shows a lag period 
before the exponential growth phase (figure 3.9). The vessel was not sampled between 8 
and 24 hours so the line between these points is extrapolated. GDH was detected before 
germination was detected using TVCs.  
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It should be noted that the amount of toxin produced in this experiment, as measured by 
both toxin titres (CCNA) and toxin EIA, is almost twice as high as the previous growth curve.  
Nevertheless, the log10 viable counts are about the same for both experiments.  
 
 
Figure 3.9 Extrapolated growth curve showing growth of C. difficile as measured 
by total viable counts, spore counts, GDH production and toxin titre; starting 
inoculum was spore preparation 
 
3.3.2 Effect of spores and vegetative cells on the diagnosis of CDI by PCR for 
C. difficile toxin genes 
3.3.2.1 Can the commercial C. difficile toxin gene PCR assay detect DNA from 
C. difficile spores as well as DNA from vegetative cells? 
Cleaning spore preparations to remove residual DNA 
The Cepheid geneXpert® C. diff PCR assay gave a positive result for the spore preparation 
after treatment with DNAse.  The CT values for all three targets in the assay were 
comparable between the two samples (table 3.3).  
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CT value at which the assay became 
positive for each target 
  tcdB  cdt  tcdC  
DNAse 19.9 19.1 20.7 
no 
DNAse 18.8 18.1 19.4 
Table 3.3 The CT values at which the Cepheid assay became positive for different 
dilutions of a C. difficile spore preparation after treatment with DNAse. The label 
tcdB indicates detection of toxin B gene, tcdC indicates detection of the deletion 
in the tcdC gene associated with PCR ribotype 027, cdt indicates detection of 
binary toxin gene.  
 
To allow for the possibility that there was too much starting material for the DNAse to work 
appropriately, the spore preparation was diluted and then each diluted sample was treated 
with DNAse, as per the kit instructions. Diluting the spore preparation before treatment 
with DNAse does not, however, appear to have affected the detection of DNA within the 
sample, as all four dilutions were still positive by the assay (figure 3.10), with roughly a four 
CT increase between dilutions (table 3.4 and figure 3.10).   
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Figure 3.10 Graph showing the CT values at which the Cepheid assay became 
positive for different dilutions of a C. difficile spore preparation after treatment 
with DNAse 
 
 
CT value at which the assay became 
positive for each target 
Dilution tcdB cdt tcdC 
Neat 18.3 17.4 18.8 
1/10 21.8 21.1 22.4 
1/100 26.3 25.4 26.7 
1/1000 30.1 29.2 30.5 
Table 3.4. The CT values at which the Cepheid assay became positive for different 
dilutions of a C. difficile spore preparation after treatment with DNAse. The label 
tcdB indicates detection of toxin B gene, tcdC indicates detection of the deletion 
in the tcdC gene associated with PCR ribotype 027, cdt indicates detection of 
binary toxin gene.  
 
After the spore preparation was sonicated, the CT value increased for all three targets, 
suggesting that the amount of target was lower in these samples (table 3.5).  
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CT value at which the assay became 
positive for each target 
Dilution tcdB cdt tcdC 
1/1000 DNAse 
with no 
sonication 30.1 29.2 30.5 
1/1000 DNAse 
with 
sonication 34.1 33.4 34.6 
Table 3.5. The CT values at which the Cepheid assay became positive for different 
dilutions of a C. difficile spore preparation after treatment with DNAse, with and 
without sonication. The label tcdB indicates detection of toxin B gene, tcdC 
indicates detection of the deletion in the tcdC gene associated with PCR ribotype 
027, cdt indicates detection of binary toxin gene.  
 
3.4 Discussion 
The issue of sub-optimal performance of CDI laboratory diagnostics is complex. In contrast 
to a previous study (Tenover et al, 2010), the toxin and GDH EIAs were not found to be less 
sensitive for specific PCR ribotypes. Indeed, they were not statistically more likely to ‘miss’ 
any one PCR ribotype over another, indicating that there are additional factors affecting 
the performance of EIAs other than which PCR ribotype is in the sample. The two toxin EIAs 
were, however, statistically less likely to give a negative result for a sample containing 
PCR ribotype 027 and both assays had statistically higher median OD values (table 3.1.) for 
samples containing this PCR ribotype than PCR ribotypes other than 027 (figure 3.1.). The 
reported increase in toxin yield for this strain (Warney et al, Lancet 2005; Freeman et al, 
2007) may partially explain this result, as it is perhaps of note that the assays were 
developed in the USA against a background of high incidence of PCR ribotype 027. It is 
possible, therefore, that the assay cut-off values were optimised to detect toxin in samples 
containing this PCR ribotype. In addition, lack of sensitivity for strains other than 027 could 
also be related to the specificity (avidity/affinity) of the antibodies used in the assays.  
Whilst both assays use polyclonal antibodies for toxin B, the antibody for toxin A is 
monoclonal, which potentially may reduce the detection of the numerous toxinotypes (n = 
31) so far discovered (Toxinotype website database, 2019) 
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The variability in performance of the two toxin EIAs previously reported is supported by 
this study (Eastwood et al, 2009; Planche et al, 2008, Planche et al 2013) as they had 
significantly different median ODs for PCR ribotypes 027 and 015, two of the three most 
common PCR ribotypes found in this study (table 3.2). Although these assays are not truly 
quantitative, theoretically, increasing ODs correlate with increasing levels of antigen (in this 
case toxin) detected. It would seem, therefore, that one of the assays, the Premier™ Tox 
A/B, is not able to detect as much toxin as the other assay, as shown by the lower OD 
values for these PCR ribotypes.  This hypothesis does, however, rely on the assumption that 
the scale of ODs between the two assays is comparable, which is yet to be demonstrated.  
The fact that 30% of the samples containing a toxigenic isolate of C. difficile that were 
negative by the toxin EIAs were positive by the cell-cytotoxicity assay supports the 
assumption that the EIAs are ‘missing’ true toxin positive samples. Cell cytotoxicity has 
been shown to be more sensitive than both the toxin detection EIAs (Eastwood et al, 2009), 
and so could be detecting low levels of toxin in the other 30% of samples. An alternative 
explanation for the ‘missed’ detection of positives by the toxin EIAs is that these patients 
could be colonised by toxigenic strains of C. difficile, but that these are not currently 
producing toxin; designated potential C. difficile excretors (PCDE) in the UK Department of 
Health guidelines (Planche et al, 2013; Department of Health, 2012). 
The contrast between previous results (Tenover et al, 2010) and those seen in this study 
could be explained by the increased number of samples in this study. There were four 
times as many as those studied previously; giving this study greater power to elucidate 
differences between assays and PCR ribotypes (Tenover et al, 2010). The previous study 
was not able to show differences between the two toxin EIAs as, due to low numbers of 
samples, the results of samples tested on either assay were pooled. Indeed, no one sample 
was tested using both assays in that study (Tenover et al, 2010).  
In contrast to the toxin EIAs, the performance of the GDH EIA does not seem to be 
adversely affected by PCR ribotype, as there were no significant differences between OD 
values for any one PCR ribotype over another. This result conflicts with the work from a 
previous study that showed that the GDH EIA was less sensitive for PCR ribotypes other 
than 027 (Tenover et al, 2010), although as already discussed that was on a much smaller 
sample size than the current study. To elucidate fully what a GDH positive/toxin negative 
(PCDE) result means, it is necessary to understand the course of C. difficile infection, which 
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can be achieved by collecting sequential samples either from patients or an in vitro CDI 
model.  
To investigate this phenomenon further the amount of both GDH and toxin, as detected by 
the commercial EIAs was investigated for different PCR ribotypes of C. difficile using batch 
culture. Although there was little difference between the median GDH values for most 
PCR ribotypes there was both a lower median GDH and toxin OD value for PCR ribotype 002 
(figures 3.3 and 3.4). In addition, the cytotoxin titre was lower for PCR ribotype 002, which 
suggests that there was a smaller amount of toxin produced by this PCR ribotype, rather 
than that the toxin assay has less affinity for this PCR ribotype.  Differences between 
PCR ribotype 002 and other PCR ribotypes have been demonstrated previously, although in 
those studies PCR ribotype 002 had increased sporulation (Cheng et al, 2011) and 
comparable toxin titre to those of hypervirulent strains (Baines et al, 2015). The total viable 
counts for all the strains were fairly consistent (standard deviation of log10 TVC = 0.359), 
and, most notably, the TVCs for the strains with the lowest GDH and toxin ODs were the 
highest of all the strains. This suggests that the lower OD values are not because there was 
less growth of these strains, but that they produced less toxin and less GDH than other 
strains. When only incubated for 24 hours, these differences were not as clear, perhaps as 
peak levels are only reached after 48 hours (as shown in the growth curve experiments). 
GDH appears to be produced by C. difficile during the exponential growth phase of the 
organism (figures 3.8 and 3.9), which has not previously been demonstrated in the 
literature. Once the organism begins to slow vegetative growth and produce spores, the 
level of GDH begins to decline (figure 3.8). From one experiment it would appear that GDH 
might be detected before germination is detected using TVCs, however, this could be an 
artefact from the way the graph has been constructed (figure 3.9). The amount of toxin 
produced in the growth curve experiment that was started with a spore preparation, was 
almost twice as high, as measured by both toxin titres (CCNA) and toxin EIA, as the previous 
growth curve. It is possible that this could be due to the way the growth was started; the 
first was started from viable growth rather than from spores. The reason for this is unclear; 
although perhaps if the growth starts from spores it induces greater toxin production in the 
cells? It should be noted that the log10 viable counts are about the same for both 
experiments, suggesting that the increased toxin production was not due to the amount of 
growth but some other factor.  Batch culture is not the ideal method to investigate the 
growth of C. difficile, as nutrient and pH limitations do not truly reflect the growth 
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conditions of the organism in vivo.  In addition, the metabolites produced are neither 
washed out of the system nor denatured, and so their concentrations could therefore be 
artificially increased. The in vitro gut model system provides the ability to model the growth 
of C. difficile in a more clinically reflective manner (Freeman et al, 2003), and experiments 
in chapter 2 will use this methodology. 
Finally, as it proved difficult to get a totally ‘clean’ spore prep, with no residual DNA from 
broken down vegetative cells, it is hard to be certain that the Cepheid GeneXpert® C. diff 
PCR assay cannot detect DNA from spores as well as from vegetative cells. The addition of 
DNAse to the samples did not affect the CT values for neat spore preparations or diluted 
preparations (table 3.3, figure 3.10). For diluted samples the CT values produced a straight 
line (figure 3.10), as would be expected for a 10-fold dilution series, with ~3.3 CT increase 
per 10-fold dilution (Thermofisher, 2019) (table 3.4), so, again, there was no impact of the 
DNAse.  After the spore preparation was sonicated, the CT value increased for all three 
targets of the PCR assay, suggesting that the amount of starting material had gone down, 
perhaps as DNA was destroyed by shear forces (table 3.5). If sonication (the method used 
by the Cepheid assay to release DNA from faecal samples) released DNA from spores that 
could then be detected by the assay, the CT values should have decreased; they did not 
change.  An alternative method would be to determine if the CT values for the PCR assay 
decrease (become positive earlier) as spores germinate (Chilton et al, PLOS One 2016); it 
would be possible to follow spore germination using phase contrast microscopy. If the PCR 
assay is not detecting the spores themselves, the CT value of the assay should decrease 
(become positive earlier) as spores germinate. There was not scope within this study to 
pursue this further but this is an important point to consider, as detection of spores by the 
PCR assay would further cloud the interpretation of this assay when used for the diagnosis 
of CDI.  
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4. Detection of GDH in an in vitro gut model of CDI using a 
commercial assay 
4.1 Introduction   
Continuous culture systems, rather than batch culture, show that PCR ribotype 027 
produces toxin for longer than does PCR ribotype 001 but not at a higher level (Freeman et 
al, 2007). The high levels seen in the batch culture model may therefore be due to an 
accumulation of toxin and potentially do not give a true representation of toxin production 
by this strain. To overcome the limitations of batch culture experiments, a validated 
continuous culture system was used as a human gut model in this project.  This model 
allows investigation of the interplay between C. difficile, normal bowel microbiota and 
antimicrobials (Freeman et al, 2003). From a clinical point of view, it is important to 
understand the status of the disease of the patient, to ensure they receive the correct 
treatment and that the appropriate infection control precautions are used (Bigardi et al, I 
2013). This requires accurate diagnostics. Although many studies have highlighted the 
variability in performance of CDI laboratory diagnostic assays (see section 1.13 of 
introduction), there is a paucity of data on the reasons for these differences. There are also 
few data on the clinical course of CDI and the optimal time for each of the different 
diagnostic assays to be used. For instance, depending on the stage of disease a test may 
perform ‘badly’ or ‘well’ as an assay for CDI. For example, if a patient is in the recovery 
phase when tested, is toxin still detectable? What does a GDH positive/toxin negative or 
GDH positive/culture negative result mean; i.e. the presence of disease or the presence of a 
non-viable organism with detectable GDH?   
Here, the in vitro gut model was used to examine the rise and fall in GDH production, 
compared with total viable and spore counts of C. difficile, against a background of colonic 
microbiota. The key findings from this chapter are; 
 GDH was produced during the exponential phase of growth and the amount 
detected increased and decreased in phase with total viable counts of the organism  
 GDH could be detected from the system when total viable counts had either begun 
to be detected, or, had gone below the limit of detection 
 The amount of GDH produced was partly due to the bioload of C. difficile within the 
system 
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4.2 Methods 
4.2.1 Methods for measuring C. difficile glutamate dehydrogenase in an 
in vitro gut model 
4.2.1.1    Measuring C. difficile glutamate dehydrogenase in an in vitro gut model 
by both enzyme immune assay and polymerase chain reaction assay. 
Hypothesis 
The amount of GDH produced by C. difficile over the course of a simulated C. difficile 
infection will vary in line with the proliferation of C. difficile as measured by culture. 
Methods 
Gut model 
C. difficile GDH was measured from fluid collected daily from an in vitro gut model of CDI, 
set up as previously described (Freeman et al, 2003) and as described in methods section 
2.3. Briefly, the model consists of a three-stage continuous weir cascade culture system, 
pre-loaded with a human faecal emulsion. The faecal bacteria were allowed to proliferate 
and population levels were stabilised over a period of about two weeks. C. difficile spores 
(~107 cfu/mL) were added twice, each dose one week apart, and again the models were left 
to equilibrate. Clindamycin was instilled into the gut model (33.9 mg/L QDS for seven days) 
to induce simulated CDI. C. difficile total viable count, spore count and toxin level in each 
vessel were enumerated daily. A CDI treatment antibiotic was then added to the system, 
C. difficile total viable count, spore count and toxin level was monitored daily for a further 
three weeks. Two models were run in parallel; denoted ‘A’ and ‘B’. The gut models were set 
up, maintained and sampled by the technicians within the HCAI Research group, under the 
guidance of the PI for that set of models. Kerrie Davies tested daily samples using the 
commercial assays and performed the analysis discussed in this thesis. Permission was 
granted for the use of excess gut model fluid to be used for this PhD project from the 
funder of the set of gut models. 
Glutamate dehydrogenase enzyme immunoassay 
A commercial automated GDH EIA, C. DIFF CHEK-60™, was used to measure the level of 
GDH within the model daily. Once samples had been collected from the model, they were 
frozen at -20°C immediately; they were then defrosted once before testing with the 
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enzyme immunoassays with the remainder stored at 4°C until all testing had been 
completed. The samples from this set of gut models were tested after four months in 
storage, due to maternity leave. The assay was performed according to manufacturer’s 
modified instructions for use on the automated DS2 platform (Dynex Magellan Biosciences, 
USA) (see materials and methods section 2.2). One hundred microliters of gut model 
samples were diluted in 400µL of kit sample diluent; to ensure there was enough sample 
volume (including dead volume) this was double the recommended volumes, and was 
recommended by the manufacturer, as described in the materials and methods section.  
Glutamate dehydrogenase gene (gluD) PCR assay 
A polymerase chain reaction (PCR) assay for the GDH gene gluD was also performed on the 
gut model fluid samples. DNA was extracted from samples that were diluted 1/10 in STAR 
buffer (Roche, Germany) containing 1/10 chloroform (v/v), on the QiaXtractor using the DX 
kit (Qiagen Ltd, UK) after the addition of an internal control (Yersinia ruckerii). Primers and 
probes for gluD and yersi (internal control) (table 4.1.) (Berry et al, 2017; Davies et al, 2015) 
were added to Brilliant QPCR multiplex master mix (Agilent, UK) along with template DNA. 
Amplification was performed on a Stratagene MX3000P (Agilent, UK) using the following 
thermocycling conditions; strand separation at 95°C for 10 minutes, followed by 45 cycles 
comprising strand separation at 95°C for 30 seconds, primer annealing at 60°C for 
30 seconds and replication at 72°C for 30 seconds, with no final extension step.  Samples 
without a positive internal control result were re-extracted and PCR repeated using the 
new template DNA.  
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Oligo Name Sequence 5’ modification 3’ modification 
Yersi F1 GGAGGAAGGGTTAAGTGTTA   
Yersi R1 GAGTTAGCCGGTGCTTCTT   
Yersi P1 GCGAGTAACGTCAATGTTCAGTGC Cy5 BHQ2 
GluD F3 GTCTTGGATGGTTGATGAGTAC   
GluD R2 TTCCTAATTTAGCAGCAGCTTC   
GluD P1 AAGCCAGTTGAATTTGGTGG FAM BHQ1 
Table 4.1  Sequence of primers and probes used in the gluD PCR assay (Berry et al, 
2017; Davies et al, 2015) 
 
4.2.1.2    Measuring C. difficile glutamate dehydrogenase in in vitro gut models A 
and B using a commercial enzyme immunoassay 
Hypothesis 
The amount of GDH produced by C. difficile over the course of a simulated CDI infection will 
vary in line with the proliferation of C. difficile as measured by culture. 
Methods 
Gut model 
C. difficile GDH was measured from fluid collected daily from an in vitro gut model of CDI, 
set up as previously described (Freeman et al, 2003). Briefly, the models were used to 
compare standard and extended vancomycin treatment for CDI. The faecal bacteria were 
allowed to proliferate and population levels to stabilise over a period of about two weeks. 
C. difficile spores (~107 cfu/mL) were added and again the model is left to equilibrate. 
Clindamycin was instilled into the gut model (33.9 mg/L QDS) to induce simulated CDI.  C. 
difficile total viable count, spore count and toxin level were enumerated daily. A CDI 
treatment antibiotic was then added to the system, C. difficile total viable count, spore 
count and toxin levels were monitored for a further three weeks. Two models were run in 
parallel; denoted ‘A’ and ‘B’. The gut models were set up, maintained and sampled by the 
technicians within the HCAI Research group, under the guidance of the PI for that set of 
models. Kerrie Davies tested daily samples using the commercial assays and performed the 
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analysis discussed in this thesis. Permission was granted for the use of excess gut model 
fluid to be used for this PhD project from the funder of the set of gut models. 
GDH enzyme immunoassay 
A commercial automated GDH EIA, C. DIFF CHEK-60™, was used to measure the level of 
GDH within the model daily. Once samples had been collected from the model they were 
frozen at -20ºC immediately; they were then defrosted once before testing with the 
enzyme immunoassays with the remainder stored at 4°C until all testing had been 
completed. The samples from this set of gut models were tested after two years in storage, 
due to the maternity leave and other work commitments of Kerrie Davies. The assay was 
performed as described above. Assay positivity (as defined by the kit) and optical density 
(OD) values were compared with the pattern of C. difficile proliferation and toxin 
production.   
 
4.2.1.3    Investigating the quantitative potential of the commercial glutamate 
dehydrogenase enzyme immunoassay 
Hypothesis 
The commercial glutamate dehydrogenase enzyme immunoassay is quantitative and can be 
diluted to give a result over the current maximum threshold optical density value. 
Methods  
A colony of C. difficile was inoculated into 20mL Brain Heart Infusion (BHI) broth and 
incubated overnight at 37°C in an A95 anaerobic workstation (Don Whitley, UK). After 
incubation, quadruplicate 10-fold dilutions of BHI were made in phosphate-buffered saline 
(PBS).  Each dilution was added to the Chek-60 kit diluent (100µL in 400uL diluent) before 
the GDH assay was performed using the DS2 platform as described above. The OD value for 
each dilution was recorded and log10 transformed.  
Twenty microliters of each dilution were spread plated, in triplicate, onto cefoxitin, 
cycloserine, egg yolk agar (CCEY) and incubated at 37°C in an A95 anaerobic workstation 
(Don Whitley, UK) for 24 hours.  The number of colonies was counted on the dilution that 
gave the most easily readable colony count. The number of colonies was multiplied by the 
dilution factor to determine the colony count per mL and log10 transformed.  
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Log10 cfu/mL and log10 OD values were plotted for the OD values that fell below the 
maximum threshold of the assay (>3.0) and the equation of the line derived. The equation 
was resolved to give the ‘true’ log10 OD value for those OD values that were above the 
maximum threshold. The inverse log10 OD values were then calculated to find the ‘true’ OD 
value.  
To confirm the results of this experiment, it was repeated in triplicate. The intra-assay 
variation of the OD values of the diluted samples was also compared.  
 
4.2.1.4    Measuring C. difficile glutamate dehydrogenase and toxins A & B in 
in vitro gut models O and M using commercial enzyme immunoassays  
Hypothesis 
The amount of glutamate dehydrogenase varies over the time of a simulated course of CDI 
in the in vitro gut model, with periods where GDH is the only detectable marker of the 
presence of C. difficile.  
Methods  
Gut model 
C. difficile GDH and Toxins A and B were measured from fluid collected daily from an 
in vitro gut model of CDI, set up as previously described (Freeman et al, 2003). Briefly, the 
model consists of a three-stage continuous weir cascade culture system, pre-loaded with a 
human faecal emulsion. The faecal bacteria were allowed to proliferate and population 
levels to stabilise over a period of about two weeks. C. difficile spores (~107 cfu/mL) from a 
PCR ribotype 027 strain were added on two occasions, one week apart, and again the 
model was left to equilibrate. As this pair of models (denoted ‘O’ and ‘M’) were being used 
to compare two antibiotics for their potential to induce CDI, one had omadacycline (O) 
added (430mg/L) and the other moxifloxacin (M) (43mg/L) once daily for seven days. C. 
difficile total viable count, spore count and toxin level were enumerated daily. C. difficile 
total viable count, spore count and toxin level were monitored for a further three weeks. 
The gut models were set up, maintained and sampled by the technicians within the HCAI 
Research group, under the guidance of the PI for that set of models. Kerrie Davies oversaw 
the testing of the daily samples using the commercial assays and performed the analysis 
discussed in this thesis. Permission was granted for the use of excess gut model fluid to be 
used for this PhD project from the funder of the set of gut models. 
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GDH and C. difficile toxin enzyme immunoassays 
A commercial automated GDH EIA, C. DIFF CHEK-60™, was used to measure the level of 
GDH and the TOX AB II™ assay was used to measure the level of toxins within the model 
daily. Once samples had been collected from the model they were frozen at -20ºC 
immediately; they were then defrosted once before testing with the enzyme 
immunoassays with the remainder stored at 4°C until all testing had been completed. The 
samples from this gut model were tested after one year in storage, due to the maternity 
leave and other work commitments of Kerrie Davies. The GDH assay was performed as 
described above. The procedure for the toxin assay mirrors that of the GDH assay and the 
same reagents can be used for both assays, except for the microplate wells, the positive 
control and the conjugate, which are specific to each assay (see materials and methods 
section 2.2). Assay positivity (as defined by the kits) and optical density (OD) values were 
compared with the pattern of C. difficile proliferation and toxin production.  In addition, 
where samples produced a maximum OD value of >3.0, they were serially diluted and 
tested again. The resultant OD value was multiplied by the dilution factor to produce a final 
OD value. The enzyme immunoassay testing on the DS2 was performed by a summer intern 
within the HCAI Research Group, Miss Flor Saporta, under the supervision of Kerrie Davies.  
 
4.2.1.5    Measuring C. difficile glutamate dehydrogenase and toxins A & B in 
in vitro gut model X using commercial enzyme immunoassays  
Hypothesis 
The amount of glutamate dehydrogenase varies over the time of a simulated course of CDI 
in the in vitro gut model, including for an episode of CDI recurrence, with periods where 
GDH is the only detectable marker of the presence of C. difficile.  
Methods  
Gut model 
C. difficile GDH and Toxins A and B were measured from fluid collected daily from an 
in vitro gut model of CDI, set up as previously described (Freeman et al, 2003). Briefly, the 
model for this experiment was used to examine CDI recurrence.  For this model the faecal 
slurry had been pre-prepared and then snap frozen using liquid nitrogen before being 
stored at -80°C.  The slurry was defrosted at room temperature before inoculation into the 
model. The faecal bacteria were allowed to proliferate and population levels to stabilise 
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over a period of about four weeks. C. difficile spores (~107 cfu/mL) of strain 210 were 
added on two occasions, one week apart, and again the models were left to equilibrate. 
Clindamycin was instilled into the gut model (33.9 mg/L QDS for seven days) to induce 
simulated CDI, followed by treatment with clinically reflective doses of vancomycin 
(125mg/L QDS for seven days) once a peak toxin level had been reached (as measured by 
cell-cytotoxicity assay). C. difficile total viable count, spore count and toxin level were 
enumerated daily for a further four weeks. One model was run in for this experiment; 
denoted ‘X’. The gut model was set up, maintained and sampled by the technicians within 
the HCAI Research group, under the guidance of the PI for this set of models. Kerrie Davies 
oversaw the testing of the daily samples using the commercial assays and performed the 
analysis discussed in this thesis. Permission was granted for the use of excess gut model 
fluid to be used for this PhD project from the funder of the set of gut models. 
GDH and C. difficile toxin enzyme immunoassays 
A commercial automated GDH EIA, C. DIFF CHEK-60™, was used to measure the level of 
GDH and the TOX AB II™ assay was used to measure the level of toxins within the model 
daily. Once samples had been collected from the model they were frozen at -20ºC 
immediately; they were then defrosted once before testing with the enzyme 
immunoassays with the remainder of the samples stored at 4°C until all testing had been 
completed. The samples from this set of gut models were tested after four months in 
storage, due to the maternity leave and other work commitments of Kerrie Davies. The 
assays were performed as described above. Assay positivity (as defined by the kits) and 
optical density (OD) values were compared with the pattern of C. difficile proliferation and 
toxin production.  In addition, where samples produced a maximum OD value of >3.0, they 
were serially diluted and tested again. The resultant OD value was multiplied by the 
dilution factor to produce a final OD value. The enzyme immunoassay testing on the DS2 
was performed by a summer intern within the HCAI Research Group, Miss Flor Saporta, 
under the supervision of Kerrie Davies. 
 
4.2.1.6    Measuring C. difficile glutamate dehydrogenase and toxins A & B in 
in vitro gut models E, F and G using commercial enzyme immunoassays  
Hypothesis 
The amount of glutamate dehydrogenase varies over the time of a simulated course of CDI 
in the in vitro gut model, with periods where GDH is the only detectable marker of the 
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presence of C. difficile, and that the amount of GDH within the model increases with each 
CDI episode 
Methods 
Gut model 
 C. difficile GDH and Toxins A and B were measured from fluid collected daily from an 
in vitro gut model of CDI, set up as previously described (Freeman et al, 2003). Briefly, the 
models for this experiment were used to compare CDI recurrence in a faecal microbiota 
transplant (FMT) model and two models treated with a manufactured ‘microbiota’.  For 
these models, the faecal slurry used was the same snap frozen, pre-prepared slurry used 
during Model X above.  The slurry was defrosted at room temperature before inoculation 
into the model. The faecal bacteria were allowed to proliferate and population levels 
stabilise over a period of about four weeks. After the stabilisation period, C. difficile spores 
(~107 cfu/mL) of strain 210 were added on two occasions, one week apart, and again the 
models were left to equilibrate. Clindamycin was instilled into the gut model (33.9 mg/L 
QDS for seven days) to induce simulated CDI, followed by treatment with clinically 
reflective doses of vancomycin (125mg/L QDS for seven days) once the peak toxin level had 
been reached (as measured by cell-cytotoxicity assay). Following the vancomycin treatment, 
a simulated faecal microbiota transplant (FMT) (pooled faecal slurry) was added to one of 
the models, and the proprietary ‘microbiota’ was added to the other two models; one 
receiving a single dose, and one receiving three doses.  C. difficile total viable count, spore 
count and toxin level were enumerated daily for a further four weeks.  Three models were 
run in parallel; denoted ‘E’ (three doses of proprietary agent), ‘F’ (one dose of proprietary 
agent) and ‘G’ (FMT with pooled faecal slurry). The gut models were set up, maintained and 
sampled by the technicians within the HCAI group, under the guidance of the PI for that set 
of models. Kerrie Davies oversaw the testing of the daily samples using the commercial 
assays and performed the analysis discussed in this thesis. Permission was granted for the 
use of excess gut model fluid to be used for this PhD project from the funder of the set of 
gut models. 
GDH and C. difficile toxin enzyme immunoassays 
A commercial automated GDH EIA, C. DIFF CHEK-60™, was used to measure the level of 
GDH and the TOX AB II™ assay was used to measure the level of toxins within the model 
daily. Once samples had been collected from the model they were frozen at -20ºC 
immediately; they were then defrosted once before testing with the enzyme 
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immunoassays with the remainder stored at 4°C until all testing had been completed. The 
samples from this set of gut models were tested in one batch after completion of the 
model experiments, after a maximum of two months in storage, with the majority tested 
within two weeks of being placed in storage. The assays were performed as described 
above. Assay positivity (as defined by the kits) and optical density (OD) values were 
compared with the pattern of C. difficile proliferation and toxin production.  In addition, 
where samples produced a maximum OD value of >3.0, they were serially diluted and 
tested again. The resultant OD value was multiplied by the dilution factor to produce a final 
OD value. The enzyme immunoassay testing on the DS2 platform was performed by a 
summer intern within the HCAI Research Group, Miss Flor Saporta, under the supervision 
of Kerrie Davies. 
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4.3 Results 
4.3.1 Results of measuring glutamate dehydrogenase in an in vitro gut model 
4.3.1.1 Measuring C. difficile glutamate dehydrogenase in an in vitro gut model by 
both enzyme immunoassay and polymerase chain reaction assay. 
 
In both models (A and B) the GDH protein was detected by the EIA in Vessels Two and 
Three of the triple stage system (figures 4.1a-c and 4.2a-c). There was a rise in GDH during 
the period where the model was left to achieve steady state after the addition of spores. In 
Model A this occurred about nine days after the introduction of spores, whilst in Model B it 
was after only two days for Vessel Two, and three days for Vessel Three. The GDH 
increased to the maximum measured by the assay within six days in Model B and remained 
at this level for four days in Vessel Two and five days for Vessel Three, before falling back to 
zero over the next eight days. At the same time, there was a small amount of toxin 
production detected in Vessel Three only; this is low level (1 Relative Unit) and lasted for 
two days. 
Once germination had been induced, the GDH level increased in phase with the total viable 
count of the organism and the production of toxin. It is interesting to note, however, that 
although the initial increase of GDH matched that of both the total viable count and toxin 
production; it remained elevated within the system for longer than both of these after the 
introduction of the treatment antibiotic. Once the GDH began to be washed out of the 
system, it did so at the same rate as the toxin, but lagged behind the toxin wash-out by at 
least two days. The overall pattern of GDH rise and fall was mirrored in Vessels Two and 
Three, although Vessel Two was about two days ahead of Vessel Three for both models. 
There was no germination or GDH detected in Vessel One of either system, apart from one 
raised GDH level on one day in Model B. 
Although gluD was detected in the model by the PCR assay, the results were inconclusive 
(figures 4.3 a-b). DNA extraction from the model may not be optimal using this method as 
the CT values for the PCR assay do not fit the pattern of peaks and troughs shown by the 
total viable count, spore and GDH enzyme level. It is outside the scope of this PhD project 
to determine the optimal method for extracting DNA from the complex fluid extracted 
from the gut model. This method was therefore not used in any further gut models within 
this project.  
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Figure 4.1.a Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel One of gut Model A 
 
 
Figure 4.1.b Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Two of gut Model A 
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Figure 4.1.c. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Three of gut Model A 
 
 
Figure 4.2.a. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel One of gut Model B 
 
120 
 
 
Figure 4.2.b Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Two of gut Model B 
 
 
Figure 4.2.c Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Three of gut Model B 
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Figure 4.3.a. GDH EIA OD values and GDH PCR CT values from faecal slurry from 
gut Model A  
 
 
Figure 4.3.b. GDH EIA OD values and GDH PCR CT values from faecal slurry from 
gut Model B 
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4.3.1.2 Measuring C. difficile glutamate dehydrogenase in in vitro gut models A 
and B by enzyme immunoassay  
Model A 
In Vessel One there was a low level of GDH detected between Days 43-46, although this did 
not coincide with any increase in total viable count or germination (figure 4.4a). 
Germination occurred at Day 55, with total viable count and spore count diverging, with a 
concurrent increase in GDH from Days 54 to 61.  The total viable count fell to an 
undetectable level by Day 58, however GDH was still detectable for a further three days. 
There was no toxin detected in Vessel One by the cell-cytotoxicity neutralisation assay. 
In Vessel Two there was an increase in GDH OD value, as measured by the enzyme 
immunoassay, on Day 37, which coincided with germination (figure 4.4b). The OD value 
rose to a peak five days later, again coinciding with a peak in the total viable count. GDH 
remained detectable by the enzyme immunoassay until Day 67, while the total viable count 
began to fall on Day 59 and was below the limit of detection by Day 62. There were, 
therefore, five days where GDH was the only marker of C. difficile that could be detected in 
the model.  Toxin was detected on Day 42, coinciding with the peak in the total viable 
count and peak GDH OD value. The highest peak of toxin was on Day 55. 
Germination, and the concurrent increase in GDH, occurred on Day 37 in Vessel Three; the 
same day as Vessel Two (figures 4.4b and 4.4c). Both GDH OD value and total viable count 
rose to a peak by Day 42, with the GDH OD value remaining at a peak level until Day 63. 
The fluid from Vessel Three was still positive for GDH, using the enzyme immunoassay, at 
the end of the experiment on Day 67. In contrast, total viable count began to fall on Day 59 
and was below the limit of detection by Day 62. Toxin was detected earlier in Vessel Three 
than Vessel Two, at Day 37, although the peak toxin concentration coincided in both 
vessels, at Day 56.  
In both Vessel Two and Vessel Three, the GDH OD value reached the maximum threshold 
OD within a few days, producing a plateau on the graph. The assay in its current form was 
unable to show if the GDH level continued to rise past this level or if it did, indeed, plateau. 
The graphs also appear to show that the GDH OD value did not begin to decline at the same 
time as the total viable count; however this could be an artefact of the assay threshold, 
masking the true picture of GDH rise and fall.  
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Model B 
In Vessel One, there is a small amount of GDH detected at Day 20, in the absence of any 
increase in the total viable count (figure 4.5a). Germination started at Day 51, with an 
increase in the total viable count and a divergence from the spore count. A coincident rise 
in the GDH level was detected from Days 51-56 and Days 57-71, indicated by two small 
peaks on the graph. The total viable count began to decline at Day 56 and was below the 
level of detection by Day 58. From the total viable count values, there appeared to be only 
one episode of germination, however, there were two peaks of GDH detection within this 
period; the reason for the decline and subsequent rise again to give these two peaks is 
unclear. Unlike the right-hand-side model there was a small amount of toxin detected in 
Vessel One between Days 52-54; during the proliferation of the organism after germination 
at Day 51.    
Once again, there was  a small amount of GDH detected from Vessel Two (Days 18-20), in 
the absence of any apparent C. difficile proliferation; as there was no concurrent rise in the 
total viable count (figure 4.5b). Germination started at Day 44; earlier than seen in Vessel 
One (Day 51). There was a lag of four days before the level of GDH began to rise, peaking at 
Days 50-60, before falling to an undetectable level by Day 64. The peak total viable count 
was seen at Day 50, with the count falling from Day 58 to below the level of detection 
within two days. C. difficile toxin was detected from Days 50-56; following the peak of 
C. difficile proliferation.  There were, therefore, four days when GDH is the only marker of 
C. difficile that could be detected in the model.  
A very similar pattern was seen in Vessel Three, with the same small amount of GDH 
detected early after introduction of spores within the model, but without signs of 
germination (figure 4.5c). Again, increasing GDH and toxin levels were detected during 
germination and proliferation. As with Vessel Two, there was a period of ~four days when 
GDH was the only marker of C. difficile that could be detected in Vessel Three of the model, 
following the decline of the total viable count below the level of detection. Again, in both 
Vessel Two and Vessel Three, the GDH OD value reached the maximum threshold OD 
within a few days, producing a plateau on the graph. As discussed above, this could be an 
artefact of the assay threshold, masking the true picture of GDH rise and fall.  
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Figure 4.4.a. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel One of gut Model A 
 
 
Figure 4.4.b. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Two of gut Model A 
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Figure 4.4.c. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Three of gut Model A 
 
 
Figure 4.5.a. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel One of gut Model B 
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Figure 4.5.b. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Two of gut Model B 
 
 
Figure 4.5.c. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Three of gut Model B 
 
4.3.1.3    Investigating the quantitative potential of the commercial glutamate 
dehydrogenase enzyme immunoassay 
For experiment one, the OD of each dilution was measured on the DS2 and the mean 
cfu/mL for each dilution was calculated, after counting colonies on the 1/1000 dilution 
plates (table 4.2). The mean colony count for each dilution was then log10 transformed and 
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plotted against the log10 OD value for each dilution with the exception of dilutions that 
gave an OD value of >3.0, as this was the maximum threshold of the assay and would skew 
the results (figure 4.6a). The equation for the line was calculated and extrapolated to 
calculate the log10 OD value for the neat and 1/10 dilutions (table 4.2). The inverse log10 OD 
value was then calculated for each dilution to give the actual OD value (had the threshold 
limit not been reached).  To check the accuracy of the method, the equation of the line was 
also used to reverse calculate the cfu/ml and compare to the actual cfu/ml.   
The calculated OD values and calculated cfu/ml was very close to the actual OD values and 
cfu/ml for the bottom three dilutions (1/100-1/10,000) (table 4.2.). However, the 
calculated cfu/ml for the neat and 1/10 dilutions underestimates the true bioload within 
the sample; therefore, any calculated OD values using this method would also 
underestimate the true OD value. These results therefore show that the GDH EIA is 
quantitative as long as the OD is below the threshold of >3.0. Therefore, samples could be 
diluted before they are tested on the GDH assay on the DS2 then multiplied by the dilution 
factor to find the actual OD. To confirm these results, the experiment was repeated. The 
second experiment confirmed the result of the first (table 4.3.), with the GDH assay 
demonstrating that it is quantitative, as long as the OD value is below that of the threshold 
(>3.0). The intra-assay variation between diluted samples is low, showing good 
reproducibility within the assay (table 4.4).   
The OD value in the neat sample was calculated by multiplying the OD value in the diluted 
sample by the dilution factor (table 4.3). When compared with the calculated OD value 
(using the equation of the line (figure 4.6b), the two OD values for the neat solution were 
within the same order of magnitude. Whilst not an exact representative of the ‘true’ OD 
value, the order of magnitude of GDH can be calculated, and the pattern of rise and fall of 
GDH within the model can be followed.  In future experiments, where the OD is the 
maximum value of >3.0, the sample will be diluted 1/100 and 1/1000, and the resultant OD 
will be multiplied by the dilution factor to give the ‘true’ OD value in the neat sample.
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Dilution factor 
of the sample 
Mean cfu/mL 
Log10 
cfu/mL 
Mean OD 
value 
Log 10 of 
OD value 
Calculated 
log10 OD value 
Calculated OD 
value 
Calculated 
log10 cfu/mL 
Calculated 
cfu/mL 
Neat 410000 5.61 3.001 0.477 2.630 426.646 3.81 6423.95 
10-1 41000 4.61 3.001 0.477 1.437 27.376 3.81 6423.95 
10-2 4100 3.61 1.641 0.215 0.245 1.757 3.59 3872.58 
10-3 410 2.61 0.109 -0.963 -0.948 0.113 2.60 398.65 
10-4 41 1.61 0.004 -2.398 -2.141 0.007 1.40 24.95 
Neat 375000 5.57 3.001 0.477 2.584 383.572 3.81 6423.95 
10-1 37500 4.57 3.001 0.477 1.391 24.612 3.81 6423.95 
10-2 3750 3.57 1.741 0.241 0.198 1.579 3.61 4069.49 
10-3 375 2.57 0.195 -0.710 -0.994 0.101 2.81 649.21 
10-4 37.5 1.57 0.006 -2.222 -2.187 0.007 1.54 35.06 
Neat 425000 5.63 3.001 0.477 2.649 445.327 3.81 6423.95 
10-1 42500 4.63 3.001 0.477 1.456 28.575 3.81 6423.95 
10-2 4250 3.63 0.93 -0.032 0.263 1.833 3.38 2405.59 
10-3 425 2.63 0.165 -0.783 -0.929 0.118 2.75 564.36 
10-4 42.5 1.63 0.005 -2.301 -2.122 0.008 1.48 30.09 
Neat 277500 5.44 3.001 0.477 2.428 267.843 3.81 6423.95 
10-1 27750 4.44 3.001 0.477 1.235 17.186 3.81 6423.95 
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10-2 2775 3.44 0.93 -0.032 0.042 1.103 3.38 2405.59 
10-3 277.5 2.44 0.165 -0.783 -1.150 0.071 2.75 564.36 
10-4 27.75 1.44 0.005 -2.301 -2.343 0.005 1.48 30.09 
Table 4.2. The measured and calculated OD values for each dilution of C. difficile culture. The cfu/ml and OD were log10 transformed 
before plotting on a graph (Figure 4.6a). Because the top two dilution skewed the data (as the OD values were the maximum 
threshold of the kit [>3.0]) they were removed from the graph. Using the equation of the graph the ‘real’ OD of the top two 
dilutions could be calculated. The inverse log10 OD values then need to be calculated in order to find the ‘true’ OD. 
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Figure 4.6.a. Graph showing the log10 OD values for the different dilutions of 
C. difficile (plotted as log10 cfu/ml) for experiment one. The neat and 1/10 dilution 
OD results were not plotted, as they gave the maximum threshold OD value, and 
skewed the results. The equation of the line was calculated and used to calculate 
the log10 OD value of the neat and 1/10 dilutions (see table 4.2).   
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Figure 4.6.b. Graph showing the log10 OD values for the different dilutions of 
C. difficile (plotted as log10 cfu/ml for experiment two. The neat and 1/10 dilution 
OD results were not plotted, as they gave the maximum threshold OD value, and 
skewed the results. The equation of the line was calculated and used to calculate 
the log10 OD value of the neat and 1/10 dilutions (see table 4.3).  
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Dilution 
factor of 
the 
sample 
Mean 
cfu/ml 
Log10 mean 
cfu/ml 
Mean OD value 
 
Log10 mean OD Calculated 
log10 
OD value 
Calculated OD 
value 
in the relevant 
diluted sample 
(inverse log10) 
Calculated OD 
in the neat 
sample 
Neat 24500 4.39 3.001 0.477 2.700 501.725 n/a 
10-1 2450 3.39 3.001 0.477 1.442 27.667 n/a 
10-2 245 2.39 1.754 0.244 0.183 1.526 175.370 
10-3 24.5 1.39 0.156 -0.808 -1.075 0.084 155.670 
10-4 4.5 0.65 0.021 -1.678 -2.001 0.010 210.000 
Neat 33750 4.53 3.001 0.477 2.876 750.814 n/a 
10-1 3375 3.53 3.001 0.477 1.617 41.403 n/a 
10-2 337.5 2.53 2.042 0.310 0.359 2.283 241.670 
10-3 33.75 1.53 0.186 -0.731 -0.900 0.126 185.670 
10-4 11.5 1.06 0.009 -2.062 -1.488 0.032 86.670 
Neat 44250 4.65 3.001 0.477 3.024 1055.800 n/a 
10-1 4425 3.65 3.001 0.477 1.765 58.221 n/a 
10-2 442.5 2.65 2.023 0.306 0.507 3.211 202.300 
10-3 44.25 1.65 0.184 -0.736 -0.752 0.177 183.670 
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10-4 8.75 0.94 0.008 -2.097 -1.638 0.023 80.000 
Neat 21000 4.32 3.001 0.477 2.616 413.250 n/a 
10-1 2100 3.32 3.001 0.477 1.358 22.788 n/a 
10-2 210 2.32 1.563 0.194 0.099 1.257 156.300 
10-3 21 1.32 0.154 -0.812 -1.159 0.069 154.340 
10-4 4.25 0.63 0.009 -2.030 -2.032 0.009 93.340 
Table 4.3. The measured and calculated OD values of the dilution series of C. difficile, based on the graph in Figure 4.6b. Calculated 
log10 OD is based on resolving the equation of the line, the inverse log was calculated to produce the calculated OD. The calculated 
OD values for the neat solution if the actual OD of the dilution is multiplied by the dilution factor is very close to that for the higher 
dilutions (1/100-1/1000). In future experiments, where the OD is the maximum value of >3.0, the sample will be diluted 1/100 and 
1/1000, and the resultant OD will be multiplied by the dilution factor to give the actual OD in the neat sample. 
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Dilution 
factor of 
the sample 
Standard 
deviation 
Run 1 
Standard 
deviation 
Run 2 
Standard 
deviation 
Run 3 
Standard 
deviation 
Run 4 
Neat 0 0 0 0 
1/10 0 0 0 0 
1/100 0.0448 0.0493 0.0056 0.0615 
1/1000 0.0084 0.0032 0.0032 0.0045 
1/10000 0.0025 0.0025 0.001 0.0006 
Table 4.4. The intra-assay variation in OD values for each set of sample dilutions. 
All OD values for the neat and 1/10 dilutions were >3.0 (the maximum threshold), 
hence a standard deviation of 0.  
 
4.3.1.5    Measuring C. difficile glutamate dehydrogenase and toxins A & B in 
in vitro gut models O and M using commercial enzyme immunoassays  
Model O 
The antimicrobial agent added to this model did not induce CDI, and therefore there was 
no increase in total viable count or GDH level and no germination (figures 4.7a-c). There 
was also no increase in GDH after the instillation of spores in Vessel One, although there 
was a very slight rise in GDH after the first and second doses of spores in Vessel Two, and 
for one sample in Vessel Three following the second dose of spores.  
Model M 
In Vessel One, both the total viable count and GDH level began to rise concurrently as 
germination occurred at Day 29, with toxin being produced during the proliferation phase 
(as detected by cell-cytotoxicity assay) (Figures 4.8a-c). The total viable count peaked on 
the following day but the level of GDH continued to rise until Day 32. Previously this has 
not been observed, due to the maximum threshold of the GDH OD value. The total viable 
count then started to fall, along with the level of GDH, after a short lag period, before both 
rose again to a second peak. Interestingly, the second peak of the total viable count was 
higher than the first, whilst the second peak of GDH was lower than the first. The total 
viable count, spore count, toxin and GDH levels began to decline at a similar time, but there 
are two days where GDH could still be detected after both total viable and spore counts 
had gone below the limit of detection.  
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In Vessel Two the GDH level started to rise after the installation of the first dose of C. 
difficile spores, increasing after the second dose. It continued to increase after germination 
and proliferation of the organism in the model, as it began to produce toxin. Both the total 
viable count and level of GDH peaked at the same time and then began to fall in phase with 
each other, and indeed toxin production. There was a small second peak in both total 
viable count and level of GDH, again in phase with each other. Once again GDH could be 
detected for a further two days after total viable and spore counts had gone below the 
limit of detection. A very similar pattern of in-phase rise and fall of total viable count and 
GDH level were seen in Vessel Three, including the two days at the end of the experiment 
where GDH was the only marker of C. difficile that could be detected from the gut model 
fluid. The occurrence of the peak total viable count and peak GDH OD value were very 
similar for both Vessel Two and Three. 
Although toxin production could clearly be seen within Vessels One and Two when using 
the cell-cytotoxicity assay, there was no concurrent rise in the OD value of the toxin 
enzyme immunoassay. In Vessel Three there was a very small rise OD value for the toxin 
assay in one sample, around the time of peak toxin production.  The reasons for the low OD 
values with the toxin enzyme immunoassay are unclear; it is possible that something within 
the complex gut model fluid is inhibiting the assay.  
 
 
Figure 4.7.a. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel One of gut Model O 
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Figure 4.7.b. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Two of gut Model O 
 
 
Figure 4.7.c. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Three of gut Model O 
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Figure 4.8.a. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel One of gut Model M 
 
 
Figure 4.8.b. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Two of gut Model M 
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Figure 4.8.c. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Three of gut Model M  
 
4.3.1.6    Measuring C. difficile glutamate dehydrogenase and toxins A & B in 
in vitro gut model X using commercial enzyme immunoassays 
Model X 
In Vessel One, there was an increase in GDH after the instillation of the first dose of spores, 
as seen with previous models (figures 4.9a-c). The level of GDH then  starts to increase, in-
line with the increase in the total viable count that signals the start of germination, with 
both reaching peak levels at the same time.  As shown previously in the other models, the 
GDH level declined in line with the total viable count, however GDH could still be detected 
for a period of ~two days after total viable count was below the limit of detection. 
Recurrence occurred approximately 25 days after the end of the previous episode, with an 
increase in total viable and spore counts. There was no increase in the OD value 
representing GDH, however, and no toxin was produced.  
The peak in GDH level after instillation of the spores was markedly higher in Vessel Two, 
than that seen in Vessel One, or indeed, any other model to date (~OD = 10, compared with 
0.165 in Vessel One). GDH then declined back to zero. Once germination began, the total 
viable count and level of GDH increased in-phase and reached peak levels at the same time. 
It is interesting to note, however, that the peak GDH level was higher than seen in previous 
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models (OD~16 compared with ~eight in the previous model) despite the total viable 
counts being similar in both models, with a peak of ~six log10cfu/mL.   The peak in toxin 
production coincided with the peak in growth and declined as the total viable count and 
GDH level declined. As with previous models, GDH could be detected from the gut model 
fluid after the total viable count had gone below the limit of detection, however, this time 
this was for a period of ~seven days compared with ~two days in previous models. Again, 
recurrence occurred approximately 25 days after the end of the previous episode, with an 
increase in total viable and spore counts. Unlike Vessel One, however, there was an 
increase in GDH and toxin levels in Vessel Two during this recurrence episode. There was a 
strange ‘dip’ in total viable and spore counts and the level of GDH on one day, with no 
concurrent drop in toxin level.  For GDH, this drop was back to zero, which seems unlikely, 
given that normally GDH can be detected for many days after the total viable count.  
Whilst there was a large peak in GDH after instillation of spores in Vessel Three, it was not 
as high as is seen in Vessel Two (OD~5 vs ~10 in Vessel Two). Germination occurred on the 
same day in Vessel Three as Vessel Two (Day 59), reaching a similar maximum OD value as 
Vessel Two (peak OD in Vessel Three ~17 vs ~16 in Vessel Two). Again, the peak total viable 
count and GDH level coincided with the peak toxin level, and all started to decline at the 
same time. As with Vessel Two, GDH could still be detected for a further seven days after 
the total viable count was below the level of detection.  In accord with Vessels One and 
Two, recurrence occurred approximately 25 days after the end of the first episode. Whilst 
the pattern of increasing total viable count and GDH OD value seen in Vessel Two was 
repeated In Vessel Three, the sample taken on the final day has a markedly high GDH OD 
value of ~25.  
There was no detection of C. difficile toxin by the enzyme immunoassay in any of the 
vessels, despite detection of toxin by the cell-cytotoxicity assay in both Vessels Two and 
Three, similar to the previous models. As with the previous gut model experiment, the 
reason for this is not clear.   
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Figure 4.9.a. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel One of gut Model X 
 
 
Figure 4.9.b. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Two of gut Model X 
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Figure 4.9.c. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Three of gut Model X 
 
 
4.3.1.7    Measuring C. difficile glutamate dehydrogenase and toxins A & B in 
in vitro gut models E. F and G using commercial enzyme immunoassays 
Model E 
Unlike previous models there was no peak in GDH level seen in any of the three vessels 
after the instillation of spores (figures 4.10a-c). Germination occurred at Day 53 in all three 
vessels, with a rise in the total viable count. There appeared to be a lag of three days 
before the GDH level subsequently starts to rise, although the peak total viable count and 
GDH level do coincide, along with peak toxin level in Vessels Two and Three. The highest 
OD level of GDH was seen in Vessel Two (~34) followed by Vessel Three (~24) and then 
Vessel One (~1.5). It is interesting to note however that there was not a significant 
difference in the total viable count between the vessels however. The GDH level started to 
decline after the total viable count was already falling, and in all three vessels GDH could 
still be detected from the model fluid for ~10 days after the total viable count had fallen 
below the limit of detection. Whilst this detection of GDH after total viable count has 
declined had been seen in previous models, this was the longest period for which this lag 
has occurred. It is important to note that not only could the GDH be detected, i.e. it had an 
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OD raised from baseline, but the OD was also above the cut-off the assay that indicates a 
‘positive’ result (had this been a clinical sample).  
There was an episode of recurrence within this model, with the total viable count rising 
again at Day 100. There was a lag of ~two day in all three vessels before the level of GDH 
begin to rise, although the peak OD value was much lower than that seen for the first 
episode.  
There was no toxin detected in any of the vessels within this model by either the cell-
cytotoxicity assay or the enzyme immunoassay.   
 
Model F 
Unlike Model E, but in agreement with earlier models, there was a peak in the level of GDH 
after the instillation of spores; this peak was higher than previously seen however and GDH 
could be detected from the gut model fluid in every sample, from all three vessels, from 
this point on until the end of the simulated CDI episode (figures 4.11a-c). It should be noted 
however that although the OD was raised in these samples for four days the OD was below 
that which wold indicate a ‘positive’ result if the test were used clinically.  
Germination occurred around Day 44, with increasing total viable count and GDH level. The 
peak value for GDH in this episode was the highest seen in any model and coincided with a 
very high level of toxin (as measured by the cell-cytotoxicity assay). The highest GDH level 
was seen in Vessel Two (OD = ~250), followed by Vessel Three (~200) and then Vessel One 
(~10). The total viable count was also slightly higher than previously seen with 6 
log10cfu/mL compared with 5 log10cfu/mL seen previously.  Unlike Model E, the GDH level 
fell very quickly, and went below the limit of detection just before the total viable count 
and toxin also reached an undetectable level.  
Recurrence occurred at Day 81; as with Model E, there was an increase in the total viable 
count followed by an increase in GDH OD value ~three days later. The peak GDH level 
coincided with the peak of toxin production; toxin levels were very high, with 5RU, 
compared with 3RU seen in most previous models. The total viable count was also higher 
than usually seen. Although the toxin level was higher in the recurrent episode the GDH 
level was lower than the first simulated CDI episode in this model. For example, the peak 
GDH OD in Episode One in Vessel Two was ~250, but it was ~100 in the recurrent episode. 
The same pattern of GDH production seen during the first episode was also seen during 
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recurrence; the highest level was in Vessel Two (~100) followed by Vessel Three (~30) and 
then Vessel One (0.3). This contrasts with the toxin level and total viable count, however, 
which were similar across Vessels Two and Three.  
Interestingly, unlike previous models, the toxin enzyme immunoassay did detect toxin, and 
the OD values for the assay followed the rise and fall of toxin production as detected by the 
cell-cytotoxicity assay.   
 
Model G 
There was no rise in the GDH level in any of the vessels after the instillation of spores in 
Model G (figures 4.12a-c); this was in contrast to most of the models but was also observed 
in Model E (figures 4.10a-c). Germination was not seen in Vessel One, however there was a 
small peak in GDH in Vessel One around the time of peak proliferation in the other vessels 
(figures 4.12a-c). As previously observed, the GDH level rose during germination and 
peaked with the total viable count and peak toxin production in Vessels Two and Three. 
The level of GDH was high, although not as high as for Model F, and was higher for Vessel 
Two (OD= ~ 84) than for Vessel Three (~74). Once again, the GDH level dropped quickly and 
the OD value went below the limit of detection about two days before the total viable 
count. In this model, toxin could still be detected from Vessel Two and Three after the total 
viable count and GDH level were below the limit of detection.  
Two days after the toxin was washed out of the system there was a small rise in GDH OD in 
both Vessels Two and Three, which lasted for two days before dropping again. There was a 
subsequent rise in total viable and spore counts after two days, but the total viable count 
did not diverge from the spore count and no toxin was detected; indicating that although 
the organism is growing in the model, this was not a recurrent episode.  
Once again, the toxin enzyme immunoassay detected toxin, and the OD values followed the 
rise and fall of toxin as detected by the cell-cytotoxicity assay. The level of toxin in this 
model was similar to those seen in earlier models (3RU), but not as high as seen in Model F 
(figures 4.11a-c).  
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Figure 4.10.a. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel One of gut Model E 
 
 
Figure 4.10.b. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Two of gut Model E 
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Figure 4.10.c. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Three of gut Model E 
 
 
Figure 4.11.a. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel One of gut Model F 
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Figure 4.11.b. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Two of gut Model F 
 
 
Figure 4.11.c. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Three of gut Model F 
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Figure 4.12.a. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel One of gut Model G 
 
 
Figure 4.12.b. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Two of gut Model G 
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Figure 4.12.c. Spore counts, total viable counts, toxin production and GDH 
measured by EIA in Vessel Three of gut Model G 
 
4.4 Discussion  
The enzyme immunoassay was able to detect GDH from the gut model fluid and showed 
rise and fall in line with the proliferation of the organism in the model.  The gluD PCR assay 
however, produced consistently high CT values, and unfortunately does not appear to be 
optimised for use in the gut model and so could not help to explain the pattern of rise and 
fall of GDH. It would be expected that as total viable count increases, the level of gluD 
within the system would also increase but that was not seen with the current gluD assay. 
Further optimisation of this assay is required before it can provide useful information on 
the proliferation of C. difficile within the model (figures 4.3 a-b). Additionally, further work 
is needed to clarify whether the PCR assay is detecting DNA in spores as well as in 
vegetative cells and/or free gluD in the system (figures 4.3 a-b). In addition, detection of 
mRNA may also provide insight into the proliferation of C. difficile. It is unfortunately 
outside of the scope of this project to develop the gluD assay further, and so this assay was 
not used for any further gut model experiments.  
The bacterial populations within the human gut model have been shown to be very similar 
to those seen at autopsy in the colon of patients who suffer sudden death, making this 
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model extremely useful for examining enteric pathogens (Macfarlane et al, 1998). The 
human gut model has been used to observe the effects of antibiotics on the growth and 
toxin production of C. difficile (Freeman et al, 2003; Baines et al, 2006; Freeman et al, 2007; 
Baines et al, 2009; Saxton et al 2009; Chilton et al, 2014b; Baines et al, 2015); the total 
viable count of C. difficile and toxin level rise and consequently fall in phase with each other 
during simulated CDI. This pattern was repeated for the gut model experiments described 
here, where the values for the total viable count and toxin production remained in phase 
(figures 4.1, 4.2, 4.4, 4.5, 4.7-4.12).  In contrast, for the first two sets of models, whilst the 
level of GDH did increase in phase with the total viable count and toxin level, it remained at 
peak levels in the model for longer. Once the level of GDH began falling, however, it was 
cleared from the model within the same number of days as the cells and toxin of C difficile. 
This may indicate that GDH is a very stable protein that is not broken down within the 
system, or possibly that it is sequestered in the model, perhaps in biofilm, and therefore 
takes longer to be cleared from the system. Alternatively, stores of GDH may be released 
by dying C. difficile cells, ‘flooding’ the model with GDH and increasing the period during 
which it can be detected. The gut model is clinically reflective (Freeman et al, 2003), 
suggesting that there could be periods where patient faecal samples could be positive for 
GDH when there are no viable organisms proliferating within their gut.   
Monitoring the level of GDH level in these models was impaired by the maximum threshold 
OD value for the GDH enzyme immunoassay. Using the assay in its current format does not 
show the ‘true’ peak levels of GDH within the model and could therefore be masking any 
subsequent rise and fall of GDH during this ‘plateau’ period. Dilution series demonstrated 
that below the maximum threshold OD of the assay, the results were quantitative, and 
diluted samples could be multiplied by the dilution factor to overcome the maximum 
threshold (tables 4.2-4.4, figures 4.6 a-b).  
Subsequent gut model experiments showed that the GDH level did indeed continue to 
increase over the previous maximum threshold OD value, during organism proliferation 
(figures 4.7-4.12).  The peak GDH OD varied between models, and between vessels. The 
highest GDH level seen in any experiment was those within gut Model F, which had a 
higher peak total viable count than any other gut model (7log10cfu/mL vs 5-6log10cfu/mL, 
figures 4.11a-c).  Interestingly, this model also had a higher peak toxin level (6 RU vs 3-5 
RU). This suggests, that the level of GDH is related to organism bioload within the model, 
with a higher bioload resulting in a higher level of GDH in the gut model fluid. When 
150 
 
comparing within models, the highest level of GDH was seen in Vessel Two, followed by 
Vessel Three, and then Vessel One. Given that the total viable counts did not vary 
significantly between Vessels Two and Three for these models, the GDH level does not 
appear to be solely related to organism bioload. 
When comparing the GDH levels seen in the initial simulated CDI episode and those when 
there is a recurrent episode (Models E and F), the levels in the recurrent episodes are lower. 
In Model F, for example, the peak GDH OD in the first episode in Vessel Two was ~250, but 
was ~100 in the recurrent episode. The peak total viable count and toxin level were actually 
higher than the first episode in this model, again suggesting that the level of GDH is not 
solely related to the bioload within the model.  In addition, there was a lag from the time 
the total viable counts began to increase and the GDH subsequently began to increase.  
This lag period was not as clear for the first episodes in any model compared with the 
recurrent episodes in Models E and F (figures 4.10a-c and 4.11a-c).  
There was often a rise in the level of GDH detected in the models when the spores were 
added to the system. This rise in GDH was not accompanied by a divergence between the 
total viable count and the spore count. This suggests that while there may be ‘turn over’ of 
the organism within the model, there was not exponential growth and proliferation. This 
rise in the level of GDH could, therefore, be a result of the organism reaching equilibrium 
within the model. If so, does this also occur when a human first encounters C. difficile 
spores? Is there a similar period of equilibrium, and could GDH be detected from their 
faeces at this point? It is possible that the spike in GDH is only seen once after the 
introduction of C. difficile spores to the model, or that if the period of steady state was 
extended, serial increases and decreases in GDH may be seen, as there is continual 
‘turnover’ of the organism. Unfortunately, the opportunity to sample a gut model with an 
extended steady state did not present itself within the timescale of this project.  
As well as detecting GDH at the beginning of the model, in the absence of proliferation, 
GDH was also been detected in the absence of any organisms in the model at all; after the 
total viable count had gone below the limit of detection. In four of the sets of models GDH 
was the only marker of C. difficile that could be detected in the gut model fluid for a 
median of 7.5 days (range of 2-10 days). However, in two of the models (F and G) the GDH 
levels fell very quickly and were below the limit of detection before all viable cells are 
washed out from the model (figures 4.11a-c and 4.12a-c). Interestingly, Model F had the 
highest level of GDH of any of the models, suggesting that the decline and wash out time of 
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GDH is not related to the load within the system. Further studies are necessary to clarify 
release and degradation of GDH in both simple and complex systems. It is possible that 
GDH is being sequestered in biofilm; such sequestration may account for the delayed 
clearance of GDH from the system compared with toxin titres and total viable counts. If this 
is the case, there may therefore have been less biofilm formation in Model F, creating 
higher loads of GDH in the planktonic system and making it easier to wash the GDH out of 
the system, after production had ceased.  
The toxin enzyme immunoassay did not function very well in detecting toxin within the gut 
model fluid, in contrast to the cell-cytotoxicity assay. The enzyme immunoassay did detect 
toxin in the last two models to be tested. As samples had been taken from the models and 
then frozen before testing, it is possible that freezing the fluid influenced the integrity of 
the toxin. It is known that toxin can be degraded by repeated freezer/thaw episodes 
(Freeman and Wilcox, 2003); however, all samples were only thawed once before testing to 
attempt to alleviate this fact. It is possible therefore that the storage time in the freezer 
had an effect; those samples with the shortest length of storage were those models tested 
last, and in which toxin was detected by the enzyme immunoassay.   
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5. Detection of GDH and toxin from longitudinal patient samples 
using commercial assays 
5.1 Introduction  
Many studies have highlighted the variability in performance of CDI laboratory diagnostic 
assays; however, there is a paucity of data on the reasons for these differences as 
discussed in section 1.13 of the introduction. In addition, there are also few data on the 
clinical course of CDI and the optimal time for each of the different diagnostic assays to be 
used. For instance, depending on the stage of disease a test may ‘perform’ badly or well as 
a marker of CDI. The data from gut model experiments of CDI showed marked differences 
in when the diagnostics targets of C. difficile or CDI can be detected (Chapter two). It is not 
clear however if the performance of the diagnostics assays in these in vitro experiments 
can be translated into their performance during clinical CDI.   For example, what does a 
GDH positive/toxin negative or GDH positive/culture negative result mean for a patient? 
Does this indicate the presence of disease or the presence of a non-viable organism in the 
presence of detectable levels of GDH?  These potential confounding issues have not been 
considered when patient samples are tested in laboratory evaluations of CDI tests, even 
though they may have a bearing on performance. 
Here a sequential faecal sampling protocol was used to examine the detection of C. difficile 
targets at different points in the patient's clinical course of infection, and during any 
potential recurrence. The key findings in this chapter are;  
 GDH could be detected from sequential faecal samples collected earlier than faecal 
samples that were positive for C. difficile toxin  
 Of the participants recruited as GDH-positive/toxin-negative, 28% went on to have 
a toxin positive faecal sample, a median of eight days later 
 GDH could be detected from sequential samples after other markers of C. difficile 
were no longer detected 
 GDH EIA appeared more sensitive than PCR for toxin genes 
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5.2 Methods 
5.2.1 Is the sensitivity of C. difficile diagnostic assays affected by the day on 
which a patient is tested? 
5.2.1.1 Analysis of PlaciD dataset to determine the difference between cases and 
controls when tested for C. difficile, its toxins and its DNA 
Hypothesis 
There are significant differences between cases of CDI and controls when using different 
C. difficile detection assays over time 
Methods 
CDI cases (diagnosed toxin positive by the routine microbiology laboratory GDH/CCNA), 
potential C. difficile excretors (PCDE’s, diagnosed GDH positive/toxin negative by the 
routine microbiology laboratory) and controls (≥50 year olds from the same hospital but 
who had no diarrhoeal symptoms) were recruited and followed during their hospital 
admission; faecal samples were collected daily where possible with routine clinical data. 
Samples were tested using culture for C. difficile, cell-cytotoxicity assay (CCNA), 
cytotoxigenic culture (CTC), enzyme immunoassays (EIAs) for glutamate dehydrogenase 
(GDH) and toxins (Chek-60 and ToxABII, Techlab, USA) and PCR for toxin genes (BD Max™, 
BD). Kerrie Davies was the study chief investigator for the PlaciD study and devised the 
study, wrote the study protocol and gained ethical approval, designed the data collection 
and study databases and analysed all the data. Patients were recruited by research nurses, 
who also collected patient samples and data. All samples were tested by Kerrie Davies, 
except for a four month period of maternity leave, when samples were tested by Claire 
Berry, Clinical Scientist within the Healthcare Associated Infections research group.  
Commercial enzyme immunoassays 
All of the commercial EIAs were performed on an automated platform (DS2, Dynex 
Magellan Biosciences, USA) to reduce operator error, following manufacturer’s protocols 
given in the kit insert, with minor changes listed within materials and methods chapter 
section 2.2, and as discussed with the manufacturer.  The optical density (OD) of each test 
was recorded as well as the result defined by the assay (using manufacturer set cut-offs). 
Reference methods 
The cell-cytotoxicity neutralisation assay, culture and cytotoxigenic culture assay were 
performed as described in materials and methods chapter, section 2.1. 
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Commercial molecular test 
The commercial molecular test was performed on a BD Max™ instrument following the 
protocol in the manufacturer’s kit insert, as described in material and methods chapter 
section 2.2.5. 
PCR ribotyping 
The C. difficile isolates identified from the study were typed using PCR ribotyping by the 
C. difficile Ribotyping Network of England and Northern Ireland (CDRN) as previously 
described (Stubbs et al, 1999) and as expounded in materials and methods chapter section 
2.1.6. 
Analyses: 
Positive results for each C. difficile assay, white cell counts, serum albumin and serum 
creatinine values were compared between cases, PCDE’s and controls. Patient 
demographics, antibiotic use and proton pump inhibitor (PPI) use were compared between 
cases, PCDE’s and controls. For cases and PCDE’s, day 0 was defined as the day of the 
routine sample that allowed entry into the study. For controls, day 0 was defined as the day 
of entry into the study. 
Means are displayed for continuous variables, medians where data is not normalised. 
Continuous variables were compared by t test for independent samples or Mann-Whitney 
(non-parametric data); categorical variables were compared by χ2 or Fisher’s exact.   
Sensitivity, specificity, positive and negative predictive values were calculated for each 
assay compared with the case definition (diagnostic sample result), CCNA, culture and CTC.  
 
5.3 Results 
5.3.1 Patient recruitment 
There were 342 patients recruited to the study; 167 GDH positive (both toxin negative and 
positive) and 175 controls. However, faecal samples were received from only 147 GDH 
positive patients (both toxin negative and positive) and 81 controls, totalling 1173 sampling 
days. Of the 147 GDH positive patients, 65 had no detectable toxin in their initial routine 
diagnostic specimen; they were therefore designated PCDE’s.   No controls became CDI 
positive during their stay. 
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5.3.2 Patient demographics 
Controls recruited to the study were significantly older than those recruited as GDH 
positive (80 Vs 71 years respectively, p <0.0001) (table 5.1). This was still true once the 
participants without samples in the study had been removed, with median ages for those 
with at least one sample included in the study of 80 years  and 70 years for controls and 
GDH positive participants respectively (p <0.0001). CDI cases were significantly older than 
PCDEs (median age 75 vs 62 years respectively, P <0.0001). There were no significant 
differences in the gender of participants either recruited or with at least one sample in the 
study.  However, there was a significantly higher proportion of females in the PCDEs than in 
the CDI cases (60% vs 40.2% respectively, P = 0.03).  
A significantly higher proportion of participants recruited as GDH positive had at least one 
antibiotic in the previous eight weeks when compared to participants recruited as controls 
(90.7% vs 47.7%, P <0.0001). This was also true for all participants with at least one sample 
in the study (controls = 50.6% vs GDH positive 91.9%, p <0.0001). CDI cases were 
significantly more likely to have had an antibiotic in the previous eight weeks than PCDEs, 
although the proportions in both groups were high (96.3% Vs 84.6% respectively, p = 0.03). 
There was no significant difference between the proportion of recruited controls that had a 
previous drug (other than an antibiotic) in the previous eight weeks compared with 
recruited GDH positive patients; there was also no significance difference when only those 
with at least one sample in the study were compared, although the proportion in GDH 
positive patients was higher in both cases.  PCDEs had a higher proportion of patients that 
had been taking a drug other than an antibiotic in the previous eight weeks compared to 
CDI cases, but this was not significant (72.3% Vs 64.6%, p = 0.19).  
Most patients did not want to have a rectal swab taken (90.9%), and the proportion of 
those refusing was not significantly different between those recruited as controls or those 
recruited as GDH positive. Interestingly of those patients that had at least one sample in 
the study, a significantly higher proportion of GDH positive patients refused the rectal swab 
than control patients (91.2% Vs 79.0%, p = 0.03). Although there was a higher rate of 
refusal in the CDI cases than PCDEs this was not significant (96.3% Vs 84.6%, p = 0.19). 
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  Recruited to the study Had at least one sample in the study 
Had at least one sample in the study and 
initial diagnostic specimen was GDH 
positive 
  
Control 
(n = 175) 
GDH 
positive 
(n = 167) 
Significance 
(p) 
Control 
(n = 81) 
GDH 
positive 
(n = 147) 
Significance 
(p) 
PCDE  
(n = 65) 
CDI case 
 (n = 82) 
Significance 
(p) 
Age                   
median 80 71 <0.0001 80 70 <0.0001 62 75 <0.0001 
mean 79 69 <0.0001 78 68 <0.0001 62 74 0.016 
min 41 18   55 18   18 27 
 max 100 101   100 101   101 101 
 Gender             
   Female 92 80 
0.41 
44 72 
0.53 
39 33 
0.03 
Male 77 82 37 75 26 49 
unknown 6 5         
   Had a rectal 
swab taken     
        
   No   150 151 
0.24 
64 133 
0.03 
56 77 
0.19 Yes 25 16 17 14 9 5 
Had an 
antibiotic in the 
previous 8 
weeks     
        
   Yes 80 147 
<0.0001 
41 134 
<0.0001 
55 79 
0.03 
No 89 15 40 13 10 3 
unknown 6 5         
   Had a drug 
(other than an 
antibiotic in the 
previous 8 
weeks)     
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Yes 104 112 
0.08 
48 100 
0.15 
47 53 
0.19 
No 64 44 32 42 14 28 
unknown 7 9   1 5   4 1 
 
Table 5.1. Patient demographics of all cases and controls, regardless of if they had samples in the study and if they had at least one 
sample included in the study. Those patients that had at least one GDH positive sample are divided into potential C. difficile 
excretors (PCDEs) and CDI cases based on the presence or absence of C. difficile toxins in the original routine sample. 
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For all recruited participants, those in the control arm were significantly more likely to have 
been admitted following a fall than those recruited into the GDH positive arm (p <0.0001) 
(table 5.2). In addition, participants in the control arm were significantly more likely than 
GDH positive participants to be admitted with a fractured neck of femur, fracture of the 
knee, fracture of the shaft of the femur and septic arthritis (table 5.2). Participants 
recruited into the GDH positive arm were significantly more likely than control participants 
to have been admitted with diarrhoea, diarrhoea and vomiting, and abdominal pain (table 
5.3).  
For all participants that had at least one sample included in the study those in the control 
arm were significantly more likely to have been admitted following a fall than those 
recruited into the GDH positive arm (p <0.0001) (table 5.2). In addition, participants in the 
control arm were significantly more likely than GDH positive participants to be admitted 
with a fractured neck of femur, fracture of the knee, fracture of the shaft of the femur and 
septic arthritis (table 5.2).  Participants recruited into the GDH positive arm were 
significantly more likely than control participants to have been admitted with diarrhoea, 
diarrhoea and vomiting, abdominal pain, with pyrexia, and for being ‘unwell’ (table 5.3). 
GDH positive participants with CDI were significantly more likely to be admitted for being 
‘unwell’ than PCDE participants.  
Control participants recruited into the study were significantly more likely than GDH 
positive participants to have a past medical history of cancer, dementia and hypertension 
(table 5.4). However, participants recruited as GDH positive were significantly more likely 
than control participants to have a past medical history of alcoholism, asthma, pancreatitis 
and renal failure (table 5.5). Once only participants that had at least one sample in the 
study were compared, only a past medical history of dementia remained significantly more 
likely in control participants than GDH participants (table 5.4).  Alcoholism and asthma 
remained as the only conditions listed in past medical histories that were significantly 
associated with GDH participants compared with control participants (table 5.5).  CDI 
participants were significantly more likely to have had angina, heart failure and epilepsy 
than PCDE’s (table 5.5).  
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Recruited to the study Had at least one sample in the study Had at least one sample in the 
study and initial diagnostic 
specimen was GDH positive 
  
  
Control 
n (%) 
GDH 
positive 
n (%) 
Total 
n 
Significance 
(p) 
Control 
n (%) 
GDH 
positive 
n (%) 
Total 
n 
Significance 
(p) 
PCDE 
n (%) 
CDI 
n (%) 
Total 
n 
Significance 
(p) 
Fall 
87 
(49.7) 
13 
(7.7) 100 <0.0001 
36 
(44.4) 
11 
(7.5) 47 <0.0001 
3 
(4.6) 
8 
(9.7) 11 0.20* 
Fractured neck 
of femur 
58 
(33.0) 
2 
(1.2) 60 <0.0001 
17 
(21.9) 
2 
(1.4) 19 <0.0001 
0 
(0.0) 
2 
(2.4) 2 0.31* 
Planned surgery 
9 
(5.1) 
19 
(11.4) 28 0.06 
7 
(8.6) 
18 
(22.2) 25 0.54 
11 
(16.9) 
7 
(8.5) 18 0.20 
Fracture of the 
Knee 
7 
(4.0) 
0 
(0.0) 7 0.009* 
5 
(6.1) 
0 
(0) 5 0.005* 
0 
(0) 
0 
(0.0) 0 N/A 
Fracture of the 
shaft of the 
femur 
7 
(4.0) 
0 
(0.0) 7 0.009* 
5 
(6.1) 
0 
(0) 5 0.005* 
0 
(0.0) 
0 
(0.0) 0 
N/A 
Not known 
7 
(4.0) 
0 
(0.0) 7 0.009* 
1 
(1.2) 
0 
(0.0) 1 0.36* 
0 
(0.0) 
0 
(0.0) 0 
N/A 
Septic arthritis 
6 
(3.4) 
0 
(0.0) 6 0.017* 
4 
(4.9) 
0 
(0) 4 0.015* 
0 
(0.0) 
0 
(0.0) 0 
N/A 
Total  175 167   81 147   65 82   
 Table 5.2. The top five reasons for admission (by n size) for control patients that were recruited to the study, regardless of if they 
had samples in the study and if they had at least one sample included in the study. Those patients that had at least one GDH 
positive sample are divided into potential C. difficile excretors (PCDEs) and CDI cases based on the presence or absence of C. difficile 
toxins in the original routine sample. Full table of admission for all participants are shown in appendix table A3.1. Each participant 
could have more than one reason for admission recorded. *indicates where Fishers exact tests was used instead of χ2 
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Recruited to the study Had at least one sample in the study 
 
Had at least one sample in the 
study and initial diagnostic 
specimen was GDH positive 
  
  
Control 
n (%) 
GDH positive 
n (%) 
Total 
n 
Significance 
(p) 
Control 
n (%) 
GDH positive 
n (%) 
Total 
n 
Significance 
(p) 
PCDE 
n (%) 
CDI 
n (%) 
Total 
n 
Significance 
(p) 
Diarrhoeaabc 
1  
(0.6) 
21  
(12.6) 22 <0.0001 
1  
(1.2) 
19  
(12.9) 20 0.006 
6  
(9.2) 
13  
(15.9) 19 0.34 
Planned surgeryabc 
9  
(5.1) 
19  
(11.4) 28 0.06 
7  
(8.6) 
18  
(12.2) 25 0.54 
11  
(16.9) 
7  
(8.5) 18 0.20 
Diarrhoea and 
vomitingabc 
0  
(0.0) 
14  
(8.4) 14 0.0003 
0  
(0) 
14  
(9.5) 14 0.002* 
7  
(10.8) 
7  
(8.5) 14 0.43 
Fallac 
87  
(49.7) 
13  
(7.8) 100 <0.0001 
36  
(44.4) 
11  
(7.5) 47 <0.0001 
3  
(4.6) 
8  
(9.8) 11 0.20* 
Abdominal painabc 
1  
(0.6) 
10  
(5.0) 11 0.011* 
1  
(1.2) 
9  
(6.1) 10 0.07* 
4  
(6.1) 
5  
(6.1) 9 0.62* 
Shortness of breathb N/A N/A 
  
3  
(0.4) 
7  
(4.8) 10 0.49* 
5  
(7.6) 
2  
(2.4) 7 0.13* 
Pyrexiac N/A N/A 
  
0  
(0) 
7  
(4.8) 7 0.04* 
2  
(3.0) 
5  
(6.1) 7 0.32* 
Unwellc N/A N/A 
  
0  
(0) 
6  
(4.1) 6 0.07* 
0  
(0.0) 
6  
(7.3) 6 0.03* 
Total  175 167   81 147   65 82   
 Table 5.3. The top five reasons for admission (by n size) for aGDH positive patients  that were recruited to the study , bPCDEs or cCDI 
patients, regardless of if they had samples in the study and if they had at least one sample included in the study. Those patients 
that had at least one GDH positive sample are divided into potential C. difficile excretors (PCDEs) and CDI cases based on the 
presence or absence of C. difficile toxins in the original routine sample. Full table of admission for all participants are shown in 
appendix table A3.1. Each participant could have more than one reason for admission recorded. *indicates where Fishers exact 
tests was used instead of χ2  
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Recruited to the study Had at least one sample in the study Had at least one sample in the study 
and initial diagnostic specimen was 
GDH positive 
  
Control 
n (%) 
GDH 
positive 
n (%) 
Total 
n 
Significance 
(p) 
Control 
n (%) 
GDH 
positive 
n (%) 
Total 
n 
Significance 
(p) 
PCDE 
n (%) 
CDI 
n (%) 
Total 
n 
Significance 
(p) 
Atrial 
fibrillationab 
15  
(8.6) 
13  
(7.8) 28 1.0 
10  
(12.3) 
13  
(8.8) 23 0.54 
3  
(4.6) 
10 
(12.2) 13 0.19 
Cancerab 
28  
(16.0) 
41  
(24.6) 69 0.07 
14  
(17.3) 
39 
(27.5) 53 0.16 
22  
(33.8) 
17 
(20.7) 38 0.11 
CABGab 
10  
(5.7) 
5  
(3.0) 15 0.33 
5  
(6.2) 
3  
(2.0) 8 0.10* 
1  
(1.5) 
2 
(2.4) 3 0.67* 
CKDab 
10  
(5.7) 
3  
(1.8) 13 0.11 
5  
(6.2) 
3  
(2.0) 8 0.10* 
0  
(0.0) 
3  
(3.7) 3 0.33* 
COPDab 
12  
(6.9) 
10  
(6.0) 22 0.92 
4  
(4.9) 
10  
(6.8) 14 0.40* 
6  
(9.2) 
4  
(4.9) 10 0.24* 
Dementiaab 
15  
(8.6) 
3  
(1.8) 18 0.01 
6  
(7.4) 
3  
(2.0) 9 0.05* 
0  
(0.0) 
3  
(3.7) 3 0.33* 
Diabetesab 
33  
(18.9) 
30  
(18.0) 63 0.92 
19  
(23.5) 
26 
(17.7) 45 0.38 
9  
(13.8) 
19 
(23.2) 28 0.22 
Heart 
diseaseab 
14  
(8.0) 
8  
(4.8) 22 0.32 
7  
(8.6) 6 (4.8) 13 0.19* 
1  
(1.5) 
6  
(7.3) 7 0.10* 
Hypertentionab 
55 
(31.4) 
34  
(20.4) 89 0.02 
22  
(27.2) 
30 
(20.4) 52 0.32 
13  
(20.0) 
18 
(22.0) 31 0.92 
Hypothyroidab 
10  
(5.7) 
5  
(3.0) 15 0.33 
3  
(3.7) 
4  
(2.7) 7 0.48* 
1  
(1.5) 
3  
(3.7) 4 0.63* 
MIab 
15  
(8.6) 
8  
(4.3) 23 0.24 
8  
(9.9) 
8  
(5.4) 16 0.32 
5  
(7.7) 
3  
(3.7) 8 0.24* 
Ostearthritisab 
15  
(8.6) 
13  
(7.8) 28 1.0 
6  
(7.4) 
12  
(8.2) 18 1.0 
5  
(7.7) 
7  
(8.5) 12 0.82 
Osteoporosisab 
11 
(6.2) 
4  
(2.4) 15 0.13 
4  
(4.9) 
4  
(2.7) 8 0.30* 
0  
(0.0) 
4  
(4.9) 4 0.22* 
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Rheumatoidab 
9  
(5.1) 
8  
(4.8) 17 0.92 
6  
(7.4) 
8  
(5.4) 14 0.37* 
4  
(6.2) 
4  
(4.9) 8 0.51* 
Strokeab 
17  
(9.7) 
15  
(9.0) 32 1.0 
6  
(7.4) 
11  
(7.5) 17 0.80 
3  
(4.6) 
8  
(9.8) 11 0.54* 
Anginab N/A N/A N/A 
 
3  
(3.7) 
3  
(2.0) 6 0.36* 
4  
(6.2) 
2  
(2.4) 6 0.07* 
Epilepsyb N/A N/A N/A 
 
4  
(5.0) 
7  
(4.8) 11 0.59* 
5  
(7.7) 
2 
(2.4) 7 0.03* 
nab N/A N/A N/A 
 
3  
(3.7) 
2  
(1.4) 5 0.24* 
0  
(0.0) 
2 
(2.4) 2 0.48* 
PVDb N/A N/A N/A 
 
3  
(3.7) 
3  
(2.0) 6 0.36* 
2  
(3.1) 
1 
(1.2) 3 0.22* 
Total  175 167 
  
81 147 
  
65 82 
  
Table 5.4. The top ten conditions listed within past medical history (by n size) for acontrol patients that were recruited to the study 
regardless of if they had samples in the study and bif they had at least one sample included in the study. Those patients that had at 
least one GDH positive sample are divided into potential C. difficile excretors (PCDEs) and CDI cases based on the presence or 
absence of C. difficile toxins in the original routine sample. Full table of past medical history for all participants are shown in 
appendix table A3.2. Each participant could have more than one reason for admission recorded. *indicates where Fishers exact 
tests was used instead of χ2  
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Recruited to the study Had at least one sample in the study Had at least one sample in the study 
and initial diagnostic specimen was 
GDH positive 
  
  
Control 
n (%) 
GDH 
positive 
n (%) 
Total 
n 
Significance 
(p) 
Control 
n (%) 
GDH 
positive 
n (%) 
Total 
n 
Significance 
(p) 
PCDE 
n (%) 
CDI 
n (%) 
Total 
n 
Significance 
(p) 
Alcoholicabc 
4  
(2.3) 
14  
(8.4) 18 0.02 
1  
(1.2) 
12  
(8.2) 13 0.02* 
5  
(7.7) 
6  
(7.3) 11 0.59* 
Asthmaabcd 
5  
(2.9) 
20  
(12.0) 25 0.002 
2  
(2.5) 
18  
(12.2) 20 0.02 
9  
(13.3) 
9  
(11.0) 18 0.78 
Atrial 
fibrillationabd 
15  
(8.6) 
13  
(7.8) 28 1.0 
10 
(12.3) 
13  
(8.8) 23 0.54 
3  
(4.6) 
10  
(12.2) 13 0.19 
Cancerabcd 
28 
(16.0) 
41  
(24.6) 69 0.07 
14 
(17.3) 
39  
(27.5) 53 0.16 
22 
(33.8) 
17 
(20.7) 38 0.11 
COPDabc 
12  
(6.9) 
10  
(6.0) 22 0.92 
4  
(4.9) 
10  
(6.8) 14 0.40* 
6  
(9.2) 
4  
(4.9) 10 0.24* 
Diabetesabcd 
33 
(18.9) 
30  
(18.0) 63 0.92 
19 
(23.5) 
26  
(17.7) 45 0.38 
9  
(13.8) 
19 
(23.2) 28 0.22 
Epilepsyabc 
5  
(2.9) 
7  
(4.2) 12 0.71 
4  
(4.9) 
7  
(4.8) 11 0.59* 
5  
(7.7) 
2  
(2.4) 7 0.14* 
Heart diseasea 
14  
(8.0) 
8  
(4.8) 22 0.32 
7  
(8.6) 
7  
(4.8) 14 0.19* 
1  
(1.5) 
6  
(7.3) 7 0.10* 
Hypertentionabc
d 
55 
(31.4) 
34  
(20.4) 89 0.02 
22 
(27.2) 
30  
(20.4) 52 0.32 
13  
(20.0) 
18 
(22.0) 31 0.92 
MIabc 
15  
(8.6) 
8  
(4.3) 23 0.24 
8  
(9.9) 
8  
(5.4) 14 0.32 
5  
(7.7) 
3  
(3.7) 8 0.24 
Ostearthritisabc 
15  
(8.6) 
13  
(7.8) 28 1.0 
6  
(7.4) 
12  
(8.2) 18 1.0 
5  
(7.7) 
7  
(8.5) 12 0.92 
Pancreatitisa 
1  
(0.6) 
7  
(4.2) 8 0.02* 
0  
(0.0) 
5  
(3.4) 5 0.11* 
3  
(4.6) 
2  
(2.4) 5 0.39* 
Renal failureab 
2  
(1.1) 
8  
(4.8) 10 0.04* 
1  
(1.2) 
8  
(5.4) 16 0.11* 
4  
(6.2) 
4  
(4.9) 8 0.51* 
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Rheumatiodab 
9  
(5.1) 
8  
(4.8) 17 0.92 
6  
(7.4) 
8  
(5.4) 9 0.37* 
4  
(6.2) 
4  
(4.9) 8 0.51* 
Strokeab 17 (9.7) 
15  
(9.0) 32 1.0 
6  
(7.4) 
11  
(7.5) 17 0.81 
3  
(4.6) 
8  
(9.8) 11 0.20* 
 
Heart failureb N/A N/A 
  
1  
(1.2) 
8  
(5.4) 9 0.11* 
0  
(0.0) 
5  
(6.1) 5 0.02* 
Ulcerative 
colitisc N/A N/A 
  
N/A N/A 
  
5  
(7.7) 
1  
(1.2) 6 0.08* 
Total  175 167 
  
81 147 
  
65 82 
  
Table 5.5. The top ten conditions listed within past medical history (by n size) for aGDH positive patients  that were recruited to the 
study , bthat had at least one sample in the study, cPCDEs or dCDI patients, regardless of if they had samples in the study and if they 
had at least one sample included in the study. Those patients that had at least one GDH positive sample are divided into potential 
C. difficile excretors (PCDEs) and CDI cases based on the presence or absence of C. difficile toxins in the original routine sample. Full 
table of past medical history for all participants are shown in appendix table A3.2. Each participant could have more than one 
reason for admission recorded. *indicates where Fishers exact tests was used instead of χ2  
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5.3.3 Participants with at least one sample in the study 
The study data was only complete for participants that submitted at least one sample into 
the study, as these are the only participants who could have samples tested with the 
diagnostic assays.  The following tables therefore only include these participants.  
The proportion of participants that received at least one dose of antibiotics was 
significantly higher for GDH positive samples compared with control participants (table 5.6). 
There was also a significant difference between control participants and GDH positive 
participants for each number of doses of antibiotic received and for the total number of 
doses of antibiotic received (table 5.6).  The proportion of CDI cases that had at least one 
antibiotic was significantly higher compared with PCDE’s, and the total number of doses 
received was significantly higher for CDI cases compared with PCDEs.  There was however 
no significant difference between the proportions of participants that received larger 
numbers of doses (table 5.6). The most commonly prescribed antibiotics for control and 
GDH positive participants are shown in tables 5.7 and 5.8. Control participants were 
significantly more likely to have been prescribed gentamicin compared with GDH positive 
participants.  In contrast, GDH positive participants were significantly more likely to have 
the following antibiotics prescribed in the previous three months compared with control 
participants; ciprofloxacin, co-trimoxazole, fidaxomicin, meropenem, metronidazole, 
pipercillin-tazobactam, trimethoprim, vancomycin and the antifungal fluconazole (table 
5.7).  CDI cases were significantly more likely to have the following antibiotics prescribed in 
the previous three months compared with PCDEs; fidaxomicin, metronidazole and 
vancomycin (table 5.8). PCDEs were significantly more likely to have been prescribed the 
antifungal fluconazole in the previous three months compared with CDI cases.   
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Had at least one sample in the 
study 
Had at least one sample in the study 
and initial diagnostic specimen was 
GDH positive 
Number 
of 
antibiotic 
doses 
Control 
n (%) 
GDH 
positive 
n (%) 
Significance 
(p) 
PCDE 
n (%) 
CDI 
n (%) 
Significance 
(p) 
One 41 (50.6) 
134 
(91.2) <0.0001 
55  
(84.6) 
79  
(96.3) 0.03 
Two 22 (27.2) 
106 
(72.1) <0.0001 
43  
(66.2) 
63  
(76.8) 
0.2 
Three 11 (13.6) 
64 
(43.5) <0.0001 
25  
(38.5) 
39  
(47.6) 0.4 
Four 
6  
(7.4) 
44 
(29.9) 0.0002 
21  
(32.3) 
23  
(28.0) 0.7 
Five 
0  
(0.0) 
27 
(18.4) <0.0001 
12  
(18.5) 
15  
(18.3) 0.8 
Six 
0  
(0.0) 
16 
(10.9) 0.005 
7  
(10.8) 
9  
(11.0) 0.8 
Seven 
0  
(0.0) 
7  
(4.8) 0.04* 
2  
(3.1) 
5  
(6.1) 0.33* 
Eight 
0  
(0.0) 
1  
(0.7) 0.6* 
0  
(0.0) 
1  
(1.2) 0.56* 
Nine 
0  
(0.0) 
1  
(0.7) 0.6* 
0  
(0.0) 
1  
(1.2) 0.56* 
Ten 
0  
(0.0) 
1  
(0.7) 0.6* 
0  
(0.0) 
1  
(1.2) 0.56* 
Eleven 
0  
(0.0) 
1  
(0.7) 0.6* 
0  
(0.0) 
1  
(1.2) 0.56* 
Twelve 
0  
(0.0) 
1  
(0.7) 0.6* 
0  
(0.0) 
1  
(1.2) 0.56* 
Total 
number 
of doses 
80 403 <0.0001 165 238 <0.0001 
Table 5.6. Number of antibiotic doses each participant received in the three 
months prior to recruitment into the study   
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 Had at least one sample in the 
study 
Had at least one sample in the 
study and initial diagnostic 
specimen was GDH positive 
  
  
Control 
n (%) 
GDH 
positive 
n (%) 
Significance 
(p) 
PCDE 
n (%) 
CDI 
n (%) 
Significance 
(p) 
Aztreonam 
3  
(3.7) 
11  
(7.5) 0.20* 
7  
(10.8) 
4  
(4.9) 0.15* 
Amoxicillin 
4  
(4.9) 
12  
(8.2) 0.52 
5  
(7.7) 
7  
(8.5) 0.92 
Clarithromycin 
3  
(3.7) 
7  
(4.8) 0.50* 
2  
(3.1) 
5  
(6.1) 0.33* 
Co- amoxiclav 
12  
(14.8) 
27  
(18.4) 0.62 
11  
(16.9) 
16  
(19.5) 0.84 
Flucloxacillin 
13  
(16.0) 
15  
(10.2) 0.28 
6  
(9.2) 
9  
(11.0) 0.92 
Gentamicin 
5  
(6.2) 
0  
(0.0) 0.005* 
0  
(0.0) 
0  
(0.0) - 
Linezolid 
3  
(3.7) 
2  
(1.4) 0.24 
1  
(1.5) 
1  
(1.2) 0.69 
Metronidazole 
3  
(3.7) 
82  
(55.8) <0.0001 
26  
(40.0) 
56  
(68.3) 0.001 
Nitrofurantoin 
4  
(4.9) 
8  
(5.4) 0.57* 
0  
(0.0) 
4  
(4.9) 0.09* 
Pipercillin 
tazobactam 
5  
(6.2) 
46  
(31.3) <0.0001 
22  
(33.8) 
24  
(29.3) 0.68 
Tazocin 
5  
(6.2) 
18  
(12.2) 0.22 
8  
(12.3) 
10  
(12.2) 0.86 
Teicoplanin 
5  
(6.2) 
3  
(2.0) 0.11* 
2  
(3.1) 
1  
(1.2) 0.41* 
Vancomycin 
3  
(3.7) 
40  
(27.2) <0.0001 
10  
(15.4) 
30  
(36.6) 0.007 
Table 5.7.  Top ten (by n size) antibiotics taken by the control participants in the 
three months prior to the study, for all recruited participants that had at least one 
sample taken in the study. *indicates where Fishers exact tests was used instead 
of χ2. Full table of antibiotic history for all participants is shown in appendix table 
A3.3  
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Had at least one sample in the 
study 
Had at least one sample in 
the study and initial 
diagnostic specimen was 
GDH positive 
  
  
Control 
n (%) 
GDH 
positive 
n (%) 
Significance 
(p) 
PCDE 
n (%) 
CDI 
n (%) 
Significance 
(p) 
Aztreonama 
3  
(3.7) 
11  
(7.5) 0.20* 
7 
(10.8) 
4  
(4.9) 0.15* 
Co- amoxiclavab 
12  
(14.8) 
27  
(18.4) 0.62 
11 
(16.9) 
16 
(19.5) 0.84 
Co-trimoxazoleab 
1  
(1.2) 
11  
(7.5) 0.04* 6 (9.2) 
5  
(6.1) 0.34* 
Flucloxacillinab 
13 
(16.0) 
15  
(10.2) 0.28 6 (9.2) 
9 
(11.0) 0.92 
Fluconazolea 
0  
(0.0) 
10  
(6.8) 0.01* 
9 
(13.8) 
1  
(1.2) 0.003* 
Meropenemab 
1  
(1.2) 
16  
(10.9) 0.0004 
9 
(13.8) 
7  
(8.5) 0.45 
Metronidazoleab 
3  
(3.7) 
82  
(55.8) <0.0001 
26 
(40.0) 
56 
(68.3) 0.001 
Pipercillin 
tazobactamab 
5  
(6.2) 
46  
(31.3) <0.0001 
22 
(33.8) 
24 
(29.3) 0.68 
Tazocinab 
5  
(6.2) 
18  
(12.2) 0.22 
8 
(12.3) 
10 
(12.2) 0.86 
Trimethoprima 
1  
(1.2) 
10  
(6.8) 0.05* 
6  
(9.2) 
4  
(4.9) 0.24* 
Vancomycinab 
3  
(3.7) 
40  
(27.2) <0.0001 
10 
(15.4) 
30 
(36.6) 0.007 
Amoxicillinb 
4  
(4.9) 
12  
(8.2) 0.52 5 (7.7) 
7  
(8.5) 0.92 
Ciprofloxacinb 
1  
(1.2) 
9  
(6.1) 0.009* 4 (6.2) 
5  
(6.1) 0.62* 
Clarithromycinb 
3  
(3.7) 
7  
(4.8) 0.50* 2 (3.1) 
5  
(6.1) 0.33* 
Fidaxomicinb 
0  
(0.0) 
28  
(19.0) <0.0001 5 (7.7) 
23 
(28.0) 0.004 
Table 5.8 Top ten (by n size) antibiotics taken by aPCDEs and bCDI participants in 
the three months prior to the study, for all recruited patients that had at least one 
sample taken in the study. *indicates where Fishers exact tests was used instead 
of χ2. Full table of antibiotic history for all participants is shown in appendix table 
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Control participants were significantly more likely than GDH positive participants to have 
taken laxatives in the three months prior to recruitment in the study (p <0.0001) (table 5.9). 
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Of these laxatives, Docusate and Senna were significantly more likely to have been 
prescribed for control participants than for GDH positive participants (table 5.10). GDH 
positive participants were not significantly more likely than controls to be prescribed any 
particular class of drugs, however they were more likely to have been prescribed 
Omeprazole and Ranitidine than control participants (tables 5.9 And 5.10). There were no 
significant differences in the class or specific drugs prescribed for PCDEs and CDI 
participants in the three months prior to recruitment in the study (tables 5.9 And 5.10).  
 
  
Had at least one sample in the 
study 
Had at least one sample in the study 
and initial diagnostic specimen was 
GDH positive 
  
  
Control 
n (%) 
GDH 
positive 
n (%) 
Significance 
(p) 
PCDE 
n (%) 
CDI 
n (%) 
Significance 
(p) 
Analgesia 
2  
(2.5) 
4  
(2.7) 0.63* 
3  
(4.6) 
1  
(1.2) 0.23* 
Anti-
diarrhoeal 
0  
(0.0) 
2  
(1.4) 0.41* 
0  
(0.0) 
2  
(2.4) 0.31* 
Anti-emetic 
1  
(1.2) 
4  
(2.7) 0.42* 
2  
(3.1) 
2  
(2.4) 0.60* 
Anti-
motility 
1  
(1.2) 
4  
(2.7) 0.42* 
3  
(4.6) 
1  
(1.2) 0.22* 
Bowel prep 
0  
(0.0) 
2  
(1.4) 0.41* 
0  
(0.0) 
2  
(2.4) 0.31* 
Enema 
0  
(0.0) 
1  
(0.7) 0.65* 
1  
(1.5) 
0  
(0.0) 0.44* 
H2 
receptor 
antagonist 
0  
(0.0) 
3  
(2.0) 0.27* 
1  
(1.5) 
2  
(2.4) 0.59* 
Laxative 
43 
(53.1) 
17  
(11.6) <0.0001 
9  
(13.8) 
8  
(9.8) 0.61 
pH 
antagonist 
3  
(3.7) 
17  
(11.6) 0.08 
6  
(9.2) 
11  
(13.4) 0.60 
PPI 
33 
(40.7) 
70  
(47.6) 0.39 
33  
(50.8) 
37  
(45.1) 0.61 
Total 81 147 
 
65 82 
 
Table 5.9 Class of drugs other than antibiotics, taken in the three months prior to 
the study, for all patients recruited to the study that had at least one sample 
taken. *indicates where Fishers exact tests was used instead of χ2 
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Had at least one sample in the 
study 
Had at least one sample in the 
study and initial diagnostic 
specimen was GDH positive 
  
  
Control 
n (%) 
GDH 
positive 
n (%) 
Significance 
(p) 
PCDE 
n (%) 
CDI 
n (%) 
Significance 
(p) 
Codeine 
2  
(2.5) 
4  
(2.7) 0.63* 
3  
(4.6) 
1  
(1.2) 0.23* 
Docusate 
4  
(4.9) 
0  
(0.0) 0.01* 
0  
(0.0) 
0  
(0.0) 1 
Esomeprazole 
1  
(1.2) 
1  
(0.7) 0.58 
1  
(1.5) 
0  
(0.0) 0.44* 
Klean prep 
0  
(0.0) 
1  
(0.7) 0.65* 
0  
(0.0) 
1  
(1.2) 0.69* 
Lactulose 
4  
(4.9) 
2  
(1.4) 0.12* 
0  
(0.0) 
2  
(2.4) 0.31* 
Lansoprazole 
24 
(29.6) 
34  
(23.1) 0.36 
16  
(24.6) 
18  
(22.0) 0.89 
Loperamide 
1  
(1.2) 
8  
(5.4) 0.11* 
5  
(7.7) 
3  
(3.7) 0.25* 
Metaclopramide 
1  
(1.2) 
4  
(2.7) 0.42* 
2  
(3.1) 
2  
(2.4) 0.60* 
Microlax 
0  
(0.0) 
1  
(0.7) 0.65* 
1  
(1.5) 
0  
(0.0) 0.44* 
Movicol 
14 
(17.3) 
12  
(8.2) 0.06 
6 
(9.2) 
6  
(7.3) 0.92 
Omeprazole 
9  
(11.1) 
42  
(28.6) 0.004 
18  
(27.7) 
24  
(29.3) 0.92 
Pantoprazole 
0  
(0.0) 
1  
(0.7) 0.65* 
0  
(0.0) 
1  
(1.2) 0.56* 
Phosphate 
enema 
2  
(2.5) 
0  
(0.0) 0.13* 
0  
(0.0) 
0  
(0.0) 1 
Picolax 
0  
(0.0) 
1  
(0.7) 0.65* 
0  
(0.0) 
1  
(1.2) 0.56* 
PO4 enema 
1  
(1.2) 
0  
(0.0) 0.35* 
0  
(0.0) 
0  
(0.0) 1 
Rabeprazole 
0  
(0.0) 
1  
(0.7) 0.65* 
1  
(1.5) 
0  
(0.0) 0.44* 
Ranitidine 
3  
(3.7) 
26  
(17.7) 0.005 
10  
(15.4) 
16  
(19.5) 0.66 
Senna 
16 
(19.8) 
7  
(4.8) 0.0005 
4  
(6.2) 
3  
(3.7) 0.37* 
Total 81 147 
 
65 82 
 
Table 5.10. Name of drugs other than antibiotics, taken in the three months prior 
to the study, for all participants recruited to the study that had at least one 
sample taken. *indicates where Fishers exact tests was used instead of χ2 
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5.3.4 Diagnostic assay results 
Although there were 1173 sampling days results for each of the assays are not available for 
every sample; CCNA n = 1086, Culture N = 1129, CTC N = 1104, GDH EIA N = 1138, Toxin EIA 
N = 1135, Toxin gene B (PCR) N = 1086 (table 5.12).  Reasons for discrepancies in the N sizes 
included lack of sample volume for processing by all assays, removal of any CCNA results 
that were ‘indeterminate’ and removal of Toxin gene PCR results that were ‘invalid’.  
There were three samples from control participants that were positive for C. difficile toxins 
by CCNA; two of which were also positive by the Toxin EIA (table 5.12). These three 
samples came from three different individuals; the sample for one of the individuals 
(participant 178) was positive by all assays and PCR ribotype 018 was isolated from the 
sample. The samples for the other two individuals were negative for all other assays. 
Participant 178 was withdrawn from the study as a control participant after this result.  
There were fourteen samples from control participants that had C. difficile isolated from 
their sample; these were from seven individuals. Six of these seven participants had only 
one PCR ribotype isolated form their samples, one had two PCR ribotypes isolated 
(table 5.11).  With the exception of participant 178 (discussed above) none of these 
participants had samples positive for C. difficile toxins. Of the 14 samples, 13 were positive 
by the GDH EIA assay, five were positive by CTC, and three positive by toxin B gene PCR. In 
addition to these 14 culture positive participants there were a further five samples positive 
for GDH  
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Study 
number 
Number of culture 
positive samples  
(n) 
Number of 
GDH EIA 
positive 
samples  
(n) 
Number of 
toxin B gene 
PCR positive 
samples 
 (n) 
PCR ribotype 
isolated from 
the samples 
1 0 1 1 N/A 
2 0 0 1 N/A 
9 5 5 0 067 
27 1 1 0 015 
63 0 1 0 N/A 
76 2 2 0 026 and 716 
82 1 0 0 073 
99 0 0 1 N/A 
117 3 6 3 020 
157 1 1 0 039 
178 1 1 1 018 
Total 14 18 7 N/A 
Table 5.11. Control participants that had C. difficile isolated from samples within 
the study and the PCR ribotype of that isolate.  
 
Participants with CDI had a higher proportion of CCNA positive samples than PCDE’s (24.7 
vs 15.3% respectively) (table 5.12); however the majority of samples were CCNA negative. 
The proportion of samples positive for toxin by EIA was lower than those positive by CCNA 
for both participants with CDI and PCDE’s (table 5.12). There were a similar number of 
samples that were culture positive and GDH EIA positive from CDI cases and PCDE’s (48.5 vs 
47.1% culture positive and 52.6 vs 51.8% GDH positive respectively), although there was a 
higher proportion of CTC positive samples and Toxin B gene PCR positive samples for CDI 
cases than for PCDE’s (44.4% vs 29.2% CTC positive and 42.1 vs 30.4% PCR positive 
respectively).   
For all samples that were CCNA positive 89.3% were also culture positive, 86.4% were CTC 
positive, 95.7% were GDH EIA positive, 64.5% were Toxin EIA positive and 90.1% were toxin 
B gene PCR positive. For all samples that were culture positive 39.9% were also CCNA 
positive, 83.0% were CTC positive, 89.3% were GDH EIA positive, 1.6% were toxin EIA 
positive and 65.4% were toxin B gene PCR positive. For all samples that were CTC positive 
46.2% were also CCNA positive, 100% were culture positive (a pre-requisite for being CTC 
positive),  88.7% were GDH EIA positive, 35.4% were Toxin EIA positive and 74.4% were 
toxin B gene PCR positive.  
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When all submitted samples were included in the analysis, the most sensitive assay for 
detecting a CDI case was the GDH EIA assay (52.6% table 5.13).  The majority of samples 
from CDI cases that were tested were not positive for toxin, as reflected in the sensitivity of 
24.7% and 17.8% for CCNA and Toxin EIA respectively. The most sensitive assay for 
detecting a PCDE was also the GDH EIA (51.8%). There were fewer toxin positive samples in 
the PCDE group than in CDI cases leading to a lower sensitivity in the PCDE’s compared to 
CDI cases for both CCNA and toxin EIA (15.3% vs 24.7% for CCNA, 13.0% vs 17.8% for toxin 
EIA respectively). When compared to reference methods the GDH EIA had the highest 
sensitivity when compared with CCNA (95.7%) followed by toxin gene PCR (90.1%) and 
culture (89.3%); GDH had the highest sensitivity when compared with culture (89.3%) 
followed by CTC (83.0%); Culture has the highest sensitivity when compared with CTC 
(100%), followed by GDH EIA (88.7%).  
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Defined by routine diagnostic test result (used 
for recruitment into the study) CCNA Culture CTC 
Assay   
Control 
n (%) 
GDH 
positive/toxin 
either positive 
or negative 
n (%) 
PCDE 
n (%) 
CDI 
n (%) 
Positive 
n (%) 
Negative 
n (%) 
Positive 
n (%) 
Negative 
n (%) 
Positive 
n (%) 
Negative 
n (%) 
CCNA 
Positive 
3 
(1.3) 
184 
(21.6) 
42 
(15.3) 
142 
(24.7) 
n/a n/a 
167 
(39.9) 
20 
(0.3) 
152 
(46.2) 
24 
(3.3) 
Negative 
232 
(98.7) 
667 
(78.4) 
233 
(84.7) 
434 
(75.3) 
n/a n/a 
252 
(60.1) 
642 
(96.7) 
177 
(53.8) 
704 
(96.7) 
N size 235 851 275 576 n/a n/a 419 662 329 728 
Culture 
Positive 
14 
(5.7) 
424 
(48.1) 
132 
(47.1) 
292 
(48.5) 
167 
(89.3) 
252 
(28.2) 
n/a n/a 
341 
(99.1) 
70 
(9.2) 
Negative 
233 
(94.3) 
458 
(51.9) 
148 
(52.9) 
310 
(51.5) 
20 
(10.7) 
642 
(71.8) 
n/a n/a 
0 
(0) 
691 
(90.8) 
N size 247 882 280 602 187 894 n/a n/a 344 76 
CTC 
Positive 
5 
(2.0) 
341 
(39.8) 
79 
(29.2) 
260 
(44.4) 
152 
(86.4) 
177 
(20.1) 
341 
(83.0) 
0 
(0) 
n/a n/a 
Negative 
242 
(98.0) 
516 
(60.2) 
192 
(70.8) 
326 
(55.6) 
24 
(13.6) 
704 
(79.9) 
70 
(17.0) 
691 
(100) 
n/a n/a 
N size 247 857 271 586 176 881 411 691 n/a n/a 
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GDH EIA 
Positive 
18 
(7.2) 
465 
(52.3) 
147 
(51.8) 
318 
(52.6) 
179 
(95.7) 
613 
(68.3) 
391 
(89.3) 
86 
(12.5) 
306 
(88.7) 
148 
(19.6) 
Negative 
231 
(93.8) 
424 
(47.7) 
137 
(48.2) 
287 
(47.4) 
8 
(4.3) 
285 
(31.7) 
47 
(10.7) 
603 
(87.5) 
39 
(11.3) 
608 
(80.4) 
N size 249 889 284 605 187 898 438 689 345 756 
Toxin EIA 
Positive 
2 
(0.8) 
144 
(16.2) 
37 
(13.0) 
107 
(17.8) 
120 
(64.5) 
20 
(2.2) 
11 
(1.6) 
135 
(30.8) 
122 
(35.4) 
14 
(1.9) 
Negative 
246 
(99.2) 
743 
(83.8) 
248 
(87.0) 
495 
(82.2) 
66 
(35.5) 
876 
(97.8) 
675 
(98.4) 
303 
(69.2) 
223 
(64.6) 
739 
(98.1) 
N size 248 887 285 602 186 896 686 438 345 753 
Toxin gene tcdB 
(PCR) 
Positive 
7 
(3.0) 
326 
(38.2) 
85 
(30.4) 
241 
(42.1) 
163 
(90.1) 
161 
(18.7) 
274 
(65.4) 
55 
(8.4) 
247 
(74.4) 
64 
(8.9) 
Negative 
224 
(97.0) 
527 
(61.8) 
195 
(69.6) 
332 
(57.9) 
18 
(9.9) 
699 
(91.3) 
145 
(34.6) 
601 
(91.6) 
85 
(25.6) 
655 
(91.1) 
N size 233 853 280 573 181 860 419 656 332 719 
Table 5.12. The results of each diagnostic assay for different categories of participants; controls, GDH positive (regardless of toxin 
status), PCDE or CDI case, and compared with each reference method, for all samples included in the study 
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  Case definition Reference method 
    
GDH positive/toxin 
either positive or 
negative  
(% (95% CI)) 
PCDE 
(% (95% CI)) 
CDI 
(% (95% CI)) 
CCNA 
(% (95% CI)) 
Culture 
(% (95% CI)) 
CTC 
(% (95% CI)) 
CCNA 
Sensitivity 
21.6 
(18.9-24.6) 
15.3 
(11.3-20.2) 
24.7 
(21.2-28.4) n/a 
39.9 
(35.1-44.7) 
46.2 
(40.7-51.8) 
Specificity 
98.7 
(96.0-99.7) 
98.7 
(96.0-99.7) 
98.7 
(96.0-99.7) n/a 
97.0 
(95.3-98.1) 
96.7 
(95.1-97.8) 
PPV 
98.4 
(95.0-99.6) 
93.3 
(80.7-98.2) 
97.9 
(93.6-99.5) n/a 
89.3 
(93.7-93.2) 
86.4 
(80.2-90.9) 
NPV 
25.8 
(23.0-28.8) 
49.9 
(45.3-54.5) 
34.8 
(31.2-38.6) n/a 
71.8 
(68.7-74.7) 
79.9 
(77.1-82.5) 
Culture 
Sensitivity 
48.1 
(44.7-51.4) 
47.1 
(41.2-53.2) 
48.5 
(44.5-52.6) 
89.3 
(83.8-93.2) n/a 
100.0 
(98.6-100) 
Specificity 
94.3 
(90.5-96.7) 
94.3 
(90.5-96.7) 
94.3 
(90.5-96.7) 
71.8 
(68.7-74.7) n/a 
90.8 
(88.5-92.7) 
PPV 
96.8 
(94.6-98.2) 
90.4 
(84.1-94.5) 
95.4 
(92.3-97.4) 
39.9 
(35.2-44.7) n/a 
83.0 
(78.9-86.4) 
NPV 
33.7 
(30.2-37.4) 
61.2 
(56.0-66.0) 
42.9 
(38.7-47.2) 
97.0 
(95.3-98.1) n/a 
100.0 
(99.3-100) 
CTC 
Sensitivity 
39.8 
(36.5-43.2) 
29.2 
(23.9-35.0) 
44.4 
(40.3-48.5) 
86.4 
(80.2-90.9) 
83.0 
(78.9-86.4) n/a 
Specificity 
98.0 
(95.1-99.3) 
98.0 
(95.1-99.3) 
98.0 
(95.1-99.3) 
79.9 
(77.0-82.5) 
100.0 
(99.3-100) n/a 
PPV 
98.6 
(96.5-99.5) 
94.0 
(86.0-97.8) 
98.1 
(95.4-99.3) 
46.2 
(40.7-51.7) 
100.0 
(98.6-100) n/a 
NPV 
31.9 
(28.6-35.4) 
55.8 
(50.9-60.5) 
42.6 
(38.5-46.8) 
96.7 
(95.1-97.8) 
90.8 
(88.5-92.7) n/a 
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GDH EIA 
Sensitivity 
52.3 
(50.0-55.6) 
51.8 
(45.8-57.7) 
52.6 
(48.5-56.6) 
95.7 
(91.4-98.0) 
89.3 
(85.9-91.9) 
88.7 
(84.8-91.7) 
Specificity 
92.8 
(88.6-95.5) 
92.8 
(88.6-95.5) 
92.8 
(88.6-95.5) 
31.7 
(28.7-34.9) 
87.5 
(84.8-89.8) 
80.4 
(77.4-83.2) 
PPV 
96.3 
(94.1-97.7) 
89.1 
(83.1-93.2) 
94.6 
(91.5-96.7) 
22.6 
(19.8-25.7) 
82.0 
(78.2-85.3) 
67.4 
(62.8-71.7) 
NPV 
35.3 
(31.6-39.1) 
62.8 
(57.6-67.7) 
44.6 
(40.3-49.0) 
97.3 
(90.4-94.6) 
92.8 
(90.4-94.6) 
94.0 
(91.8-95.6) 
Toxin EIA 
Sensitivity 
16.2 
(13.9-39.1) 
13.0 
(9.4-17.6) 
17.8 
(14.9-21.1) 
64.5 
(57.1-71.3) 
1.6 
(0.8-2.9) 
35.4 
(30.3-40.7) 
Specificity 
99.2 
(96.8-99.9) 
99.2 
(96.8-99.9) 
99.2 
(96.8-99.9) 
97.8 
(96.5-98.6) 
69.2 
(64.6-73.4) 
98.1 
(96.8-98.9) 
PPV 
98.6 
(94.6-99.8) 
94.9 
(81.4-99.1) 
98.2 
(92.9-99.7) 
85.7 
(78.6-90.9) 
7.5 
(4.0-13.4) 
89.7 
(83.0-94.0) 
NPV 
24.9 
(22.2-27.7) 
49.8 
(45.3-54.3) 
33.2 
(29.8-36.7) 
93.0 
(91.1-94.5) 
31.0 
(28.1-34.0) 
76.8 
(74.0-79.4) 
Toxin gene tcdB (PCR) 
Sensitivity 
38.2 
(35.0-41.6) 
30.4 
(25.1-36.2) 
42.1 
(38.0-46.2) 
90.1 
(84.5-93.8) 
65.4 
(60.6-69.9) 
74.4 
(69.3-78.9) 
Specificity 
96.1 
(93.6-98.7) 
97.0 
(93.6-98.7) 
96.1 
(93.6-98.7) 
81.3 
(78.5-93.8) 
91.6 
(89.1-93.6) 
91.1 
(88.7-93.0) 
PPV 
97.9 
(95.5-99.1) 
92.4 
(84.4-96.6) 
97.2 
(94.0-98.8) 
50.3  
(44.7-55.9) 
83.3 
(78.7-87.1) 
79.4 
(74.4-83.7) 
NPV 
29.8 
(26.6-33.3) 
53.5 
(48.6-58.3) 
40.3 
(36.2-44.5) 
97.5 
(96.0-98.4) 
80.6 
(77.5-83.3) 
88.5 
(85.9-90.7) 
Table 5.13. Sensitivity, specificity, PPV and NPV for each assay compared with the case definition, CCNA, Culture and CTC, for all 
samples included in the study 
178 
 
The number of positive samples, sensitivity and specificity of each assay were also 
compared using only samples collected within the first 72 hours after recruitment into the 
study (table 5.14 and 5.15). CDI cases had a higher proportion of CCNA positive samples 
than PCDE’s (24.4 vs 10.6% respectively) (table 5.14); however the majority of samples 
were CCNA negative.  Although the proportion of CCNA positive samples in CDI cases 
within the first 72 hours was similar to the proportion of CCNA positive samples in CDI 
cases for all samples (24.4 vs 24.7% respectively), there were more CCNA positive samples 
in the PCDE group when all samples were included than when just those taken within the 
first 72 hours were analysed (15.3 vs 10.6% respectively) (table 5.14).  The proportion of 
samples within the first 72 hours that were positive for toxin by EIA was lower than those 
positive by CCNA for both CDI cases and PCDE’s (table 5.14). There were more samples 
within 72 hours that were culture positive and GDH EIA positive from PCDE’s than CDI cases 
(53.1 vs 40.4% culture positive and 60.4 vs 56.5% GDH positive respectively), although 
there was a higher proportion of CTC positive samples and Toxin B gene PCR positive 
samples for CDI cases than for PCDE’s (37.8% vs 25.0% CTC positive and 39.1 vs 23.4% PCR 
positive respectively).   
For all samples that were CCNA positive 76.9% were also culture positive, 76.9% were CTC 
positive, 84.6% were GDH EIA positive, 50.0% were Toxin EIA positive and 92.3% were toxin 
B gene PCR positive. For all samples that were culture positive 24.4% were also CCNA 
positive, 67.0% were CTC positive, 88.1% were GDH EIA positive, 16.7% were toxin EIA 
positive and 52.4% were toxin B gene PCR positive. For all samples that were CTC positive 
38.5% were also CCNA positive, 100% were culture positive (a pre-requisite for being CTC 
positive),  88.5% were GDH EIA positive, 2.7% were Toxin EIA positive and 80.8% were toxin 
B gene PCR positive.  
A large number of CDI cases were negative by the time their first sample was tested in the 
study. The 16 CCNA positive samples that were tested within 72 hours of diagnosis were 
from 13 patients, however only 10 of these were CDI when recruited, rather than just GDH 
positive. This means that only 10/82 (12.2%) of patients that were recruited as CDI had 
another toxin positive sample during the 72 hours after initial diagnosis. This is reflected by 
the low sensitivity for CCNA of 24.4% and for Toxin EIA of 9.3% for detecting a CDI case 
with samples taken up to 72 hours after diagnosis (table 5.15). The GDH EIA had the 
highest sensitivity for detecting a CDI case within 72 hours of diagnosis (56.5%), followed 
by the culture (40.4%), PCR (39.1%) and CTC (37.8%). The assay with the highest sensitivity 
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for detecting a PCDE within 72 hours was the GDH assay (60.4%), followed by culture 
(53.1%), CTC (25.0)% and PCR (23.4%).   
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Defined by routine diagnostic test result 
(used for recruitment into the study) CCNA Culture CTC 
Assay   
Control 
n (%) 
GDH 
positive/toxin 
either positive 
or negative 
n (%) 
PCDE 
n (%) 
CDI 
n (%) 
Positive 
n (%) 
Negative 
n (%) 
Positive 
n (%) 
Negative 
n (%) 
Positive 
n (%) 
Negative 
n (%) 
CCNA 
Positive 
1 
(1.6) 
16 
(17.4) 
5 
(10.6) 
11 
(24.4) n/a n/a 
10 
(24.4) 
3 
(2.6) 
10 
(38.5) 
3 
(2.3) 
Negative 
62 
(98.4) 
76 
(82.6) 
42 
(89.4) 
34 
(75.6) n/a n/a 
31 
(75.6) 
114 
(97.4) 
16 
(61.5) 
126 
(97.7) 
N size 
63 92 47 45 n/a n/a 41 117 26 129 
Culture 
Positive 
2 
(3.0) 
45 
(46.9) 
26 
(53.1) 
19 
(40.4) 
10 
(76.9) 
31 
(21.4) n/a n/a 
26 
(100) 
13 
(9.2) 
Negative 
63 
(97.0) 
51 
(53.1) 
23 
(46.9) 
28 
(59.6) 
3 
(23.1) 
114 
(78.6) n/a n/a 
0 
(0.0) 
128 
(90.8) 
N size 
65 96 49 47 13 145 n/a n/a 26 141 
CTC 
Positive 
1 
(1.5) 
29 
(31.2) 
12 
(25.0) 
17 
(37.8) 
10 
(76.9) 
16 
(11.3) 
26 
(67.0) 
0 
(0.0) n/a n/a 
Negative 
64 
(98.5) 
64 
(68.8) 
36 
(75.0) 
28 
(62.2) 
3 
(23.1) 
126 
(88.7) 
13 
(33.0) 
128 
(100) n/a n/a 
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N size 
65 93 48 45 13 142 39 128 n/a n/a 
GDH EIA 
Positive 
2 
(3.0) 
55 
(58.5) 
29 
(60.4) 
26 
(56.5) 
11 
(84.6) 
39 
(27.1) 
37 
(88.1) 
14 
(11.1) 
23 
(88.5) 
26 
(18.7) 
Negative 
63 
(97.0) 
39 
(41.5) 
19 
(39.6) 
20 
(43.5) 
2 
(15.4) 
105 
(72.9) 
5 
(11.9) 
112 
(88.9) 
3 
(11.5) 
113 
(81.3) 
N size 
65 94 48 46 13 144 42 126 26 139 
Toxin EIA 
Positive 
1 
(1.5) 
9 
(9.8) 
5 
(10.2) 
4 
(9.3) 
6 
(50.0) 
1 
(0.7) 
7 
(16.7) 
0 
(0.0) 
7 
(2.7) 
0 
(0.0) 
Negative 
64 
(98.0) 
83 
(88.0) 
44 
(89.8) 
39 
(90.7) 
6 
(50.0) 
142 
(99.3) 
35 
(83.3) 
124 
(100.0) 
19 
(73.1) 
137 
(100.0) 
N size 
65 92 49 43 12 143 42 124 26 137 
Toxin gene tcdB 
(PCR) 
Positive 
3 
(3.0) 
29 
(31.2) 
11 
(23.4) 
18 
(39.1) 
12 
(92.3) 
16 
(11.6) 
22 
(52.4) 
6 
(5.1) 
21 
(80.8) 
6 
(4.6) 
Negative 
62 
(97.0) 
64 
(68.8) 
36 
(76.6) 
28 
(60.9) 
1 
(7.7) 
122 
(88.4) 
20 
(47.6) 
111 
(94.9) 
5 
(19.2) 
124 
(95.4) 
N size 
65 93 47 46 13 138 42 117 26 130 
Table 5.14. The results of each diagnostic assay for different categories of participants; controls, GDH positive (regardless of toxin 
status), PCDE or CDI case, and compared with each reference method, for all samples collected within 72 hours of the initial routine 
diagnostic sample (cases) or entry to the study (controls) 
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  Case definition Reference method 
  
 
GDH positive/toxin 
either positive or 
negative 
(% (95% CI)) 
PCDE 
(% (95% CI)) 
CDI 
(% (95% CI)) 
CCNA 
(% (95% CI)) 
Culture 
(% (95% CI)) 
CTC 
(% (95% CI)) 
CCNA 
Sensitivity 
17.4 
(10.5-27.0) 
10.6 
(4.0-23.9) 
24.4 
(13.4-39.8) 
n/a 
24.4 
(12.9-40.6) 
38.5 
920.9-59.20 
Specificity 
98.4 
(90.3-99.9) 
98.4 
(90.3-99.9) 
98.4 
(90.3-99.9) 
n/a 
97.4 
(92.1-99.3) 
97.7 
992.8-99.4) 
PPV 
94.1 
(69.2-99.7) 
83.3 
(36.5-99.1) 
91.7 
(59.8-99.6) 
n/a 
76.9 
950.0-93.8) 
76.9 
(50.0-93.80 
NPV 
44.9 
(36.5-53.6) 
59.6 
(49.5-69.0) 
64.6 
(54.1-73.9) 
n/a 
78.6 
(70.9-84.8) 
88.7 
982.1-93.2) 
Culture 
Sensitivity 
46.9 
(36.7-57.3) 
53.1 
(38.4-37.2) 
40.4 
(26.7-55.7) 
76.9 
(46.0-93.9) 
n/a 
100.0 
(84.0-100) 
Specificity 
96.9 
(88.4-99.5) 
97.0 
(88.4-99.5) 
97.0 
(88.4-99.5) 
78.1 
(70.9-84.8) 
n/a 
90.8 
(84.4-94.8) 
PPV 
95.7 
(84.3-99.3) 
92.9 
(75.0-98.8) 
90.5 
(68.2-98.3) 
24.4 
(12.9-40.6) 
n/a 
66.7 
(49.7-80.4) 
NPV 
55.3 
(45.7-64.5) 
73.3 
(62.4-82.0) 
69.2 
(58.6-78.3) 
97.4 
(92.1-99.3) 
n/a 
100.0 
(96.4-100) 
CTC 
Sensitivity 
31.2 
(22.2-41.7) 
25.0 
(14.1-40.0) 
37.8 
(24.2-53.5) 
76.9 
(50.0-93.8) 
66.7 
(49.7-80.4) 
n/a 
Specificity 
98.5 
(90.6-99.9) 
98.5 
(90.6-99.9) 
98.5 
(90.6-99.9) 
88.7 
(82.1-93.2) 
100 
(96.4-100) 
n/a 
PPV 
96.7 
(80.9-99.8) 
92.3 
(62.1-99.6) 
94.4 
(70.6-99.7) 
38.5 
(20.9-59.3) 
100 
(84.0-100) 
n/a 
NPV 
50.0 
(41.1-58.9) 
64.0 
(53.7-73.2) 
69.6 
(59.0-78.5) 
97.7 
(92.8-99.4) 
90.8 
(84.4-94.8) 
n/a 
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GDH EIA 
Sensitivity 
58.5 
(47.9-68.4) 
60.4 
(45.3-73.2) 
56.5 
(41.2-70.8) 
84.6 
(53.7-97.3) 
88.1 
(73.6-95.5) 
88.5 
(68.7-97.0) 
Specificity 
96.9 
(88.4-99.5) 
96.9 
(88.4-99.5) 
96.9 
(88.4-99.5) 
72.9 
(64.8-79.8) 
88.9 
(81.7-93.6) 
81.3 
(73.6-87.2) 
PPV 
96.5 
(86.6-99.4) 
93.5 
(77.2-98.9) 
92.9 
(75.0-98.9) 
22.0 
(12.0-36.3) 
72.5 
(58.0-83.7) 
46.9 
(32.8-61.6) 
NPV 
61.8 
(51.6-71.1) 
76.8 
(66.0-85.1) 
75.9 
(65.0-84.3) 
98.1 
(92.8-99.7) 
95.7 
(89.8-98.4) 
97.4 
(92.1-99.3) 
Toxin EIA 
Sensitivity 
9.8 
(4.8-18.2) 
10.2 
(3.8-23.0) 
9.3 
(3.0-23.1) 
50.0 
(22.3-77.7) 
16.7 
(7.5-32.0) 
26.9 
(12.3-48.1) 
Specificity 
98.5 
(90.5-99.9) 
98.4 
(90.6-99.9) 
98.4 
(90.6-99.9) 
99.3 
(95.6-99.9) 
100.0 
(96.3-100) 
100.0 
(96.6-100) 
PPV 
90.0 
(54.1-99.5) 
83.3 
(36.5-99.1) 
80.0 
(29.9-98.9) 
85.7 
(42.0-99.2) 
100.0 
(56.1-100 
100.0 
(56.1-100) 
NPV 
43.5 
(35.4-52.0) 
59.3 
(49.4-68.5) 
62.1 
(52.0-71.4) 
95.9 
(91.0-98.3) 
78.0 
(71.0-84.0) 
87.8 
(81.4-92.3) 
Toxin gene tcdB 
(PCR) 
Sensitivity 
31.2 
(22.2-41.7) 
23.4 
(12.8-38.4) 
39.1 
(25.5-54.6) 
92.3 
(62.1-99.6) 
52.4 
(26.6-67.7) 
80.8 
(60.0-92.7) 
Specificity 
95.4 
(86.2-98.8) 
97.1 
(86.2-98.8) 
97.1 
(86.2-98.8) 
88.4 
(81.6-93.0) 
94.9 
(88.7-97.9) 
95.4 
(89.8-98.1) 
PPV 
90.6 
(78.8-97.5) 
78.6 
(48.8-94.3) 
85.7 
(48.8-94.3) 
42.9 
(25.0-62.6) 
78.6 
(58.5-91.0) 
77.8 
(57.3-90.6) 
NPV 
49.2 
(40.2-58.2) 
63.3 
(52.9-72.6) 
68.9 
(52.9-72.6) 
99.2 
(94.9-99.9) 
84.7 
(77.2-90.2) 
96.1 
(90.7-98.6) 
Table 5.15. Sensitivity, specificity, PPV and NPV for each assay compared with the case definition, CCNA, Culture and CTC, for all 
samples collected within 72 hours of the initial routine diagnostic sample (cases) or entry to the study (controls) 
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5.3.5 Potential C. difficile excretors 
There were 65 participants whose initial routine diagnostic samples tested positive for GDH 
only; these were recruited as PCDE’s.  Of these 65, 18 (27.7%) went on to have at least one 
sample that tested positive by CCNA; median number of days to CCNA positive sample was 
8 days (range 0-28) (table 5.16). 
 
 Participant 
number 
Number of days 
until toxin 
positive result 
PCR ribotype isolated 
from the sample 
513 20 020 
525 13 015 
537 4 341 
550 13 015 
589 14 014 
592 19 015 
593 4 050 
607 20 078 
609 0 078 
617 7 020 
621 0 014 
628 8 Culture negativea 
634 8 Culture negativea 
641 28 023 
643 3 011 
650 10 207 
655 4 012 
657 4 005 
Table 5.16. The number of days from initial GDH positive sample until another 
sample was CCNA positive, and the PCR ribotype of C. difficile isolated from that 
sample. a Had treatment with fidaxomicin from day 0, all other participants were 
not on a concurrent antibiotic with activity against C. difficile  
 
Both the mean white cell count and the mean serum creatinine level were higher in those 
PCDE that went on to have a toxin positive sample, compared to those PCDE that remained 
toxin negative; however only the serum creatinine was significantly higher (p = 0.009) 
(table 5.17).  
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Table 5.17 The mean white cell count, serum albumin and serum creatinine levels 
in PCDE participants that were either toxin positive or negative in later samples. a 
t test (two tailed)  
 
 
 
Figure 5.1 The number of samples that were positive for each assay on each day 
following the diagnostic specimen for PCDE’s that go on to have at least one CCNA 
positive sample 
 
 
PCDE that 
become 
toxin positive 
PCDE that 
stay toxin 
negative 
p valuea 
 
White cell 
count 9.2 6.4 0.209 
Serum 
albumin 32.8 33.0 0.900 
Serum 
creatinine 160.1 94.1 0.009 
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Figure 5.2 The percentage of samples that were positive for each assay on each 
day following the diagnostic specimen for PCDE’s that go on to have at least one 
CCNA positive sample 
 
 
Figure 5.3 The number of samples that were positive for each assay on each day 
following the diagnostic specimen for PCDE’s that do not go on to have at least 
one CCNA positive sample 
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Figure 5.4 The percentage of samples that were positive for each assay on each 
day following the diagnostic specimen for PCDE’s that do not go on to have at 
least one CCNA positive sample 
 
For the PCDE that become toxin positive, the proportion of positive C. difficile diagnostic 
assays are all very similar, as are the proportion of positive C. difficile toxin diagnostic 
assays (figures 5.1 and 5.2). The proportion of positive GDH EIA and culture results in 
PCDE’s that do not go on to have any CCNA positive samples, are similar, but are both 
higher than the proportion of positive CTC and PCR results (figures 5.3 and 5.4). Of those 
that were culture positive, 5/25 had a known non-toxigenic PCR ribotype isolated from the 
sample (table 5.18)  
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Participant 
number 
PCR ribotype Known non-
toxigenic PCR 
ribotypea 
Inferred 
toxinotypeb 
Inferred toxin 
status from 
toxinotypec 
508 014/129/334 
 
XVIII A+B+CDT- 
517 051 
 
  
520 010 Yes   
542 081 
 
  
548 005 
 
  
552 Not available 
 
  
559 046 
 
  
563 018 
 
  
566 023 
 
IV A+B+CDT+ 
573 010 Yes   
577 009 
 
  
588 078 
 
V A+B+CDT+ 
595 009 
 
  
602 031 
 
  
603 327 
 
  
606 020 
 
  
608 012 
 
I A+B+CDT- 
611 031 
 
  
631 054 Yes   
645 026 
 
  
647 Not available 
 
  
652 027 
 
III A+B+CDT+ 
656 039 Yes   
663 026 
 
  
666 039 Yes   
Table 5.18 The PCR ribotype of C. difficile isolated from PCDE’s that did not have 
any CCNA positive samples, and known non-toxigenic status a from published 
literature (Fawley et al, 2016). b from toxinotype correlation website  and 
c toxinotype characteristics website 
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5.3.6 Results of diagnostic tests on each day following the diagnostic sample 
for all recruited participants that were GDH positive (regardless of toxin 
status)  
 
Figure 5.5. The number of samples with a positive result by each assay on each 
day for all participants with an initial GDH positive diagnostic sample  
 
 
Figure 5.6. The number of samples with a positive result by each assay on each 
day of the first 20 days, for all participants with an initial GDH positive diagnostic 
sample  
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The number of samples collected was highest within the first 20 days after diagnosis, 
peaking at day seven (figure 5.5). To enable better visualisation of the patterns in the 
number of positive samples, the graphs were replotted for the first 20 days only, as not 
only were the highest number of samples collected during this time, this is also the period 
most likely to represent primary infection, not recurrence (figure 5.6). The GDH EIA 
consistently has the highest number of positive samples, followed by culture, then CTC. The 
pattern of the number of CTC positive samples is closely mirrored by the number of 
positive PCR samples. The CCNA and Toxin EIA tests have the lowest numbers of positive 
samples throughout the study period, with CCNA generally having more positive samples 
than the Toxin EIA. Peak white cell counts can be seen around day 2 after diagnosis (figure 
5.6).  
 
 
Figure 5.7. The percentage of samples with a positive result by each assay on each 
day for all participants with an initial GDH positive diagnostic sample 
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Figure 5.8. The percentage of samples with a positive result by each assay on each 
day of the first 20 days, for all participants with an initial GDH positive diagnostic 
sample 
When converted to percentage of samples tested that had a positive result by each assay 
the same patterns as described above are observed. The GDH EIA had a consistently higher 
percentage of positive samples throughout the study period, up to around day 42, when 
the number of samples drops dramatically, so skewing the percentage data (figure 5.7). 
There is an increase in the positivity rate of all the tests between days 20 to 40 (figure 5.7). 
When only viewing up to day 20 the patterns can be more easily seen (figure 5.8). The 
pattern of GDH positivity is mirrored by culture with a positivity rate about 5-10% lower 
than that of GDH. The pattern of culture positivity is then in turn mirrored by the CTC assay, 
again at a positivity rate about 10% lower than the culture positivity rate.  The PCR assay 
closely follows the pattern and positivity rate of the CTC assay, occasionally showing a 
higher percentage of positive samples than CTC, and occasionally showing a lower positivity 
rate.  
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5.3.7 Results of diagnostic tests on each day following the diagnostic sample 
from either PCDE or CDI cases at recruitment 
 
 
Figure 5.9. The number of samples with a positive result by each assay on each 
day for all PCDE participants 
 
 
Figure 5.10. The number of samples with a positive result by each assay on each 
day for all CDI cases 
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Figure 5.11. The number of samples with a positive result by each assay on each 
day, for the first 20 days only, for all PCDE participants 
 
 
Figure 5.12. The number of samples with a positive result by each assay on each 
day, for the first 20 days, for all CDI cases 
After splitting all GDH-positive participants into those recruited with GDH positive test only 
(potential C. difficile excretors (PCDE)) and those recruited with GDH/toxin positive (CDI 
cases), a similar pattern can be seen in the number of samples collected, with most of the 
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samples collected within the first 20 days and the highest peaks being on day five and day 
seven respectively (figures 5.9 and 5.10).  The GDH EIA consistently has the highest number 
of positive samples in both groups, although this is closely mirrored by the number of 
culture positives in the PCDE group (figure 5.11). In the PCDE group there is a large 
difference in the number of samples positive by CTC compared to culture, whereas in the 
CDI case group culture and CTC are almost identical (figure 5.11 and 5.12). The pattern of 
the number of CTC positive samples is closely mirrored by the number of positive PCR 
samples, although in the PCDE group the number of PCR positive samples appears to be 
shifted by one-two days after CTC (figure 5.11). The CCNA and toxin EIA tests have the 
lowest numbers of positive samples throughout the study period, with CCNA generally 
having more positive samples than the toxin EIA (figure 5.12. There were more sample 
collection days in the CDI case group, although the latter samples were almost exclusively 
from one patient (figure 5.12). Peak white cell counts for the CDI cases are at day 0 (day of 
diagnosis) with a mean WCC of 10.7 cells/L. The PCDE group mean WCC at day 0 was 5.54 
cells/L, with a peak of 10.13 cells/L on day nine after diagnosis.  
 
 
Figure 5.13. The percentage of samples with a positive result by each assay on 
each day for all PCDE participants 
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Figure 5.14. The percentage of samples with a positive result by each assay on 
each day, for the first 20 days only, for all PCDE participants 
When converted to the proportion of samples tested that are positive by each assay, the 
GDH assay has a consistently  higher positivity rate than any other assay for the PCDE group, 
although this is very closely matched by the culture positive rate (figures 5.13 and 5.14). 
There is a marked difference in the positive rate of CTC compared with culture, being some 
5-40% lower at most time points. The PCR assay positivity rate is of a similar level to, and 
follows the pattern of, the CTC positivity rate However, at several time points the PCR rate 
appears to be shifted later than the CTC rate by one-two days.  Interestingly this is in line 
with the pattern of the positivity of the CCNA test, which is also shifted approximately 
one-two days later than the CTC rate.  The biggest peak in PCR positivity (day 16) coincides 
with the biggest peak of CCNA positivity; this occurs approximately two days after a large 
peak in GDH and culture positivity (figure 5.14). The toxin EIA assay follows the general 
pattern of CCNA positivity rate but often with a reduced positivity rate of 0-15% (figure 
5.14). 
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Figure 5.15 The percentage of samples with a positive result by each assay on 
each day, for all CDI cases 
 
 
Figure 5.16 The percentage of samples with a positive result by each assay on 
each day, for the first 20 days only, for all CDI cases 
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The GDH assay positivity rate is lower for CDI cases than for the PCDE group, with 50% in 
the CDI cases and 60% in the PCDE group (figures 5.13 and 5.15). As with the PCDE group, 
the GDH assay positivity rate is consistently the highest of all the assays for the CDI cases; 
however the culture positive rate does not exactly mirror the GDH positive rate and can be 
from 0-20% lower on some days (figure 5.16). Unlike the PCDE group, the CTC positive rate 
more closely follows the culture positive rate for CDI cases than for PCDE’s, and is only 0-10% 
lower, compared with 5-40% lower for PCDE’s. Similar to the PCDE group the PCR positive 
rate is shifted behind that of the CTC positive rate by approximately two days at certain 
time points (figures 5.14 and 5.16). The CCNA and toxin EIA positive rates more closely 
follow each other in this dataset, but with a similar overall positivity rate to the PCDE group 
over the first 20 days of 16.8% and 17.4% for PCDE and CDI cases respectively (p = 0.52) 
(figures 3.14 and 3.16). 
 
5.3.8 Ribotyping 
There were 415/438 isolates from 102 participants available to be PCR ribotyped (seven 
controls and 95 GDH positive participants); 12 participants had two different ribotypes and 
one participant had three.  The most common PCR ribotype isolated from samples was 002 
(20.2% of all isolates), followed by 026 (8.7%), 014 (8.2% and 015 (8.2%) (figure 5.17). 
There were very few isolates of PCR ribotype 027 (n = 3, however), these three isolates 
came from three different participants.  
The PCR ribotypes of isolates from controls, PCDEs and CDI cases are shown in figures 5.18, 
5.19 and 5.20 respectively. There were some known non-toxigenic strain isolates, notably 
010 (3.1% of the total isolates, two cases), 039 (1.0% of total isolates, one control and two 
PCDE’s) and 054 (0.7% of total isolates, one PCDE and one CDI case).  For the two 
participants with 010 isolates, both had only this PCR ribotype isolated from their samples; 
all of their samples were CCNA and CTC negative. For the three participants with 039 
isolated from their samples, two (one control and one PCDE) had only one sample in the 
study, and were negative when tested by both CCNA and CTC. The third participant (PCDE) 
with 039 had three samples in the study, with 039 isolated from two of these; only one of 
the three was positive by CTC, none were positive by CCNA. Of the two GDH positive 
participants with 054 isolated from their samples, one (PCDE) had 054 isolated from 1/6 
samples, which was positive by CTC but negative by CCNA. The second (CDI) with 054 had 
nine samples in the study, five of which were positive by CCNA and four of which were 
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positive by CTC; 054 was isolated from two samples and 002 was isolated from two other 
samples, suggesting a mixed infection. 
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Figure 5.17. The PCR ribotypes of isolates from all participants and the number of isolates of each PCR ribotype.  
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Figure 5.18. The PCR ribotypes of isolates from all control participants and the number of times each PCR ribotype was isolated 
from that participant.  
 
201 
 
 
Figure 5.19. The PCR ribotypes of isolates from all PCDE participants and the number of times each PCR ribotype was isolated from 
that participant.  
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Figure 5.20. The PCR ribotypes of isolates from all CDI participants and the number number of times each PCR ribotype was isolated 
from that participant. 
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5.4 Discussion 
The data from prospectively collected faecal samples from both control participants and 
those who were initially GDH positive has shown that the course of C. difficile infection in 
patients has similar patterns of proliferation and growth of the organism, as measured by 
diagnostic assays, as those seen in the gut model (Chapter 2).  The GDH EIA consistently 
had the highest proportion of positive samples/day for all participants recruited as GDH 
positive, or for all participants when split into PCDE’s and CDI cases,  although in PCDE’s 
this is closely mirrored by the proportion of culture positive samples. It would appear that 
there were more non-toxigenic strains in the PCDE vs CDI group, as there was a large 
difference in the number of samples positive by CTC compared with culture; by contrast, in 
the CDI cases, the proportion of samples positive by culture and CTC was almost identical. 
It should be noted however, that only 5/25 of PCDE’s that did not go on to have a C. difficile 
toxin positive sample, had a known non-toxigenic PCR ribotype isolated from their samples 
(table 5.18). This suggests therefore that the difference in CTC and culture positive rates is 
due to factors other than just the presence of non-toxigenic PCR ribotypes. For all of the 
assays, there is an increase in the proportion of positive samples between days 20 to 40 
(figure 5.7). This may represent recurrence, which will be investigated further in Chapter 4.  
The proportion of PCR assay positives follows the pattern of, and is at a similar level to, the 
CTC positivity rate; however, at several time points the PCR rate appears to be shifted later 
than the CTC rate by one-two days (figures 5.11 and 5.12).  Interestingly this shift is also 
seen in the pattern of the positivity of CCNA. Certainly, for CCNA, this mirrors the patterns 
seen in the gut model, where toxin production follows proliferation by a shift of a few days 
(Chapter 2).  It is unclear why the PCR assay is shifted to follow the pattern of CCNA rather 
than CTC, as the PCR assay detects the toxin B gene and it could therefore, be hypothesised 
that the gene should increase at the same rate as proliferation. It may be explained by the 
fact that toxin production is not constitutive, but influenced by external factors.  This is 
easily demonstrated within the laboratory, as C. difficile growing in BHI will produce toxin, 
whereas C. difficile growing in media with additional biotin will not (Yamakawa et al, 1998). 
In addition, the PCR assay used in this study did not perform as well as the GDH assay, with 
a sensitivity of 74.4% vs 88.7% respectively when compared to cytotoxigenic culture (table 
5.13). This is in contrast to the data from the Department of Health study, where PCR and 
GDH assays had comparable sensitivities compared to CTC of 93.2 and 93.6%, respectively 
(Planche et al,  2013). It should be noted however, that a different PCR assay was used in 
the present study to that used previously, which may have lower sensitivity. Unfortunately, 
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this PCR assay also does not allow the user to collect cycle threshold (CT) values, which may 
have provided more information than the binary ‘positive’ and ‘negative’ result. CT values 
are discussed further in Chapter 4.    
There was a similar daily CCNA positivity rate for PCDE and CDI cases (16.8%and 17.4% 
respectively, p = 0.52) over the first 20 days (figures 5.14 and 5.16). Interestingly, of the 65 
PCDE, 18 (27.7%) went on to have at least one sample that tested positive by CCNA; 
median number of days to CCNA positive sample was eight days (range 0-28) (table 5.16). 
Peak white cell counts for the PCDE group were on day nine (10.13 cells/L), compared with 
day 0 (day of diagnosis) for CDI cases (10.7 cells/L). In addition both the mean white cell 
count and the mean serum creatinine level were higher in those PCDE that went on to have 
a toxin positive sample, compared to those PCDE that remained toxin negative; however 
only the serum creatinine was significantly higher (p = 0.009). Concomitant antibiotics with 
activity against C. difficile may have supressed growth of the organism and therefore toxin 
production in these PCDEs, however, only two of these participants were on an antibiotic 
with activity against C. difficile at the time of their initial sample.   Does this perhaps 
suggest that the organism had not yet reached a level of growth where a) it had started to 
produce toxin, or b) had produced toxin but at a level below the limit of detection of CCNA?  
Testing these samples with the newly developed ultra-sensitive C. difficile toxin detection 
assays may have resolved this question; however such assays were not available at the 
time of this study (Pollock, 2016, Banz et al, 2018). The detection of these PCDEs that go on 
to have a toxin positive sample does not provide evidence that repeat testing of GDH 
positive/toxin negative samples is warranted. Repeat testing is currently not recommended 
in the C. difficile diagnostic guidelines, due to the issues of increasing the likelihood of false 
positive results (Crobach et al, 2016; McDonald et al 2018). Further data would be required 
to fully understand this group before any such change to the guidelines could be suggested. 
Indeed, this is a single centre study, and could be biased by the patient population studied; 
multicentre studies would be needed to confirm that this is not only a local phenomenon. 
Lactoferrin, a marker of gut inflammation, has been suggested as an adjunctive test for CDI 
(Wren et al, 2009). Recent work (Davies et al, 2019b) has demonstrated a correlation 
between lactoferrin level and level of toxin (as measured semi-quantitatively). Future 
studies are required to determine if raised lactoferrin in these GDH positive/toxin negative 
samples may provide an indication of gut inflammation, and potentially therefore, 
presence of toxin. 
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Overall, for all samples, participants with CDI had a significantly higher proportion of CCNA 
positive samples than PCDE’s (24.7 vs 15.3% respectively, p = 0.003) (table 5.12); however 
the majority of samples were CCNA negative. A large number of CDI cases were negative by 
the time their first sample was tested in the study, and only 10/82 (12.2%) had another 
toxin positive sample within 72 hours of their initial diagnosis (table 5.14). This is reflected 
by the low sensitivity for CCNA of 24.4% and for toxin EIA of 9.3% for detecting toxin in 
samples taken up to 72 hours after diagnosis (table 5.15). The GDH EIA had the highest 
sensitivity in samples from both PCDEs and CDI cases within 72 hours of diagnosis (60.4% 
and 56.5% respectively), followed by culture (53.1 % and 40.4% respectively). In addition, 
the sensitivities of the GDH EIA and culture were higher in samples from PCDEs than CDI 
cases, while CTC and PCR were more sensitive in samples from CDI cases than PCDEs (CTC 
37.8% vs 25.0%, and 39.1% vs 23.4%, respectively) (table 5.15).  These data suggest that 
GDH remains detectable within patient faecal samples for much longer than other 
C. difficile markers, mirroring the patterns of detection seen in the gut model (Chapter 4). 
In patients that have been toxin positive, detection of GDH could therefore, indicate that 
the organism is no longer proliferating, but also that it has also not been cleared from the 
gut; potentially making that patient vulnerable to recurrence, especially if exposed to 
further antibiotic therapy.  
The most common PCR ribotype isolated from samples was 002 (20.2% of all isolates), 
followed by 026 (8.7%), 014 (8.2% and 015 (8.2%)) (figure 5.17). There were very few 
isolates of PCR ribotype 027 (only n=3); however, these three isolates came from three 
different participants. This is not unexpected as there has been a shift in proportion of 
cases caused by PCR ribotype 027 in the UK, with 027 rate declining since 2007 (Dingle et al, 
2017). There was some evidence of mixed infections (12.7% of all culture positive 
participants), with 12 participants having two different PCR ribotypes and one participant 
having three different PCR ribotypes isolated from their samples. One recent study found 
that patients with more than one PCR ribotype of C. difficile were more likely to go on to 
have a recurrent episode (Seekatz et al, 2018). The proportion of patients who had mixed 
infections in that study were higher than those seen in the PlaciD study (12.7%); 78.6% in 
the group who went on to have recurrence vs 18.1% in the group who did not develop 
recurrence. The reasons behind the lower mixed infection rate in the PlaciD study are 
unclear, although it is plausible that it may be linked to different infection control practices 
between the study sites.  
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CDI cases were significantly older than PCDEs (median age 75 vs 62 years respectively, P 
<0.0001), and there was a significantly higher proportion of females in the PCDEs than in 
the CDI cases (60% vs 40.2% respectively, P = 0.03, table 5.1). Increasing age is a well-
known risk factor for CDI (McDonald et al, 2006, Miniño et al 2011), but this is the first time 
that the age of GDH-positive/toxin-negative and GDH-positive/toxin-positive patients has 
been compared. Participants in the control group were significantly older than GDH 
positive patients (median age = 80 years and 70 years respectively, p <0.0001, table 5.1). As 
CDI is more likely in those >65 years old (McDonald et al, 2006, Miniño et al, 2011), the 
control groups were selected from potential participants >50 years old; however, those 
that were recruited were actually significantly older.  The rate of asymptomatic carriage of 
C. difficile in hospitalised patients in the literature is 0.6-15% (Furuya-Kanamori et al, 2015); 
however, it was at the lower end of this range in this study at 8.6% (table 5.12). The 
reasons for this are unclear but may have been due to the way the cohort was selected.  
Another well characterised risk factor for CDI is prior antibiotic therapy (Bartlett and 
Gerding, 2008). In this study we were able to compare GDH positive participants (rather 
than just CDI)  with controls, and a significantly higher proportion of patients recruited as 
GDH positive had at least one antibiotic in the previous eight weeks when compared to 
patients recruited as controls (90.7% vs 47.7%, P <0.0001, table 5.1). This was also true for 
all participants with at least one sample in the study (controls = 50.6% vs GDH positive 
91.9%, p <0.0001, table 5.1). There was also a significant difference between control 
participants and GDH positive participants for each number of doses of antibiotic received 
and for the total number of doses of antibiotic received (table 5.6).  GDH positive 
participants were significantly more likely to have the following antibiotics prescribed in 
the previous three months compared with control participants; ciprofloxacin, co-
trimoxazole, fidaxomicin, meropenem, metronidazole, pipercillin-tazobactam, 
trimethoprim, vancomycin and the antifungal fluconazole (table 3.7). Exposure to 
ciprofloxacin and pipercillin-tazobactam has previously been shown to be a risk factor for 
CDI (Bartlett and Gerding, 2008).  A previous prescription for fidaxomicin, must indicate 
previous CDI treatment, as this antibiotic has no other indication for use, while vancomycin 
and metronidazole may represent previous CDI treatment in this group.  
Of the GDH positive participants, those with CDI were significantly more likely to have had 
an antibiotic in the previous eight weeks than PCDEs, although the proportions in both 
groups were high (96.3% Vs 84.6% respectively, p = 0.03, table 3.1). This demonstrates that 
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prior antibiotic therapy is a risk factor for acquisition of C. difficile, not just the 
development of CDI, in similarity to a previous study where prior use of antibiotics was 
significantly associated with carriage of C. difficile (Bignardi, 1998).  However, the 
proportion of CDI cases that had at least one antibiotic and the total number of doses 
received by CDI cases were significantly higher compared with PCDEs, suggesting that 
increased antibiotic exposure changes the risk from just acquisition of C. difficile  to 
development of CDI (p = 0.03 and <0.0001, respectively, table 5.6). Importantly, increasing 
risk of CDI from increasing does of antibiotic has been demonstrated previously (Stevens et 
al, 2011; Davies et al, 2016c) while the shift from risk of acquisition to risk of CDI with 
increasing antibiotic doses is a novel finding.   However, only CDI treatment antibiotics 
were significantly more likely to have been prescribed to CDI cases than PCDEs in the 
previous three months; presumably to treat a previous case of CDI (table 5.8). A single type 
of antibiotic could not therefore be linked to the shift from acquisition to risk of CDI; 
indeed this study was not designed for such analysis and may be under powered to answer 
this question.  
GDH positive participants were not significantly more likely than controls to be prescribed 
any particular class of drugs, such as PPIs; however, they were more likely to have been 
prescribed omeprazole and ranitidine than control participants (tables 5.9 and 5.10).The 
risk of developing CDI while on PPIs is disputed in the literature, and indeed maybe derived 
from the selection of the cohort studied (Dial et al, 2004; Davies et al, 2016c). It should be 
noted that there was no significant difference in the number of participants taking PPIs in 
the prior three months between PCDEs and CDI cases (table 5.9).  
We wanted to investigate the possibility of using rectal swabs in future studies, as often 
faecal samples can be difficult to obtain. To this end, we asked participants in the study to 
also have a rectal swab taken when they were recruited into the study. This was declined 
by 90.9% of participants, and interestingly, a significantly higher proportion of GDH positive 
patients refused the rectal swab than control patients (91.2% Vs 79.0%, p = 0.03, table 5.1). 
Although there was a higher rate of refusal in the CDI cases than PCDEs this was not 
significant (96.3% Vs 84.6%, p = 0.19, table 5.1). This may suggest that those who are more 
sick, or those with diarrhoea, are more likely to refuse to have a rectal swab taken. If this is 
true, using rectal swabs for diagnosis may not be a viable option, as these are the very 
patients you would want to sample. There is obviously a difference in opting out of a 
voluntary rectal swab and having to have one for diagnosis however, but this does indicate 
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patient preference; they were willing to donate faecal samples to the study but not have a 
rectal swab taken. 
There were significant differences between the control group and GDH positive group, with 
control participants significantly more likely to have been admitted following a fall, or with  
a fractured neck of femur, fracture of the knee, fracture of the shaft of the femur and 
septic arthritis ( all p <0.01) (table 5.2). Control participants were also significantly more 
likely to have dementia than GDH positive participants (p = 0.01), while GDH positive 
participants were significantly more likely to have a history of alcoholism or asthma (p = 
0.02 and 0.002 respectively, table 5.4). Participants recruited into the GDH positive arm 
were significantly more likely than control participants to have been admitted with 
gastrointestinal symptoms (diarrhoea, diarrhoea and vomiting, abdominal pain) or with 
pyrexia, or for being ‘unwell’ (table 5.3). GDH positive participants with CDI were 
significantly more likely to be admitted for being ‘unwell’ than PCDE participants (p = 0.03, 
table 5.3).   
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6. Prediction of poor outcome or recurrence using commercial 
assays 
6.1 Introduction  
Although the use of direct PCR detection of C. difficile toxin gene detection for CDI 
diagnosis is still contested within the literature (Fang et al, 2017) it is possible that the cycle 
threshold value of such assays may provide additional information for the clinician. The 
point at which a PCR assay becomes positive, the cycle threshold value (CT value), is 
determined by the amount of starting material. The more starting material (target) there is, 
the faster the assay will become positive, and therefore the lower the CT value will be.  A 
low CT value has been associated with poorer patient outcomes since the pathogen load 
will be high.  However, previous studies are limited by the use of composite outcomes, lack 
of reference methods, small samples size and single centre design (Kamboj et al, 2018; 
Reigadas et al, 2016b)  
Recurrence of infection occurs in ~20% of CDI cases (Cornely et al, 2012; Kelly et al, 2008), 
however predicting such occurrences is extremely difficult. Prediction models have 
attempted, to overcome this issue (Escobar et al, 2017; Reveles et al,  2018), but a 
diagnostic assay that could predict recurrence would enable clinicians to use antibiotic 
therapies that are known to provide greater protection to the gut microbiome, such as 
fidaxomicin or immunological adjunctive therapies such as bezlotoxumab (Cornely et al, 
2012, Wilcox et al, 2018). The high cost of such treatments often precludes their use, 
however: cost-effectiveness studies demonstrate that fidaxomicin may be the most cost-
effective option, due to the reduction in recurrence cases, and on-going care costs 
(Lapointe-Shaw et al, 2016). A predictive diagnostic assay would therefore strengthen the 
justification for use.  
Here, the data gathered from the Department of Health (DoH) study to optimise laboratory 
diagnosis of CDI, and data from the PlaciD study (Chapter 5) have been interrogated to 
investigate both the utility of CT values to predict patient outcomes, and alternative assays 
that could predict CDI recurrence.  The key findings from this chapter are; 
 The CT value of a PCR test for detection of toxin gene was significantly associated 
with a toxin-positive result, presence of PCR ribotype 027 and mortality 
 The positive predictive value of low CT (≤25) for toxin detection was 84% 
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 The relative risk of mortality for patients with low CT (≤25) was 1.45, and increased 
to 2.18 if patients also had infection caused by PCR ribotype 027 
 GDH OD value was related to the bacterial load of C. difficile within the sample  
 A cohort of patients were discovered that were constantly positive for GDH in their 
sequential faecal samples, despite resolution of symptoms. All of these patients 
went on to have a recurrent episode of CDI following additional antibiotic therapy 
 
6.2 Methods 
6.2.1 Can the cycle threshold value of commercial molecular assays for 
C. difficile toxin genes provide additional information to the diagnosis of a 
toxigenic C. difficile strain? 
6.2.1.1 Analysis of existing data set to determine if the cycle threshold value of 
commercial molecular assays for C. difficile toxin genes can provide additional 
information to the diagnosis of a toxigenic C. difficile strain 
Hypothesis 
A lower cycle threshold (CT) value from a molecular assay for the detection of a toxigenic 
strain of C. difficile will correlate with mortality, toxin status and recurrence. This work has 
been published; Davies K, Planche T and Wilcox M. The predictive value of quantitative 
nucleic acid amplification detection of Clostridium difficile toxin gene for faecal sample 
toxin status and patient outcome. PLoS One 13(12): e0205941 2018. The concept of the 
work was devised by Kerrie Davies, the analysis and initial draft of the manuscript was 
completed by Kerrie Davies with review by Dr Tim Planche and Prof Mark Wilcox.  
Methods 
Diarrhoeal faecal samples, collected as part of the Department of Health, multicentre 
evaluation of CDI laboratory diagnostics, as described in Chapter 3, were tested with two 
reference methods; cell cytotoxicity and cytotoxigenic culture, and by three enzyme 
immunoassays (EIAs); one for detection of glutamate dehydrogenase (C. diff CHEK-60™, 
Techlab, USA) and two for the detection of toxins A and B (Toxin AB II™, Techlab, USA and 
Premier Toxins A & B™, Meridian, USA) (Planche et al, 2013). In addition, samples were also 
tested using the commercial molecular assay Cepheid geneXpert® C. diff (Cepheid, 
Sunnyvale, CA, US), for the detection of C. difficile toxin genes (tcdB, binary toxin and a 
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truncated form of tcdC); as described in methods section 2.2.4. All isolates of C. difficile 
were typed by CDRN using PCR-ribotyping, as described in methods section 2.1.6.   
The samples were collected between October 2010 and September 2011 from Leeds 
Teaching Hospitals, Leeds; St George’s University of London, London; University College 
Hospital NHS Foundation Trust, London and Oxford University Hospitals NHS Trust, Oxford. 
Assays and reference methods were performed on the same day by the same evaluator at 
three sites (Leeds and both London sites) or two evaluators in one site (Oxford). In total, 
one evaluator worked at each of the two London sites, two at Leeds, and three at Oxford. 
Kerrie Davies was one of the evaluators at the Leeds site and scientific coordinator for the 
entire study. Ethical approval for the extended analysis of the study data was given by the 
NHS REC, approval number 12/EE/0495. The initial study ethical approval number was 
10/H0715/34. 
Commercial enzyme immunoassays 
All of the commercial EIAs were performed on an automated platform (DS2, Dynex 
Magellan Biosciences, USA) to reduce operator error, following manufacturer’s protocols 
given in the kit insert, with minor changes listed within the Materials and Methods chapter 
section 2.2, and as discussed with the manufacturer. The optical density (OD) of each test 
was recorded as well as the result defined by the assay (using manufacturer’s set cut-offs). 
Reference methods 
The cell-cytotoxicity neutralisation assay, culture and cytotoxigenic culture assay were 
performed as described in the Materials and methods chapter section 2.1.  
Commercial molecular test 
The commercial molecular test was performed on a Cepheid geneXpert® instrument 
following the protocol in the manufacturer’s kit insert, as described in the Material and 
Methods chapter section 2.2.4. 
PCR ribotyping 
The C. difficile isolates identified from the study were typed using PCR ribotyping by the 
C. difficile Ribotyping Network of England and Northern Ireland (CDRN) as previously 
described (Stubbs et al, 1999) and as expounded in the Materials and Methods chapter 
section 2.1.6. 
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Analysis 
Only those patients who had at least one PCR-positive sample were included in the analysis. 
The Area Under Receiver Operator Curve (AUROC) was calculated for those samples that 
were positive by the PCR assay (as defined by the algorithm within the assay software of 
the Cepheid Xpert® platform) to determine if there was an association between low cycle 
threshold (CT) and patient mortality, recurrence and the presence of a toxin-positive faecal 
sample.  Recurrence was defined as a sample that tested positive for toxin (by CCNA) at 
least 14 days after the initial CCNA-positive sample for that same patient was tested.  
Recurrence could only be assessed in those patients who had repeat samples submitted 
within the study period. Once low CT was defined, associations between low CT (≤25) and 
markers of CDI severity and outcome were investigated by univariate analysis; t test was 
used to compare means, Mann-Whitney for Medians (LOS) and 2 test for categorical 
variables. 
 
6.2.2 Can diagnostic assays be used to predict recurrence? 
6.2.2.1 Analysis of existing data set to determine if there is an association 
between a positive primary C. difficile diagnostic assay and recurrent infection 
Hypothesis 
There is an association between laboratory assays used to diagnose the presence of 
C. difficile or C. difficile infection on a primary sample, and the likelihood of that patient 
suffering from a recurrent infection. 
Methods 
Diarrhoeal faecal samples, collected as part of the Department of Health, multicentre 
evaluation of CDI laboratory diagnostics, as described in Chapter 3, were tested with two 
reference methods; cell cytotoxicity and cytotoxigenic culture, and by three enzyme 
immunoassays (EIAs); one for detection of glutamate dehydrogenase (C. diff CHEK-60™, 
Techlab, USA) and two for the detection of toxins A and B (Toxin AB II™, Techlab, USA and 
Premier Toxins A & B™, Meridian, USA) (Planche et al, 2013). In addition, samples were also 
tested using the commercial molecular assay Cepheid geneXpert® C. diff (Cepheid, 
Sunnyvale, CA, US), for the detection of C. difficile toxin genes (tcdB, binary toxin and a 
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truncated form of tcdC); as described in methods section 2.2.4. All isolates of C. difficile 
were typed by CDRN using PCR-ribotyping, as described in methods section 2.1.6.   
The samples were collected between October 2010 and September 2011 from Leeds 
Teaching Hospitals, Leeds; St George’s University of London, London; University College 
Hospital NHS Foundation Trust, London and Oxford University Hospitals NHS Trust, Oxford. 
Assays and reference methods were performed on the same day by the same evaluator at 
three sites (Leeds and both London sites) or two evaluators in one site (Oxford). In total, 
one evaluator worked at each of the two London sites, two at Leeds, and three at Oxford. 
Kerrie Davies was one of the evaluators at the Leeds site and scientific coordinator for the 
entire study. Ethical approval for the extended analysis of the study data was given by the 
NHS REC, approval number 12/EE/0495. The initial study ethical approval number was 
10/H0715/34.  
Commercial enzyme immunoassays 
All of the commercial EIAs were performed on an automated platform (DS2, Dynex 
Magellan Biosciences, USA) to reduce operator error, following manufacturer’s protocols 
given in the kit insert, with minor changes listed within the Materials and Methods chapter 
section 2.2 and as discussed with the manufacturer. The optical density (OD) of each test 
was recorded as well as the result defined by the assay (using manufacturer’s set cut-offs). 
Reference methods 
The cell-cytotoxicity neutralisation assay, culture and cytotoxigenic culture assay were 
performed as described in the Materials and Methods chapter section 2.1. 
Commercial molecular test 
The commercial molecular test was performed on a Cepheid geneXpert® instrument 
following the protocol in the manufacturer’s kit insert, as described in the Material and 
Methods chapter section 2.2.5. 
PCR ribotyping 
The C. difficile isolates identified from the study were typed using PCR ribotyping by the 
C. difficile Ribotyping Network of England and Northern Ireland (CDRN) as previously 
described (Stubbs et al, 1999) and as expounded in the Materials and Methods chapter 
section 2.1.6. 
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Analysis 
Recurrence was assessed in those patients that had repeat samples submitted within the 
study period and was defined as a sample that tested positive for toxin (by CCNA) at least 
14 days after the initial CCNA positive sample for that same patient was tested (Group 1). 
Odds ratios (OR) for recurrence were calculated for each assay type. Due to the association 
of CCNA with recurrence, CCNA positives were removed from the sample pool for the other 
assay types to leave CTC positive/CCNA negative (Group 2), PCR positive/CCNA negative 
(Group 3) and CT<25/CCNA negative (Group 4). A binary logistic regression model was 
constructed for recurrence, with all data, and with group data as defined above, with a cut 
off of 0.5.  
 
6.2.2.2 Analysis of data from the PlaciD dataset to determine if there is an 
association between the bacterial bioload during primary infection and 
recurrence 
Hypothesis 
There is an association between bacterial bioload (as measured by EIAs) during the primary 
infection and recurrence? 
Methods 
Patients with GDH positive faecal samples  (diagnosed by the routine microbiology 
laboratory) and controls (≥50 year olds from the same hospital but who had no diarrhoeal 
symptoms) were recruited and followed during their hospital admission; faecal samples 
were collected daily where possible with routine clinical data. Samples were tested using 
culture for C. difficile, cell-cytotoxicity assay (CCNA), cytotoxigenic culture (CTC), enzyme 
immunoassays (EIAs) for glutamate dehydrogenase (GDH) and toxins (Chek-60 and ToxABII, 
Techlab, USA) and PCR for toxin genes (BD Max™, BD). All samples were tested by Kerrie 
Davies, except for a four month period of maternity leave, when samples were tested by 
Claire Berry, Clinical Scientist within the Healthcare Associated Infections research group. A 
full description of the PlaciD study is given in Chapter 5. Ethical approval for PlaciD was 
given by NHS REC, approval number 13/NE/0255.  
Commercial enzyme immunoassays 
All of the commercial EIAs were performed on an automated platform (DS2, Dynex 
Magellan Biosciences, USA) to reduce operator error, following manufacturer’s protocols 
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given in the kit insert, with minor changes listed within the Materials and Methods chapter 
section 2.2, and as discussed with the manufacturer. The optical density (OD) of each test 
was recorded as well as the result defined by the assay (using manufacturer set cut-offs). 
Reference methods 
The cell-cytotoxicity neutralisation assay, culture and cytotoxigenic culture assay were 
performed as described in the Materials and Methods chapter section 2.1.  
Commercial molecular test 
The commercial molecular test was performed on a BD Max™ instrument following the 
protocol in the manufacturer’s kit insert, as described in the Material and Methods chapter 
section 2.2.6. 
PCR ribotyping 
The C. difficile isolates identified from the study were typed using PCR ribotyping by the 
C. difficile Ribotyping Network of England and Northern Ireland (CDRN) as previously 
described (Stubbs et al, 1999) and expounded in the Materials and Methods chapter 
section 2.1.6. 
Analyses 
Of 228 patients recruited (with samples collected), 82 were cases and 81 were controls 
(totally contributing 1173 sampling days). Cases were categorised into single cases (n=62) 
and recurrent cases. Recurrence was defined as more than one CCNA-positive sample in a 
case >14 days after they had a CCNA-negative sample (n=20).  
Optical density (OD) values for EIAs, white cell counts, serum albumin and serum creatinine 
values were compared between cases and controls, and between cases with a single 
episode and those with recurrent episodes. Antibiotic and proton pump inhibitor (PPI) use 
in those patients with recurrent episodes were also examined.   
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6.3 Results 
6.3.1 Can the cycle threshold value of commercial molecular assays for 
C. difficile toxin genes provide additional information to the diagnosis of a 
toxigenic C. difficile strain? 
6.3.1.1 Analysis of existing data set to determine if the cycle threshold value of 
commercial molecular assays for C. difficile toxin genes can provide additional 
information to the diagnosis of a toxigenic C. difficile strain 
The study collected 8853 samples from 7335 patients across the four sites; 1281 of these 
samples tested positive using the PCR assay and were therefore included in the analysis.  Of 
the 1281, 713 were CCNA positive and 917 were CTC positive, with a positive agreement 
between the two reference assays of 51.2% (figure 4.1).  The median CT value for tcdB gene 
detection by the PCR assay for samples from patients who died was 25.5 vs 27.5 for those 
who survived (p = 0.021), 24.9 vs 31.6 for CCNA positive samples vs CCNA negative faecal 
samples respectively (p <0.001) and 25.6 vs 27.3 for samples from patients who went on 
the have a recurrent episode vs those who had a single episode of CDI (p = 0.111).  The 
AUROC was plotted for CT value against death, CCNA-positive result and recurrence (figure 
4.2). The highest AUROC was for toxin positivity (0.831, 95% CI 0.808-0.853, P<0.001) 
(figure 4.2b) followed by mortality (0.572, 95% CI 0.519-0.624, p = 0.009) (Figure 4.2a) and 
recurrence (0.557, 95% CI 0.490-0.624 p = 0.11) (figure 4.2c). In addition, box plots of 
CT value for mortality/survival, CCNA positive/negative and recurrence/single infection 
were plotted to show the differences between the median CT values for each group (Figure 
4.3).   
CT values of ≤24 (to optimise for CCNA positivity) and ≤25 (to optimise for mortality) were 
both investigated as possible cut-off values for the PCR assay.  The agreement between the 
reference assays using each of these CT value cut-offs was investigated.  Using a cut-off of 
≤25, there were 436 samples, 366 of which were CCNA positive and 399 of which were CTC 
positive, with a positive agreement of 78.4%. Using a cut-off of ≤24 there were 145 samples, 
120 of which were CCNA positive and 131 of which were CTC positive, with a positive 
agreement of 76.6% (figure 4.1).The positive predictive value for recurrence with both cut-
off values were 49.3% and 18.3% for CT≤25 and CT≤24 respectively.    
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Low CT 
Univariate analysis demonstrated that a CT cut-off of ≤25 was significantly associated with 
a toxin-positive sample result, the presence of PCR ribotype 027 in the sample, and patient 
mortality with a positive predictive value of 83.9% for the detection of toxin from the 
sample by CCNA (table 6.1). A  CT cut-off of ≤24 was also found to be significantly 
associated with a toxin positive sample result and the presence of PCR ribotype 027 in the 
sample, with a positive predictive value of 86.1% for the detection of toxin from the sample 
by CCNA (table 6.1).  The cut-off of CT ≤24 was not, however, significantly associated with 
patient mortality, in contrast to the cut-off of CT ≤25.  Due to the slight advantage of using 
CT ≤25 rather than ≤24 as the cut-off, further analyses defined ‘low CT’ as ≤25.  
Patients with a low CT (≤25) had higher mean white cell count, a higher mean baseline 
serum creatinine, lower mean serum albumin and longer length of hospital stay, however 
none of these differences were significant, with the exception of serum creatinine (p = 0.04, 
table 6.1).  
As both low CT and the presence of PCR ribotype 027 were associated with mortality and 
length of stay, the combined effect of these two variables was examined. Mortality and 
increased length of stay were both significantly associated with samples that had both a 
low CT and the presence of PCR ribotype 027 combined (table 6.1.). The positive predictive 
value of low CT for mortality in this population was 17.4% (95% CI 13.5-22.2%) with a 
negative predictive value of 88.0% (95% CI 85.0-90.5%).  The relative risk of mortality in 
patients with low CT was 1.45 (95% CI 1.0-2.0, p = 0.04), however this increased to 2.18 (95% 
CI 1.2-4.0 p = 0.03) in those cases that were due to PCR ribotype 027 (in addition to the low 
CT result). The relative risk of mortality in those patients with a sample with a low CT result 
and a positive binary toxin gene test was 1.72 (95% CI 1.1-2.8, p = 0.05). In addition, there 
was a significant difference in the mortality rates between those patients with versus 
without binary toxin gene detection from their samples (25.3 vs 14.7%, p = 0.049, table 6.1). 
Importantly, however, there was no difference in the rate of toxin positive (CCNA) samples 
between those with or without detection of the binary toxin gene from their samples 
(table 6.1). Patients with a low CT and whose samples tested positive for binary toxin had 
higher mean WCC, a higher mean serum creatinine, lower mean serum albumin and had a 
shorter length of stay in hospital. Again, the only significant difference was between the 
serum creatinine levels of the two groups (p = 0.006) (table 6.1). Unsurprisingly, a positive 
binary toxin gene result was significantly associated with samples containing PCR ribotype 
027 (p<0.001) (table 6.1.).  
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Variable 
CT≤25 
(n/N (%)) 
 
CT>25 
(n/N (%)) 
 
p value* CT≤24 
(n/N (%)) 
 
CT>24 
(n/N (%)) 
 
p value* CT≤25 and 
Binary toxin 
PCR positive 
(n/N [%]) 
CT≤25 and 
Binary toxin 
PCR 
negative 
(n/N [%]) 
p value* 
All PCR-positive patients         
CCNA positive 
366/436  
(83.9) 
347/838  
(41.4) 
<0.001 278/323 
(86.1) 
435/523 
(45.4) 
<0.001 100/112 
(89.3) 
266/324 
(82.1) 
0.10 
Died 
54/310  
(17.4) 
69/575  
(12.0) 
0.032 41/233 
(17.6) 
82/652 
(12.6) 
0.52 20/79  
(25.3) 
34/231  
(14.7) 
0.049 
Recurrence 
36/189  
(19.0) 
42/307  
(13.7) 
0.111 27/145 
(18.6) 
51/351 
(14.5) 
0.70    
Had 
PCR ribotype 
027 
46/272  
(16.9) 
41/387  
(10.6) 
0.025 35/323 
(10.8) 
52/958 
(5.4) 
0.003 42/79  
(53.2) 
1/189  
(0.5) 
<0.001 
Median length 
of stay (days) 
28 23 0.77 n/ac n/ac n/ac 20 29 0.11 
Mean white cell 
count (x109/L) 
12.1 10.9 0.3 n/ac n/ac n/ac 13.2 11.8 0.13 
Mean serum 
creatinine 
120.0 110.7 0.04 n/ac n/ac n/ac 112.9 111.8 0.006 
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(mg/dL) 
Mean serum 
albumin (g/L) 
31.3 32.4 0.34 n/ac n/ac n/ac 31.0 31.3 0.46 
          
All PCR positive patients with 
PCR ribotype 027 
        
Median length 
of stay (days) 
32.5 28 0.018 n/ac n/ac n/ac N/A N/A  
Died 11/33 (33.3) 26/170 (15.3) 0.024b n/ac n/ac n/ac 11/32 (34.4) 0/1 (0) 0.66b 
* t test for comparisons of means, Mann Whitney for comparisons of medians, 2 for categorical comparisons. b Fisher’s exact probability. c CT ≤ 24 
not investigated further as low CT defined as ≤5 for further analyses.  
Table 6.1 Outcomes and severity markers for patients with CT values ≤ 25 or > 25. Reproduced from PLOS One with permission  
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Figure 6.1 Results of C. difficile reference methods A) all PCR positive samples (n = 1281) positive agreement 51.2%; (B) those with 
only CT < 25 (n = 436) positive agreement 78.4%; (C) those with only CT ≤ 24 (n = 145) positive agreement 76.6%. Reproduced from 
PLOS One with permission 
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Figure 6.2 ROCs for PCR tcdB CT value against a) mortality (AUROC 0.569) and b) CCNA (0.83) and c) recurrence (0.557). Reproduced 
from PLOS One with permission 
 
  
a) b) c) 
222 
 
 
Figure 6.3 Boxplot of PCR tcdB CT value against a) mortality b) CCNA result and c) recurrence. Values clustered around the top bar 
indicate outlier values.  Reproduced from PLOS One with permission
a) b) c) 
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6.3.2 Can diagnostic assays be used to predict recurrence? 
6.3.2.1 Analysis of existing data set to determine if there is an association 
between a positive primary C. difficile diagnostic assay and recurrent infection 
 
There were 1578 patients that had with more than one sample submitted during the period 
of the study, equating to a total of 3808 samples that could be used for the analysis of 
recurrence. The highest risk of recurrence occurred in those patients who had a previous 
sample that was CCNA positive (recurrence rate 20.3%, OR 8.04, 95% CI 5.69-8.18, p <0.001, 
table 6.2.). However, having a sample that had been previously positive by any of the 
assays was significantly associated with recurrence (all p <0.011, table 6.2.). Although the 
OR for recurrence if the previous sample was positive by PCR was 6.84, this analysis also 
contained samples that were also CCNA positive. The data were therefore adjusted to 
contain only those that were PCR positive (Group 3) and the OR decreased to 2.52 (95% CI 
1.56-4.07, p <0.001, table 6.2.). The same pattern was seen for recurrence risk in those 
patients whose previous sample had been CTC positive; the OR decreased from 5.86 (95% 
CI 4.21-8.18, p <0.001) to 2.13 (95% CI 1.18-3.84, p = 0.011, Table 6.2.) once CCNA-positive 
samples were removed from this group (Group 2). Whilst the ORs were similar between all 
those with an initial positive PCR test vs those with a PCR test with tcdB CT≤25 (6.84 vs 6.31 
[95% CI 4.96-9.43 and 4.21-9.44, respectively]), it should be noted that the rate of 
recurrence in the tcdB PCR CT≤25 group was higher than that in the whole group that was 
positive by PCR, although this was not significant (19% vs 15.7%, p = 0.35) (table 6.2.). 
There was however a significant difference between group 3 (PCR positive/CCNA negative) 
and Group 4 (PCR positive with CT≤25/CCNA negative) (9.6% vs 19.0%, p = 0.009, table 6.2.). 
There was also a higher rate of recurrence in those patients with tcdB PCR-positive samples 
that were also positive for binary toxin gene, compared with those without binary toxin 
gene (24.2% vs 13.6%, OR 2.03 95% CI 1.18-3.49, p = 0.009, table 6.2.1). However, the 
difference in recurrence rates between those with and without binary toxin gene in those 
samples with tcdB PCR CT≤25 (23.7 vs 17.9%, OR 1.43 95% CI 0.61-3.35, p = 0.42, table 6.2.1) 
was not significant.  
The relationship between initial samples that were baseline positive by any assay, followed 
by a CCNA-positive sample within 14 days was also analysed (table 6.2.)  Interestingly, the 
CCNA positive rate in subsequent samples within 14 days when the initial positive result 
was by CCNA (Group 1), CTC only (Group 2) or PCR with low CT only (Group 4) was 
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approximately half that of the positive number after 14 days. However, the positive rate for 
those in Group 3 (initial sample positive by PCR only) was the same (9.6 vs 9.9%) within 
both periods.  
In a binary logistic regression model for recurrence (n = 3804 samples), with the variables; 
initial test positive by CTC, CCNA, GDH, PCR or tcdB PCR CT ≤25, having an initial sample 
that was positive by CCNA or PCR was significantly associated with recurrence (p <0.001, 
table 6.2.). However, as the PCR group also contained samples that were positive by CCNA, 
the binary logistic regression analysis was also repeated for the variables CCNA (Group 1, 
Group 2, Group 3 and Group 4, n=496 samples).  Following this analysis, recurrence was 
only significantly associated with having an initial sample that was positive by CCNA 
(p = 0.046, table 6.2.).  
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Patient had another CCNA 
positive sample after 14 days         
 
Initial test 
Initial 
test 
result No Yes Total 
Recurrence 
% OR 95% CI for OR 
p value 
(χ2) 
Binary logistic 
regression 
p value 
Cytotoxigenic 
culture 
negative 3298 103 3401 3.0  
5.86 
 
4.21-8.18 
 
<0.001 
 
0.55 positive 344 63 407 15.5 
Cell cytotoxicity 
neutralisation 
assay (Group 1) 
negative 3414 108 3522 3.1 
 
8.04 
 
5.69-8.18 
 
<0.001 
0.001 (0.046 in 
second model) 
positive 228 58 286 20.3 
Group 2 
negative 3502 153 3655 4.2  
2.13 
 
1.18-3.84 
 
0.011 
 
 
0.840 positive 140 13 153 8.5 
GDH negative 3113 90 3203 2.8  
4.96 
 
3.61-6.82 
 
<0.001 
 
0.56 positive 530 76 606 12.5 
PCR negative 3225 88 3313 2.7  
6.84 
 
4.96-9.43 
 
<0.001 
 
<0.001 positive 418 78 496 15.7 
Group 3 negative 3445 145 3590 4.0 
  
 
<0.001 
Dropped from 
model positive 198 21 219 9.6 2.52 1.56-4.07 
CT<25 CT>25 3486 130 3616 3.6 
  
 
<0.001 
 
0.73 CT<25 153 36 189 19.0 6.31 4.21-9.44 
Group 4 CT>25 265 42 307 13.7 
1.49 0.91-2.4 0.111 
 
0.76 CT<25 153 36 189 19.0 
PCR and Binary 
toxin PCR 
Positive 24 75 99 24.2 
2.03 1.18-3.49 0.009 
 
N/A Negative 54 343 397 13.6 
CT<25 and Binary 
toxin PCR 
Positive 9 29 38 23.7 
1.43 0.61-3.35 0.42 
N/A 
Negative 27 124 151 17.9 
   
Patient had another CTA 
positive sample within 14 
days      
 
Initial test 
Initial 
test No Yes Total 
CCNA 
positive OR 95% CI for OR 
p value 
(χ2) 
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result % 
Cell cytotoxicity 
neutralisation 
assay (group 1) 
Negative 3431 17 3522 0.5 
24.5 13.8-43.2 <0.001 N/A positive 363 44 407 10.8 
Group 2 
Negative 3600 55 3655 1.5 
2.67 1.13-6.3 0.045 N/A Positive 147 6 153 3.9 
Group 3 
Negative 3225 88 3313 2.8 
4.1 2.9-5.9 <0.001 N/A Positive 437 49 496 9.9 
Group 4 
Negative 237 70 307 22.8 
0.47 0.28-0.78 0.005 N/A Positive 166 23 189 12.6 
Odds ratios and χ2 results for categorical comparisons. Initial binary logistic regression included the variables CTC, CCNA, GDH, PCR or PCR tcdB 
CT<25, second model included the variables CCNA (Group 1), CTC positive/CCNA negative (Group 2), PCR positive/CCNA negative (Group 3) and 
CT<25/CTA negative (Group 4). 
Table 6.2 The risk of recurrent CDI according to prior C. difficile test results in patients who had more than one sample 
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6.3.2.2 Analysis of data from the PlaciD dataset to determine if there is an 
association between the bacterial bioload during primary infection and 
recurrence 
 
GDH OD values correlated with bacterial load in the sample, as measured by semi-
quantitative culture (figure 6.4a-c) with a significant Spearman’s correlation of 0.74 
(p <0.001) suggesting that GDH OD values could be used to measure the faecal bacterial 
burden. There were significant differences between the GDH OD values for cases and 
controls (median GDH OD for cases = 0.182 vs 0.005 for controls; Mann Whitney p <0.001), 
and between cases with a single episode and those with recurrent episodes (median GDH 
OD for recurrent cases = 0.778 vs 0.058 for controls; Mann Whitney p <0.001), with those 
with recurrence having the highest median GDH OD values of all.  
There were 20 patients (mean age 70) with CDI who had a recurrent infection with a total 
of 25 recurrent episodes. In 16 of these 25 recurrent episodes (64%), which occurred in 14 
of the 20 patients with CDI, GDH was detected before the CCNA positive sample that 
signalled the recurrent CDI episode (median 8.5 days before). In five of the 14 patients 
(equating to six out of the 16 episodes where GDH was detected first) individuals (median 
age 77) had consistent GDH-positive results, despite having a resolution of their diarrhoea 
symptoms. In total, these five patients had 70 samples tested; 69/70 samples were positive 
for GDH, 55/70 were positive by cytotoxigenic culture and 59/70 were positive for toxin 
genes by PCR assay (figures 6.5a-e). Interestingly, the toxin gene PCR assay was not positive 
on as many occasions as the GDH assay, suggesting that the GDH assay potentially has a 
lower limit of detection. We were unable to recover C. difficile by culture from any samples 
from one of the patients; the patient had, however, been treated with fidaxomicin, which 
has been shown to reduce bacterial recovery from clinical samples (Chilton, PLOS one 
2016). 
Six of the six recurrence episodes in these five patients were precipitated by antibiotic 
therapy, for four of the six antibiotic therapies these were not given to treat CDI (figures 
6.5a-e). In addition, four of the five patients were using concomitant PPIs. These five 
patients appear to have been more ill than those who cleared the bacteria below the limit 
of detection for the GDH assay between CDI episodes, with higher WCC’s, higher serum 
albumin levels and lower serum creatinine levels (table 6.3). 
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Figure 6.4 a) GDH OD values for different bacterial loads, as measured by semi-quantitative culture. Spearman’s = 0.74, p <0.001); b) 
GDH OD values for cases and controls. Median GDH OD for cases = 0.182 vs 0.005 for controls (U p <0.001); c) GDH OD values for 
recurrent cases and single CDI cases.  Median GDH OD for recurrent cases = 0.778 vs 0.058 for controls (U p <0.001) 
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Figures 6.5a-e. The days on which the five recurrent cases had samples taken and tested, and the results of each of those tests  
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WCC 
(10.8 x 109 
cells per 
litre) 
Serum 
albumin 
(g/ʟ) 
Serum 
creatinine 
(µmol/ʟ) 
Controls 
mean 7.34 32.77 93.51 
min 0.13 23 26 
max 16.81 42 552 
Cases 
mean 10.92 31.12 105.67 
min 0.01 5.8 23 
max 1135 45 752 
p value   
(case/ control) 
 
0.47 0.1 0.44 
Single 
mean 11.14 32.07 110.79 
min 0.01 18 31 
max 1135 45 752 
Recurrent 
mean 10.34 28.66 93.38 
min 3.45 5.8 23 
max 45.35 44 747 
p value       
(single/ recurrent) 
 
0.28 <0.001 0.21 
Recurrence without 
constant GDH 
mean 10.18 28.36 99.9 
min 3.45 5.8 27 
max 45.35 44 747 
Recurrence with 
constant GDH 
mean 10.97 30.07 69.12 
min 6.99 21 23 
max 15.03 38 181 
p value  
(inconstant/constant) 
 
0.05 0.2 0.04 
Table 6.3 The white cell count, serum albumin and serum creatinine results for 
different groups of patients within the study. Comparison between groups were 
made using t tests 
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6.4 Discussion 
Utilising the largest dataset collected on CDI diagnostic assays and patient outcomes 
enabled analysis to examine the potential of CT value to inform on the diagnosis and 
outcomes of CDI, and. Importantly, this dataset comes from the only study which tested all 
samples with both of the CCNA and CTC reference assays.  A low CT value for a C. difficile 
tcdB PCR assay was significantly associated with a toxin-positive result, presence of 
PCR ribotype 027, and mortality (table 6.1). In addition, recurrence was also associated 
with low CT, although this was not a significant finding, possibly due to the low number of 
recurrent cases within the dataset. There was a significant AUROC for tcdB PCR CT value 
against sample toxin positivity, as measured by CCNA of 0.83 (p <0.001) with a median tcdB 
PCR CT for toxin positive samples of 24.9 vs 31.6 for toxin negative samples (p <0.001). In 
addition, the median tcdB PCR CT value for patients who died was significantly lower than 
for those who survived (25.5 vs 27.5 p = 0.021) with a significant AUROCC for tcdB PCR CT 
positives against mortality; 0.572 p =0.009. In order to optimise the CT cut-off both ≤24 and 
≤25 cycles were further investigated, but there was little difference between the two cut-
off values (table 6.1); a slighter higher PPV for toxin positivity using CT ≤24 was offset by a 
lack of significant association with mortality seen with CT≤25 .  A ‘low CT’ was therefore 
defined as tcdB PCR CT of ≤25. This cut-off was slightly higher than cut-offs used in two 
smaller studies which reported CT values. Indeed, one of these studies reported an AUROC 
of 0.857 when using a cut-off of <23.5 cycles; however, this was for a composite end-point 
of ‘poor outcome’ which included recurrent infection, treatment failure or progressing to 
severe complicated CDI (Reigadas et al, 2016b). The large dataset in this study, 7.5 times 
larger than that of the previous study, has highlighted the association of low CT with single 
outcome measures, rather than a composite end-point.  Indeed, with a positive predictive 
value of low CT (≤25) for toxin detection of 83.9% it is possible that a low tcdB PCR CT value 
could be used as a proxy for toxin detection as suggested from a recent small study 
(Kamboj et al, 2018).  
The risk of mortality was higher in patients with a low CT (≤25) compared with those with a 
PCR CT value >25 (relative risk [RR] 1.45) (table 6.2). The risk of mortality was further 
increased in those patients who had a low CT and had an infection caused by C. difficile 
PCR ribotype 027 (RR 2.18). Indeed, in those patients with a low CT (≤25), mortality and 
longer length of stay were also significantly associated with the presence of C. difficile 
PCR ribotype 027 in their sample, compared to other PCR ribotypes, highlighting a possible 
‘at risk’ group. There is conflicting evidence regarding the role of the presence of the binary 
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toxin gene in CDI outcomes (Reigadas et al, 2016a, Berry et al, 2017), however in this 
dataset the relative risk for mortality for those patients with low CT increased from 1.45 to 
1.72 when the presence of binary toxin gene was taken into account.  
Patients with a low CT appeared to be sicker than those with a tcdB PCR CT value >25, as 
they had a higher mean WCC, higher mean serum creatinine, lower mean serum albumin 
and longer length of stay, but only the difference in serum albumin levels was significant 
(table 6.2). This was possibly due to the small sample size in these subgroups, as data could 
only be collected when patients had routine blood tests, they were not tested 
systematically. The same pattern of differences in CDI severity markers was seen in patients 
who had a low CT and whose samples tested positive for binary toxin gene detection, with 
the exception that these patients had a shorter length of stay than binary toxin negative 
patients. The predictive value of tcdB PCR low CT to determine those patients who are 
more sick warrants further investigation. Any future study would need to be larger, and use 
prospective, systematic sampling of patients.  
Prevention of recurrence is a key goal of patient management in cases of CDI, indeed the 
antibiotic fidaxomicin is recommend in first recurrent cases to prevent further episodes 
(Debast et al, 2014, McDonald et al, 2018) due to the reduction in recurrence risk with this 
antibiotic, compared with vancomycin.  The high cost of this treatment does, however, 
impact on a hospital’s decision to fund this drug. A diagnostic tool that could indicate those 
patients in which it would be most cost-effective to use, i.e. those at biggest risk of 
recurrence, such as in those patients with low CT, may help to guide antibiotic 
management. Although recurrence was associated with a low CT in this dataset, this was 
not a significant finding, possibly due to the low number of recurrent cases within the 
PCR-positive samples that were used for the CT value analysis (table 6.1 and figures 6.2 and 
6.3). Risk of recurrence has also previously been shown to be higher in PCR ribotype 027 
(Marsh et al, 2012). In order for this to be a timely measure however, clinicians cannot rely 
on traditional PCR-ribotyping methods; in this regard a rapid assay with a ‘presumptive 027’ 
result would be of importance.  The Cepheid geneXpert® C. diff assay has a high NPV for 
‘presumptive RT027’ but does overcall the number of samples that truly contain a strain of 
PCR ribotype 027, as demonstrated by the low PPV (69.9%). The presence of the gene 
target used to identify PCR ribotype 027 by the Cepheid geneXpert® C. diff assay in other 
ribotypes related to PCR ribotype 027 can confound the results produced by this assay 
(Spigaglia and Mastrantonio, 2002, Rupnik et al, 1998). 
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In order to investigate recurrence further, all patients who had more than one sample 
taken during the study were included, regardless of PCR positivity. Using this larger dataset 
recurrence was significantly associated with a sample that had tested positive by any of the 
diagnostic assays used; however, the highest risk was in those with a previous 
CCNA-positive sample (OR 8.04), PCR-positive sample (as defined by the software algorithm 
within the Cepheid geneXpert®)  (OR 6.84) or low tcdB PCR CT value (OR 6.31) (table 6.2). 
Importantly, however, the OR for both PCR and low CT decrease when samples within 
these groups that were also CCNA positive were removed from the analysis; CCNA was the 
only significant variable associated with recurrence after binary logistic regression (Table 
6.2).  In addition, the rate of subsequent CCNA-positive samples within 14 days of the initial 
sample is the same for those that are PCR positive only (9.9% vs 9.6% for those >14 days), 
whilst for CCNA, CTC only (Group 2) and low CT only (Group 4) the incidence is 
approximately half within that 14-day period (table 6.2). This suggests that CCNA and low 
CT are better predictors of a true recurrence, as they are diagnosing the first sample with a 
‘true’ case of CDI, whereas a positive toxigenic C. difficile PCR result (with any CT) could be 
detecting a patient without toxin and therefore without ‘true’ disease.  Without a ‘true’ 
initial CDI episode, can there be a ‘true’ recurrence, or are these patients developing a 
toxin positive disease for the first time?   
There are some limitations associated with this retrospective data analysis of a pre-existing 
dataset, such as the lack of a validation dataset. It should be noted, however, that this 
dataset was from the largest ever study of C. difficile diagnostic assays, and was therefore a 
valuable resource, in terms of sheer numbers, for this analysis. In order to analyse the data 
for recurrence, only those patients who had more than one sample submitted could be 
included in the analysis. Unfortunately, in the original study some recurrent samples may 
have been missed as there was a break in sample collection of a few months, as the study 
changed from a derivation to a validation testing set (Planche et al, LID 2012), and indeed 
the study was not designed to prospectively capture recurrence data. Therefore, a 
prospective study to investigate the impact of CT value information provided to clinicians 
on the rate of recurrence and any potential changes in patient management is warranted.  
In addition, these data only relate to one NAAT assay (Cepheid geneXpert® C. diff); it 
cannot be assumed that all assays will perform in the same way; however, there is some 
evidence emerging from other groups using different NAATs about the potential value of 
the CT value (Crobach et al, 2018). 
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If the theory that recurrence is more likely in those patients who have a higher bacterial 
burden of disease during their primary infection, are there assays, other than PCR CT values, 
that could be used to predict recurrence? A study in 2017 found that a higher bacterial 
burden, as measured by cfu of toxigenic C. difficile/g of stool, was associated with a poor 
outcome (composed of recurrence, or treatment failure or severe complicated CDI) 
(Reigadas et al, 2017). The GDH OD values from the PlaciD dataset  correlated with the 
bacterial load in the sample, as measured by semi-quantitative culture of C. difficile, 
suggesting that GDH OD values could be used to measure the bacterial burden with faecal 
samples (figure 6.4). As discussed in Chapter 1, the GDH EIA is a quantitative assay, and 
increasing OD values correlate with increasing bacterial burden within the gut model.  The 
highest median GDH OD values were seen in those patients with recurrent infection, with 
significant differences seen between cases and controls and those patients with single 
verses recurrent CDI (figure 6.4). This appears to confirm that a higher bacterial burden, as 
measured by either GDH OD could be used to predict recurrence. In addition, GDH could be 
detected from samples a median of 8.5 days before samples were produced that were 
toxin positive (as measured by CCNA).  
In addition to examining the GDH OD values of all patients, five patients were identified 
who had consistent GDH-positive samples throughout their hospital stay, despite 
resolution of their diarrhoeal symptoms.  This would appear to indicate that this group of 
patients were unable to clear the organism from their gut, but were colonised until they 
had another clinical recurrence. In all six of the recurrent infections that occurred in this 
group of five patients, their recurrent episode was precipitated by antibiotic therapy 
(figures 6.5a-e). In addition, four of these five patients were also using concomitant PPIs, 
although the potential role of PPIs as a risk factor for CDI is contentious (Faleck et al, 2016, 
Dial et al, 2004, Vesteinsdottir et al, 2012).   
Interestingly, for these five patients, culture and the toxin gene PCR assay were not positive 
on as many occasions as the GDH assay, perhaps suggesting that the GDH assay has a lower 
limit of detection than both culture and the PCR assay. This appears to contradict the data 
from the Department of Health (DoH) study, where PCR was as sensitive as the GDH assay, 
however the PCR assay used in the DoH study was the Cepheid geneXpert® C. diff, whereas 
the PCR assay used here was the BD Max™ C.diff assay  (Planche et al, 2012). This could 
therefore highlight differences between molecular platforms, as shown by Gilbreath et al, 
where the BD Max™ assay had the lowest sensitivity of the platforms tested (2014). 
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C. difficile could not be cultured from any of the samples from one patient; this patient had, 
however, been treated with fidaxomicin, which has been shown to reduce bacterial 
recovery from clinical samples (Biswas et al,  2015).  
The reasons behind the persistent carriage of C. difficile in these five patients are unclear. 
They appear to be more ill than those patients who cleared the bacteria below the limit of 
detection for the GDH assay between CDI episodes, as they had higher WCCs, higher serum 
albumin levels and lower serum creatinine levels (Table 6.3). However, whether these 
deranged values are due to the presence of the bacteria, or are a demonstration of the 
frailty of the patient, and therefore, perhaps a compromised immune system that cannot 
clear the infection, is unclear.   
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7. Final Discussion 
CDI laboratory diagnostic methods have been shown to have variable performance 
(introduction section 1.13), but what are the reasons for this? The PCR ribotype has been 
cited as a factor in reduced sensitivity for both the GDH and toxin EIAs (Tenover et al,   
2010), while in this study, none of the EIAs tested were significantly more likely to miss any 
one PCR ribotype over another. Importantly, however, there were significant differences 
between the median OD values of PCR ribotypes 027 and 015 for both of the toxin EIAs 
tested (figure 3.1). Given that the GDH EIA has been shown to be quantitative (Chapter 4), 
it could be theorised that the same is true for the toxin assays, and that the different 
median values reflect differences in the level of toxin produced by different PCR ribotypes.  
This is supported by the data from batch culture experiments, where the cytotoxin titre for 
PCR ribotype 002 was lower than the titre for other PCR ribotypes tested, even though 
total viable counts remained consistent between the strains (figures 3.2 and 3.5). There 
were also significant differences between median OD values of the two toxin EIA for the 
same PCR ribotypes (table 3.2), further highlighting the variability between toxin EIAs.  
The GDH EIA does not appear have the same variation in performance with different 
PCR ribotypes (table 3.1, figures 3.2 and 3.5). Indeed, the GDH assay appeared to be the 
most sensitive method for detection of C. difficile from sequential faecal samples, 
compared with culture, CTC and PCR (BD Max™) (tables 5.13 and 5.15). In contrast, the PCR 
assay (Cepheid GeneXpert®) had comparable sensitivity to the GDH assay in an earlier 
study (Planche et al, 2012), suggesting that different PCR platforms have different 
sensitivity for detecting C. difficile from faecal samples (Gilbreath et al, 2014).  It should 
also be noted that the earlier study was testing faecal samples from patients in whom a 
diagnosis of CDI was suspected, while in the present study the samples were tested on 
sequential days after an initial GDH positive sample had been identified. Testing sequential 
samples, however, gives an indication of how long markers of C. difficile or CDI remain 
detectable within patient samples, and therefore also provides an indication about the limit 
of detection of these assays. In addition, GDH was detectable from samples from the gut-
model experiments when no organisms could be cultured from the samples (figures 4.1, 4.2, 
4.4, 4.5, and 4.7-4.12), demonstrating that GDH remained within the system after the 
organism had washed out. The reasons for the extended detection of GDH both in vitro and 
in vivo are unclear; it may be related to the large amounts of GDH produced, sequestration 
within biofilm, and/or release from dead cells.  There is not, however, an additional peak in 
GDH after cell death within the gut models, just a continual decline, in-line with the 
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reduction in cell numbers, suggesting that GDH is not released after cell death. This is 
supported by the data from growth curve experiments, which show that GDH was 
produced during the exponential phase of growth, then declined as vegetative growth 
slowed and there was conversion from vegetative cells to spores (figures 3.8 and 3.9). 
Dilution of gut model samples allowed visualisation of peak GDH levels produced during 
the gut model experiments, which in later experiments reached very high levels (Model F 
figures 4.11a-c).  It is possible therefore that the high sensitivity of the GDH EIA could be 
related to the large amounts of the protein produced by the organism. Further studies are 
required to investigate the copy number of the gluD gene within C. difficile, expression of 
the gene and perhaps what promoter genes are associated with gluD, in order to fully 
understand the production of GDH by the organism.   
In addition to increased GDH levels within Model F, the highest peak total viable count and 
toxin titre was also observed within this model (Model F figures 4.11a-c), suggesting that 
levels of both GDH and toxin are related to the bioload during infection. This correlates 
with a recent study where poor outcome was associated with higher bacterial burden, as 
measured by cfu of toxigenic C. difficile/g of stool (Reigadas et al, 2017). Within faecal 
samples in the current study, GDH EIA OD values also correlated with culture, as measured 
semi-quantitatively (figure 6.4a), further supporting the theory that GDH EIA OD values can 
be used as a measure of bioload within the sample. In addition, the median OD value of 
cases was significantly higher than control participants, and the median OD value of 
recurrent cases was significantly higher than those participants who only had one episode 
of CDI (figures 6.4b-c). The GDH OD value may therefore, potentially offer the opportunity 
to predict recurrence. Similarly, the CT value of PCR assays, specifically the Cepheid 
geneXpert®, may also provide information to help predict those participants who are toxin-
positive, have an infection caused by PCR ribotype 027, and are at greater risk of mortality 
(table 6.1). Although low CT (<25) was associated with recurrence, this was not a significant 
finding; the only assay significantly associated with recurrence after binary logistic 
regression was CCNA (table 6.2). It should be noted, however, that not all commercial PCR 
systems provide CT values to the user, meaning that this ‘extra’ analysis could not take 
place. In addition, not all PCR systems may be comparable; the BD Max™ C. diff assay used 
in the sequential faecal sample testing for the present study appeared to have decreased 
sensitivity compared with the Cepheid geneXpert® C. diff assay used in our earlier study 
(Planche et al, 2012), although this was not a true head-to-head comparison. This potential 
variability was highlighted in a recent comparison of four molecular assays, with sensitivity 
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ranging from 90-100%, but with 95% CI ranging from 82-100% (Caulfield et al, 2018), 
although this comparison was not against a recognised reference method. A second smaller 
study found sensitivities of 92-99%% with 95% CI ranging from 84.6-100.0, compared with 
toxigenic culture for six different molecular assays (Paitan et al, 2017).  
The current C. difficile diagnostic guidelines in the UK and Europe (Crobach et al, 2016) 
state that a two-stage algorithm should be used for the diagnosis of CDI, to counter the 
lack of sensitivity of stand-alone toxin EIAs. The most commonly used option in the UK 
(Davies et al, 2016b) is GDH/toxin. This does, however, highlight a ‘new’ patient group, 
denoted potential C. difficile excretors (PCDEs), i.e. those patients who have a sample that 
tests positive for GDH but negative for toxin (Planche et al, 2012). It could be argued that 
some of these PCDE’s are ‘missed’ infections, due to the use of a toxin EIA (with reduced 
sensitivity) as the second test. However, using CCNA to test sequential samples 
demonstrates that toxin cannot be detected, even by this more sensitive method.  Samples 
could be further investigated by the use of novel ultra-sensitive toxin detection assays 
(Pollock, 2016; Banz et al, 2018). It is possible that failure to detect toxin from a C. difficile 
positive sample is because the patient is carrying a non-toxigenic strain, which is therefore 
incapable of producing toxin. However, of the 25 PCDEs that had no samples with 
detectable toxin, 20/25 had a toxigenic PCR ribotype of C. difficile isolated from their 
sample. This is an important point, as CDI is a toxin mediated disease (Bartlett et al, 1978). 
Interestingly, 27% of PCDEs went on to have a toxin positive sample, after a median of 8 
days. Does this indicate that the initial samples were taken before the organism had started 
to proliferate and produce toxin, or that the level of toxin was not yet detectable by CCNA, 
so yielding a GDH-positive/toxin-negative result? Indeed, the converse could be true; only 
12.2% of CDI cases went on to have another toxin positive sample within 72 hours of the 
initial sample (table 5.14). 
The data from gut models demonstrate the fast decline of toxin following treatment with 
an appropriate antibiotic (figures 4.1, 4.2, 4.4, 4.5, and 4.7-4.12). The gut model cannot, 
however, simulate the effect of the immune system on the levels of toxin within the gut 
and how fast levels decline in vivo. It is therefore possible that a 
GDH-positive/toxin-negative result could be obtained for a sample collected at either end 
of the episode of infection. Current guidance does not support repeated testing of patients, 
due to the potential for increased false-positives, and the data from this study are currently 
not strong enough to contradict that advice. Further studies are required to determine if 
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ultra-sensitive toxin detection methods could detect low levels of toxin, below those 
currently detected by CCNA, in these GDH-positive/toxin-negative (by CCNA) patient 
samples, and indeed to determine the clinical importance of these results. In addition, as 
there has been a correlation demonstrated between lactoferrin (Davies et al, 2019b), and 
toxin level in a faecal samples, tests for gut inflammation, such as lactoferrin or calprotectin 
could be used to provide an indication of toxin damage to the gut mucosa in patients with 
GDH-positive/toxin-negative results.  Further studies are also needed to determine the 
utility of lactoferrin and calprotectin when used as an adjunct to ultra-sensitive toxin 
detection assays.  
Antibiotic stewardship is important to reduce the risk of emergence and spread of 
antibiotic resistance, and so increase the chance that the current portfolio of antibiotics 
remains effective. Within the context of CDI, antibiotic stewardship is additionally 
important, as a method of protecting the vital gut microbiome. Almost all classes of 
antibiotic have been shown to damage the microbiome, allowing a niche for C. difficile to 
proliferate (Bartlett and Gerding, 2008), including some used to treat CDI itself, such as 
vancomycin. A subset of patients has been highlighted in this study, which was consistently 
GDH positive in almost every sample (69/70, 98.5%) despite resolution of symptoms. The 
reasons that they were unable to clear the infection are unclear; however, all of these 
patients went on to have a recurrent CDI following antibiotic treatment for another 
suspected or proven (non-CDI) infection (figures 6.5 a-e). Risk prediction models are not 
currently reproducible (Escobar et al, 2017), and so, if the patients had been tested before 
the new antibiotic prescription had been written, and found to be GDH positive, would this 
have changed the decision of the prescriber to use a more gut-protective agent? These 
data, taken with those discussed above mean that diagnostic assays may therefore, be able 
to provide more information than a binary positive/negative result, and thereby, augment 
existing testing methodology, by providing guidance for opportunities for antibiotic 
stewardship or the use of therapies such as bezlotoxumab to help prevent recurrence. 
Alternatively, there are investigational drugs that are designed to reduce the negative 
impact of antibiotics on gut microbiota (and so reduce the risk of CDI) i.e. SYN-004 
(ribaxamase) (Kokai-Kun et al, 2017b) and DAV-132 (de Gunzberg et al, 2015).  The novel 
GDH results from the present study offer a potential way to target the use of such 
preventative therapies to those patients most likely to benefit.  
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Appendix 3. Supplementary tables for Chapter 3 
 
  
Recruited to the study 
 
 
Had at least one sample 
in the study 
Had at least one 
sample in the study 
and initial diagnostic 
specimen was GDH 
positive 
  Control 
GDH 
positive 
Total Control 
GDH 
positive 
Total PCDE CDI Total 
  
n  
(%) 
n  
(%) 
n 
n  
(%) 
n  
(%) 
n 
n  
(%) 
N 
 (%) 
n 
Abdominal pain 
1  
(9.1) 
10 
(90.9) 
11 
1  
(9.1) 
9  
(90.0) 
10 
4  
(44.4) 
5  
(66.6) 
9 
Abdominal aortic 
aneurysm 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
0  
(0) 
0  
(0) 
0 
Acute kidney 
injury 
1  
(20.0) 
4  
(80.0) 
5 
1  
(20.0) 
4  
(80.0) 
5 
1  
(25.0) 
3  
(75.0) 
4 
Alcohol 
withdrawal 
0  
(0) 
2  
(100) 
2 
0  
(0) 
2  
(100) 
2 
1  
(50.0) 
1  
(50.0) 
2 
Appendix 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Bacteraemia 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Biliary sepsis 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Bladder cancer 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Community 
acquired 
pneumonia 
0  
(0) 
2  
(100) 
2 
0  
(0) 
2  
(100) 
2 
1  
(50.0) 
1  
(50.0) 
2 
CDI 
0  
(0) 
3  
(100) 
3 
0  
(0) 
3  
(100) 
3 
1  
(33.3) 
2  
(66.7) 
3 
Cellulitis 
1  
(33.3) 
2  
(66.7) 
3 
1  
(33.3) 
2  
(66.7) 
3 
1  
(50.0) 
1  
(50.0) 
2 
Chest infection 
1  
(100) 
0  
(0) 
1 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Chest pain 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
0  
(0) 
0  
(0) 
0 
Cholangitis 
1  
(100) 
0  
(0) 
1 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Chronic 
osteomyelitis 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
1  
(100) 
0  
(0) 
1 
Chronic kidney 
disease 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
0  
(0) 
0  
(0) 
0 
Collapse 
0  
(0) 
1  
(100) 
1 
0  
(0) 
0  
(0) 
0 
0  
(0) 
0  
(0) 
0 
Confusion 
2  
(25.0) 
6  
(75.0) 
8 
0  
(0) 
4  
(100) 
4 
2  
(50.0) 
2  
(50.0) 
4 
Constipation 1  1  2 1  1  2 0  1  1 
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(50.0) (50.0) (50.0) (50.0) (0) (100) 
COPD 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
1  
(100) 
0  
(0) 
1 
Crohn’s 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
1  
(100) 
0  
(0) 
1 
Diarrhoea and 
vomiting 
0  
(0) 
14  
(100) 
14 
0  
(0) 
14  
(100) 
14 
7  
(50.0) 
7  
(50.0) 
14 
Decreased 
mobility 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
0  
(0) 
0  
(0) 
0 
Dementia 
1  
(100) 
0  
(0) 
1 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Dental abscess 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Diabetic foot 
3  
(60.0) 
2  
(40.0) 
5 
2  
(50.0) 
2  
(50.0) 
4 
1  
(50.0) 
1  
(50.0) 
2 
Diarrhoea 
1  
(4.5) 
21  
(95.5) 
22 
1  
(5.0) 
19  
(95.0) 
20 
6  
(31.6) 
13  
(68.4) 
19 
Discitis 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Dislocated ankle 
1  
(100) 
0  
(0) 
1 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Dislocated hip 
1  
(100) 
0  
(0) 
1 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Dizziness 
0  
(0) 
2  
(100) 
2 
0  
(0) 
2  
(100) 
2 
1  
(50.0) 
1  
(50.0) 
2 
Dysphagia 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
0  
(0) 
0  
(0) 
0 
DVT 
1  
(50.0) 
1  
(50.0) 
2 
1  
(50.0) 
1  
(50.0) 
2 
1  
(100) 
0  
(0) 
1 
Elective 
chemotherapy 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Elective Stem cell 
Transplant 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
0  
(0) 
1 
Emergency 
surgery 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
1  
(100) 
0  
(0) 
1 
Encephalopathy 
0  
(0) 
2  
(100) 
2 
0  
(0) 
2  
(100) 
2 
1  
(50.0) 
1  
(50.0) 
2 
Endocarditis 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Epigastric pain 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
1  
(100) 
0  
(0) 
1 
Fracture of the 
ankle 
3  
(100) 
0  
(0) 
3 
2  
(100) 
0  
(0) 
2 
0  
(0) 
0  
(0) 
0 
Fracture of the 
elbow 
1 (50.0) 
1  
(50.0) 
2 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Fracture of the 
fibula 
1 (100) 
0  
(0) 
1 
0 
(0) 
0  
(0) 
0 
0  
(0) 
0  
(0) 
0 
Fracture of the 
foot 
0 (0) 
1  
(100) 
1 
0  
(0) 
0  
(0) 
0 
0  
(0) 
0  
(0) 
0 
Fracture of the 4  0  4 2  0  2 0  0  0 
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humorous (100) (0) (100) (0) (0) (0) 
Fracture of the 
knee 
7  
(100) 
0  
(0) 
7 
5  
(100) 
0  
(0) 
5 
0  
(0) 
0  
(0) 
0 
Fracture of the 
shaft of the femur 
7  
(100) 
0  
(0) 
7 
5  
(100) 
0  
(0) 
5 
0  
(0) 
0  
(0) 
0 
Fracture of the 
tibia 
4  
(100) 
0  
(0) 
4 
2  
(100) 
0  
(0) 
2 
0  
(0) 
0  
(0) 
0 
Fracture of the 
wrist 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
0  
(0) 
0  
(0) 
0 
Fall 
87  
(87.0) 
13  
(13.0) 
100 
36  
(76.6) 
11  
(23.4) 
47 
3  
(27.3) 
8  
(72.7) 
11 
Fatigue 
0  
(0) 
2  
(100) 
2 
0  
(0) 
2  
(100) 
2 
0  
(0) 
2  
(100) 
2 
Fits 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
1  
(100) 
0  
(0) 
1 
Flu 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Fractured neck of 
femur 
58  
(96.7) 
2  
(3.3) 
60 
17  
(89.5) 
2  
(10.5) 
19 
0  
(0) 
2  
(100) 
2 
Foot ulcer 
1  
(100) 
0  
(0) 
1 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Gallstones 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Haematuria 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
1  
(100) 
0  
(0) 
1 
Hepatic 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Hip pain 
5  
(83.3) 
1  
(16.7) 
6 
3  
(75.0) 
1  
(25.0) 
4 
0  
(0) 
0  
(0) 
0 
Hypercalcaemia 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
1  
(100) 
0  
(0) 
1 
Hyperkalaemia 
0  
(0) 
2  
(100) 
2 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Inflammatory 
bowel disease 
0  
(0) 
1  
(100) 
1 
0  
(0) 
0  
(0) 
0 
0  
(0) 
0  
(0) 
0 
Ischaemia 
1  
(100) 
0  
(0) 
1 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Leg pain 
3  
(75.0) 
1  
(25.0) 
4 
0  
(0) 
1  
(100) 
1 
1  
(100) 
0  
(0) 
1 
Leg swelling 
1  
(100) 
0  
(0) 
1 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Leg ulcers 
1  
(100) 
0  
(0) 
1 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Lower respiratory 
tract infection 
3  
(37.5) 
5  
(62.5) 
8 
1  
(20.0) 
5  
(80.0) 
6 
3  
(42.9) 
4  
(57.1) 
6 
Multi organ 
failure 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
1  
(100) 
0  
(0) 
1 
Necrotising 
fasciitis 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Neutropenic 2  0  2 2  0  2 0  0  0 
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(100) (0) (100) (0) (0) (0) 
Neutropenic 
sepsis 
0  
(0) 
4  
(100) 
4 
0  
(0) 
2  
(100) 
2 
1  
(50.0) 
1  
(50.0) 
2 
Not known 
7  
(100) 
0  
(0) 
7 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Pain in ankle 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
0  
(0) 
0  
(0) 
0 
Pancreatitis 
0  
(0) 
3  
(100) 
3 
0  
(0) 
3  
(100) 
3 
2  
(66.7) 
1  
(33.3) 
3 
Planned surgery 
9  
(32.1) 
19  
(67.9) 
28 
7  
(28.0) 
18  
(72.0) 
25 
11  
(61.1) 
7  
(38.9) 
18 
Planned 
Treatment 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
1  
(100) 
0  
(0) 
1 
Pyrexia 
0  
(0) 
8  
(100) 
8 
0  
(0) 
7  
(100) 
7 
2  
(28.6) 
5  
(71.4) 
7 
Recurrent CDI 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Reduced Glasgow 
coma scale 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Sepsis 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Septic arthritis 
6  
(100) 
0  
(0) 
6 
4  
(100) 
0  
(0) 
4 
0  
(0) 
0  
(0) 
0 
Shortness of 
breath 
5  
(41.7) 
7  
(58.3) 
12 
3  
(30.0) 
7  
(70.0) 
10 
5  
(71.4) 
2  
(28.6) 
7 
Stem cell 
transplant 
0  
(0) 
2  
(100) 
2 
0  
(0) 
2  
(100) 
2 
2  
(100) 
0  
(0) 
2 
Stoma leak 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
1  
(100) 
0  
(0) 
1 
Stroke 
2  
(40.0) 
3  
(60.0) 
5 
1  
(25.0) 
3  
(75.0) 
4 
0  
(0) 
3  
(100) 
3 
Subdural 
haematoma 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Tachycardia 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Transfusion 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
0  
(0) 
0  
(0) 
0 
Ulcerative colitis 0 (0) 
3  
(100) 
3 
0  
(0) 
3  
(100) 
3 
3  
(100) 
0  
(0) 
3 
Unsteady 0 (0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
0  
(0) 
1  
(100) 
1 
Unwell 0 (0) 
7  
(100) 
7 
0  
(0) 
6  
(100) 
6 
0  
(0) 
6  
(100) 
6 
Upper GI bleed 0 (0) 
1  
(100) 
1 
0  
(0) 
0  
(0) 
0 
0  
(0) 
0  
(0) 
0 
Urinary sepsis 0 (0) 
4  
(100) 
4 
0  
(0) 
4  
(100) 
4 
3  
(75.0) 
1  
(25.0) 
4 
Upper respiratory 
tract infection 
1  
(50.0) 
1  
(50.0) 
2 
1  
(50.0) 
1  
(50.0) 
2 
0  
(0) 
1  
(100) 
1 
Urinary tract 5  4  9 1  4  5 1  3  4 
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infection (55.6) (44.4) (20.0) (80.0) (25.0) (75.0) 
Vertigo 
0  
(0) 
1  
(100) 
1 
0 
(0) 
0 
(0) 
0 
 
0  
(0) 
0  
(0) 
0 
Vomiting 
4  
(44.4) 
5  
(55.6) 
9 
2  
(33.3) 
4  
(66.7) 
6 
1  
(25.0) 
3  
(75.0) 
4 
Whipple’s 
0  
(0) 
2  
(100) 
2 
0  
(0) 
2  
(100) 
2 
0  
(0) 
2  
(100) 
2 
Total 252 206 458 112 187 299 78 109 187 
Table A3.1 The reasons for admission for control patients that were recruited to 
the study, regardless of if they had samples in the study and if they had at least 
one sample included in the study. Those patents that had at least one GDH 
positive sample are divided into potential C. difficile excretors (PCDEs) and CDI 
cases based on the presence or absence of C. difficile toxins in the original routine 
sample. Each participant could have more than one reason for admission 
recorded. Summary table of the top ten conditions listed in admission for all 
participants are shown in tables 5.2 and 5.3 
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Recruited to the study Had at least one sample in 
the study 
Had at least one 
sample in the study 
and initial diagnostic 
specimen was GDH 
positive 
  Control 
GDH 
positive 
Total Control 
GDH 
positive 
Total PCDE CDI Total 
  
n  
(%) 
N 
 (%) 
n 
n  
(%) 
n  
(%) 
n 
n  
(%) 
n  
(%) 
n 
Abdominal 
sepsis 
1  
(100.0) 
0  
(0) 
1 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Abdominal 
aortic aneurysm 
1  
(33.3) 
2  
(66.7) 
3 
1  
(33.3) 
2  
(66.7) 
2 
1  
(50.0) 
1  
(50.0) 
2 
Acute kidney 
injury 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
2  
(100.0) 
2 
1  
(50.0) 
1 
(50.0) 
2 
Alcoholic 
4  
(22.2) 
14  
(77.8) 
18 
1  
(7.7) 
12  
(92.3) 
13 
5  
(45.5) 
6  
(54.5) 
11 
Alcoholic liver 
disease 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0
) 
0  
(0) 
1 
Alzheimer’s 
3  
(75.0) 
1  
(25.0) 
4 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Acute myeloid 
leukaemia 
2  
(28.6) 
5  
(71.4) 
7 
2  
(28.6) 
5  
(71.4) 
7 
2  
(40.0) 
3  
(60.0) 
5 
Anaemia 
5  
(62.5) 
3  
(37.5) 
8 
2  
(40.0) 
3  
(60.0) 
5 
1  
(33.3) 
2  
(66.7) 
3 
Angina 
8  
(57.1) 
6  
(42.9) 
14 
3  
(50.0) 
3  
(50.0) 
6 
4  
(66.7) 
2  
(33.3) 
6 
Ankylosing 
spondylitis 
1  
(100.0) 
0  
(0) 
1 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Arthritis 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0)  
0  
(0) 
0  
(0) 
0 
Asthma 
5  
(20.0) 
20  
(80.0) 
25 
2  
(10.0) 
18  
(90.0) 
20 
9  
(50.0) 
9  
(50.0) 
18 
Atrial 
fibrillation 
15  
(53.6) 
13  
(46.4) 
28 
10  
(43.5) 
13  
(56.5) 
23 
3  
(23.1) 
10 
(76.9) 
13 
Autism 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0
) 
0  
(0) 
1 
Atrial 
ventricular 
fibrillation  
1  
(100.0) 
0  
(0) 
1 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
B12 deficiency 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0
) 
0  
(0) 
1 
Biliary sepsis 
1  
(33.3) 
2  
(66.7) 
3 
1  
(33.3) 
2  
(66.7) 
3 
2  
(100.0
) 
0  
(0) 
2 
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Bone marrow 
transplant 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
2  
(100.0) 
2 
2  
(100.0
) 
0  
(0) 
2 
Bronchiectasis 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
0  
(0)  
0  
(0) 
0  
(0) 
0 
Bronchitis 
1  
(33.3) 
2  
(66.7) 
3 
0  
(0) 
2  
(100) 
2 
0  
(0) 
2  
(100.
0) 
2 
Cancer 
28  
(40.6) 
41  
(59.4) 
69 
14  
(26.4) 
39  
(73.6) 
53 
1  
(33.3) 
2  
(66.7) 
3 
CABG 
10  
(66.7) 
5  
(33.3) 
15 
5  
(62.5) 
3  
(37.5) 
8 
22  
(56.4) 
17  
(43.6) 
39 
Cardiac failure 
2  
(100.0) 
0  
(0) 
2 
0  
(0) 
0  
(0)  
0  
(0) 
0  
(0) 
0 
CDI 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0)  
0  
(0) 
0  
(0) 
0 
Cellulitis 
1  
(50.0) 
1  
(50.0) 
2 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Cerebral palsy 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
2  
(100.0) 
2 
2  
(100.0
) 
0  
(0) 
2 
Child C 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Cirrhosis 
1  
(50.0) 
1  
(50.0) 
2 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Cholecystectom
y 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
2  
(100.
0) 
2 
Chronic kidney 
injury 
10  
(76.9) 
3  
(23.1) 
13 
5  
(62.5) 
3  
(37.5) 
8 
0  
(0) 
3  
(100) 
3 
Cystic fibrosis 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Chronic 
lymphocytic 
leukaemia 
1  
(50.0) 
1  
(50.0) 
2 
1  
(50.0) 
1  
(50.0) 
2 
0  
(0) 
1  
(100.
0) 
1 
Coeliac 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1 
(100.
0) 
1 
Colostomy 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0)  
0  
(0) 
0  
(0) 
0 
Confusion 
2  
(100.0) 
0  
(0) 
2 
2  
(100.0) 
0  
(0) 
2 
0  
(0) 
0  
(0) 
0 
Constipation 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
COPD 
12  
(54.5) 
10  
(45.5) 
22 
4  
(28.6) 
10  
(71.4) 
14 
6  
(60.0) 
4  
(40.0) 
10 
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Crohn’s 
1  
(25.0) 
3  
(75.0) 
4 
1  
(33.3) 
2  
(66.7) 
3 
1  
(50.0) 
1  
(50.0) 
2 
Cystectomy 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Dementia 
15  
(83.3) 
3  
(16.7) 
18 
6  
(66.7) 
3  
(33.3) 
9 
0  
(0) 
3  
(100) 
3 
Diabetes 
33  
(52.4) 
30  
(47.6) 
63 
19  
(42.2) 
26  
(57.8) 
45 
9  
(32.1) 
19  
(67.9) 
28 
Diverticulitis 
1  
(14.3) 
6  
(85.7) 
7 
1  
(14.2) 
6  
(85.7) 
7 
2  
(33.3) 
4  
(66.7) 
6 
Deep vein 
thrombosis 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
2  
(100.0) 
2 
1  
(50.0) 
1  
(50.0) 
2 
Dyspepsia 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0)  
0  
(0) 
0  
(0) 
0 
Emphysema 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0
) 
0  
(0) 
1 
Enteritis 
1  
(50.0) 
1  
(50.0) 
2 
1  
(50.0) 
1  
(50.0) 
2 
1  
(100.0
) 
0  
(0) 
1 
Epilepsy 
5  
(41.7) 
7  
(58.3) 
12 
4  
(36.4) 
7  
(63.6) 
11 
5  
(71.4) 
2  
(28.6) 
7 
Fibromyalgia 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
1  
(100) 
0  
(0) 
1 
Gall stones 
1  
(33.3) 
2  
(66.7) 
3 
1  
(33.3) 
2  
(66.7) 
3 
1  
(50.0) 
1  
(50.0) 
2 
Gastritis 
0  
(0) 
4  
(100.0) 
4 
0 ( 
0) 
3  
(100) 
3 
1  
(33.3) 
2  
(66.7) 
3 
Gastro-
oesophageal 
reflux disease 
3  
(100.0) 
0  
(0) 
3 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Gout 
2  
(50.0) 
2  
(50.0) 
4 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
2  
(100.
0) 
2 
Heart disease 
14   
(63.6) 
8  
(36.4) 
22 
7  
(50.0) 
7  
(50.0) 
14 
1  
(14.3) 
6  
(85.7) 
7 
Heart failure 
3  
(37.5) 
5  
(62.5) 
8 
1  
(11.1) 
8  
(88.9) 
9 
0  
(0) 
5  
(100) 
5 
Heart 
Transplant 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100) 
1 
Heart valve 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
2  
(100.
0) 
2 
Hepatitis C 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
1  
(100.
0) 
1 
Hepatitis 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Heart failure 1  0  1 1  0  1 0  0  0 
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(100.0) (0) (100.0) (0) (0) (0) 
HIV 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0
) 
0  
(0) 
1 
Hodgkin’s 
lymphoma 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Home 
parenteral 
nutrition 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0)  
0  
(0) 
0  
(0) 
0 
Hypercholester
olemia 
2  
(66.7) 
1  
(33.3) 
3 
1  
(50.0) 
1  
(50.0) 
2 
1  
(100.0
) 
0  
(0) 
1 
Hypertension 
55  
(61.8) 
34  
(38.2) 
89 
22  
(42.3) 
30  
(57.7) 
52 
13  
(41.9) 
18  
(58.1) 
31 
Hyponatraemia 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100) 
1 
Hypothyroid 
10  
(66.7) 
5  
(33.3) 
15 
3  
(42.9) 
4  
(57.1) 
7 
1  
(25.0) 
3  
(75.0) 
4 
Inflammatory 
bowel disease 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0
) 
0  
(0) 
1 
Irritable bowel 
syndrome 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Incontinence 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Intravenous 
drug user 
1  
(50.0) 
1  
(50.0) 
2 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
0  
(0) 
0 
Knee 
replacements 
1  
(100.0) 
0  
(0) 
1 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Laryngectomy 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Leg amputation 
1  
(100.0) 
0  
(0) 
1 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0)  
Leg ulcers 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Leukaemia 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
1  
(100) 
0  
(0) 
1 
Liver disease 
0  
(0) 
6  
(100.0) 
6 
0  
(0) 
5  
(100) 
5 
4  
(80.0) 
1  
(20.0) 
5 
Liver Transplant 
0  
(0) 
2 
(100.0) 
2 
0  
(0) 
2  
(100.0) 
2 
2  
(100.0
) 
0  
(0) 
2 
Lobectomy 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Left ventricular 2  0  2 2  0  2 0  0  0 
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failure (100.0) (0) (100) (0) (0) (0) 
Lymphoma 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0
) 
0  
(0) 
1 
Memory loss 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0)  
0  
(0) 
0  
(0) 
0 
Myocardial 
infarction 
15  
(65.2) 
8  
(34.8) 
23 
8  
(50.0) 
8  
(50.0) 
16 
5  
(62.5) 
3  
(37.5) 
8 
Motor neurone 
1  
(100.0) 
0  
(0) 
1 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Multiple 
sclerosis 
1  
(100.0) 
0  
(0) 
1 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Myeloma 
0  
(0) 
3  
(100.0) 
3 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
2  
(100.
0) 
2 
None 
7  
(77.8) 
2  
(22.2) 
9 
3  
(60.0) 
2  
(40.0) 
5 
0  
(0) 
2  
(100.
0) 
2 
Nausea and 
vomiting 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0
) 
0  
(0) 
1 
Neurogenic 
bladder 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0
) 
0  
(0) 
1 
Neurofibromat
osis 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0)  
0  
(0) 
0  
(0) 
0 
Not known 
3  
(100.0) 
0  
(0) 
3 
2  
(100.0) 
0  
(0) 
2 
0  
(0) 
0  
(0) 
0 
Obesity 
3  
(75.0) 
1  
(25.0) 
4 
1  
(50.0) 
1  
(50.0) 
2 
0  
(0) 
1  
(100.
0) 
1 
Osteoarthritis 
15  
(53.6) 
13  
(46.4) 
28 
6  
(33.3) 
12  
(66.7) 
18 
5  
(41.7) 
7  
(58.3) 
12 
Osteomyelitis 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
2  
(100) 
2 
0  
(0) 
2  
(100. 
0) 
2 
Osteoporosis 
11  
(73.3) 
4  
(26.7) 
15 
4  
(50.0) 
4  
(50.0) 
8 
0  
(0) 
4  
(100) 
4 
Pacemaker 
1  
(33.3) 
2  
(66.7) 
3 
1  
(50.0) 
1  
(50.0) 
2 
0  
(0) 
2  
(100.
0) 
2 
Pancreatectom
y and 
splenectomy 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Pancreatitis 
1  
(100.0) 
7  
(87.5) 
8 
0  
(0) 
5  
(100) 
5 
3  
(60.0) 
2  
(40.0) 
5 
Pancytopenia 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Paralysis 
1  
(100.0) 
0  
(0) 
1 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
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Parkinson’s 
2  
(40.0) 
3  
(60.0) 
5 
1  
(25.0) 
3  
(75.0) 
4 
1  
(33.3) 
2  
(66.7) 
3 
Pneumocystis 
pneumonia 
1  
(100.0) 
0  
(0) 
1 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0)  
Pulmonary 
embolism 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0 
) 
1 
1  
(100.0
) 
0  
(0) 
1 
Pericardial 
effusion 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0
) 
0  
(0) 
1 
Pneumonia 
0  
(0) 
2  
(100.0) 
2 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0
) 
0  
(0) 
1 
Prostate 
1  
(100.0) 
0  
(0) 
1 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Pulmonary 
embolism 
1  
(100.0) 
0  
(0) 
1 
1 
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Pulmonary 
fibrosis 
2  
(100.0) 
0  
(0) 
2 
2  
(100.0) 
0  
(0) 
2 
0  
(0) 
0  
(0) 
0 
Peripheral 
ventricular 
disease 
3  
(50.0) 
3  
(50.0) 
6 
3  
(50.0) 
3  
(50.0) 
6 
2  
(66.7) 
1  
(33.3) 
3 
Renal disease 
1  
(16.7) 
5  
(83.3) 
6 
0  
(0) 
4  
(100) 
4 
2  
(50.0) 
2  
(50.0) 
4 
Renal failure 
2  
(20.0) 
8  
(80.0) 
10 
1  
(11.1) 
8  
(88.9) 
9 
4  
(50.0) 
4  
(50.0) 
8 
Renal 
Transplant 
0  
(0) 
5  
(100.0) 
5 
0  
(0) 
5  
(100) 
5 
4  
(100) 
0  
(0) 
4 
Rheumatoid 
9  
(52.9) 
8  
(47.1) 
17 
6  
(42.9) 
8  
(57.1) 
14 
4  
(50.0) 
4  
(50.0) 
8 
Scoliosis 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0)  
0  
(0) 
0  
(0) 
0 
Sepsis 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Sleep apnoea 
1  
(100.0) 
0  
(0) 
1 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0)  
Splenectomy 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
 
(100.0) 
1 
1  
(100.0
) 
0  
(0) 
1 
Spondylitis 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0)  
0  
(0) 
0  
(0) 
0 
Stent for CBD 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
0  
(0)  
0  
(0) 
0  
(0) 
0 
Stroke 
17  
(53.1) 
15  
(46.9) 
32 
6  
(35.3) 
11  
(64.7) 
17 
3  
(27.3) 
8   
(72.7) 
11 
Trauma 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0
) 
0  
(0) 
1 
Ulcerative 
colitis 
0  
(0) 
6  
(100.0) 
6 
0  
(0) 
6  
(100) 
6 
5  
(83.3) 
1  
(16.7) 
6 
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Urinary sepsis 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0
) 
0  
(0) 
1 
Urinary stent 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Ventricular 
fibrillation 
1  
(100.0) 
0  
(0) 
1 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
VP shunt 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0
) 
0  
(0) 
1 
Vancomycin 
resistant 
Enterobacteriac
ae 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Whipple’s 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.
0) 
1 
Total 377 402 779 181 366 547 160 206 366 
Table A3.2 Past medical history for control patients that were recruited to the 
study regardless of if they had samples in the study and if they had at least one 
sample included in the study. Those patents that had at least one GDH positive 
sample are divided into potential C. difficile excretors (PCDEs) and CDI cases 
based on the presence or absence of C. difficile toxins in the original routine 
sample. Each participant could have more than one reason for admission 
recorded. Summary table of the top ten conditions listed in past medical history 
for all participants are shown in tables 5.4 and 5.5  
  
304 
 
 
  
Had at least one sample in the study Had at least one sample in the 
study and initial diagnostic 
specimen was GDH positive 
Control  
n (%) 
GDH 
positive  
n (%) 
total  
n 
PCDE  
n (%) 
CDI  
n (%) 
tota
l n 
Amikacin 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
Amoxicillin 
4  
(25.0) 
12  
(75.0) 
16 
5  
(41.7) 
7  
(58.3) 
12 
Anidulafungin 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
Aztreonam 
3  
(21.4) 
11  
(78.6) 
14 
7  
(63.6) 
4  
(36.4) 
11 
Benzyl/Penicillin 
0  
(0) 
3  
(100.0) 
3 
2  
(66.7) 
1  
(33.3) 
3 
Caspofungin 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0) 
0  
(0) 
1 
Cefotaxime 
0  
(0) 
2  
(100.0) 
2 
1  
(50.0) 
1  
(50.0) 
2 
Cefuroxime 
0  
(0) 
6  
(100.0) 
6 
4  
(66.7) 
2  
(33.3) 
6 
Cephalexin 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
Ciprofloxacin 
1  
(10.0) 
9  
(90.0) 
10 
4  
(44.4) 
5  
(55.6) 
9 
Clarithromycin 
3  
(30.0) 
7  
(70.0) 
10 
2  
(28.6) 
5  
(71.4) 
7 
Clindamycin 
0  
(0) 
2  
(100.0) 
2 
1  
(50.0) 
1  
(50.0) 
2 
Co- amoxiclav 
12  
(30.8) 
27  
(69.2) 
39 
11  
(40.7) 
16  
59.3) 
27 
Co-Fluampicil 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0) 
0  
(0) 
1 
Cotrimazole 
1  
(100) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Co-trimoxazole 
1  
(8.3) 
11  
(91.7) 
12 
6  
(54.5) 
5  
(45.4) 
11 
Daptomycin 
0  
(0) 
1  
(100.0) 
1 
1  
(100.0) 
0  
(0) 
1 
Doxycycline 
0  
(0) 
4  
(100.0) 
4 
0  
(0) 
4  
(100.0) 
4 
Ertapenem 
1  
(50.0) 
1  
(50.0) 
2 
0  
(0) 
0  
(0) 
0 
Erythromycin 
0  
(0) 
2  
(100.0) 
2 
2  
(100.0) 
0  
(0) 
2 
Fidaxomicin 
0  
(0) 
28  
(100.0) 
28 
5  
(17.9) 
23  
(82.1) 
28 
Flucloxacillin 13  15  28 6  9  15 
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(46.4) (53.6) (40.0) (60.0) 
Fluconazole 
0  
(0) 
10  
(100.0) 
10 
9  
(90.0) 
1  
(10.0) 
10 
Fucidin 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Gentamicin 
5  
(100.0) 
0  
(0) 
5 
0  
(0) 
0  
(0) 
0 
Itraconazole 
0  
(0) 
5  
(100.0) 
5 
3  
(60.0) 
2  
(40.0) 
5 
Levofloxacin 
1  
(10.0) 
9  
(90.0) 
10 
5  
(55.6) 
4  
(44.4) 
9 
Linezolid 
3  
(60.0) 
2  
(40.0) 
5 
1  
(50.0) 
1  
(50.0) 
2 
Meropenem 
1  
(5.9) 
16  
(94.1) 
17 
9  
(56.3) 
7  
(43.7) 
16 
Metronidazole 
3  
(3.5) 
82  
(96.5) 
85 
26  
(31.7) 
56  
(38.3) 
82 
Nitrofurantoin 
4  
(33.3) 
8  
(66.7) 
12 
0  
(0) 
4  
(100.0) 
4 
Nystatin 
0  
(0) 
3  
(100.0) 
3 
2  
(66.7) 
1  
(33.3) 
3 
Pipercillin 
tazobactam 
5  
(9.8) 
46  
(90.2) 
51 
22  
(47.8) 
24  
(52.2) 
46 
Pivmecillinam 
1  
(12.5) 
7  
(87.5) 
8 
3  
(42.8) 
4  
(57.1) 
7 
Posaconazole 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1 ( 
100.0) 
1 
Tazocin 
5  
(21.7) 
18  
(78.3) 
23 
8  
(44.4) 
10  
(55.6) 
18 
Teicoplanin 
5  
(62.5) 
3  
(37.5) 
8 
2  
(66.7) 
1  
(33.3) 
3 
Temicillin 
0  
(0) 
1  
(100.0) 
1 
0  
(0) 
1  
(100.0) 
1 
Tigecycline 
1  
(100.0) 
0  
(0) 
1 
0  
(0) 
0  
(0) 
0 
Trimethoprim 
1  
(9.1) 
10  
(90.9) 
11 
6  
(60.0) 
4  
(40.0) 
10 
Vancomycin 
3  
(7.0) 
40  
(93.0) 
43 
10  
(25.0) 
30  
(75.0) 
40 
Number of  
participants  in 
each group 
81 147 228 65 82 147 
Table A3.3 Antibiotics taken by controls, GDH positive, PCDEs and CDI participants 
in the three months prior to the study, for all recruited patients that had at least 
one sample taken in the study. Summary tables of antibiotic history for all 
participants are shown in tables 5.7 and 5.8  
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Background: 
 
Clostridium difficile is still the major cause of nosocomial diarrhoea in the developed world and 
rapid and accurate diagnosis is paramount for patient care and infection prevention1. 
Furthermore, infection reduction targets have been imposed on healthcare facilities in England. 
Patients with C. difficile Infection (CDI) often have protracted periods of hospital stay, usually in 
isolation facilities with specialist nursing care, resulting in a huge financial burden on the NHS. 
One UK study attributed costs of approximately £6986 per case of CDI (2010 prices)2. There has 
been an increase in the measured incidence of CDI in countries with active surveillance 
programmes, and a marked shift in epidemiology over the last decade3. Outbreaks caused by a 
strain of C. difficile known as PCR-ribotype 027 have been reported worldwide since 2002-03. 
This fluoroquinolone resistant strain has been associated with increased morbidity and 
mortality4. Recurrent infection is a known sequela of CDI; a recent study showed that the risk of 
re-infection, as distinct from relapse, increased by >58% every time the interval between 
positive samples doubled; mixed infections (>1 genotype) were found in 7% of CDI cases5. 
Although the ‘classical’ picture of C. difficile transmission has been that it is spread from other 
patients and or the environment within hospitals, recent data have shown that only 20-25% of 
inpatient cases can be linked to another in-patient case, leaving the ‘source’ of infection 
unknown in the majority of cases6-7. It is known however that the rate of asymptomatic carriage 
in hospitalised patients (21%) is higher than in the community (1.6%)20.  
 
The anaerobic, spore-forming bacterium Clostridium difficile is a well-recognised nosocomial 
pathogen, which produces two toxins; an enterotoxin, A, and a cytotoxin, B. Clostridium difficile 
is the aetiological agent of pseudomembranous colitis and is implicated in most cases of 
antibiotic associated diarrhoea1. Symptoms can range from mild to severe diarrhoea and may 
even be fatal; either from CDI alone, or due to exacerbation of co-morbidities1. Elderly 
hospitalised patients and patients previously treated with antibiotics (especially 3rd generation 
cephalosporins, and protracted courses) are at an increased risk for CDI. The investigation of CDI 
in the elderly, including risk factors, such as waning immunity, comorbidities, frequent 
hospitalisations and exposure to antibiotics, is a growing field. Indeed, a recent review of CDI in 
the elderly noted that the number of published articles per year on the subject doubled 
between 2006 and 20088. In the USA in 2006 patients >65 years old were disproportionately 
affected by CDI compared with other age groups, and in 2008 93% of CDI deaths were aged >65 
years old9-10. Advanced age has also been linked to the risk of recurrent C. difficile disease. A 
recent study looking at the effect of age on treatment outcomes in CDI developed a 
mathematical model that predicted lower clinical cure (17%), greater recurrence (17%) and 
lower sustained clinical response (13%) for each increased decade of life11. Accurate, rapid 
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diagnosis of CDI is therefore imperative to ensure early recognition and treatment of this 
disease.  
 
Sub-optimal laboratory diagnostics have impacted on both patient care and epidemiological 
data, meaning that the true burden of CDI remains unclear12-15. Laboratory diagnosis has largely 
relied on the detection of C. difficile toxins within a faecal sample by direct cytotoxin assay or 
immunoassays (EIA). A large study in 2009 highlighted the poor performance of these 
immunoassays, and Department of Health (DH) guidance published subsequently suggested that 
no toxin immunoassay should be used in isolation for the diagnosis of CDI15-16. Alternative 
methods of detection have now been introduced, including detection of C. difficile specific 
Glutamate dehydrogenase (GDH) a cell surface enzyme and Polymerase Chain Reaction (PCR) 
assay for the detection of the ToxB gene, or the TcdC deletion suggestive of PCR-ribotype 027 
(table 1, appendix 1). Guidance from the DH has now been updated following a large 
multicentre study, recommending GDH EIA/toxin EIA or cytotoxin as the optimal method for 
diagnosis of CDI15, 17. Using this algorithm patients can be divided into those with CDI, those 
likely with C. difficile and those without CDI/C. difficile15, 17. Patients identified as potential C. 
difficile excretors (GDH positive/toxin negative) may pose a possible infection control risk, 
requiring source isolation. Crucially, whilst the variability in performance of diagnostics assays is 
now well documented15, 17, there are few data on the effect of sample, patient and organism 
factors on the performance of these assays. Recent studies have shown that the presence of 
toxin in the faecal sample is closely correlated with mortality and severity of infection, whilst the 
presence of a toxigenic strain of C. difficile or its DNA in the sample is not18-19. Initial data from a 
Human Gut model shows that C. difficile GDH remains detectable in the system for longer than 
toxin after treatment of CDI (data unpublished), highlighting the fact that each of the targets 
may reflect a different point in the disease. 
 
There is a significant knowledge gap regarding the clinical course of CDI as determined by the 
different diagnostic markers of C. difficile; organism, toxin or DNA. The aim of this study is to 
elucidate the clinical course of C. difficile infection detected by these different diagnostic assays 
and match this with severity markers. In order to determine this we will need to follow known 
CDI positive patients to examine what happens to these tests during disease; similarly, in order 
to understand the natural history of how these tests perform, we will need to follow all patients 
from selected wards from admission. Elderly medical wards have been selected for this purpose 
as these patients are the group most at risk from CDI and its sequelae.  
The serial samples collected on symptomatic and asymptomatic patients as part of this study 
will also prove invaluable for investigating asymptomatic carriage and potential C. difficile 
excretors and the relatedness of isolates from these different patient groups. The role of 
diagnostic assays in detecting these two potential disease states, along with their use as 
admission surveillance tools is as yet unclear.  
 
Hypothesis:  
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Current commercial CDI diagnostic tests detect different targets: the bacterium, DNA or toxin. 
We hypothesise that each test and target are optimal at different points in the course of CDI 
infection.  
 
Objectives: 
 
Primary objective: 
To determine the time course of C. difficile test results during C. difficile infection in relation to 
severity markers.  
 
Secondary objectives: 
To determine the accuracy of laboratory diagnostic assays in detecting asymptomatic 
colonisation/carriage on admission to hospital, different testing methodologies will be 
compared.  
 
To compare the PCR-ribotype of isolates from patients with CDI, asymptomatic carriage of C. 
difficile, recurrent CDI and new infections with CDI. 
 
To determine the utility of rectal swabs compared with faecal samples for detecting 
asymptomatic colonisation/carriage at time of admission.  
 
To examine the utility of determining CD colonisation status on admission as a predictor of CDI 
risk in this patient cohort.  
 
 
Methodology for objectives: 
Primary objective: 
The clinical course of infection will be examined for each patient (diarrhoea status, temperature, 
white cell count, serum albumin, serum creatinine, antibiotic therapy) and analysed with results 
of each of the C. difficile test results to demonstrate if different assays are more likely to be 
positive at different time points during episodes of C. difficile infection (CDI).  
 
Secondary objectives: 
Asymptomatic carriage will be defined as a positive test for C. difficile in a patient without 
symptoms of diarrhoea. 
Molecular typing analysis will be used to elucidate any relationship between the isolates of C. 
difficile from patients and whether they had asymptomatic carriage, recurrent CDI or a new 
infection with CDI. 
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In addition to collecting a faecal sample on admission from a patient, the patient will be asked if 
they can be sampled using a rectal swab (for the first sample only). The results from the rectal 
swab by different testing methodologies would be compared to those from the faecal sample. 
There are a paucity of data on the use of rectal swabs for detection of C. difficile, as most assays 
are not CE marked for this sample type.  
.If patients with asymptomatic carriage on admission are treated with antibiotics do they go on 
to develop CDI? Our null hypothesis is that the rate of CDI is equal between patients screened 
positive and negative for CDI on admission. If we have a 4:1 ratio of negatives:carriers then we 
would need 101 positives and 404 negatives to detect a difference between 2% CDI (negatives) 
and 10% CDI (positives) with 90% power and a 5% threshold of significance.  
Study design: 
Proposed study duration: 01/08/2013 -31/07/2014 
Proposed duration of patient recruitment: 6 months (01/10/2013-31/03/2014) 
 
Following patients from admission:  
To take place on two elderly medicine wards (ward 17/7 at SJUH) at LTHT.  
Potential eligible patients will be identified by the clinical care staff to the research nurse. 
Patients will be enrolled in the study on admission, once informed consent is obtained. Baseline 
data (age, gender, previous exposure of antibiotics, co-morbidities) will be collected using a data 
capture form. A stool chart will be kept for the patient daily. A faecal sample and/or an optional 
rectal swab will be collected on enrolment. Further faecal samples will be collected as often as 
produced (max 1 per day) and sent to the R&D laboratory for testing. Samples can be self-
collected or by the medical staff, as a large proportion of these patients will be using a bed pan 
or commode. The research nurse will visit the ward every day to ensure that there are adequate 
supplies of samples containers and to remind staff to save samples where possible.  
 
Samples received in the R&D lab will be stored at 5°C and tested within 5 days using GDH EIA, 
GDH PCR, Toxin EIA, Toxin PCR, cell-cytotoxicity assay and cytotoxigenic culture. Isolates will be 
stored (spore preparation in 10% glycerol broth) at -80°C before typing using PCR-ribotyping. If 
the patient has had routine blood samples taken these will be collected, once requested 
laboratory diagnostics have been completed, and stored at -20°C before testing for antibodies 
to C. difficile and C. difficile toxin. No additional blood samples will be taken. Once patients have 
been discharged their medical records will be reviewed and further clinical data collected using 
a second data capture form. Patients from each ward will be recruited during a 6 month period, 
and followed until discharged or until 30 days after the end of the recruitment period. 
 
Following known positive patients:  
To take place at LTHT.  
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Potential eligible patient will be identified by the laboratory staff to the research nurse. In-
patients (>16 years old) that have had a routine faecal sample with a positive GDH EIA result will 
be enrolled on the study, once informed consent is obtained. Baseline data (age, gender, 
previous exposure of antibiotics, co-morbidities) will be collected using a data capture form. A 
stool chart will be kept for the patient daily. Faecal samples and/or an optional rectal swab will 
be collected on enrolment. Further faecal samples will be collected as often as produced (max 1 
per day) and sent to the R&D laboratory for testing. Samples can be self-collected or by the 
medical staff, especially if the patient is using a bed pan or commode. The research nurse will 
visit the ward every day to ensure that there are adequate supplies of samples containers and to 
remind staff to save samples where possible.  
 
Samples received in the R&D lab will be stored at 5°C and tested within 5 days using GDH EIA, 
GDH PCR, Toxin EIA, Toxin PCR, cell-cytotoxicity assay and cytotoxigenic culture. Isolates will be 
stored (spore preparation in 10% glycerol broth) at -80°C before typing using PCR-ribotyping. If 
the patient has had routine blood samples taken these will be collected, once requested 
laboratory diagnostics have been completed, and stored at -20°C before testing for antibodies 
to C. difficile and C. difficile toxin. No additional blood samples will be taken. Once patients have 
been discharged their medical records will be reviewed and further clinical data collected using 
a second data capture form. Patients from LTHT will be recruited during a 6 month period, and 
followed until discharged or until 30 days after the end of the recruitment period. 
 
Inclusion criteria for patient enrolment: 
 
Following from admission: 
Any patient admitted to ward 17 (female elderly care) or 7 (male elderly care) at SJUH during 
the study period  
 
Following known positive patients: 
Any in-patient(>16 years old) with a positive GDH result on a routine faecal sample not already 
enrolled on the study, during the study period 
Exclusion criteria for patient enrolment: 
Patients aged <16 years.  
Unable/unwilling to give informed consent and unable to gain consultee approval.  
 
Patient recruitment and consent 
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All patients will be assessed by the research nurse, who has training in mental capacity, in 
combination with the clinical care team to ensure they have mental capacity to give informed 
consent. In line with the Mental Capacity Act all patients will be assumed to have capacity unless 
judged by the research nurse and clinical care team to lack capacity to understand and consent 
to the study. As capacity is decision specific the patient involvement in the study has been made 
as simple as possible to maximise the chance that the patient will have capacity to consent. 
Where patients are judged to be unable to give informed consent the next of kin will be 
approached to give consultee approval. Where possible, if consent can be taken we will still ask 
for a consultee to be present to support the participant through the process. There are 
insufficient funds to provide an interpreter for non-English speaking patients in this study. An 
interpreter would need to be present every day for the research nurse visit to ask about bowel 
habits since the last visit. Exclusion of non-English speakers due to cost is in line with the 
exclusion guidelines on the NRES website, especially in the context of student led research.  
 
This study does not involve any invasive interventions or risk to the patient, simply the collection 
of faecal samples. In many cases these frail patients will be bed-bound and use bed pans or 
commodes, which makes collection of a sample by the clinical care team simpler and with little 
burden upon the patient. Where patients have mental capacity and are mobile, they will be 
supplied with commode bowls to fit over the toilet bowl to aid collection of their sample. They 
will be able to do this themselves in privacy in the toilet. Sample pots will also be available in the 
toilets for the participant to use. Previous donors have found using larger samples pots and 
tongue depressors makes saving samples easier than when using standard sample pots, so these 
will be supplied. Again, the burden on the patient and the invasion of their privacy would be 
minimal.  
 
Potential participants will be visited by the study research nurse and presented with a patient 
information leaflet either upon admission to one of the study wards or after the identification of 
C. difficile GDH from their routine faecal sample by the study research nurse. The research nurse 
will explain the study and 24 hours after the initial contact informed consent will be sought by 
the research nurse, who has training in mental capacity. The nurse will consent, recruit, perform 
initial data gather, re-data gather after discharge, and collect samples (daily or when 
produced).Full ethical approval will be sought, and adoption by the NIHR portfolio. 
 
A copy of the consent form/consultee approval and the patient information sheet will be filed in 
the patient’s notes and the original copy held by the research team. The patient/consultee will 
also have a copy of the patient information sheet and consent form/consultee approval to keep 
which includes contact details for the research team.  
 
Loss to follow up/patient withdrawal 
If a patient wishes to withdraw from the study then they are free to do so. This may be because 
they have changed their mind or because they have gained the mental capacity to make 
informed decisions and wish to overturn the consultee consent. The research nurse will ask 
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them to complete a withdrawal form, a copy of which will be added to the patient’s notes, a 
copy given to the participant and the original held by the research team. The original consent 
process will make it clear that any samples already collected before withdrawal will still be 
included in the study, along with any clinical data already collected.  
Sample storage: 
Anonymised faecal samples will initially be stored at 5°C for up to 5 days before testing with the 
commercial assays is completed. For longer term storage samples will be stored at -20°C to 
enable further investigation. Isolates will also be stored at -20°C in 10% glyercol broths before 
typing using PCR-ribotyping. Blood samples will also be stored anonymously at -20°C.  
Clinical data: 
Clinical data will be collected on enrolment and at the end of the study period on patient 
demographics (age, gender, ethnicity), patient length of stay, patient movement (between 
wards/clinics), antibiotic treatment, co-morbidities, white cell count, albumin, creatinine, 
presence/absence of diarrhoea, evidence of colitis and clinical team diagnosis. All data will be 
recorded on specific study clinical report forms (CRFs) for both initial data capture and follow 
up, which will then be input onto an electronic secure password protected database. 
Data storage 
Patients will be assigned a unique study number; which along with the patient’s hospital 
number will be used to identify that patient in the study, to allow searching of electronic clinical 
records. The informed consent/consultee approval form will be held separately. All data will be 
held on security protected encrypted servers at Leeds Teaching Hospitals NHS Trust. All CRFs will 
be held in a secure lockable cabinet in the research office of the Microbiology Department in the 
Old Medical School. Only those involved with the project will have access to both the written 
and electronic data collected for the study. Patient confidentially will be preserved throughout. 
Data will be stored for 10 years in accordance with local policy.  
Reporting: 
This is an observational study. Results will not be reported back to clinicians. Patients will 
continue only to be treated for CDI when symptomatic. Furthermore, results obtained on those 
samples obtained for the study will not be available in a timescale that is conducive to patient 
intervention. Patients will continue to get routine samples sent if CDI is suspected in-line with 
LTHT policy.  
Statistical considerations: 
 
Following patients from admission: 
Based on testing everyone as soon as they are admitted to the selected wards and testing daily 
until they leave: 
 
Admissions for study wards last year: 
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Ward17 (SJH), 16 beds in bays plus 6 side rooms, female elderly medicine; bed turnover ~530 
patients/year 
Ward 7 (SJH), 16 beds in bays, 0 side rooms, male elderly medicine: bed turnover ~550 
patients/year 
 
In LTHT current cytotoxin +ve rate = 4-6% 
Current GDH +ve rate = 13.6% 
 
520 patients/6 months (wards 17 and 7)) 
520 x 4.6% = 20.8 toxin positive patients in 6 months 
520 x 13.6% = 70.72 GDH positive patients in 6 months 
 
If each patient roughly stays for one week then there will be 3640 samples to test in total 
Expected enrollment of 50% = 1820 samples 
 
It is noted that there will be a lot of ‘negative’ test results in this cohort but it is important to 
be able to follow the course of infection from the very early stages and this will only be 
possible by following people from admission. It will also allow the detection of asymptomatic 
carriers and potential C. difficile excretors.  
 
Following known positive patients: 
Based on testing all GDH positive patients for follow up (each patient stays for roughly one 
week). The figures are based upon the trust as a whole initially, as there may be issues with 
getting enough people to consent. If numbers appear unwieldy the study will centre of specific 
locations, e.g. elderly medicine.  
 
No of GDH/toxin positive patients last year 185 (2011-2012),  
In 6 months there were 300 GDH positive samples 
300 GDH positive patients’ daily samples = 2100 samples to test in total  
Expected enrollment of 50% = 1050 samples 
 
Statistical analysis 
Statistical analyses will be carried out on STATA 12; using descriptive statistics to monitor the 
experience of patients as they are admitted to the target wards, such as Gantt Charts, 
percentages and histograms (for carriage, CDI incidence and for ribotype distributions). 
Diagnostic assays will be assessed by sensitivity, specificity, negative and positive predictive 
value and Area Under Receiver Operator Curve (AUROCs). Hypotheses tests will be done via 
standard methods such as Fisher's exact tests (for comparing percentages); for AUROCs we will 
use the Boostrap method for 95% confidence intervals and for testing the significance of 
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differences between tests as described elsewhere19. Multivariate unconditional logistic 
regression analysis will be used to address some of the secondary objectives, so as to control for 
confounders 
 
Project management 
This project will be managed by the Chief Investigator (Kerrie Davies), who has previously 
managed the Department of Health study ‘The optimum algorithm for laboratory diagnosis of C. 
difficile’, and is the European coordinator for the EUropean, multi-centre, prospective bi-annual 
point prevalence study of CLostridium difficile Infection in hospitalised patients with Diarrhoea 
(EUCLID). The research study team will consist of the Chief Investigator, a research nurse (Claire 
Brown), and a data entry clerk (Frank Lee). Additional supervision will be provided by Prof. Mark 
Wilcox.  
 
This study will comply with the principals of Good Clinical Practice, the Mental Capacity Act, the 
Data Protection Act and NHS research Governance.  
Publication 
Analyses will be submitted for publication as poster or oral presentations at international 
microbiology conferences and in a peer reviewed journal. All patient data will be fully 
anonymised. A summary sheet will be available for study participants if requested. This study 
will also be included in a PhD thesis (Kerrie Davies).  
Finances: 
This study is fully funded by Public Health England. 
Staff: 
 
Clinical Scientist (80% full time) 12 months £38,473.60 
 
Research Nurse (100% full time) 6 months £22,976.52 
 
Total: £61,450.12 
 
Non staff: 
 
Consumables (Kits including collection/sample pots) 
 
GDH EIA 
Toxin EIA 
Cytotoxin & Cytotoxigenic Culture 
GDH PCR (in-house) 
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Toxin PCR (commercial) 
 
£18.50 per sample  
3195 estimated samples 
 
Sub total: £59,672.00 
 
PCR-Ribotyping 
 
£6.36 per sample 
1400 estimated samples (positives only) 
 
Sub total: £8,904 
 
Total: £68,576.00 
 
 
TOTAL FUNDING:  £130,026.12 
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Appendix 1 
 
Table 1. Current C. difficile assays and their differences 
Assay Target Pros Cons 
C. difficile culture C. difficile in the 
faeces 
Good sensitivity Cannot distinguish 
between toxigenic 
and non-toxigenic 
strains 
Cell-cytotoxicity C. difficile toxin in the 
faeces 
Good sensitivity and 
specificity 
Detects toxin direct 
from the sample 
Negative result can 
take up to 48 hours 
Cytotoxigenic culture C. difficile in the Good sensitivity Cannot detect toxin in 
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faeces capable of 
producing toxin 
the sample, only that 
the C. difficile in the 
sample has the 
potential to produce 
toxin 
C. difficile GDH EIA C. difficile in the 
faeces 
Good sensitivity Cannot distinguish 
between toxigenic 
and non-toxigenic 
strains 
C. difficile toxins EIA C. difficile toxin in the 
faeces 
Good specificity 
Detects toxin directly 
from the sample 
Poor sensitivity 
C. difficile toxin genes 
PCR 
C. difficile DNA in the 
faeces 
Good sensitivity Cannot detect toxin 
or organism in the 
sample, only the toxin 
gene DNA; lacks 
specificity 
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Appendix 7. Ethical approval for gut model studies up to April 2016 
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Appendix 8. Ethical approval for gut model studies after April 2016 
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1. Sample processing 
 
1.1 Performing assays for evaluation 
Every sample submitted to the routine hospital laboratory for investigation for C. difficile 
is to be included in this study.  Each sample is allocated a study number; supplied in the 
study pack. The numbers run consecutively and start with the code for the study site at 
which the testing is taking place.  
 
Each sample will be tested by each assay: 
 
Cytotoxin assay     Reference assays 
Cytotoxigenic culture 
 
Premier Toxin A+B EIA assay   Commercial assays 
TechLab Toxin A/B II EIA assay 
TechLab C. diff Chek 60 EIA assay 
Cepheid C. difficile GeneXpert PCR assay 
 
 
The routine assay of the testing hospital site will be performed first. The samples will 
then be collected from the routine lab and the other assays performed. If there is 
insufficient sample to complete all of the assays they will be performed in the following 
order until the sample runs out: 
 
Cytotoxin assay 
Cytotoxigenic culture assay 
GDH EIA  
Toxin EIA 
  
1.2 Storage of specimens 
 
The routine laboratory will routinely store any sample positive by the standard method 
used at that hospital site. For the study, each site will also need to save any samples that 
are positive by either of the two reference methods or by the two toxin detection EIA’s. 
Samples should be stored at 4°C for one week after testing, then at -20°C. Negatives need 
not be stored beyond one week post testing, or longer if dictated by routine laboratory 
practice.  
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1.3 Safety considerations 
 
All work should be carried out in containment level two (or higher) facilities.  Any 
process that may give rise to infectious aerosols must be performed in a microbiological 
safety cabinet.  
 
Safety goggles are required when using UV fluorescent lamps.  
 
COSHH and risk assessments should be performed locally.  
 
 
2. Cytotoxin testing 
 
2.1 Materials 
Tissue culture flasks 
Tissue culture trays 
Automatic pipettes 
Microcentrifuge tubes 
Universals 
Bijoux bottles 
Syringes and filters (if needed) 
Inverted microscope 
Microcentrifuge 
CO2 Incubator 
 
2.2 Reagents 
 Trypsin + EDTA.  20 ml bottle is distributed into 0.5ml amounts in sterile plastic 
bijou, then stored at -20°C. 
 
 Hanks Balanced Salt Solution (HBSS). 100 ml bottle stored at room temperature. 
 
 Calf serum. 100 ml bottle arrives frozen. Thaw and distribute into 25 ml amounts 
in sterile universals. Label the universals including the date made & freeze at -
20°C. Thaw for use when required. 
 
 G.A.G. Contains: 
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– L-Glutamine. Arrives in 20 ml amounts (100x strength). Stored at -20°C. 
Thaw out & pipette 5 ml into each of 4 sterile universals. 
 
– Antimycotic/antibiotic mix. Arrives in 20 ml amounts (100x strength). 
Stored at -20° C. Thaw out and pipette 5 ml into each of the universals 
containing L-glutamine. 
 
– Gentamicin. Arrives as 10 ml bottle at a concentration of 50 mg/ml. Place 
2 mls into a sterile universal and make up to 25 mls with sterile distilled 
water. This gives a final concentration of 4 mg/ml. Pipette 5 ml of this 
solution into each of the universals containing L-
glutamine/antimycotic/antibiotic.  
 
– Label the universals including the date made and store at -20oC. Thaw for 
use when required. 
 
 Phosphate buffered saline (PBS).  Store at 4oC. 
 
 Dulbecco Medium (DMEM). Arrives as 500 ml bottles. Store in the fridge. 
IT IS ONLY USED WITH THE ADDITIVES. 
– Add one thawed universal containing calf serum and one thawed universal 
containing GAG to each 500 ml bottle of Dulbecco prior to use. Date and 
label the bottle to which additives have been added. 
 
Ensure Lot numbers and expiry dates of new reagents are recorded on the reagent log in 
the laboratory data folder (Appendix 11.2). 
 
2.3 Method 
 
2.3.1 Tissue culture 
 
Receiving cell lines 
 
Follow instructions received with cell lines from ECACC on how to process received 
growing cells lines 
 
Cell harvesting 
 
1. Examine flasks using the inverted microscope to confirm satisfactory growth of 
cells. Flasks are usually used after 4 days growth (i.e. make Monday, use Friday).  
 
2. Remove one bijou (per flask) containing 0.5 ml trypsin + EDTA from the -20°C 
freezer, allow to thaw, and then aseptically add 4.5 ml Hanks BS solution. 
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3. Open the flask and pour off the culture medium aseptically into a waste container. 
 
4.  Aseptically add half of the Trypsin/Hanks solution from a bijou to the flask. 
 
5. Recap flask and wash the solution over the cell sheet. Decant aseptically into a 
yellow waste sharps container. 
 
6.  Aseptically add the remaining half of the Trypsin/Hanks solution to the flask. 
 
7. Recap the flask and lay it flat on the bench so that the cell sheet is covered with 
the solution. Leave for one minute. 
 
8. Decant aseptically into a waste container. 
 
9. Lay the flask flat in a 37°C CO2 incubator for approximately 5 minutes, after 
which time the cells will have detached from the bottom of the flask.  
 
Note. Before the cell sheet has detached from the bottom of the flask it will appear 
opaque/hazy. A gentle tap on the flask may be sufficient to detach the cells. 
 
10. Aseptically add 10 ml of Dulbecco Medium to the flask and use a 1 ml automatic 
pipette to gently mix the cell suspension until smooth.  
 
 
Preparing flasks and trays 
 
1. Add 750 µl of cell suspension to each of 3 flasks and make up to 10 ml with 
Dulbecco medium. Record date and passage number (goes up by 1 each time) on 
the side of the flask and incubate flat side down at 37
o
C in a plastic box in the 
CO2  incubator. 
 
2. Label bottom of each tray with the day, order of use, passage number and date 
made. (E.g. Monday 1, 2, 3 – pass 211 – 3.6).  Label lid with day and order of 
use. 
 
3. Each tray requires 17 ml of diluted cell suspension (1 ml of cells diluted in 17 ml 
Dulbecco). 
 
Therefore for a set of 
3 trays - dilute 3 ml of cells with 2 universals (approx. 50 ml) of Dulbecco in a sterile 
Petri dish. 
4 trays – dilute 4 ml of cells with 3 universals (approx 65 ml) of Dulbecco in a sterile 
Petri dish. 
 
4. Using a 8 channel multi pipette and sterile tips, mix the diluted cells well. Add 
160 µl of suspension to each well of the tray. Repeat for each tray.  
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5. Use a clean universal and Petri dish for each set of trays. 
 
6. Incubate the trays at 37oC in a plastic box in a CO2 incubator. 
 
 
 
Antitoxin  
Clostridium sordelli antitoxin is purchased commercially. The 5 ml stock bottle is stored 
at 4
o
C. The antitoxin is diluted before use; 0.1 ml antitoxin in 4.9 ml sterile distilled 
water in a sterile plastic bijou. The lot number, expiry date and date made up is written on 
each bottle of diluted antitoxin. 
 
Positive control 
Pool the supernatant from several recent known positive samples. Filter as described in 
sample processing 2.3.2. Test the filtrate alongside the current control and dilute to give 
+/- result in well 3 or 4 (filtrate may need diluting with PBS). Label bijou with lot letter 
(A-Z) and date made. 
 
 
2.3.2 Sample processing 
 
Label microcentrifuge tubes with sample number. 
 
Add 1 ml of PBS to each tube. 
 
Add sufficient faeces to make a 1 in 5 dilution and mix thoroughly. 
 
Centrifuge at maximum rpm (10,000 rpm or greater) for 10 minutes in a microcentrifuge. 
 
If the supernatant is turbid transfer it to a 1 ml syringe. Fix a syringe filter onto the 
syringe and apply gentle pressure to pass the supernatant through the filter into a new 
(labelled) microcentrifuge tube. 
 
If microcentrifuge preparations are not to be tested immediately store in the fridge at 4
o
C. 
 
Select a tray and using the inverted microscope check that there is a reasonable 
monolayer of cells with a low proportion of dead (rounded) cells and no microbial 
contamination. 
 
Add 20 µl of C. sordelli antitoxin to each well of rows B, D, F & H. 
 
Take a blank template (Appendix 11.6) and fill in the tray ID and date, the positive 
control batch number used, the antitoxin batch number used and the rows in which the 
334 
 
KE v1.3 Page 334 6th December 2010 
antitoxin has been added.  Then label the worksheet with the study numbers of the test 
samples to be added to the tray. Store template in laboratory data folder, use later to 
record result. 
 
Add 20 µl of the positive control to well A1, mix and transfer 20 µl to well A2, mix again 
and transfer 20 µl to well A3, mix again and transfer 20 ul to well A4. Repeat this 
process with the positive control in wells B1 to B4. 
 
For the test samples start with well A5 – adding 20 µl of supernatant, mix well and 
transfer 20 µl to well A6. Repeat the process in wells B5 to B6. Continue with the test 
supernatants using two pairs of wells for each test, following template. 
 
Incubate the tray at 37
o
C in a plastic box in the CO2 incubator. 
 
Store microcentrifuge tube at 4
 o
C until after result is recorded, in case the supernatant 
needs to be filtered and retested.  
 
2.3.3 Results  
 
Read using an inverted microscope at both 24 and 48 hours.  
 
Cells can be read after 72 hours (when set up over a weekend). Negatives should be 
recorded as negative. Positives can be recorded as positive as long as the cells in the 
protected wells look healthy. A negative control should be set up on the plate along with 
the positive control to ensure healthy cells after 72 hours. If cells are poor, positives 
should be repeated.  
 
Toxin detected (positive) – indicated by the rounding up of 50% of the cells in the upper 
row of the set of wells for that sample, this effect has to be neutralised by the antitoxin. 
(If only first well positive, record as weak positive) 
 
Toxin not detected – no rounding up of the cells in the upper row of the set. 
 
If bacterial contamination is noted in the wells then the supernatant is passed through a 
syringe filter and the test set up again as above. 
 
If the cells in the wells all show signs of rounding up (i.e. both rows in the set) the 
supernatant is passed through a syringe filter and the test set up again diluting it over 4 
wells. 
 
Where the rounding up occurs after filtering and diluting the test is reported as 
inconclusive. 
 
- - 
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- -  Negative 
 
+ + 
-  -  Positive 
 
+ - 
- -  Weak Positive  
 
+ + 
+  -  Positive (plus non-specific cpe in first wells) 
 
+ - 
+ -  Toxic, filter and retest 
 
+ + 
+  +  Toxic, filter and retest 
 
 
3. C. difficile culture 
 
3.1 Materials 
 
Industrial alcohol (Absolute ethanol 95%) 
Sterile distilled water 
Plastic universal 
Cotton tip swab 
Plastic inoculation loop 
Braziers agar plate (Oxoid) 
 
3.2 Method 
 
3.2.1 Alcohol shock 
Label one universal for each sample 
 
Dispense 500 μl industrial ethanol into a sterile plastic universal container. Add 500 μl 
sterile distilled water. Mix well. 
 
Remove a pea-sized amount of faecal sample with a swab and immerse in ethanol/water 
in the universal container.  
 
Vortex each universal and leave at room temperature for a minimum of 1 hr. 
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3.2.2 Culture 
After 1 hr, take a swab and immerse in the alcohol shock sample. Use this swab to 
inoculate a Braziers agar plate and streak out for single colonies.  
 
Incubate plates at 37
o
C in an anaerobic cabinet for 48 hours. 
 
3.2.3 Identification 
Examine plates for growth after 48 hours. 
 
Suspect isolates (with classic C. difficile appearance of grey-brown, irregular edge, horse 
manure odour) should be checked for green/yellow fluorescence under longwave (365 
nm) UV light and latex agglutination for somatic antigen. ID organism based on the 
following table.  
 
 
 C. difficile C. bifermentans 
C. sordellii 
C. glycolicum 
C. innocuum 
Fluorescence under 
UV at 365 nm 
+ - + 
Latex agglutination + + - 
 
Record the ID on the laboratory data worksheet. All isolates identified as C. difficile must 
be saved (see section 5. saving isolates). ID only needs to be to C. difficile or non- 
C.difficile level.  
 
4. Cytotoxigenic culture 
 
 
4.1 Materials 
 
Brain Heart Infusion broth 
Cotton tip swab 
Microcentrifuge tube 
Automatic pipette 
Syringe and syringe filter (if needed) 
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4.2 Method 
 
Cytotoxigenic culture is to be carried out when C. difficile is isolated by culture from a 
sample.  
 
4.2.1 Broth culture 
 
Pre-reduce BHI broths (one per C. difficile culture positive sample to be tested) by 
incubating in an anaerobic cabinet for at least 48 hours before use. 
 
Inoculate one BHI broth per sample from the Brazier’s agar plate using a cotton tip swab.  
 
Incubate broths for 48 hours in an anaerobic cabinet at 37
o
C.  
 
 
4.2.2 Cytotoxin testing 
 
Label one microcentrifuge tube per sample 
 
Remove 1 ml supernatant from the BHI broth and place into a sterile microcentrifuge 
tube.  
 
Test for cytotoxin following method given in section 2 of this manual (cytotoxin testing). 
 
 
5. Saving isolates 
 
5.1 Materials 
Columbia blood agar plate 
Inoculation loop 
Cotton tip swab 
Cryogenic microtube 
Cryogenic freezer box 
 
5.2 Method 
 
Label a Columbia blood agar plate for each C. difficile culture positive sample (toxigenic 
and non-toxigenic strains) with specimen study number and date.  
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Using a sterile loop, transfer a colony from the Braziers agar plate onto the Columbia 
blood agar plate and streak out for single colonies.  
 
Incubate plates at 37
o
C in an anaerobic cabinet for 7 days to encourage growth of spores.  
 
Label a cryogenic microtube for each plate and add 1 ml nutrient broth with 10% 
glycerol. 
 
Harvest all growth (if pure) from the Columbia blood agar plate using a cotton tip swab 
and inoculate the broth.  
 
Store in nalgene cryobox in -70
o
C freezer. Record freezer box number and position of the 
isolate on the laboratory data worksheet (appendix 11.3). 
 
Note:  If nutrient broth with glycerol unavailable please store using local protocols.  
 
 
6. Inter-laboratory Quality control – Sending laboratory  
 
6.1 Materials 
 
6 study samples (1 or 2 positives, 4 or 5 negatives) with at least 4 ml remaining after 
normal study testing 
 
Bijou bottle 
Cotton tip swab 
Hayes DX plastic container and box 
 
6.2 Method 
Label 3 bijoux bottles per sample with QC number (next in numerical sequence) and 
transfer 1ml of the sample to each bottle.  
 
Record original sample study number, and QC number on the QC worksheet. 
 
For each set of 6 samples: 
 Wrap parafilm around the lid of each bottle 
 Wrap bottles in paper towel 
Place in specimen bag, seal and place inside Hayes DX plastic container with a list of the 
samples included 
Place in Hayes DX box 
 
Send a set of 6 samples to each of the other 3 study sites. Hayes DX codes for each site 
are included in this study manual (appendix 11.7.) 
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7. Inter-laboratory Quality control – Receiving laboratory  
 
Process each QC sample in the same way as a study sample but record the results on the 
Quality control Excel spreadsheet. This spreadsheet must be emailed at the beginning of 
each month to kerrie.eastwood@leedsth.nhs.uk.  
 
 
8. Commercial assays 
 
8.1 Materials 
Premier Toxin A+B EIA assay 
TechLab Toxin A/B II EIA assay 
TechLab C. diff Chek 60 EIA assay 
Cepheid C. difficile GeneXpert PCR assay 
 
8.2 Equipment 
DS2 for automated performance of EIA’s 
Cepheid GeneXpert for performance of PCR 
 
8.3 Method 
 
8.3.1 DS2  
All assays are carried out according to manufacturers’ instructions in the product insert, 
with the following exceptions;  
 
1. The Premier Toxin A + B assay is run with a larger volume (800µL diluent with 
200µL sample) to enable processing on the DS2; supporting information will be 
given at training.   
 
2. The same sample diluent is used for the two Techlab assays. The sample can 
therefore be diluted once, in 2x diluent (i.e. 100µL of sample in 400µL of 
diluent) and used for both assays, to reduce sample processing time. This is 
supported by the manufacturer.  
 
For plate ID on the DS2’s please use the following notation: 
 
Premier toxin  A +B  Ptab date initials of operator           e.g. Ptab20/10/10KE 
Techlab Toxin A B II  ToxAB date initials of operator       e.g. ToxAB20/10/10KE 
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Teclab GDH   GDH date initials of operator          e.g. GDH20/10/10KE 
 
 
All operators must receive training before using the DS2’s. Daily washes must be 
completed on both machines.  
 
8.3.2 GeneXpert 
Training will be provided for the Cepheid GeneXpert. All users must receive training 
before using the Instrument.  
 
If sample result is ‘invalid’ repeat the test once. The result of the second test should be 
recorded in the study database (even if it is invalid again).  
 
Only use the Copan swabs supplied for performing the GeneXpert assay as these are the 
only swabs to have been validated for the assay.  
 
Please archive all data daily, and place into another folder in the C:drive of the laptop 
attached to the machine. Down load this data onto your office pc daily (using memory 
stick) and save in secure folder. Data can then either be transcribed in to the study 
database by hand 
 
 
For any problems with instruments or training requirements please contact 
kerrie.eastwood@leedsth.nhs.uk.  
 
 
9. Data Collection  
 
9.1 Laboratory data 
 
A laboratory folder containing laboratory data sheets and templates should be kept at 
each site.  
 
All printouts from the DS2 and the Cepheid GeneXpert are to be kept in the correct 
section in the laboratory folder. Each sheet should be signed by the operator; date is 
added by the computer.  
 
All backing sheets for the cytotoxin assay, culture plates and cytotoxigenic culture are to 
be kept in the correct section in the laboratory folder.  Each sheet should be signed and 
dated by the operator.  
 
At the end of each day the laboratory results are entered onto the laboratory data Excel 
spreadsheet (see Appendix 11.3-11.5 for laboratory data sheets).  
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Paper records should be kept for 5 years after the completion of the study. 
9.2 Clinical data  
 
Please collect the data listed in table 9.2.1 on every sample and enter onto the clinical 
data Excel spreadsheet, in the ‘all’ section;  
Table 9.2.1 Data to be collected for EVERY specimen 
Variable Definition units 
Patient study number Number allocated to each 
patient on the study (The 
patient number can only be 
allocated once but a 
patient can have more than 
one sample included in the 
study) 
e.g. PLT0001 
Study specimen number Number allocated to each 
specimen (The number can 
only be allocated once and 
each specimen can only be 
included in the study once) 
e.g. LTH0001 
Patient Name Name of patient  
Date of sample  Date sample taken dd/mm/yy 
Processing hospital 
laboratory number 
  
Gender  Gender of patient M= male 
F=female 
Age  Age of patient at time of 
sample 
Years (whole number) 
Ward name/number or GP  
 
Ward name or if GP give 
name 
N/A 
Recurrent or new 
diagnosis (R/N) 
Whether the patient has 
had a previous diagnosis 
within the previous 12 
months 
R=recurrent 
N=new 
N/A=not applicable 
White cell count  Peripheral white cell count 
on the day of stool sample 
(or the nearest one within 
3 days) – If equal time 
then take sample AFTER 
stool sample 
x10
9
/L 
Serum creatinine  Serum creatinine 
concentration on the day 
of stool sample (or the 
nearest one within 3 days) 
µmol/L 
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– If equal time then take 
sample AFTER stool 
sample 
baseline creatinine  Lowest Serum creatinine 
concentration taken within 
the 6 months before the 
stool sample 
µmol/L 
Serum albumin  Serum albumin 
concentration on the day 
of stool sample (or the 
nearest one within 3 days) 
– If equal time then take 
sample AFTER stool 
sample 
g/L 
Date of hospital admission Date of this admission to 
hospital 
dd/mm/yy 
Date of hospital 
discharge/death 
Date patient discharged 
from hospital or died  
dd/mm/yy 
Survival at 30 days or 
discharged  
Survival to day 30 as an 
inpatient or discharge 
home before day 30 
Survived 
Died 
Discharged 
N.B. please answer N/A – not available/not applicable if there is no value available for 
any field 
 
N.B. – the day of the stool sample is defined as day 1 
 
 
Please collect the extra data listed in table 9.2.2. on samples positive for C. difficile by at 
least one of the gold standard methods or by PCR (GeneXpert).  Enter this data onto the 
clinical data Excel spreadsheet in the ‘Pos extended clinical data’ section; 
Table 9.2.2. Extra data to be collected on all positive samples (Gold 
standard or PCR) 
Variable Definition units 
Highest serum lactate 
within 3 days of the sample  
Highest serum lactate 
concentration within 3 
days of the first positive 
stool sample – If equal 
time then take sample 
AFTER stool sample 
mmol/L 
NA – not available 
Admission onto ITU  Admission to intensive 
care unit for any reason 
within 3 days before the 
first positive stool 
specimen or 10 days after 
the first positive stool 
Y - Yes 
N = No 
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specimen 
Is there evidence of colitis 
as reported on CT scan  
Evidence of the colitis 
noted on any 
Computerised tomography 
scan (CT scan) 
Y = Yes 
N = No 
N/A – not applicable 
Is C. difficile mentioned on 
either part 1 or part 2 of the 
death certificate  
The mention of C. 
difficile, or a synonym on 
the death certificate, if the 
person has died 
Y = Yes 
N = No 
N/A – not applicable 
N.B. please answer N/A – not available/not applicable if there is no value available for 
any field 
 
N.B. – the day of the stool sample is defined as day 1 
 
 
Please collect the extra data listed in table 9.2.3 on samples that are positive by ONE, 
but NOT BOTH, of the Gold standard methods, and enter onto the clinical data Excel 
spreadsheet in the ‘discrepant sample clinical data’ section; 
Table 9.2.3 Extra data to be collected for discrepant samples 
Variable Definition units 
Treating team clinical 
diagnosis 
Diagnosis for the cause of 
diarrhoea recorded by the 
attending clinical team 
 
Is treatment given for C. 
difficile infection (CDI) 
Was treatment for C. 
difficile started within 3 
days before the first positive 
stool specimen or 10 days 
after the first positive stool 
specimen 
Y = Yes 
N = No 
 
What agent is given to treat 
CDI 
Name of C. difficile 
antibacterial chemotherapy 
Vancomycin 
Metronidazole 
Did the patient have 
diarrhoea documented 
Documented diarrhoea  
(>3 loose (Bristol stool ≥5) 
stools in a 24 hour period) 
in the medical or nursing 
notes 
Y = Yes 
N = No 
 
How many days did the 
patient have diarrhoea for  
Number of days of recorded 
diarrhoea from start of 
symptoms until stool 
sample 
days 
How many stools did the 
patient pass on the day of 
sample 
How many stools did the 
patient pass on the day of 
sample – as recorded in the 
nursing or medical notes 
 
What was the Bristol stool (if not documented please 1-7 
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chart rating for that sample  record for nearest stool 
sample in same episode of 
diarrhoea) 
 
N.B. please answer N/A – not available/not applicable if there is no value available for 
any field 
 
N.B. – the day of the stool sample is defined as day 1 
 
 
Quick guide:  
Negative samples will therefore have all the data from table 9.2.1 collected. 
 
 
Samples positive by gold standard or by PCR will have the data from tables 9.2.1 
AND 9.2.2 collected. 
 
 
Samples positive by ONLY ONE of the gold standards will have the data from 
tables 9.2.1, 9.2.2 AND 9.2.3 collected.  
 
 
10. Data management 
 
10.1 Storage of data 
 
All electronic data must be kept on a secure password protected (N3 compliant) server 
and should only be accessible to those personnel involved in the study. All paper copies 
with patient identifiable details should be kept in a secure office.  
 
10.2 Movement of data 
 
At the beginning of each month the Quality control spreadsheet should be emailed to 
kerrie.eastwood@leedsth.nhs.uk 
 
At the end of the training set (first 4 months) the laboratory data set should be checked 
for accuracy, locked and emailed to kerrie.eastwood@leedsth.nhs.uk 
 
At the end of the training set (first four months) the clinical data set should be checked 
for accuracy and the patient name and processing hospital laboratory number 
removed and the spreadsheet resaved under the name clinical data Sitev1, e.g. clinical 
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data Leedsv1. The spreadsheet can then be locked and emailed to 
kerrie.eastwood@leedsth.nhs.uk. The original spreadsheet with patient details on must 
remain on the local secure server.  
  
New databases will be supplied for the testing set (second 4 months). The same policies 
for the storage and management of data will apply to these new databases.
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11. Appendix 
 
11.1 Order sheet for Gold standard reagents 
 
To be ordered by processing laboratory (budget supplied). All other kits/media/cell lines will be ordered centrally and delivered to you.  
 
Consummables order sheet        
        
      Number to order 
 Unit volume/number List price Supplier Item code Leeds/Oxford SGH/UCH 
Reference assays        
Industrial alcohol Bottle 2.5l 23.24 SLS CHE1938 1 1 
Brain Heart Infusion broth 10ml Bottle 50 31.00 E&O BM0070 4 3 
                
Tissue culture               
Antibiotic/Antimycotic 100X bottle 20ml 10.05 Invitrogen 15240-096 2 1 
L-Glutamine (100x 20.2mg/ml) bottle 20ml 3.71 Invitrogen 25030-032 2 1 
Newborn Calf serum  bottle 100ml 5.67 Invitrogen 16010-167 2 1 
Hanks balanced salt solution bottle 100ml 3.61 Invitrogen 14170-070 1 1 
Dulbecco Modified Eagles medium bottle 500ml 8.23 Invitrogen 10938-025 6 3 
Gentamicin (50mg/mll) bottle 10ml 51.10 Sigma G1397-10ml 1 1 
C. sordellii antitoxin bottle 5ml 60.60 Prolab PL6507 1 1 
Trypsin-EDTA 0.5% (10x) bottle 100ml 25.80 Invitrogen 15400-054 1 1 
Flasks nunclon, filter cap pk 300 190.52 Sarstedt 83.1810.002 1 1 
TC microwell 96F sterile pk 50 102.00 VWR 402032808 4 2 
Bijoux  pk 700 161.00 Sterilin VWR 215-0328 1 1 
Microcentrifuge tubes 1.5ml pk 1000 30.90 Alpha  LW2075 4 2 
Syringe filter Nalgene (CA 
membrane) pk 50 111.00 VWR  513-1911 2 1 
Syringes 2ml pk 100 13.67 Fisher Scientific SZR-160- 1 1 
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019L 
phosphate buffered saline pk  1L 16.00 sigma D8662 4 2 
                
Consumables               
Universals Pk 500 71.55 Sarstedt 63.9922.252 7 4 
10 uL Culture loops Pk 1920 78.68 Sarstedt 86.1562.050 2 1 
Cryogenic tubes 1.2 ml case 500 95 Sarstedt 72.377 1 1 
Microtube 2.0ml skirted with cap case 5000 491.9 Sarstedt 72.694 3 2 
Storage boxes (cryo) 9x9 each (min 5) 1 39.45 Sarstedt 93.873.481 1 set of 5 1 set of 5 
Blue tips with filter Racked1000uL case 
1000 (10 boxes of 
100) 76.38 Sarstedt 70.762.211 4 2 
cotton tipped swabs pk  5000 88.00 Fisher Scientific TS10 2 1 
latex agglutination kit box 50 tests 203.74 
Microgen 
bioproducts M41CE 1 1 
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11.2 Tissue culture reagent log 
 
Please record the Lot number, expiry date and date of all reagents used. 
DATE   DMEM TRYPSIN HBSS CALF L-GLUTAMINE ANTIBIOTIC   
        SERUM  MYCOTIC GENTAMYCIN 
  LOT No               
  Expiry date               
  LOT No               
  Expiry date               
  LOT No               
  Expiry date               
  LOT No               
  Expiry date               
  LOT No               
  Expiry date               
  LOT No               
  Expiry date               
  LOT No               
  Expiry date               
  LOT No               
  Expiry date               
  LOT No               
  Expiry date               
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11.3 Gold Standards Laboratory data sheet      
       
Specimen study 
number Date of sample 
Cytotoxin assay 
(Pos/Neg) Culture (Pos/Neg) 
Cytotoxigenic 
culture (Pos/Neg) QC number  
Isolate storage 
(Freezer 
box/position) 
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              
       
Operator………………………………………….  Date……………………………………………….  
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11.4 Commercial EIA Laboratory data sheet  
 
Specimen study 
number Date of sample 
Premier Toxin A+B 
result  
Premier Toxin A 
+ B OD value 
TechLab Tox A/B II 
OD value  
TechLab Quik Chek 60 
OD value  
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
      
Operator………………………………………….  Date………………………………............... 
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11.5 GeneXpert Laboratory data sheet     
      
Specimen study 
number Date of sample 
Cepheid 
GeneXpert result 
Cepheid geneXpert 
Tox B cycle No. 
Cepheid GeneXpert 
Binary Toxin cycle No. 
Cepheid GeneXpert Tcd 
C cycle No.  
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
      
Operator………………………………………….  Date……………………………………………….  
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11.6 Cytotoxin assay template  
Tray/Date ………………………..Positive control batch no. …………… 24hr tray read by 
………… 
Antitoxin batch no. ……………… Antitoxin in rows …………………… 48hr tray read by  
Tray/Date …………………………Positive control batch no. …………… 24hr tray read by … 
Antitoxin batch no. ………………...Antitoxin in rows …………………… 48hr tray read by 
 1 2 3 4 5 6 7 8 9 10 11 12  
A .          .          .         . . . . . . . . . A 
B     .          .          .         . . . . . . . . . B 
C . . . . . .  . . . . . . C 
D . . . . . . . . . . . . D 
E . . . . . . . . . . . . E 
F . . . . . . . . . . . . F 
G . . . . . . . . . . . . G 
H . . . . . . . . . . . . H 
 1 2 3 4 5 6 7 8 9 10 11 12  
 
POSITIVE CONTROL 
 1 2 3 4 5 6 7 8 9 10 11 12  
A .          .          .         . . . . . . . . . A 
B . . . . . . . . . . . . B 
C . . . . . .  . . . . . . C 
D . . . . . . . . . . . . D 
E . . . . . . . . . . . . E 
F . . . . . . . . . . . . F 
G . . . . . . . . . . . . G 
H . . . . . . . . . . . . H 
 1 2 3 4 5 6 7 8 9 10 11 12  
 
POSITIVE CONTROL 
